UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-K

(mark one)

[ X ] Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended December 29, 2001

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

Commission file number 1-8002

THERMO ELECTRON CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware                                                              04-2209186
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)

81 Wyman Street, P.O. Box 9046
Waltham, Massachusetts                                                02454-9046
(Address of principal executive offices)                              (Zip Code)

Registrant's telephone number, including area code: (781) 622-1000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class                    Name of each exchange on which registered
--------------------------------------------------------------------------------
Common Stock, $1.00 par value                            New York Stock Exchange
Preferred Stock Purchase Rights                          New York Stock Exchange
3 1/4% Subordinated Convertible Debentures due 2007      American Stock Exchange
4% Subordinated Convertible Debentures due 2005          American Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:
None

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to the filing requirements for at least the past 90 days. Yes [ X ] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference into Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

The aggregate market value of the voting stock held by nonaffiliates of the Registrant as of January 25, 2002, was approximately $3,946,627,000.

As of January 25, 2002, the Registrant had 175,210,210 shares of Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Sections of Thermo Electron's Annual Report to Shareholders for the year ended December 29, 2001, are incorporated by reference into Parts I and II, and sections of the company's definitive Proxy Statement for the Annual Meeting of Shareholders to be held on May 15, 2002, are incorporated by reference into Part
III. Copies of these documents can be obtained at no cost by calling the company's Investor Relations department at 781-622-1111.


PART I

Item 1. Business

(a) General Development of Business

Thermo Electron Corporation (also referred to in this document as "Thermo Electron," "we," the "company," or the "registrant") is a global leader in the development, manufacture, and sale of technology-based instrument systems, components, and solutions used in virtually every industry to monitor, collect, and analyze data to provide knowledge for the user. For example, our powerful analysis technologies help biotech researchers sift through data to make the discoveries that will fight disease or prolong life; allow telecommunications equipment manufacturers to fabricate components required to increase the speed and quality of communications; and monitor and control industrial processes on-line to ensure that critical quality standards are met efficiently and safely.

In the late 1980s, Thermo Electron adopted a strategy of spinning out certain businesses into separate public subsidiaries in which we kept a majority ownership. By 1997, we had spun out 22 public entities serving many diverse markets. To simplify our structure, we commenced in 1999 a major reorganization that ultimately consisted of taking private all of our public subsidiaries, selling noncore businesses with aggregate revenues in excess of $1.5 billion, and spinning off our paper-recycling and medical products businesses. This reorganization was substantially completed in February 2002, with the spin-in of Spectra-Physics, Inc., our last publicly traded subsidiary.

The businesses spun off and sold as part of our reorganization have been accounted for as discontinued operations (see "Description of Business - Principal Products and Services"). Except where indicated, the information presented in this Form 10-K pertains to our continuing operations.

Our strategy going forward is to focus on integrating our operations to improve productivity and enable us to better serve our customers with improved products, technologies, and complete integrated systems and services. We also intend to emphasize internal growth by investing proceeds from the sale of noncore businesses to pursue developments in the markets that we serve that have potential for high-growth. In addition, we plan to augment that growth with strategic acquisitions that expand the reach of our technology by either rounding out our product lines or bringing them to new markets.

Thermo Electron is a Delaware corporation and was incorporated in 1956. The company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980.

Forward-looking Statements

We may make forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, throughout this Annual Report on Form 10-K. Any statements in this document that are not statements of historical fact may be considered forward-looking. As you read this document, the words "believes," "anticipates," "plans," "expects," "seeks," "estimates," and other similar expressions are intended to identify forward-looking statements. A number of important factors could cause the company's results to differ materially from those indicated by such forward-looking statements, including those detailed under the heading "Forward-looking Statements" in our 2001* Annual Report to Shareholders, which statements are incorporated in this document by reference.

(b) Financial Information About Segments

Financial information about the company's segments (also called "sectors") is summarized in Note 3 to Consolidated Financial Statements in our 2001 Annual Report to Shareholders, which is incorporated in this document by reference.


* References to 2001, 2000, and 1999 herein are for the fiscal years ended December 29, 2001, December 30, 2000, and January 1, 2000, respectively.

<

2

>

(c) Description of Business

(i) Principal Products and Services

We report our business in three principal sectors (segments):
Life Sciences, Optical Technologies, and Measurement and Control.

Life Sciences

We address the biotechnology and pharmaceutical markets, as well as the clinical laboratory and healthcare industries, through our Life Sciences sector. This sector is organized into four divisions: bioscience technologies, analytical instruments, informatics, and clinical diagnostics.

Bioscience technologies encompasses a broad range of instruments and consumables, such as microplate-based handling and reading equipment, optical biosensors, polymerase chain reaction (PCR) thermal cyclers for deoxyribonucleic acid (DNA) amplification, magnetic particle-based molecular separation instruments, and single nucleotide polymorphism (SNP) scoring systems. Consumables include reagents, microtiter plates, liquid-handling pipettes, and pipette tips. Biosciences instruments are used primarily by pharmaceutical companies for drug discovery and development, testing, and quality control, and by biotechnology companies and universities for research leading to knowledge about diseases and possible treatments. These products are typically used on the "front end" of multi-instrument systems, as the instruments prepare and handle samples prior to being loaded into other, advanced instruments.

This division also includes a range of scientific equipment used for the preparation and preservation of chemical and biological samples, principally in research settings for pharmaceutical, academic, and government customers. Products include cell culture incubators, ultralow-temperature freezers, high-speed centrifuges, centrifugal vacuum concentrators, biological safety cabinets, cryopreservation storage tanks, and laboratory freeze dryers. We also design, manufacture, and market electrochemistry products, including pH and ion-selective electrolyte (ISE) and other technologies for quality assurance and regulatory compliance, primarily in the environmental, food and beverage, chemical, pharmaceutical, and biomedical research industries. These products determine the quality of various substances, from food and pharmaceuticals to water and wastewater, by measuring their pH, specific ion concentration, dissolved oxygen, and conductivity.

Analytical instruments includes our offerings of mass spectrometers, liquid and gas chromatographs, and multi-meters instrument combinations of these products, along with consumable products such as the vials, syringes, and columns necessary for chromatography. These systems are used by the pharmaceutical industry for drug development, testing, and quality control, and by the biotechnology industry for research leading to knowledge about disease and possible treatments. A significant and growing application for these instruments is proteomics, the study of proteins. Most drugs - about 90 percent
- interact with proteins, so multi-instrument systems that can rapidly identify and quantify proteins are of increasing value to pharmaceutical and biotechnology customers. We continue to introduce new systems that offer a total solution for high-throughput analysis, such as our Surveyor high performance liquid chromatograph, LCQ Deca mass spectrometer, TurboSEQUEST(R) software, and TSQ(R) Quantum - the first high-resolution, ultracompact benchtop triple quadrupole mass spectrometer.

Informatics laboratory information management systems facilitate the monitoring and analysis of samples by storing and organizing the massive amounts of analytical data gathered in laboratories, industrial settings, and clinical-testing sites. We are a leading supplier of laboratory information management systems, and provide chromatography data systems (CDS) to analyze chromatographic data obtained via gas or liquid chromatography and capillary electrophoresis.

<

3

>

Clinical diagnostics equipment and supplies are used by healthcare laboratories in doctors' offices and hospitals to detect and diagnose disease. Products in this group include sample-preparation instruments and materials to highlight abnormal cells, blood gas and ISE consumables, chemistry reagents, clinical-biochemistry instruments and automation equipment, and rapid diagnostic tests for use in physicians' offices. Our rapid diagnostic products currently test for influenza A and B, Streptococcus A and B, pregnancy, Rotavirus, mononucleosis, Chlamydia, and Clostridium difficile toxin A.

Optical Technologies

We are a leader in optical and semiconductor equipment systems and technologies that control and apply light throughout the electromagnetic spectrum for many different uses. Products within the Optical Technologies sector are used in multiple markets - particularly the scientific instrument, microelectronics, biomedical, and telecommunications industries - to research, fabricate, and analyze advanced materials. These products are grouped into three divisions: photonics, semiconductor, and temperature control.

Photonics businesses manufacture optical and optoelectronics components and systems that are used in a variety of industries, including scientific and medical instruments, telecommunications, and semiconductor applications. For example, our diffraction gratings are used in the line-narrowing packages of excimer lasers used for photolithography systems in semiconductor manufacturing, and in the fabrication of "grisms" (grating and prism) for the multiplexing and demultiplexing of wavelengths in optical telecommunications.

This division also includes Spectra-Physics, a leader in the design, development, manufacture, and distribution of semiconductor-based lasers and laser optics for a broad range of applications, including active and passive components for telecommunications. Passive components are used to mix, filter, and adjust the optical signals transmitted through a fiber-optic network, while active components generate and amplify optical signals, or light.
Spectra-Physics has also developed high-power semiconductor-based laser products for a variety of other commercial markets, including computer and microelectronics manufacturing, industrial manufacturing, medical image recording, and research and development.

Semiconductor products are used in the manufacture of capital equipment that produces and tests semiconductor chips. In particular, we are the leading supplier of molecular beam epitaxy (MBE) systems for the manufacture of gallium arsenide and other compound semiconductor devices. The largest application of these systems is for microwave devices used in cellular telephones and other high-speed wireless communications devices. In 1999, we introduced the V150 MBE, a successor to our V100 MBE system. The V150 MBE helps customers keep pace with the rapidly growing demand for high-speed telecommunications devices by significantly increasing semiconductor production capacity. In 2000, we introduced the Theta Probe, a next-generation semiconductor metrology tool, to analyze defects in ultra-thin surface layers of a chip.

Temperature control systems are necessary for laser, semiconductor, analytical, laboratory, industrial, and research and development applications. We are the leading manufacturer of precision temperature-control products for these applications, and also supply instruments that analyze materials for viscosity, surface tension, and thermal properties. Customers include the food and beverage industries as well as manufacturers of paints and ink products, which use high-precision viscometers to maintain the quality and consistency of their products.

<

4

>

Measurement and Control

We provide a range of real-time, on-line sensors, monitors, and control systems through our Measurement and Control sector. These products help manufacturers improve and refine their processes to increase productivity and quality. These improvements also help our customers meet government standards for product and worker safety. This sector is organized into three divisions:
spectroscopy, process instruments, and environmental instruments.

Spectroscopy instrumentation uses various optical techniques to determine, in a nondestructive manner, the elemental and molecular composition of a wide range of complex liquids and solids. Customers include pharmaceutical, specialty chemical, steel, and basic material producers, who use these instruments either in a laboratory or integrated directly into the production line.

Process instruments includes a comprehensive family of online weighing and inspection equipment for consumer products, packaged goods, and bulk materials. Products for the packaged and consumer goods market ensure that each package contains the proper quantity of a specific item. We use a variety of technologies, including X-ray imaging and ultratrace chemical detection, to inspect food, beverage, and pharmaceutical packages to see that they are free of physical contaminants and contain no missing or broken parts. In bulk materials, our product line includes solids-flow-monitoring and level measurement for a wide variety of process industries including food, chemicals, plastics, and pharmaceuticals.

Also included in this division are online process optimization systems that use proprietary, ultrahigh-speed, noninvasive measurement technologies to analyze the physical and chemical properties of streams of raw materials, such as coal, cement, minerals, and pharmaceuticals, in real time. This technology allows the entire stream of material to be analyzed and eliminates the need for off-line sampling, which can add production time and cost. We also provide process optimization systems that measure the total thickness, basis weight, and coating thickness of web-type finished materials, such as metal strip, plastics, foil, rubber, glass, and paper.

In addition, we provide sophisticated systems for the field-measurement and sensor sector of the process-control market to improve efficiency, provide process and quality control, maintain regulatory compliance, and increase worker safety. These systems provide real-time data collection, analysis, and local control functions using a variety of technologies, including radiation, radar, ultrasonic, and vibrational measurement principles, as well as flow-monitoring meters, gas chromatography, mass spectrography, and X-ray fluorescence. Industries served include oil and gas, chemical, semiconductor, pharmaceutical, electric utility, minerals and mining, water and wastewater treatment, and pulp and paper.

Environmental instruments and systems monitor pollutants generated by industrial and mobile sources. These include continuous gaseous and aerosol monitors, and water-quality instruments for assessing ambient air quality, emissions, and effluents from stationary sources. Compounds measured include common air pollutants, aerosols, and organic halogens and carbon. We also provide a comprehensive line of gas detectors for controlling and detecting the presence of combustible and toxic gases for worker and plant safety. These products range from simple handheld, general-purpose portable equipment to more sophisticated fixed systems. In addition, we supply a range of products for monitoring and detecting radiation at power plants, including portable radiation and contamination monitors, as well as electronic dosimetry and hand probes for protecting power plant personnel. These devices are also being used in border crossings and other public venues for public-safety purposes.

Sector Changes
During the first quarter of 2002, we fine-tuned the make-up of our three sectors. The Spectroscopy division, formerly part of our Measurement and Control sector, became part of the re-named Life and Laboratory Sciences sector, and our Temperature Control division moved from Optical Technologies to Measurement and Control. We also transferred our business that markets electrochemistry products from the Life and Laboratory Sciences sector into the Measurement and Control sector. We believe this structure enables us to better develop and provide integrated end-to-end solutions based on our customers' needs. These changes will be reflected in our financial reports beginning in the first quarter of 2002.

<

5

>

Discontinued Operations

As a result of our January 2000 reorganization plan, a number of businesses have been accounted for as discontinued operations. Businesses in this category included Kadant Inc., a supplier of systems to the paper-making and recycling industry, as well as fiber-based consumer products, and Viasys Healthcare Inc., a manufacturer of a range of medical products for diagnosis and monitoring. Kadant was spun off to shareholders in August 2001 and Viasys was spun off in November 2001. These businesses, together with a number of operating units sold, constituted the company's former Energy and Environment, Biomedical and Emerging Technologies, and Recycling and Resource Recovery segments. At March 15, 2002, two operating units with aggregate revenue of approximately $90 million remained for sale in discontinued operations.

(ii) and (xi) New Products; Research and Development

Our business includes the development and introduction of new products and may include entry into new business sectors. We are not currently committed to any new products that require the investment of a material amount of our assets, nor do we have any definitive plans to enter new businesses that would require such an investment.

During 2001, 2000, and 1999, we spent $171.6 million, $176.8 million, and $171.1 million, respectively, on research and development.

(iii) Raw Materials

Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. We do not anticipate any difficulties obtaining the raw materials essential to our business.

(iv) Patents, Licenses, and Trademarks

Patents are important to our business; no particular patent, or related group of patents, is so important, however, that its loss would significantly affect our operations as a whole. Generally, we seek patent protection for inventions and developments made by our personnel and incorporated into our products or otherwise falling within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always accrue exclusively to the company and may be limited by agreements or contracts.

We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register our products. We also enter into license agreements with others to grant and/or receive rights to patents and know-how.

(v) Seasonal Influences

Revenues in the fourth calendar quarter are historically stronger than in the other quarters due to capital spending patterns of industrial and academic customers.

(vi) Working Capital Requirements

There are no special inventory requirements or credit terms extended to customers that would have a material adverse effect on our working capital.

(vii) Dependency on a Single Customer

No customer accounted for more than 10% of our total revenues in any of the past three years.

<

6

>

      (viii)  Backlog
              -------

      Our backlog of firm orders at year-end 2001 and 2000 was as follows:

(In thousands)                                                                             2001       2000
----------------------------------------------------------------------------------------------------------

Life Sciences                                                                          $128,652   $118,284
Optical Technologies                                                                    171,572    257,485
Measurement and Control                                                                 133,485    184,621
Other                                                                                     1,328          -
Intersegment                                                                             (2,413)    (4,000)
                                                                                       --------   --------

                                                                                       $432,624   $556,390
                                                                                       ========   ========

The decrease in backlog in the Optical Technologies and Measurement and Control sectors arose principally due to a slowdown in markets served by these businesses. For further discussion see Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations. The Measurement and Control sector's backlog was $168 million at the end of 2000, excluding businesses subsequently divested. We believe that virtually all of our backlog at the end of 2001 will be filled during 2002.

(ix) Government Contracts

Not applicable.

(x) Competition

The markets for our products are highly competitive. In general, our success in these markets depends on four factors:

- technical advances that result in new products and improved price/ performance ratios,
- our reputation among customers as a quality provider of products and services,
- active research and application-development programs, and
- relative prices of our products and services.

In many markets, we compete with large analytical instrument companies such as Agilent Technologies Inc.; PerkinElmer, Inc.; Varian Associates, Inc.; Waters Corporation; and Hitachi, Ltd. In other markets, we compete with numerous smaller, more specialized firms.

Life Sciences

Bioscience Technologies. Our principal competitors for laboratory equipment are Kendro Laboratory Products, which is owned by SPX Corporation; New Brunswick Scientific; Jouan S.A.; NuAire Inc.; Sanyo Electric Co. Ltd.; Labconco Corporation; Corning-Costar Corporation; Fisher Scientific International Inc.; Mettler-Toledo International Inc.; Danaher Corporation; Eppendorf AG; Beckman Coulter, Inc.; Metrohm Ltd.; Radiometer; Kyoto; ManTech; and Denver Instruments. We compete primarily on the basis of technical performance, customer service and support, and price.

In biosciences instruments and consumables, we compete with PerkinElmer; Molecular Devices Corporation; Beckman Coulter; Bio-Rad Laboratories, Inc.; Agilent; MJ Research Technology; Qiagen Corporation; Biacore International, Inc.; Nalge Nunc Inc.; Corning-Costar; Rainin Instruments; Greiner GmbH; and Eppendorf AG. In this market, we compete primarily on the basis of technical performance, user convenience, and price.

<

7

>

Analytical instruments. Our principal competitors in this market include Agilent, Waters, Shimadzu Corporation, PerkinElmer, Bruker, and Applied Biosystems, and we compete primarily on the basis of technical performance, customer service and support, and price.

Informatics. Our competitors include PerkinElmer, PE Biosystems, Beckman Coulter, Agilent, LabVantage Solutions, LIMS U.S., Scientific Software Inc., and Waters. We compete primarily on the basis of technical performance and price.

Clinical diagnostics. In this market, our principal competitors are Leica Microsystems; Sakura Finetek U.S.A., Inc.; Ventana Corporation; Cytyc Corporation; Wescor Inc.; and Mopec Inc., and we compete primarily on the basis of product quality, price, and customer service.

In the clinical chemistry reagent market, our competitors include Abbott Laboratories; BioChem Pharma; Chiron Corporation; and Sigma Diagnostics, a division of Sigma-Aldrich Co. Competition in this market is primarily based on product quality and price.

Competitors in the market for rapid diagnostic test kits include Abbott Laboratories; Becton, Dickinson and Company; Roche-Boeringher Manheim; and Quidel Corporation. We compete primarily on the basis of innovative technology as well as price.

Optical Technologies

Photonics. We compete primarily on the basis of technical performance, reliability, and price. Principal competitors include Optical Coating Laboratory, Inc.; Newport Corporation; Hamamatsu Photonics K.K.; Barr Associates, Inc; and JY Horiba. At Spectra-Physics we compete primarily on the basis of product quality, technical performance, customer service, and innovative technology. Principal competitors include SDL, Inc.; Coherent, Inc.; Siemens; Thompson-CSF; Lightwave Electronics Inc.; Continuum (a division of Hoya); and JDS/Uniphase Corporation.

Semiconductor. We compete primarily with Riber Instruments S.A., Oxford Instruments plc., Physical Electronics Inc., Veeco Instruments Inc., Aixtron AG, EDAX Inc., Kratos Analytical (a subsidiary of Shimadzu), Omicron GmbH, and Oryx Inc. In this market, we compete primarily on the basis of product quality, technical performance, innovative technology, and price.

Temperature Control. Our temperature control products compete with those of Lauda (Dr. Wobser GmbH & Co. KG); Julabo Labortechnik GmbH; Affinity, Inc.; and Lytron, Inc., primarily on the basis of technical performance, price, and customer service. In the market for mid-level products that operate on a personal-computer platform, our principal competitors are TA Instruments, Inc., a subsidiary of Waters, and Rheometrics Scientific Inc. and we compete primarily on the basis of product quality, technical performance, and price.

Measurement and Control

Spectroscopy. In the spectroscopy market, our principal competitors are PerkinElmer, Varian, Agilent, and Bio-Rad, and we compete primarily on the basis of product quality, technical performance, innovative technology, and price.

Process Instruments. Major competitors in the packaged-goods and bulk- materials markets are Ishida Scales Mfg. Co., Ltd.; Mettler-Toledo; Industrial Dynamics Corporation; Carl Schenck AG; and Milltronics Corporation. We compete primarily on the basis of customer service, product quality, and price.

<

8

>

Our major competitors for online analysis systems are Scantech Limited; Integrated Measurement Systems, Inc.; Toshiba Corporation; Yokogawa Electric Corporation; and Infrared Engineering Limited. We compete primarily on the basis of technical performance, customer service, and price.

In the field measurement instruments and sensors market we compete primarily on the basis of product quality, price, and customer service. We compete with a few large competitors in each product area and with many companies within specific industries. Our major competitors include Fisher- Rosemount, a division of Emerson Electric Co., Inc.; Asea Brown Boveri (Holding) Ltd.; and Yokogawa.

We have a relatively small presence within the large and varied process-control marketplace, which is extremely fragmented and consists of several large companies, including Fisher-Rosemount, Elsag Bailey, and Honeywell Process Control, as well as numerous smaller companies. We compete in this market primarily on the basis of technical performance, customer service, and price.

Environmental Instruments. Our principal competitors include Monitor Labs Incorporated; Advanced Pollution Instruments; Rupprecht & Pataschnick Co., Inc.; and Mine Safety Appliances Co. We compete in this market primarily on the basis of technical performance, price, and customer service.

(xii) Environmental Protection Regulations

Complying with federal, state, and local environmental protection regulations should not significantly affect our capital spending, our earnings, or our competitive position.

(xiii) Number of Employees

As of December 29, 2001, we employed approximately 12,000 persons as part of our continuing operations.

(d) Financial Information About Geographic Areas

Financial information about geographic areas is summarized in Note 3 to Consolidated Financial Statements in our 2001 Annual Report to Shareholders, which information is incorporated in this document by reference.

(e) Executive Officers of the Registrant

                             Present Title (Fiscal Year First Became
Name                   Age   Executive Officer)
--------------------------------------------------------------------------

Richard F. Syron        58   Chief Executive Officer and Chairman of the
                             Board (1999)
Marijn E. Dekkers       44   President and Chief Operating Officer (2000)
Guy Broadbent           38   Vice President; President, Optical
                             Technologies (2001)
Marc N. Casper          33   Vice President; President, Life Sciences
                             (2001)
Barry S. Howe           46   Vice President; President, Measurement and
                             Control (2001)
Theo Melas-Kyriazi      42   Vice President and Chief Financial Officer
                             (1998)
Seth H. Hoogasian       47   Vice President, General Counsel, and
                             Secretary (2001)
Peter E. Hornstra       42   Corporate Controller and Chief Accounting
                             Officer (2001)

Mr. Syron was appointed President and Chief Executive Officer in June 1999 and Chairman of the Board in January 2000. From April 1994 until May 1999, Mr. Syron was the Chairman and Chief Executive Officer of the American Stock Exchange Inc.

Mr. Dekkers was appointed President and Chief Operating Officer in July 2000. From June 1999 to June 2000 Mr. Dekkers served as president of Honeywell International's (formerly Allied Signal) electronic materials division, from August 1997 to May 1999 he served as vice president and general manager of its fluorine products division, and from July 1995 to July 1997 he served as vice president and general manager of its specialty films division.

<

9

>

Mr. Broadbent was appointed Vice President of Thermo Electron in January 2001 and President, Optical Technologies in October 2000. From May 2000 to October 2000, Mr. Broadbent was vice president and general manager of the amorphous metals division of Honeywell International and from November 1998 to April 2000 he was business director for Honeywell International's specialty fluorine division. From June 1996 to October 1998, he was the marketing manager of new business development of the plastics division of General Electric Company. He also served as product manager of this division from December 1994 to May 1996.

Mr. Casper was appointed Vice President of Thermo Electron and President, Life Sciences in December 2001. From July 2000 to July 2001, Mr. Casper was president and chief executive officer of Kendro Laboratory Products, a life sciences company that provides sample-preparation and processing equipment. From May 1999 to June 2000, Mr. Casper was president for the Americas at Dade Behring Inc., a manufacturer of products for the clinical-diagnosis market. From January 1997 to May 1999, Mr. Casper was executive vice president for Europe, Asia, and Intercontinental at Dade Behring Inc. From June 1995 to December 1996, Mr. Casper worked at Bain Capital as a member of the portfolio management group.

Mr. Howe was appointed Vice President of Thermo Electron in January 2001 and President, Measurement and Control in October 2000. Since 1995, Mr. Howe has held various operating positions at Thermo Electron. These included President, Optical Technologies from February 2000 to October 2000; President and Chief Executive Officer of its Thermo Optek Corporation subsidiary from March 1999 to February 2000; President and Chief Executive Officer of its ThermoSpectra Corporation subsidiary from March 1998 to March 1999; and President and Chief Executive Officer of its Thermo BioAnalysis Corporation subsidiary from February 1995 to March 1998.

Mr. Melas-Kyriazi was appointed Chief Financial Officer in January 1999. He joined the company in 1986 as Assistant Treasurer and served as Treasurer from 1988 until 1994. He was named President and Chief Executive Officer of the company's ThermoSpectra subsidiary in 1994, a position he held until becoming Vice President of Corporate Strategy for Thermo Electron in 1998.

Mr. Hoogasian was appointed General Counsel in 1992, Vice President in 1996, and Secretary in 2001.

Mr. Hornstra was appointed Chief Accounting Officer in January 2001 and Corporate Controller in 1996. From 1995 until 1996 Mr. Hornstra was Assistant Corporate Controller.

Item 2. Properties

The location and general character of our principal properties by sector as of December 29, 2001, are as follows:

Life Sciences

We own approximately 1,079,000 square feet of office, engineering, laboratory, and production space, principally in Ohio, California, Massachusetts, Pennsylvania, Texas, Italy, and Germany. We lease approximately 1,115,000 square feet of office, engineering, laboratory, and production space, principally in Massachusetts, Texas, New York, Virginia, Finland, England, and France, under various leases that expire between 2002 and 2015.

Optical Technologies

We own approximately 664,000 square feet of office, engineering, laboratory, and production space, principally in New Hampshire, California, Wisconsin, Arizona, Colorado, and Germany. We lease approximately 655,000 square feet of office, engineering, laboratory, and production space, principally in California, Massachusetts, and England, under various leases that expire between 2002 and 2016.

<

10

>

Measurement and Control

We own approximately 765,000 square feet of office, engineering, laboratory, and production space, principally in Wisconsin, Minnesota, New York, New Mexico, Germany, and Switzerland. We lease approximately 1,458,000 square feet of office, engineering, laboratory, and production space, principally in Massachusetts, Texas, California, Maryland, England, the Netherlands, Canada, and Australia, under various leases that expire between 2002 and 2030.

Corporate Headquarters

We own approximately 81,000 square feet of office space in Massachusetts and lease approximately 18,000 square feet of office space in Massachusetts under a lease that expires in 2004.

We believe that all these facilities are in good condition and are suitable and adequate to meet our current needs. If we are unable to renew any of the leases that are due to expire in the next year or two, we believe that suitable replacement properties are available on commercially reasonable terms.

Item 3. Legal Proceedings

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters

Information concerning the market and market price for our common stock, and our dividend policy, is included under the sections labeled "Common Stock Market Information" and "Dividend Policy" in our 2001 Annual Report to Shareholders, which information is incorporated in this document by reference.

Item 6. Selected Financial Data

This data is included under the sections labeled "Selected Financial Information" and "Dividend Policy" in our 2001 Annual Report to Shareholders, which data is incorporated in this document by reference.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

This information is included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2001 Annual Report to Shareholders, which information is incorporated in this document by reference.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

These disclosures are included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2001 Annual Report to Shareholders, which disclosures are incorporated in this document by reference.

Item 8. Financial Statements and Supplementary Data

This data is included in our 2001 Annual Report to Shareholders, which data is incorporated in this document by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

Not Applicable.

<

11

>

PART III

Item 10. Directors and Executive Officers of the Registrant

The information with respect to Directors is listed under the caption "Election of Directors" in our definitive proxy statement to be filed with the Securities and Exchange Commission (SEC), not later than 120 days after the close of the fiscal year. This information is incorporated in this document by reference.

We are also required, under Item 405 of Registration S-K, to provide information concerning delinquent filers of reports under Section 16 of the Securities Exchange Act of 1934, as amended. This information is listed under the heading "Section 16(a) Beneficial Ownership Reporting Compliance" under the caption "Stock Ownership" in our definitive proxy statement to be filed with the SEC, not later than 120 days after the close of the fiscal year. This information is incorporated in this document by reference.

Item 11. Executive Compensation

This information is listed under the caption "Executive Compensation" in our definitive proxy statement to be filed with the SEC, not later than 120 days after the close of the fiscal year. This information is incorporated in this document by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management

This information is listed under the caption "Stock Ownership" in our definitive proxy statement to be filed with the SEC, not later than 120 days after the close of the fiscal year. This information is incorporated in this document by reference.

Item 13. Certain Relationships and Related Transactions

This information is listed under the captions "Relationship with Affiliates" and "Compensation Committee Interlocks and Insider Participation" in our definitive proxy statement to be filed with the SEC, not later than 120 days after the close of the fiscal year. This information is incorporated in this document by reference.

<

12

>

PART IV

Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K

(a, d)  Financial Statements and Schedules
        ----------------------------------

        (1) The financial statements set forth in the list below are filed as
            part of this Report.

        (2) The financial statement schedule set forth in the list below is
            filed as part of this Report.

        (3) Exhibits filed here or incorporated here by reference are listed in
            Item 14(c) below.

        List of Financial Statements and Schedules Referenced in this Item 14
        ---------------------------------------------------------------------

        Information incorporated by reference from Exhibit 13 filed herewith:

            Consolidated Statement of Operations
            Consolidated Balance Sheet
            Consolidated Statement of Cash Flows
            Consolidated Statement of Comprehensive Loss and Shareholders'
              Investment
            Notes to Consolidated Financial Statements
            Report of Independent Public Accountants

        Financial Schedule included herewith:

            Schedule II:  Valuation and Qualifying Accounts

        All other schedules are omitted because they are not applicable or not
        required, or because the required information is shown either in the
        financial statements or in the notes thereto.

(b)     Reports on Form 8-K
        -------------------

        On October 12, 2001, the company filed a Current Report on Form 8-K with
        respect to the Board of Director's approval of the distribution of all
        of the shares of common stock of Viasys Healthcare Inc. held by the
        company to holders of record of Thermo Electron's common stock as of
        November 7, 2001.

        On November 2, 2001, the company filed a Current Report on Form 8-K with
        respect to the Information Statement detailing the distribution of the
        shares of common stock of Viasys Healthcare Inc. held by Thermo
        Electron.

        On November 2, 2001, the company filed a Current Report on Form 8-K with
        respect to the company's financial results for the quarter ended
        September 29, 2001.

        On November 16, 2001, the company filed a Current Report on Form 8-K
        with respect to the distribution on November 15, 2001, of 0.1461 of a
        share of common stock of Viasys Healthcare Inc. as a dividend on each
        share of the company's common stock outstanding as of November 7, 2001.

(c)     Exhibits
        --------

See the Exhibit Index on page 17.

<

13

>

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:  March 15, 2002                              THERMO ELECTRON CORPORATION

                                                   By: /s/ Richard F. Syron
                                                       -------------------------
                                                       Richard F. Syron
                                                       Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated, as of March 15, 2002.

Signature                        Title
--------------------------------------------------------------------------------

By:  /s/ Richard F. Syron        Chairman of the Board, Chief Executive Officer,
     Richard F. Syron            and Director (Principal Executive Officer)

By:  /s/ Theo Melas-Kyriazi      Vice President and Chief Financial Officer
     Theo Melas-Kyriazi

By:  /s/ Peter E. Hornstra       Corporate Controller and Chief Accounting
     Peter E. Hornstra           Officer

By:  /s/ Peter O. Crisp          Director
     Peter O. Crisp

By:  /s/ Marijn E. Dekkers       President, Chief Operating Officer, and
     Marijn E. Dekkers           Director

By:  /s/ Frank Jungers           Director
     Frank Jungers

By:  /s/ John L. LaMattina       Director
     John L. LaMattina

By:  /s/ Jim P. Manzi            Director
     Jim P. Manzi

By:  /s/ Robert A. McCabe        Director
     Robert A. McCabe

By:  /s/ Hutham S. Olayan        Director
     Hutham S. Olayan

By:  /s/ Robert W. O'Leary       Director
     Robert W. O'Leary

By:  /s/ Michael E. Porter       Director
     Michael E. Porter

By:  /s/ Elaine S. Ullian        Director
     Elaine S. Ullian


<
                                       14


>

Report of Independent Public Accountants

To the Shareholders and Board of Directors of Thermo Electron Corporation:

We have audited in accordance with auditing standards generally accepted in the United States, the consolidated financial statements included in Thermo Electron Corporation's Annual Report to Shareholders incorporated by reference in this Form 10-K, and have issued our report thereon dated February 7, 2002 (except with respect to the matters discussed in Note 19, as to which the date is February 25, 2002). Our audits were made for the purpose of forming an opinion on those statements taken as a whole. The schedule listed in Item 14 on page 13 is the responsibility of the company's management and is presented for purposes of complying with the Securities and Exchange Commission's rules and is not part of the basic consolidated financial statements. This schedule has been subjected to the auditing procedures applied in the audits of the basic consolidated financial statements and, in our opinion, fairly states in all material respects the financial data required to be set forth therein in relation to the basic consolidated financial statements taken as a whole.

Arthur Andersen LLP

Boston, Massachusetts
February 7, 2002

<

15

>

SCHEDULE II

                                       Thermo Electron Corporation

                                    Valuation and Qualifying Accounts
                                              (In thousands)



                                    Balance at   Provision                Accounts                 Balance
                                     Beginning  Charged to    Accounts     Written                  at End
Description                            of Year     Expense   Recovered         Off   Other (a)     of Year
----------------------------------------------------------------------------------------------------------

Allowance for Doubtful Accounts

Year Ended December 29, 2001          $ 30,593    $  6,316    $     23    $ (8,147)   $ (2,260)   $ 26,525

Year Ended December 30, 2000          $ 33,650    $  9,264    $    450    $ (7,211)   $ (5,560)   $ 30,593

Year Ended January 1, 2000            $ 26,938    $  8,614    $    253    $ (8,908)   $  6,753    $ 33,650




                                            Balance at   Established    Activity                   Balance
                                             Beginning    as Cost of  Charged to                    at End
Description                                    of Year  Acquisitions     Reserve    Other (c)      of Year
----------------------------------------------------------------------------------------------------------

Accrued Acquisition Expenses (b)

Year Ended December 29, 2001                  $ 10,070      $    144    $ (1,920)    $ (1,190)    $  7,104

Year Ended December 30, 2000                  $ 19,445      $    352    $ (6,445)    $ (3,282)    $ 10,070

Year Ended January 1, 2000                    $ 16,284      $ 17,252    $ (11,539)   $ (2,552)    $ 19,445



                                            Balance at     Provision    Activity                   Balance
                                             Beginning    Charged to  Charged to                    at End
Description                                    of Year   Expense (e)     Reserve    Other (f)      of Year
----------------------------------------------------------------------------------------------------------

Accrued Restructuring Costs (d)

Year Ended December 29, 2001                  $ 21,024      $ 76,314    $(35,747)    $   (906)    $ 60,685

Year Ended December 30, 2000                  $  5,425      $ 35,785    $(20,216)    $     30     $ 21,024

Year Ended January 1, 2000                    $ 11,320      $  5,931    $(11,177)    $   (649)    $  5,425

(a) Includes allowance of businesses, acquired and sold during the year as described in Note 2 to
    Consolidated Financial Statements in our 2001 Annual Report to Shareholders and the effect of currency
    translation.
(b) The nature of activity in this account is described in Note 2 to Consolidated Financial Statements in
    our 2001 Annual Report to Shareholders.
(c) Represents reversal of accrued acquisition expenses and corresponding reduction of goodwill or other
    intangible assets resulting from finalization of restructuring plans, the effect of currency
    translation and, in 2001 and 2000, the reserves of businesses sold.
(d) The nature of activity in this account is described in Note 15 to Consolidated Financial Statements in
    our 2001 Annual Report to Shareholders.
(e) In 2001, excludes $51.1 million of noncash costs, net, primarily for asset writedowns, and excludes a
    $5.9 million loss on litigation. In 2000, excludes $104.6 million of noncash income, net, primarily
    from the sale of businesses, offset by provisions for asset writedowns, and excludes $0.8 million of
    cash costs related to two lawsuits. In 1999, includes the reversal of $2.3 million of previously
    recorded restructuring costs, and excludes provisions of $31.4 million primarily for asset writedowns.
(f) Represents the effect of currency translation.

<
                                       16

>


                                  EXHIBIT INDEX
Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

   3.1         Amended and Restated Certificate of Incorporation of the
               Registrant, (filed as Exhibit 1 to the Registrant's Amendment
               No. 3 to Registration Statement on Form 8-A/A [File No. 1-8002]
               and incorporated in this document by reference).

   3.2         By-laws of the Registrant, as amended and effective as of
               February 7, 2002.

   4.1         Fiscal Agency Agreement dated as of January 3, 1996, between the
               Registrant and Chemical Bank pertaining to the Registrant's 4
               1/4% Subordinated Convertible Debentures due 2003 (filed as
               Exhibit 4.1 to the Registrant's Annual Report on Form 10-K for
               the fiscal year ended December 30, 1995 [File No. 1-8002] and
               incorporated in this document by reference).

               The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of
               Regulation S-K, to furnish to the Commission upon request, a copy
               of each instrument with respect to other long-term debt of the
               Registrant or its consolidated subsidiaries.

   4.2         Rights Agreement dated as of October 29, 2001, between the
               Registrant and American Stock Transfer & Trust Company, which
               includes as Exhibit A the Form of Certificate of Designations, as
               Exhibit B the Form of Rights Certificate, and as Exhibit C the
               Summary of Rights to Purchase Preferred Stock.

   4.3         Amendment No. 1 to Rights Agreement dated as of February 7, 2002,
               between the Registrant and American Stock Transfer & Trust
               Company.

  10.1         Thermo Electron Corporate Charter as amended and restated
               effective January 3, 1993 (filed as Exhibit 10.1 to the
               Registrant's Annual Report on Form 10-K for the fiscal year ended
               January 2, 1993 [File No. 1-8002] and incorporated in this
               document by reference).

  10.2         Thermo Electron Corporation Executive Retention Plan/Form of
               Executive Retention Agreement (filed as Exhibit 10.1 to the
               Registrant's Quarterly Report on Form 10-Q for the quarter ended
               October 3, 1998 [File No. 1-8002] and incorporated in this
               document by reference). (Each executive officer has a two-year
               agreement except Mr. Richard F. Syron and Mr. Marijn Dekkers,
               each of whom has a three-year agreement, and Mr. Peter E.
               Hornstra who has a one-year agreement.)

  10.3         Executive Severance Agreement dated as of January 27, 2000,
               between the Registrant and Theo Melas-Kyriazi.

  10.4         Revolving Credit Facility Letters from Barclays Bank PLC in favor
               of the Registrant and its subsidiaries (filed as Exhibit 10.8 to
               the Registrant's Annual Report on Form 10-K for the year ended
               January 3, 1998 [File No. 1-8002] and incorporated in this
               document by reference).

  10.5         Stock Holdings Assistance Plan and Form of Promissory Note (filed
               as Exhibit 10.9 to the Registrant's Annual Report on Form 10-K
               for the year ended January 3, 1998 [File No. 1-8002] and
               incorporated in this document by reference).

  10.6         Amended and Restated Deferred Compensation Plan for Directors of
               the Registrant (filed as Exhibit 10.1 to the Registrant's
               Quarterly Report on Form 10-Q for the quarter ended July 3, 1999
               [File No. 1-8002] and incorporated in this document by
               reference).


<
                                       17

>
                                  EXHIBIT INDEX

Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

  10.7         Thermo Electron Corporation Directors Stock Option Plan, as
               amended and restated as of February 7, 2002.

  10.8         Incentive Stock Option Plan of the Registrant (filed as Exhibit
               4(d) to the Registrant's Registration Statement on Form S-8 [Reg.
               No. 33-8993] and incorporated in this document by reference).

  10.9         Amended and Restated Nonqualified Stock Option Plan of the
               Registrant (filed as Exhibit 10.3 to the Registrant's Quarterly
               Report on Form 10-Q for the quarter ended July 3, 1999 [File No.
               1-8002] and incorporated in this document by reference). (Plan
               amended in 1984 to extend expiration date to December 14, 1994.)

  10.10        Thermo Electron Corporation Equity Incentive Plan, as amended and
               restated as of February 7, 2002.

  10.11        Thermo Electron Corporation 2001 Equity Incentive Plan, as
               amended and restated as of February 7, 2002.

  10.12        Thermo Electron Corporation Employees Equity Incentive Plan, as
               amended and restated as of February 7, 2002.

  10.13        Thermo Electron Corporation Deferred Compensation Plan, effective
               November 1, 2001.

  10.14        Amended and Restated Thermo Electron Corporation - Thermo
               TerraTech Inc. Nonqualified Stock Option Plan (filed as Exhibit
               10.7 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On September 22, 2000, Thermo
               TerraTech merged with Thermo Electron and all outstanding options
               granted under this plan were assumed by Thermo Electron.)

  10.15        Amended and Restated Thermo Electron Corporation - Thermo Power
               Corporation Nonqualified Stock Option Plan (filed as Exhibit 10.8
               to the Registrant's Quarterly Report on Form 10-Q for the quarter
               ended July 3, 1999 [File No. 1-8002] and incorporated in this
               document by reference). (On October 28, 1999, Thermo Power merged
               with Thermo Electron and all outstanding options granted under
               this plan were assumed by Thermo Electron.)

  10.16        Amended and Restated Thermo Electron Corporation - Thermo Ecotek
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.10 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On August 10, 2000, Thermo Ecotek
               merged with Thermo Electron and all outstanding options granted
               under this plan were assumed by Thermo Electron.)

  10.17        Amended and Restated Thermo Electron Corporation - ThermoTrex
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.11 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On August 14, 2000, ThermoTrex
               merged with Thermo Electron and all outstanding options granted
               under this plan were assumed by Thermo Electron.)

<
                                       18

>
                                  EXHIBIT INDEX

Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

  10.18        Amended and Restated Thermo Electron Corporation - Thermo
               BioAnalysis Corporation Nonqualified Stock Option Plan (filed as
               Exhibit 10.14 to the Registrant's Quarterly Report on Form 10-Q
               for the quarter ended July 3, 1999 [File No. 1-8002] and
               incorporated in this document by reference). (On April 19, 2000,
               Thermo BioAnalysis merged with Thermo Instrument Systems Inc. and
               on June 30, 2000, Thermo Instrument merged with Thermo Electron
               and all outstanding options granted under this plan were
               ultimately assumed by Thermo Electron.)

  10.19        Amended and Restated Thermo Electron Corporation - ThermoLase
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.18 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On August 14, 2000, ThermoLase
               merged with Thermo Electron and all outstanding options granted
               under this plan were assumed by Thermo Electron.)

  10.20        Amended and Restated Thermo Electron Corporation - ThermoQuest
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.19 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On May 11, 2000, ThermoQuest merged
               with Thermo Instrument and on June 30, 2000, Thermo Instrument
               merged with Thermo Electron and all outstanding options granted
               under this plan were ultimately assumed by Thermo Electron.)

  10.21        Amended and Restated Thermo Electron Corporation - Thermo Optek
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.20 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On May 11, 2000, Thermo Optek
               merged with Thermo Instrument and on June 30, 2000, Thermo
               Instrument merged with Thermo Electron and all outstanding
               options granted under this plan were ultimately assumed by Thermo
               Electron.)

  10.22        Amended and Restated Thermo Electron Corporation - Thermo Sentron
               Inc. Nonqualified Stock Option Plan (filed as Exhibit 10.21 to
               the Registrant's Quarterly Report on Form 10-Q for the quarter
               ended July 3, 1999 [File No. 1-8002] and incorporated in this
               document by reference). (On April 4, 2000, Thermo Sentron merged
               with Thermedics Inc. and on June 30, 2000, Thermedics merged with
               Thermo Electron and all outstanding options granted under this
               plan were ultimately assumed by Thermo Electron.)

  10.23        Amended and Restated Thermo Electron Corporation - Trex Medical
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.22 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On November 29, 2000, Trex Medical
               merged with Thermo Electron and all outstanding options granted
               under this plan were assumed by Thermo Electron.)

  10.24        Amended and Restated Thermo Electron Corporation - Thermedics
               Detection Inc. Nonqualified Stock Option Plan (filed as Exhibit
               10.24 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On April 12, 2000, Thermedics
               Detection merged with Thermedics and on June 30, 2000, Thermedics
               merged with Thermo Electron and all outstanding options granted
               under this plan were ultimately assumed by Thermo Electron.)

<
                                       19

>
                                  EXHIBIT INDEX

Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

  10.25        Amended and Restated Thermo Electron Corporation - Thermo Vision
               Corporation Nonqualified Stock Option Plan (filed as Exhibit
               10.26 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 3, 1999 [File No. 1-8002] and incorporated in
               this document by reference). (On January 6, 2000, Thermo Vision
               merged with Thermo Instrument and on June 30, 2000, Thermo
               Instrument merged with Thermo Electron and all outstanding
               options granted under this plan were ultimately assumed by Thermo
               Electron.)

  10.26        Amended and Restated Thermo Electron Corporation - ONIX Systems
               Inc. Nonqualified Stock Option Plan (filed as Exhibit 10.27 to
               the Registrant's Quarterly Report on Form 10-Q for the quarter
               ended July 3, 1999 [File No. 1-8002] and incorporated in this
               document by reference). (On April 12, 2000, ONIX merged with
               Thermo Instrument and on June 30, 2000, Thermo Instrument merged
               with Thermo Electron and all outstanding options granted under
               this plan were ultimately assumed by Thermo Electron.)

  10.27        Amended and Restated Thermo Electron Corporation - The Randers
               Killam Group Inc. Nonqualified Stock Option Plan (filed as
               Exhibit 10.28 to the Registrant's Quarterly Report on Form 10-Q
               for the quarter ended July 3, 1999 [File No. 1-8002] and
               incorporated in this document by reference). (On May 15, 2000,
               Randers Killam merged with Thermo TerraTech and on September 22,
               2000, Thermo TerraTech merged with Thermo Electron and all
               outstanding options granted under this plan were ultimately
               assumed by Thermo Electron.)

  10.28        Amended and Restated Thermo Electron Corporation - Trex
               Communications Corporation Nonqualified Stock Option Plan (filed
               as Exhibit 10.29 to the Registrant's Quarterly Report on Form
               10-Q for the quarter ended July 3, 1999 [File No. 1-8002] and
               incorporated in this document by reference). (On November 8,
               1999, Trex Communications merged with ThermoTrex and on August
               14, 2000, ThermoTrex merged with Thermo Electron and all
               outstanding options granted under this plan were ultimately
               assumed by Thermo Electron.)

  10.29        1997 Spectra-Physics Lasers, Inc. Stock Option Plan (filed as
               Exhibit 10.6 of Amendment No. 1 to Spectra-Physics Lasers, Inc.'s
               Registration Statement on Form S-1 [File No. 333-38329] and
               incorporated in this document by reference).  (On February 25,
               2002, Spectra-Physics merged with Thermo Electron and all
               outstanding options granted under this plan were assumed by
               Thermo Electron.)

  10.30        2000 Spectra-Physics Lasers, Inc. Stock Option Plan (filed as
               Exhibit 10.1 to Spectra-Physics Quarterly Report on Form 10-Q for
               the quarter ended September 30, 2000 [File No. 000-23461] and
               incorporated in this document by reference). (On February 25,
               2002, Spectra-Physics merged with Thermo Electron and all
               outstanding options granted under this plan were assumed by
               Thermo Electron.)

  10.31        Description of Amendments to Certain Stock Option Plans made in
               February 2002.

  10.32        Form of Indemnification Agreement between the Registrant and the
               directors and officers of its majority-owned subsidiaries (filed
               as Exhibit 10.1 to the Registrant's Registration Statement on
               Form S-4 [Reg. No. 333-90661] and incorporated in this document
               by reference).

<
                                       20

>
                                  EXHIBIT INDEX

Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

  10.33        Form of Amended and Restated Indemnification Agreement between
               the Registrant and its directors and officers (filed as Exhibit
               10.2 to the Registrant's Registration Statement on Form S-4 [Reg.
               No. 333-90661] and incorporated in this document by reference).

  10.34        Executive Severance Agreement dated as of January 27, 2000,
               between the Registrant and Seth H. Hoogasian.

  10.35        Employment and Consulting Agreement dated as of March 31, 2000,
               between the Registrant and George N. Hatsopoulos (filed as
               Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q
               for the quarter ended April 1, 2000 [File No. 1-8002] and
               incorporated in this document by reference).

  10.36        Transaction Bonus Letter Agreement dated May 18, 2000, between
               the Registrant and Brian D. Holt.

  10.37        Letter agreement dated July 10, 2000, between the Registrant and
               Earl R. Lewis pertaining to his resignation (filed as Exhibit
               10.1 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 1, 2000 [File No. 1-8002] and incorporated in
               this document by reference).

  10.38        Executive Severance Agreement dated as of January 27, 2000, by
               and between the Registrant and Brian D. Holt (filed as Exhibit
               10.2 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended July 1, 2000 [File No. 1-8002] and incorporated in
               this document by reference).

  10.39        Employment Agreement between the Registrant and Marijn Dekkers
               (filed as Exhibit 10.1 to the Registrant's Quarterly Report on
               Form 10-Q for the quarter ended September 30, 2000 [File No.
               1-8002] and incorporated in this document by reference).

  10.40        Amended and Restated Employment Agreement dated as of July 11,
               2000, between the Registrant and Mr. Richard F. Syron (filed as
               Exhibit 10.38 to the Registrant's Annual Report on Form 10-K for
               the fiscal year ended December 30, 2000 [File No. 1-8002] and
               incorporated in this document by reference).

  10.41        Executive Severance Agreement dated January 25, 2001, by and
               between the Registrant and Mr. John T. Keiser (filed as Exhibit
               10.39 to the Registrant's Annual Report on Form 10-K for the
               fiscal year ended December 30, 2000 [File No. 1-8002] and
               incorporated in this document by reference).

  10.42        Employment Offer Letter dated October 3, 2000, between the
               Registrant and Mr. Guy Broadbent (filed as Exhibit 10.40 to the
               Registrant's Annual Report on Form 10-K for the fiscal year ended
               December 30, 2000 [File No. 1-8002] and incorporated in this
               document by reference).

  10.43        Amendment to Amended and Restated Employment Agreement dated as
               of March 14, 2001, between the Registrant and Mr. Richard F.
               Syron (filed as Exhibit 10.41 to the Registrant's Annual Report
               on Form 10-K for the fiscal year ended December 30, 2000 [File
               No. 1-8002] and incorporated in this document by reference).

  10.44        Retention Agreement dated January 31, 2000, between the
               Registrant and Mr. Peter E. Hornstra (filed as Exhibit 10.42 to
               the Registrant's Annual Report on Form 10-K for the fiscal year
               ended December 30, 2000 [File No. 1-8002] and incorporated in
               this document by reference).

<
                                       21

>
                                  EXHIBIT INDEX

Exhibit
Number         Description of Exhibit
--------------------------------------------------------------------------------

  10.45        Plan and Agreement of Distribution dated August 3, 2001, between
               the Registrant and Kadant Inc. (filed as Exhibit 99.3 to the
               Registrant's Current Report on Form 8-K dated August 6, 2001
               [File No. 1-8002] and incorporated in this document by reference).

  10.46        Tax Matters Agreement effective as of August 8, 2001, between the
               Registrant and Kadant Inc. (filed as Exhibit 99.4 to the
               Registrant's Current Report on Form 8-K dated August 6, 2001
               [File No. 1-8002] and incorporated in this document by
               reference).

  10.47        Transition Services Agreement dated August 3, 2001, between the
               Registrant and Kadant Inc. (filed as Exhibit 99.5 to the
               Registrant's Current Report on Form 8-K dated August 6, 2001
               [File No. 1-8002] and incorporated in this document by reference).

  10.48        Amendment to the Plan and Agreement of Distribution dated
               December 27, 2001, between the Registrant and Kadant Inc.

  10.49        Executive Severance Agreement dated as of September 21, 2001, by
               and between the Registrant and Brian D. Holt (filed as Exhibit
               10.1 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended September 29, 2001 [File No. 1-8002] and
               incorporated in this document by reference).

  10.50        Executive Severance Agreement dated as of October 30, 2001, by
               and between the Registrant and Colin Maddix (filed as Exhibit
               10.2 to the Registrant's Quarterly Report on Form 10-Q for the
               quarter ended September 29, 2001 [File No. 1-8002] and
               incorporated in this document by reference).

  10.51        Plan and Agreement of Distribution dated November 15, 2001,
               between the Registrant and Viasys Healthcare Inc. (filed as
               Exhibit 99.2 to the Registrant's Current Report on Form 8-K dated
               November 15, 2001 [File No. 1-8002] and incorporated in this
               document by reference).

  10.52        Tax Matters Agreement dated November 15, 2001, between the
               Registrant and Viasys Healthcare Inc. (filed as Exhibit 99.3 to
               the Registrant's Current Report on Form 8-K dated November 15,
               2001 [File No. 1-8002] and incorporated in this document by
               reference).

  10.53        Transition Services Agreement dated November 15, 2001, between
               the Registrant and Viasys Healthcare Inc. (filed as Exhibit 99.4
               to the Registrant's Current Report on Form 8-K dated November 15,
               2001 [File No. 1-8002] and incorporated in this document by
               reference).

  10.54        Employment Agreement dated as of November 29, 2001, between the
               Registrant and Marc N. Casper.

  10.55        Letter Agreement dated as of November 27, 2001, among SPX
               Corporation, Kendro Laboratory Products, L.P., the Registrant,
               and Marc N. Casper.

  13           Annual Report to Shareholders for the year ended December 29,
               2001 (only those portions incorporated in this document by
               reference).

  21           Subsidiaries of the Registrant.

  23           Consent of Arthur Andersen LLP.


Exhibit 10.48

FIRST AMENDMENT TO
PLAN AND AGREEMENT OF DISTRIBUTION

This first amendment TO THE Plan and Agreement of Distribution (this "Amendment") is made as of the 27th day of December, 2001 by and between Thermo Electron Corporation, a Delaware corporation ("Thermo Electron"), and Kadant Inc., a Delaware corporation ("Kadant"). Capitalized terms used herein without definition shall have the same meanings ascribed to such terms in the Distribution Agreement (as defined below).

RECITALS

WHEREAS, Thermo Electron and Kadant are parties to that certain Plan and Agreement of Distribution dated as of August 3, 2001 (the "Distribution Agreement");

WHEREAS, the parties hereto desire to amend the Distribution Agreement as herein provided:

NOW THEREFORE, in consideration of the covenants and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

1. That Section 9.6(a) of the Distribution Agreement is amended and restated in its entirety to read as follows:

"9.6 Financial Covenants.

(a) Kadant will not, for so long as the guarantee by Thermo Electron of obligations under the Kadant Debentures is outstanding:

(i) permit Net Debt divided by Net Capital to be greater than 40% measured at the end of each fiscal quarter commencing on September 29, 2001; or

(ii) permit the quotient obtained by dividing (x) the sum of EBITA and Interest Income by (y) Interest Expense to be less than 4.0, measured at the end of each fiscal quarter commencing on September 29, 2001 on an annualized basis using the quarter then ended and the previous three quarters.

Notwithstanding the foregoing, in the event that the percentage calculated in paragraph (i) of this Section 9.6 is less than or equal to 20% for any measurement date, the required quotient specified in paragraph (ii) of this
Section 9.6 shall be lowered from 4.0 to 3.0 (measured at the end of each fiscal


quarter on an annualized basis using the quarter then ended and the previous three quarters) for such period."

2. This Amendment and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the laws of the State of Delaware.

3. This Amendment may be executed in counterparts, each of which shall be considered an original, but all of which together shall constitute one and the same agreement.

4. At all times on and after the date hereof, all references in the Distribution Agreement and each of the Ancillary Agreements to the Distribution Agreement shall be deemed to be references to such Distribution Agreement after giving effect to this Amendment.

[REMAINDER OF PAGE INTENTIONALY LEFT BLANK]


IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set forth above.

THERMO ELECTRON CORPORATION

By:     /s/ Kenneth J. Apicerno
        ----------------------------
Name:   Kenneth J. Apicerno
Title:  Treasurer

KADANT INC.

By:     /s/ Thomas M. O'Brien
        ----------------------------
Name:   Thomas M. O'Brien
Title:  Executive Vice President and CFO


Exhibit 10.54

November 29, 2001

Mr. Marc N. Casper
144 Clark Road
Brookline, MA 02445

Dear Marc:

I am pleased to offer you a position as Vice President of Thermo Electron Corporation and President of the Life Sciences Sector of Thermo Electron Corporation, effective November 26, 2001, and subject to the terms of the letter agreement among SPX Corporation ("SPX"), Kendro Laboratory Products, L.P. ("Kendro"), Thermo Electron Corporation ("Thermo Electron"), and you dated November 27, 2001 (the "SPX Letter"). This offer is expressly conditioned on obtaining approval at the next meeting of the Thermo Electron Board of Directors, scheduled to meet on November 29, 2001.

The salary for the position will be at a rate of $300,000 per year, subject to annual review beginning in 2003 as described below. In addition, you will be eligible for an annual incentive award in accordance with Thermo Electron's policies for annual incentives to professional employees. To be eligible for an annual incentive award, you must be actively employed at the end of the incentive period. Your annual reference bonus for purposes of the annual incentive award will be $150,000 (beginning in 2003), with a multiplier of zero to two based on a combination of subjective and objective factors. You will be eligible for review of your compensation package beginning in 2003 at the time Thermo Electron reviews all officers, which is usually in the first quarter.

In addition, you will receive a $200,000 one-time bonus payable in January 2002 with respect to your performance in 2002. Should you voluntarily leave Thermo Electron before January 1, 2003 without good reason (as defined below), you will be responsible for repaying a pro-rated portion of the sign-on bonus to Thermo Electron.

You will receive, upon commencement of employment, a non-statutory option for 275,000 shares, which shares shall vest on a cumulative basis at the rate of one-third per annum on each anniversary date of your employment. Your options will be evidenced by a Stock Option Agreement in the form of Exhibit A attached hereto. Additional stock option grants would be at the discretion of the Thermo Electron Board of Directors.


Mr. Marc N. Casper
November 29, 2001

Page 2

You will be entitled to four weeks vacation each year, accrued in accordance with Thermo Electron's vacation policy, together with such other benefits as are generally made available to professional employees and officers of Thermo Electron, including Thermo Electron's car lease/allowance program and its Executive Medical Supplemental Program.

Under Thermo Electron's car lease/allowance program, you may either (i) have the company lease a company car for you, or (ii) receive a quarterly allowance of $3,124. If you decide to have the company lease a vehicle, you can select the make, model and options as long as the vehicle is appropriate for business use. If the acquisition cost of the car exceeds $26,000, the balance will be deducted from your payroll checks. The sales tax and insurance are paid separately by the company and are not calculated in the $26,000 limit.

Under Thermo Electron's Executive Medical Supplemental Program you will be paid $1,250 quarterly, which you can use to reduce any medical deductible or co-insurance costs that you incur. These funds are for your discretionary use, are not restricted to medical payments, and are taxable income.

You will also be entitled to receive expense reimbursement for legal fees incurred in the negotiation and preparation of this agreement up to the amount of $5,000.

If your employment is terminated by Thermo Electron without cause or by you with good reason, you will be entitled to receive a lump sum severance payment of eighteen months salary in lieu of any other severance benefit, except that if your termination entitles you to greater benefits under any change in control arrangement, you will be entitled to benefits under the change in control arrangement, but not both. Upon commencement of your employment, Thermo Electron will execute and deliver to you an Executive Retention Agreement in the form of Exhibit B attached hereto.

For the purpose of this letter "cause" shall mean: (i) conviction of a felony or any crime involving moral turpitude, or (ii) conduct that constitutes gross neglect or gross misconduct, insubordination, or a willful and deliberate violation of a company rule or regulation that results in material injury to Thermo Electron, and "good reason" shall mean: (i) a material diminution in your duties or responsibilities, (ii) a downgrade in title, (iii) a reduction in your salary, (iv) a change in the reporting structure so that you report to someone other than the Chief Operating Officer, or (v) a change by the company in the location at which you perform your principal duties for the company to a new location that is outside a radius of 50 miles of the company's headquarters in Waltham, Massachusetts.


Mr. Marc N. Casper
November 29, 2001

Page 3

You will be entitled to indemnification if by reason of your status as an officer of Thermo Electron you are made or threatened to be made a party to a legal action, on the terms and conditions set forth in the form of Indemnification Agreement attached hereto as Exhibit C. Thermo Electron will also indemnify you for any liability, loss, cost or expense (including reasonable attorneys fees) that you suffer or incur with respect to actions brought against you by SPX or Kendro for violation of the SPX Letter or the Agreements (referenced in the SPX Letter) that relate to the performance of your duties on behalf of Thermo Electron, including the exercise of any remedies under the SPX Letter or the Agreements, provided that Thermo Electron will control the selection of legal counsel to represent you as well as the defense of such actions and all decisions relating to any proposed settlement thereof.

In accordance with Thermo Electron's standard employment practices, you will be required to sign an agreement covering Thermo Electron's Company Information and Inventions Policy and Drug Testing Policy, as well as an acknowledgment of Thermo Electron's policies related to Business Conduct and Drugs and Alcohol in the Workplace, copies of which are attached hereto as Exhibits D, E, F and G. You will be required to take a drug-screening test for illegal drugs and controlled substances.

Since Thermo Electron's standard policy does not provide for agreements guaranteeing employment for any specific period of time, this offer is not intended to be construed as an employment contract (except as specifically provided herein) and your employment will therefore be "at will." The terms of employment contained in this letter, including "at will" status, may not be altered except by written agreement signed by an officer of Thermo Electron.

Please indicate your acceptance of our offer by signing a copy of this letter and returning it to me. We are looking forward to your joining us.

Sincerely,

THERMO ELECTRON CORPORATION

/s/ Marijn Dekkers
----------------------------------
Marijn Dekkers
President and COO


Mr. Marc N. Casper
November 29, 2001

Page 4

Attachments:

Exhibit A:        Form of Stock Option Agreement
Exhibit B:        Form of Executive Retention Agreement
Exhibit C:        Form of Indemnification Agreement
Exhibit D:        Information and Inventions Policy
Exhibit E:        Drug Testing Policy
Exhibit F:        Business Conduct Policy
Exhibit G:        Drugs and Alcohol in the Workplace

AGREED:

/s/ Marc N. Casper
---------------------------
Marc N. Casper

Date: November 29, 2001
      -----------------------------------------------


Exhibit A

Grant ID # 21-0199
[A/7;POST-7/1/00;D&O]

THERMO ELECTRON CORPORATION

EMPLOYEES EQUITY INCENTIVE PLAN

STOCK OPTION AGREEMENT

Marc N. Casper
Optionee

275,000                                                                 $22.18
Number of Shares of                                               Exercise Price
Common Stock Subject                                                  Per Share
to the Option ("Option Shares")

                                Vesting Schedule
                 # of Shares                            Vesting Date(s)

                one-third of Option Shares              11/30/02
                one-third of Option Shares              11/30/03
                one-third of Option Shares              11/30/04

November 30, 2001                                             November 30, 2008
Grant Date                                                      Expiration Date

Thermo Electron Corporation (the "Company") confirms the grant to you of an option (the "Option") to acquire the number of shares of common stock (the "Common Stock") specified above, of the Company, subject to the provisions of the Employees Equity Incentive Plan (the "Plan") and the terms, conditions and restrictions contained in this agreement (the "Agreement"). You acknowledge receipt of the Plan and the Agreement for your records.

THERMO ELECTRON CORPORATION

By:     /s/ Richard F. Syron
        ------------------------------
        Richard F. Syron
        Chairman and Chief Executive
        Officer

1

THERMO ELECTRON CORPORATION

EMPLOYEES EQUITY INCENTIVE PLAN

Stock Option Agreement

1. Grant of Option. This Stock Option Agreement (the "Agreement") contains the terms and conditions of a grant of a nonqualified stock option to purchase the shares of the common stock of the Company (the "Option Shares") made to you, the Optionee named on the first page of this Agreement, pursuant to the Plan. Attached is a copy of the Plan which is incorporated in this Agreement by reference and made a part hereof. This Option is intended to be a non-statutory stock option under the Internal Revenue Code of 1986, as amended.

2. Exercisability and Vesting of Option. The Option may be exercised only to the extent the Option Shares shall have vested in accordance with this Agreement. The Option Shares will vest and become exercisable in accordance with the schedule set forth on the first page of this Agreement, provided that on each vesting date you are then, and have been since the Grant Date, continuously employed by the Company or an "Affiliated Employer". Notwithstanding the foregoing, you shall become fully vested in the Option Shares prior to the vesting date set forth on the first page of this Agreement in the event of a Change in Control, as that event is defined in the Plan, that occurs prior to the date on which you cease to be an employee of the Company or an Affiliated Employer. The date on which you cease to be an employee of the Company or an Affiliated Employer is defined as your "Employment Termination Date". For purposes of this Agreement, an "Affiliated Employer" shall mean a subsidiary of the Company of which the Company owns more than 50% of the outstanding common stock. Upon your Employment Termination Date, all Option Shares that have not previously vested prior to that date, shall be immediately forfeited to the Company and cancelled.

3. Termination of Option. The date on which the Option shall terminate in whole or in part as provided in this Section 3 is hereinafter referred to as the "Option Termination Date." This Option shall terminate on the date which is the earliest of:

(a) the Expiration Date of the Option set forth on page 1 of this Agreement; or

(b) three months after your Employment Termination Date if the Employment Termination Date occurs for any reason other than the reasons specified in Sections 3(c), 3(d) or 3(e).; or

(c) one year after your Employment Termination Date if the Employment Termination Date occurs by reason of your death or disability. For purposes of this Agreement, "disability" shall mean that you are receiving disability benefits under the Company's Long Term Disability Coverage, as then in effect, on the Employment Termination Date; or

2

(d) two years after your Employment Termination Date if the Employment Termination Date occurs by reason of your retirement. For purposes of this Agreement, (i) if you are a non-employee director of the Company, then "retirement" shall mean the date on which you cease to serve as a director of the Company, and (ii) if you are an employee of the Company or an Affiliated Employer, then "retirement" shall mean the termination of your employment with the Company or an Affiliated Employer after age 55 and the completion of 10 years of continuous service to the Company or an Affiliated Employer comprising at least 20 hours per week; or

(e) the date of the dissolution or liquidation of the Company.

4. No Assignment of Rights. Except for assignments or transfers by will or the applicable laws of descent and distribution, your rights and interests under this Agreement and the Plan may not be assigned or transferred in whole or in part either directly or by operation of law or otherwise, including without limitation by way of execution, levy, garnishment, attachment, pledge or bankruptcy, and no such rights or interests shall be subject to any of your obligations or liabilities.

5. Exercise of Option; Delivery and Deposit of Certificate(s). You (or in the case of your death, your legal representative) may exercise the Option (to the extent the Option Shares have vested) in whole or in part by giving written notice to the Company on the form provided by the Company (the "Exercise Notice") prior to the Option Termination Date, accompanied by full payment for the Option Shares being purchased (a) in cash or by certified or bank cashier's check payable to the order of the Company, in an amount equal to the number of Option Shares being purchased multiplied by the Exercise Price (the "Aggregate Exercise Price"), (b) in unrestricted shares of the Company's Common Stock (the "Tendered Shares") with a market value equal to the Aggregate Exercise Price or
(c) any combination of cash, certified or bank cashier's check or Tendered Shares having a total value equal to the Aggregate Exercise Price (such cash, check or Tendered Shares with such value being referred to as the "Exercise Consideration"). However, Tendered Shares that were acquired directly from the Company may be surrendered as all or part of the Exercise Consideration only if you shall have acquired such Tendered Shares more than six months prior to the date of exercise. Receipt by the Company of the Exercise Notice and the Exercise Consideration shall constitute the exercise of the Option or a part thereof. As soon as reasonably practicable thereafter, the Company shall deliver or cause to be delivered to you a certificate or certificates representing the number of Option Shares purchased, registered in your name.

6. Rights With Respect to Option Shares. Prior to the date the Option is exercised, you shall not be deemed for any purpose to be a stockholder of the Company with respect to any of the Option Shares. Upon initial issuance to you of a certificate or certificates representing Option Shares, you shall have ownership of such Option Shares, including the right to vote and receive dividends, subject, however, to the other restrictions and limitations imposed

3

thereon pursuant to the Plan and this Agreement and which may be now or hereafter imposed by the Certificate of Incorporation or the By-Laws of the Company.

7. Dilution and Other Adjustments. In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, occurring after the date of this Agreement and prior to the exercise in full of the Option, the committee appointed by the Company's Board of Directors to administer the Plan (the "Committee") shall make appropriate adjustments to the number of shares for which the Option may be exercised and the Exercise Price for the Option. In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Committee, (any of the foregoing, a "covered transaction") occuring while the option is outstanding, the Committee in its discretion may (i) accelerate the exercisability of the Option, or (ii) adjust the terms of the Option (whether or not in a manner that complies with the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended (the "Code")), or (iii) if there is a survivor or acquiror entity, provide for the assumption of the Option by such survivor or acquiror or an affiliate thereof or for the grant of one or more replacement options by such survivor or acquiror or an affiliate thereof, in each case on such terms (which may, but need not, comply with the requirements of Section 424(a) of the Code) as the Committee may determine, or (iv) terminate the Option (provided, that if the Committee terminates the Option, it shall, in connection therewith, either (A) accelerate the exercisability of the Option prior to such termination, or (B) provide for a payment to the holder of the Option of cash or other property or a combination of cash or other property in an amount reasonably determined by the Committee to approximate the value of the Option assuming an exercise immediately prior to the transaction, or (C) if there is a survivor or acquiror entity, provide for the grant of one or more replacement options pursuant to clasue (iii) above), or (v) provide for none of, or any combination of, the foregoing. No fraction of a share or fractional shares shall be purchasable or deliverable under this Agreement.

8. Reservation of Shares. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares of the Common Stock as will be sufficient to satisfy the requirements of this Agreement and shall pay all fees and expenses necessarily incurred by the Company in connection with this Agreement and the issuance of Option Shares.

9. Taxes. If the Company, in its sole discretion, determines that the Company or any subsidiary of the Company or any other person has incurred or will incur any liability to withhold any federal, state or local income or other taxes by reason of the grant of the Option, the issuance of Option Shares to you upon the exercise thereof or the lapse of any restrictions upon the Option Shares, you will, promptly upon demand therefor by the Company or any such subsidiary of the Company, pay to the Company or such subsidiary any amount requested by it for the purpose of satisfying such liability. If the amount so requested is not paid promptly, the Company may refuse to permit the issuance to you of Option Shares and may, without further consent by you, have the right to deduct such taxes from any payment of any kind otherwise due to you, the Optionee, including but not limited to, the hold back from the shares to be

4

delivered pursuant to Section 5 of this Agreement of that number of shares calculated to satisfy all federal, state, local or other applicable taxes required to be withheld in connection with such exercise.

You may satisfy the minimum statutory withholding tax requirement (the "Obligation") arising from exercise of all or a part of the Option by making an election (an "Election") to have the Company withhold from the number of shares to be issued upon exercise of the Option, or to otherwise tender to the Company, that number of shares of Common Stock having a value equal to the amount of the Obligation. The value of the shares to be withheld or tendered shall be based upon the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of the Obligation shall be determined (the "Tax Date"). Each Election must be made at the time the Option is exercised or the Tax Date, whichever is later. The Committee may disapprove of any Election or may suspend or terminate the right to make Elections. An Election is irrevocable.

10. Determination of Rights. Any dispute or disagreement that may arise under or as a result of or pursuant to the Plan or this Agreement shall be determined by the committee appointed by the Company's Board of Directors to administer the Plan (the "Committee"), in its sole discretion, and any decision made by the Committee in good faith shall be conclusive on all parties. The interpretation and construction by the Committee of any provision of, and the determination of any question arising under, this Agreement, the Plan, or any rule or regulation adopted pursuant to the Plan, shall be final and conclusive.

11. Limitation of Employment Rights. The Option confers upon you no right to continue in the employ of the Company or an Affiliated Employer or interferes in any way with the right of the Company or an Affiliated Employer to terminate your employment at any time.

12. Communications. Any communication or notice required or permitted to be given under this Agreement shall be in writing, and mailed by registered or certified mail or delivered in hand, if to the Company to its Stock Option Manager c/o Thermo Electron Corporation, 81 Wyman Street, Post Office Box 9046, Waltham, Massachusetts 02454-9046, and if to you, to the address you shall last have furnished to the Company, or such other address, in each case, as the addressee shall have last provided in writing to the communicating party.

5

Exhibit B

EXECUTIVE RETENTION AGREEMENT

THIS AGREEMENT by and between THERMO ELECTRON CORPORATION, a Delaware corporation (the "Company"), and Marc N. Casper (the "Executive") is made as of November 26, 2001 (the "Effective Date").

WHEREAS, the Company recognizes that, as is the case with many publicly-held corporations, the possibility of a change in control of the Company exists and that such possibility, and the uncertainty and questions which it may raise among key personnel, may result in the departure or distraction of key personnel to the detriment of the Company and its stockholders; and

WHEREAS, the Board of Directors of the Company (the "Board") has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the Company's key personnel without distraction from the possibility of a change in control of the Company and related events and circumstances.

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in its employ, the Company agrees that the Executive shall receive the severance benefits set forth in this Agreement in the event the Executive's employment with the Company is terminated under the circumstances described below subsequent to a Change in Control (as defined in Section 1.1).

1. Key Definitions.

As used herein, the following terms shall have the following respective meanings:

1.1 "Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation

1

controlled by the Company, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.1; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term "Continuing Director" means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.2 "Change in Control Date" means the first date during the Term (as defined in Section 2) on which a Change in Control occurs. Anything in this

2

Agreement to the contrary notwithstanding, if (a) a Change in Control occurs,
(b) the Executive's employment with the Company is terminated prior to the date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change in Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then for all purposes of this Agreement the "Change in Control Date" shall mean the date immediately prior to the date of such termination of employment.

1.3 "Cause" means the Executive's willful engagement in illegal conduct or gross misconduct after the Change in Control Date which is materially and demonstrably injurious to the Company. For purposes of this Section 1.3, no act or failure to act by the Executive shall be considered "willful" unless it is done, or omitted to be done, in bad faith and without reasonable belief that the Executive's action or omission was in the best interests of the Company.

1.4 "Good Reason" means the occurrence, without the Executive's written consent, of any of the events or circumstances set forth in clauses (a) through (g) below. Notwithstanding the occurrence of any such event or circumstance, such occurrence shall not be deemed to constitute Good Reason if, prior to the Date of Termination specified in the Notice of Termination (each as defined in Section 3.2(a)) given by the Executive in respect thereof, such event or circumstance has been fully corrected and the Executive has been reasonably compensated for any losses or damages resulting therefrom (provided that such right of correction by the Company shall only apply to the first Notice of Termination for Good Reason given by the Executive).

(a) the assignment to the Executive of duties inconsistent in any material respect with the Executive's position (including status, offices, titles and reporting requirements), authority or responsibilities in effect immediately prior to the earliest to occur of (i) the Change in Control Date,
(ii) the date of the execution by the Company of the initial written agreement or instrument providing for the Change in Control or (iii) the date of the adoption by the Board of Directors of a resolution providing for the Change in Control (with the earliest to occur of such dates referred to herein as the "Measurement Date") or a material diminution in such position, authority or responsibilities;

(b) a reduction in the Executive's annual base salary as in effect on the Measurement Date or as the same was or may be increased thereafter from time to time;

(c) the failure by the Company to (i) continue in effect any material compensation or benefit plan or program (including without limitation any life insurance, medical, health and accident or disability plan and any vacation or automobile program or policy) (a "Benefit Plan") in which the Executive participates or which is applicable to the Executive immediately prior to the Measurement Date, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or program, (ii) continue the Executive's participation therein (or in such substitute or alternative plan) on a basis not materially less favorable than

3

the basis existing immediately prior to the Measurement Date (iii) award cash bonuses to the Executive in amounts and in a manner substantially consistent with past practice in light of the Company's financial performance or (iv) continue to provide any material fringe benefit enjoyed by Executive immediately prior to the Measurement Date;

(d) a change by the Company in the location at which the Executive performs his or her principal duties for the Company to a new location that is both (i) outside a radius of 50 miles from the Executive's principal residence immediately prior to the Measurement Date and (ii) more than 30 miles from the location at which the Executive performed his or her principal duties for the Company immediately prior to the Measurement Date; or a requirement by the Company that the Executive travel on Company business to a substantially greater extent than required immediately prior to the Measurement Date;

(e) the failure of the Company to obtain the agreement from any successor to the Company to assume and agree to perform this Agreement, as required by Section 6.1;

(f) a purported termination of the Executive's employment which is not effected pursuant to a Notice of Termination satisfying the requirements of Section 3.2(a); or

(g) any failure of the Company to pay or provide to the Executive any portion of the Executive's compensation or benefits due under any Benefit Plan within seven days of the date such compensation or benefits are due, or any material breach by the Company of this Agreement or any employment agreement with the Executive.

The Executive's right to terminate his or her employment for Good Reason shall not be affected by the Executive's incapacity due to physical or mental illness.

1.5 "Disability" means the Executive's absence from the full-time performance of the Executive's duties with the Company for 180 consecutive calendar days as a result of incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive's legal representative.

2. Term of Agreement. This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) if a Change in Control has not occurred during the Term, (b) the date 18 months after the Change in Control Date, if the Executive is still employed by the Company as of such later date, or (c) the fulfillment by the Company of all of its obligations under Sections 4 and 5.2 if the Executive's employment with the

4

Company terminates within 18 months following the Change in Control Date. "Term" shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2003; provided, however, that commencing on January 1, 2003 and each January 1, thereafter, the Term shall be automatically extended for one additional year unless, not later than 90 days prior to the scheduled expiration of the Term (or any extension thereof), the Company shall have given the Executive written notice that the Term will not be extended.

3. Employment Status; Termination Following Change in Control.

3.1 Not an Employment Contract. The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time. If the Executive's employment with the Company terminates for any reason and subsequently a Change in Control shall occur, the Executive shall not be entitled to any benefits hereunder except as otherwise provided pursuant to
Section 1.2.

3.2 Termination of Employment.

(a) If the Change in Control Date occurs during the Term, any termination of the Executive's employment by the Company or by the Executive within 18 months following the Change in Control Date (other than due to the death of the Executive) shall be communicated by a written notice to the other party hereto (the "Notice of Termination"), given in accordance with Section 7. Any Notice of Termination shall: (i) indicate the specific termination provision (if any) of this Agreement relied upon by the party giving such notice, (ii) to the extent applicable, set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (iii) specify the Date of Termination (as defined below). The effective date of an employment termination (the "Date of Termination") shall be the close of business on the date specified in the Notice of Termination (which date may not be less than 15 days or more than 120 days after the date of delivery of such Notice of Termination), in the case of a termination other than one due to the Executive's death, or the date of the Executive's death, as the case may be. In the event the Company fails to satisfy the requirements of Section 3.2(a) regarding a Notice of Termination, the purported termination of the Executive's employment pursuant to such Notice of Termination shall not be effective for purposes of this Agreement.

(b) The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting any such fact or circumstance in enforcing the Executive's or the Company's rights hereunder.

5

(c) Any Notice of Termination for Cause given by the Company must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Cause. Prior to any Notice of Termination for Cause being given (and prior to any termination for Cause being effective), the Executive shall be entitled to a hearing before the Board of Directors of the Company at which the Executive's may, at the Executive's election, be represented by counsel and at which the Executive shall have a reasonable opportunity to be heard. Such hearing shall be held on not less than 15 days prior written notice to the Executive stating the Board of Directors' intention to terminate the Executive for Cause and stating in detail the particular event(s) or circumstance(s) which the Board of Directors believes constitutes Cause for termination.

(d) Any Notice of Termination for Good Reason given by the Executive must be given within 90 days of the occurrence of the event(s) or circumstance(s) which constitute(s) Good Reason.

4. Benefits to Executive.

4.1 Stock Acceleration. If the Change in Control Date occurs during the Term, then, effective upon the Change in Control Date, (a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive shall become immediately exercisable in full and will no longer be subject to a right of repurchase by the Company and (b) each outstanding restricted stock award shall be deemed to be fully vested and will no longer be subject to a right of repurchase by the Company.

4.2 Compensation. If the Change in Control Date occurs during the Term and the Executive's employment with the Company terminates within 18 months following the Change in Control Date, the Executive shall be entitled to the following benefits:

(a) Termination Without Cause or for Good Reason. If the Executive's employment with the Company is terminated by the Company (other than for Cause, Disability or Death) or by the Executive for Good Reason within 18 months following the Change in Control Date, then the Executive shall be entitled to the following benefits:

(i) the Company shall pay to the Executive in a lump sum in cash within 30 days after the Date of Termination the aggregate of the following amounts:

(1) the sum of (A) the Executive's base salary through the Date of Termination, (B) the product of (x) the annual bonus paid or payable (including any bonus or portion thereof which has been earned but deferred) for the most recently completed fiscal year and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365 and (C) the amount of any compensation previously deferred by the Executive (together with any accrued

6

interest or earnings thereon) and any accrued vacation pay, in each case to the extent not previously paid (the sum of the amounts described in clauses (A), (B), and (C) shall be hereinafter referred to as the "Accrued Obligations"); and

(2) the amount equal to the sum of (x) the Executive's highest annual base salary in any twelve-month period (on a rolling basis) during the five-year period prior to the Change in Control Date and (y) the Executive's highest annual bonus in any twelve-month period (on a rolling basis) during the five-year period prior to the Change in Control Date.

(ii) for one year after the Date of Termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue to provide benefits to the Executive and the Executive's family at least equal to those which would have been provided to them if the Executive's employment had not been terminated, in accordance with the applicable Benefit Plans in effect on the Measurement Date or, if more favorable to the Executive and the Executive's family, in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies; provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., health insurance benefits) from such employer on terms at least as favorable to the Executive and the Executive's family as those being provided by the Company, then the Company shall no longer be required to provide those particular benefits to the Executive and the Executive's family;

(iii) to the extent not previously paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"); and

(iv) for purposes of determining eligibility (but not the time of commencement of benefits) of the Executive for retiree benefits to which the Executive is entitled, the Executive shall be considered to have remained employed by the Company until one year after the Date of Termination.

(b) Resignation without Good Reason; Termination for Death or Disability. If the Executive voluntarily terminates his or her employment with the Company within 18 months following the Change in Control Date, excluding a termination for Good Reason, or if the Executive's employment with the Company is terminated by reason of the Executive's death or Disability within 18 months following the Change in Control Date, then the Company shall (i) pay the Executive (or the Executive's estate, if applicable), in a lump sum in cash within 30 days after the Date of Termination, the Accrued Obligations and (ii) timely pay or provide to the Executive the Other Benefits.

7

(c) Termination for Cause. If the Company terminates the Executive's employment with the Company for Cause within 18 months following the Change in Control Date, then the Company shall (i) pay the Executive, in a lump sum in cash within 30 days after the Date of Termination, the sum of (A) the Executive's annual base salary through the Date of Termination and (B) the amount of any compensation previously deferred by the Executive, in each case to the extent not previously paid, and (ii) timely pay or provide to the Executive the Other Benefits.

4.3 Taxes.

(a) In the event that the Company undergoes a "Change in Ownership or Control" (as defined below), and thereafter, the Executive becomes eligible to receive "Contingent Compensation Payments" (as defined below) the Company shall, as soon as administratively feasible after the Executive becomes so eligible determine and notify the Executive (with reasonable detail regarding the basis for its determinations) (i) which of the payments or benefits due to the Executive following such Change in Ownership or Control constitute Contingent Compensation Payments, (ii) the amount, if any, of the excise tax (the "Excise Tax") payable pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the "Code"), by the Executive with respect to such Contingent Compensation Payment and (iii) the amount of the "Gross-Up Payment" (as defined below) due to the Executive with respect to such Contingent Compensation Payment. Within 30 days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the "Executive Response") stating either (A) that the Executive agrees with the Company's determination pursuant to the preceding sentence or (B) that the Executive disagrees with such determination, in which case the Executive shall indicate which payment and/or benefits should be characterized as a Contingent Compensation Payment, the amount of the Excise Tax with respect to such Contingent Compensation Payment and the amount of the Gross-Up Payment due to the Executive with respect to such Contingent Compensation Payment. If the Executive states in the Executive Response that the Executive agrees with the Company's determination, the Company shall make the Gross-Up Payment to the Executive within three business days following delivery to the Company of the Executive Response. If the Executive states in the Executive Response that the Executive disagrees with the Company's determination, then, for a period of 15 days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute. If such dispute is not resolved within such 15-day period, such dispute shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction. The Company shall, within three business days following delivery to the Company of the Executive Response, make to the Executive those Gross-Up Payments as to which there is no dispute between the Company and the Executive regarding whether they should be made. The balance of the Gross-Up Payments shall be made within three business days following the resolution of such dispute. The amount of any payments to be made to the Executive following the resolution of such dispute shall be increased by

8

the amount of the accrued interest thereon computed at the prime rate announced from time to time by The Wall Street Journal compounded monthly from the date that such payments originally were due. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company's initial determination shall be final.

(b) For purposes of this Section 4.3, the following terms shall have the following respective meanings:

(i) "Change in Ownership or Control" shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with
Section 280G(b)(2) of the Code.

(ii) "Contingent Compensation Payment" shall mean any payment (or benefit) in the nature of compensation that is made or supplied to a "disqualified individual" (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.

(iii) "Gross-Up Payment" shall mean an amount equal to the sum of (i) the amount of the Excise Tax payable with respect to a Contingent Compensation Payment and (ii) the amount necessary to pay all additional taxes imposed on (or economically borne by) the Executive (including the Excise Taxes, state and federal income taxes and all applicable withholding taxes) attributable to the receipt of such Gross-Up Payment. For purposes of the preceding sentence, all taxes attributable to the receipt of the Gross-Up Payment shall be computed assuming the application of the maximum tax rates provided by law.

4.4 Outplacement Services. In the event the Executive is terminated by the Company (other than for Cause, Disability or Death), or the Executive terminates employment for Good Reason, within 18 months following the Change in Control Date, the Company shall provide outplacement services through one or more outside firms of the Executive's choosing up to an aggregate of $15,000, with such services to extend until the earlier of (i) 12 months following the termination of Executive's employment or (ii) the date the Executive secures full time employment.

4.5 Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in this Section 4 by seeking other employment or otherwise. Further, except as provided in Section 4.2(a)(ii), the amount of any payment or benefits provided for in this Section 4 shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

9

5. Disputes.

5.1 Settlement of Disputes; Arbitration. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board of Directors of the Company and shall be in writing. Any denial by the Board of Directors of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board of Directors shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim. Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

5.2 Expenses. The Company agrees to pay as incurred, to the full extent permitted by law, all legal, accounting and other fees and expenses which the Executive may reasonably incur as a result of any claim or contest (regardless of the outcome thereof) by the Company, the Executive or others regarding the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Code.

6. Successors.

6.1 Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a breach of this Agreement and shall constitute Good Reason if the Executive elects to terminate employment, except that for purposes of implementing the foregoing, the date on which any such succession becomes effective shall be deemed the Date of Termination. As used in this Agreement, "Company" shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

6.2 Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or the Executive's family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

10

7. Notice. All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 81 Wyman Street, Waltham, Massachusetts and to the Executive at the Executive's principal residence as currently reflected on the Company's records (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.

8. Miscellaneous.

8.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

8.2 Injunctive Relief. The Company and the Executive agree that any breach of this Agreement by the Company is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

8.3 Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.4 Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

8.5 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

8.6 Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

8.7 Entire Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any

11

officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled.

8.8 Amendments. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

THERMO ELECTRON CORPORATION

By:     /s/ Seth H. Hoogasian
        ---------------------------------
Name:   Seth H. Hoogasian
Title:  Vice President, General Counsel and
        Secretary

EXECUTIVE

/s/ Marc N. Casper
-----------------------------------
Marc N. Casper

11

Exhibit C
THERMO ELECTRON CORPORATION

INDEMNIFICATION AGREEMENT

This Agreement, made and entered into as of the 26th day of November 2001, ("Agreement"), by and between Thermo Electron Corporation, a Delaware corporation (the "Company"), and Marc N. Casper ("Indemnitee"):

WHEREAS, highly competent persons are becoming more reluctant to serve publicly-held corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to, and activities on behalf of, the corporation;

WHEREAS, uncertainties relating to the continued availability of adequate directors and officers liability insurance ("D&O Insurance") and uncertainties relating to indemnification have increased the difficulty of attracting and retaining such persons;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that the difficulty in attracting and retaining such persons is detrimental to the best interests of the Company's stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

WHEREAS, it is reasonable, prudent and necessary for the Company to obligate itself contractually to indemnify such persons so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

WHEREAS, Indemnitee is willing to serve, continue to serve and/or take on additional service for or on behalf of the Company on the condition that he or she be so indemnified and that such indemnification be so guaranteed;

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

1. Services by Indemnitee. Indemnitee agrees to serve or continue to serve as a director or officer of the Company. This Agreement shall not impose any obligation on Indemnitee or the Company to continue Indemnitee's position with the Company beyond any period otherwise applicable.

2. Indemnity. The Company shall indemnify, and shall advance Expenses (as hereinafter defined) to, Indemnitee as provided in this Agreement and to the fullest extent permitted by law.

3. General. Indemnitee shall be entitled to the rights of indemnification provided in this Section 3 if, by reason of his or her Corporate Status (as hereinafter defined), Indemnitee is, or is threatened to be made, a party to any threatened, pending, or completed action, suit, arbitration, alternative dispute


resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative (other than an action, suit or proceeding covered by Section 4 hereof). Pursuant to this Section 3, Indemnitee shall be indemnified against Expenses, judgments, penalties, fines and/or amounts paid in settlement incurred by Indemnitee or on his or her behalf in connection with such action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative or any claim, issue or matter therein and whether or not Indemnitee is made a party thereto, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

4. Proceedings by or in the Right of the Company. In the case of any threatened, pending or completed action, suit or proceeding by or in the right of the Company, indemnification shall be made to the maximum extent permitted under Delaware law.

5. Indemnification for Expenses of a Party who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a party to and is successful, on the merits or otherwise, in any action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative, Indemnitee shall be indemnified against all Expenses incurred by Indemnitee or on his or her behalf in connection therewith. If Indemnitee is not wholly successful but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative, the Company shall indemnify Indemnitee against all Expenses incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter by dismissal, or withdrawal with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

6. Advance of Expenses. The Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding involving his or her Corporate Status whether civil, criminal, administrative or investigative within twenty (20) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to

2

repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses, which undertaking shall be accepted by or on behalf of the Company without reference to the financial ability of Indemnitee to make repayment.

7. Procedure for Determination of Entitlement to Indemnification.

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.

(b) Upon written request by Indemnitee for indemnification pursuant to
Section 7(a) hereof, a determination, if required (but only to the extent required) by applicable law as a precondition to payment, with respect to Indemnitee's entitlement thereto shall be made in the specific case: (i) if a Change in Control (as hereinafter defined) shall have occurred, by Independent Counsel (as hereinafter defined) in a written opinion to the Board, a copy of which shall be delivered to Indemnitee (unless Indemnitee shall request that such determination be made by the Board or the stockholders, in which case the determination shall be made in the manner provided below in clauses (ii) or
(iii)); (ii) if a Change of Control shall not have occurred, (A) by the Board by a majority vote of Disinterested Directors (as hereinafter defined), even if less than a quorum, or (B) by a committee of Disinterested Directors designated by a majority vote of Disinterested Directors, even if less than a quorum, or
(C) if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) by the stockholders of the Company; or (iii) as provided in Section 8(b) of this Agreement; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee's entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorney's fees and disbursements) incurred by Indemnitee in so cooperating shall be borne by the Company (irrespective of the determination as to Indemnitee's entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

(c) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 7(b) of this Agreement, the Independent Counsel shall be selected as provided in this Section 7(c). If a Change of Control shall not have occurred, the Independent Counsel shall be

3

selected by the Board, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change of Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within seven (7) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection. Such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel" as defined in Section 14 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. If such written objection is made, the Independent Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without merit. If, within twenty
(20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 7(a) hereof, no Independent Counsel shall have been selected or if selected, shall have been objected to, in accordance with this Section 7(c), either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom an objection is favorably resolved or the person so appointed shall act as Independent Counsel under Section 7(b) hereof. The Company shall pay reasonable fees and expenses of Independent Counsel incurred in connection with its acting in such capacity pursuant to Section 7(b) hereof. The Company shall pay any and all reasonable fees and expenses incident to the procedures of this Section
7(c), regardless of the manner in which such Independent Counsel was selected or appointed. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 9(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

8. Presumptions and Effect of Certain Proceedings.

(a) If a Change of Control shall have occurred, in making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 7(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption.

(b) If the person, persons or entity empowered or selected under Section 7 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made such determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement

4

to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 8(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 7(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within one hundred twenty (120) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within one hundred five
(105) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 7(b) of this Agreement.

(c) The termination of any action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or other proceeding whether civil, criminal, administrative or investigative or of any claim, issue or matter therein by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.

9. Remedies of Indemnitee.

(a) In the event that (i) a determination is made pursuant to Section 7 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 6 of this Agreement, (iii) the determination of entitlement to indemnification is to be by Independent Counsel pursuant to Section 7(b) of this Agreement and such determination shall not have been made and delivered in a written opinion within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5 of this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to
Section 8 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of Indemnitee's entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 9(a). The Company shall not oppose Indemnitee's right to seek any such adjudication or award in arbitration.

(b) In the event that a determination shall have been made pursuant to
Section 7 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 9

5

shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. If a Change of Control shall have occurred, in any judicial proceeding or arbitration commenced pursuant to this Section 9 the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.

(c) If a determination shall have been made or deemed to have been made pursuant to Section 7 or 8 of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 9, absent
(i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee's statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 9 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

(e) In the event that Indemnitee, pursuant to this Section 9, seeks a judicial adjudication of or an award in arbitration to enforce Indemnitee's rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all expenses (of the types described in the definition of Expenses in Section 14 of this Agreement) actually and reasonably incurred by him or her in such judicial adjudication or arbitration, but only if Indemnitee prevails therein. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or advancement of expenses sought, the expenses incurred by Indemnitee in connection with such judicial adjudication or arbitration shall be appropriately prorated.

6

10. Security. To the extent requested by Indemnitee and approved by the Board, the Company shall at any time and from time to time provide security to Indemnitee for the Company's obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.

11. Non-Exclusivity; Duration of Agreement; Insurance; Subrogation.

(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement are in addition to and shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company's certificate of incorporation or by-laws, any other agreement, a vote of stockholders or a resolution of directors, or otherwise. Without limiting the foregoing, the Company shall indemnify Indemnitee to the fullest extent permitted under Delaware law. This Agreement shall continue until and terminate upon the later of (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or director, officer or other fiduciary of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which Indemnitee served at the request of the Company; or (b) the final termination of all pending actions, suits, arbitrations, alternative dispute resolution proceedings, investigations, administrative hearings or other proceedings whether civil, criminal, administrative or investigative in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 9 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators.

(b) To the extent that the Company maintains D&O Insurance, Indemnitee shall be covered by such D&O Insurance in accordance with its terms to the maximum extent of the coverage available for any director or officer under such policy or policies.

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

12. Severability; Reformation. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any
Section of this Agreement containing any such provision held to be invalid,

7

illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

13. Exception to Right of Indemnification or Advancement of Expenses. Notwithstanding any other provision of this Agreement, Indemnitee shall not be entitled to indemnification or advancement of Expenses under this Agreement with respect to any action, suit or proceeding, or any claim therein, initiated, brought or made by Indemnitee (i) against the Company, unless a Change in Control shall have occurred, or (ii) against any person other than the Company, unless approved in advance by the Board.

14. Definitions. For purposes of this Agreement:

(a) "Change in Control" means an event or occurrence set forth in any one or more of subsection (i) through (iv) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (A) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (B) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (A) any acquisition by the Company, (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (C) any acquisition by any corporation pursuant to a transaction which complies with clauses (A) and (B) of subsection (iii) of this Section 14(a); or

(ii) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term "Continuing Director" means at any date a member of the Board (A) who was a member of the Board on September 23, 1999 or (B) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded form this clause (B) any

8

individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(iii) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (A) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(iv) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company; or

(b) "Corporate Status" describes the status of a person who is or was or has agreed to become a director of the Company, or is or was an officer or fiduciary of the Company or a director, officer or fiduciary of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company.

(c) "Disinterested Director" means a director of the Company who is not and was not a party to the action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative in respect of which indemnification is sought by Indemnitee.

9

(d) "Expenses" shall include all reasonable attorneys' fees, retainers, court costs, transcript costs, fees and expenses of experts, including but not limited to fees and expenses of investment bankers and/or consultants which the Company has authorized Indemnitee to hire and attorneys for such experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, deliver service fees, a reasonable per diem fee to compensate Indemnitee for his or her professional time and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend or investigating an action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative.

(e) "Independent Counsel" means a law firm, with over 100 lawyers, that is experienced in matters of corporation law and neither currently is, nor in the past five years has been, retained to represent: (i) the Company (including any subsidiary thereof) or Indemnitee in any matter material to either such party or
(ii) any other party to the action, suit, arbitration, alternative dispute resolution proceeding, investigation, administrative hearing or any other proceeding whether civil, criminal, administrative or investigative giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement.

15. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

16. Modification and Waiver. This Agreement may be amended from time to time to reflect changes in Delaware law or for other reasons. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

17. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any matter which may be subject to indemnification or advancement of Expenses covered hereunder; provided, however, that the failure to give any such notice shall not disqualify Indemnitee from indemnification hereunder.

18. Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

10

(a) If to Indemnitee, to: The address shown beneath his or her signature on the last page hereof

(b) If to the Company to: Thermo Electron Corporation 81 Wyman Street P.O. Box 9046 Waltham, MA 02454-9046 Attn: Corporate Secretary

or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

19. Governing Law. The parties agree that this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware.

20. Entire Agreement. This agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

Attest: THERMO ELECTRON CORPORATION

By:     /s/ Sheila J. Moylan            By:     /s/ Seth H. Hoogasian
      -----------------------           ----------------------------------------
                                        Name:   Seth H. Hoogasian
                                        Title:  Vice President, General Counsel
                                                and Secretary

INDEMNITEE

/s/ Marc N. Casper
----------------------------------------
Marc N. Casper
Address:  144 Clark Road
          Brookline, MA  02445

11

Exhibit D

Thermo Electron Corporation [logo]

COMPANY INFORMATION AND INVENTION AGREEMENT

In consideration and as a condition of my employment, or if now employed, the continuation of my employment by Thermo Electron Corporation or a subsidiary thereof (hereinafter collectively called the "Company") and the compensation paid therefor:

1. I agree not to disclose to others or use for my own benefit during my employment by the Company or thereafter any trade secrets or Company private information pertaining to any of the actual or anticipated business of the Company or any of its customers, consultants, or licensees acquired by me during the period of my employment, except to such an extent as may be necessary in the ordinary course of performing my particular duties as an employee of the Company.

2. I agree not to disclose to the Company, or to induce the Company to use, any confidential information or material belonging to others.

3. I understand that the making of inventions, improvements, and discoveries is one of the incidents of my employment, or that if not I may nonetheless make inventions while employed by the Company, and I agree to assign to Thermo Electron Corporation or its nominee my entire right, title, and interest in any invention, idea, device, or process, whether patentable or not, hereafter made or conceived by me solely or jointly with others during the period of my employment by the Company in an executive, managerial, planning, technical, research, engineering, or other capacity and which relates in any manner to the business of the Company, or relates to its actual or planned research or development, or is suggested or results from any task assigned to me or work performed by me for or in behalf of the Company, except any invention or idea which cannot be assigned by the Company because of a prior agreement with ___none___________________ effective until __________________________ (give name and date or write "none").

4. I agree, in connection with any invention, idea, device, or process covered by paragraph 3:

a) To disclose it promptly in writing to the proper officers or attorney of the Company.

b) To execute promptly, on request, patent applications and assignments thereof to Thermo Electron or its nominees and to assist the Company in any reasonable manner to enable it to secure a patent therefor in the United States and any foreign countries, all without further compensation except as provided herein.


5. I further agree that all papers and records of every kind relating to any invention or improvement included with the terms of the Agreement, which shall at any time come into my possession shall be the sole and exclusive property of the Company and shall be surrendered to the Company or upon request at any other time either during or after the termination of such employment.

6. I further agree that the obligations and undertakings stated above in paragraph 4b shall continue beyond the termination of my employment by the Company, but if I am called upon to render such assistance after the termination of my employment, then I shall be entitled to a fair and reasonable per diem in addition to reimbursement of any expenses incurred at the request of the Company.

7. I agree to identify in an attachment to this Agreement all inventions or ideas related to the business or actual or planned research or development of the Company in which I have right, title, or interest, and which were conceived either wholly or in part by me prior to my employment by the Company but neither published nor filed in the U.S. Patent and Trademark Office.

8. I understand that this Agreement supersedes any agreement previously executed by me relating to the disclosure, assignment and patenting of inventions, improvements, and discoveries made during my employment by the Company. This Agreement shall inure to the benefits of the successors and assigns of the Company and shall be binding upon my heirs, assigns, administrators, and representatives.

9. I understand that this Agreement does not apply to an invention which qualifies fully under the provisions of any statute or regulation which renders unenforceable the required assignment or transfer of certain inventions made by an employee such as, but not limited to, Section 2870 of the California Labor Code.

                                        /s/ Marc N. Casper
                                        -----------------------------------
                                        Employee

/s/ Sheila J. Moylan                    November 29, 2001
-----------------------                 -----------------------------------
Witness                                          Date

                                       THERMO ELECTRON CORPORATION


/s/ Sheila J. Moylan                    By:     /s/ Seth H. Hoogasian
-----------------------                 -----------------------------------
Witness                                 Vice President, General Counsel and
                                        Secretary

                                        Date:   November 29, 2001


Exhibit E Thermo Electron Corporation [logo]

Thermo Electron Corporation Corporate Office Pre-employment Drug Testing Policy

At Thermo Electron Corporation, we are committed to providing a productive, safe, and drug free workplace for our employees. As a result, an employment offer is conditional upon an applicant's passing a pre-employment examination, which includes the collection and testing of the applicant's urine specimen for illegal drugs or controlled substances. Failure to pass the test will result in rejection for employment.

The major drug and drug categories tested for include: amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methaqualone, opiates, phencyclidine, and propoxyphene. The testing is performed by a reputable clinical laboratory accredited by the College of American Pathologist (CAP). Comprehensive and strict procedures have been established to safeguard confidentiality and privacy for prospective employees. When an initial test result is positive (failing), two additional tests, (using the original specimen) will be performed to confirm the test results.

The Human Resources department will notify applicants regarding the status of their pre-employment medical examination. Applicants who receive conditional employment offers are advised against giving notice to their current employer until medical clearance has been received. Applicants who do not pass the drug-screening test will be informed that they cannot be considered for employment.


I have read the foregoing and hereby authorize any company designated medical examiner to conduct a drug screening test and provide the results to the company, and I release the company and any designated institution or person from any liability resulting from the medical examination.

Applicant's Name: Marc N. Casper

Signature: /s/ Marc N. Casper   Date:  11/21/01
           ------------------          -------------

Witness:   /s/ Sheila J. Moylan
           ------------------------


                                                                       Exhibit F
                            --------------------------------------
[Thermo Electron
Corporation logo]     Title:  Business Conduct                Policies &
                              Policy                          Procedures

-------------------------------------------------------------------------------
 Supersedes:          Date: March 26, 1999                    Total Pages:
 July 1, 1988                                                         4
                            No.
-------------------------------------------------------------------------------

BUSINESS CONDUCT POLICY

POLICY

It is the policy of Thermo Electron Corporation ("Thermo Electron" or the "Company") to (i) require the highest standards of business ethics and integrity on the part of all employees and (ii) to comply with all applicable laws and regulations in the conduct of its business. To that end, Thermo Electron has adopted and implemented this Business Conduct Policy.

The Company's management will vigorously enforce this Policy and will take prompt and appropriate action, which could include termination, against any employee found to be in violation.

The manager of each Thermo Electron operating unit is responsible for providing every employee in his or her operating unit with a copy of the Business Conduct Policy and establishing reasonable procedures to promote compliance with such policy.

SCOPE

This policy applies to Thermo Electron Corporation and all of its worldwide divisions, subsidiaries and affiliated companies.


I. CONFLICTS OF INTEREST

All employees are required to avoid any relationship with other individuals or organizations that might impair, or even appear to impair, the proper performance of their Company-related responsibilities. Employees must avoid any situation that might affect their independence of judgment with respect to any business dealings between the Company and any other organization or individual. Any employee who believes that he or she may have such a conflict, whether actual or potential, or who is aware of any conflict involving any other Company employee, must report all pertinent details to his or her Division or other corporate supervisor. A conflict of interest situation can arise in many ways, some of which are set forth below.

A. Related-Party Transactions

Related-party transactions are those in which the parties do not deal with one another at arm's length. They include, but are not limited to, any employee of the Company who is in a position to influence a business transaction between the Company and: (1) an individual who is his or her spouse, child, sibling, parent, partner, present or former close business associate; (2) a non-Company organization for which he or she currently serves as an officer, trustee or partner, or for which he or she has recently served in such capacity; or (3) any individual or organization with whom he or she is negotiating, or with whom he or she has an arrangement, concerning prospective employment.

The Company should avoid significant related-party transactions. If any employee believes that a significant related-party transaction exists or might occur, he or she must make full disclosure to the appropriate executive. After such full disclosure, the existing or potential conflict will be reviewed, and a decision will be made about whether the related-party transaction is appropriate, and whether the Company should proceed with the transaction.

B. Outside Business Interests

Employees are expected to give their full and undivided attention to their Company duties. They should not use Company facilities or their association with the Company to carry on a private business or profession. Unless express approval is obtained in advance from his or her direct supervisor, employees shall not engage in a profit-making business, or become involved with a nonprofit organization, outside of their employment with the Company, if such business or organization:

o Provides goods, services or assistance to a competitor, customer or supplier of the Company; or

o Interferes with the employee's assigned duties at the Company.

2

C. Acceptance of Costly Entertainment or Gifts

Employees are prohibited from accepting or giving costly entertainment or gifts from or to suppliers, competitors or customers; such situations may create either a conflict or the appearance of a conflict between the interests of the employee and the Company. Where acceptance of such a gift is unavoidable because of local custom, the employee must report the matter to his or her direct supervisor so a determination can be made concerning the extent to which such a gift can be considered the personal property of the recipient.

D. Confidential Business Information

Confidential business information is information acquired by Company employees as a result of their position with the Company, which pertains to the Company, and which has not been disclosed to the public. The Company has proprietary rights to such confidential business information. Therefore, employees are prohibited from using such confidential business information for their financial gain, for the financial gain of any other person, or to obtain a benefit of any kind.

All Company employees are prohibited from engaging, or assisting others in engaging, in any transactions involving the securities of the Company, or the securities of any other entity with whom the Company is engaged, or with whom it will be engaged, in a business transaction, while in possession of any material confidential information about the Company or the other entity. Such acts may constitute violations of the law and could result in criminal prosecution of the individual and the Company, or result in serious fines or penalties.

II. COMPLIANCE WITH LAWS

All Company employees are prohibited from engaging in any transaction or matter on behalf of the Company which would violate any applicable law or regulation.

III. USE OF COMPANY FUNDS

The use of Company funds for any unlawful or unethical purpose is strictly prohibited. Employees are prohibited from making, or causing others to make, any illegal payment to anyone within the United States, or to any officials of any foreign government, including for the purpose of advancing, promoting or expediting Company interests. Such prohibited payments include money, favors, gifts, entertainment, or use of Company facilities. Similarly, all employees also must be careful that any acts of hospitality toward public officials and Government employees avoid compromising the integrity or the reputation of the Company or the public official or Government employee.

IV. POLITICAL CONTRIBUTIONS

Political contributions to U.S. federal election campaigns made directly or indirectly from Company funds are prohibited. The legality of political

3

contributions to state, local or foreign campaigns or causes must be determined on a jurisdiction-by-jurisdiction basis and, therefore, must be approved in advance by the Corporate Legal Department. Political contributions include any donation, gift, or loan of Company funds, assets, or property, directly or indirectly, to or for the benefit of any political party, committee, or candidate, and any use of Company funds, assets, or property, directly or indirectly to oppose or support any Government or subdivision thereof, or to oppose or to support any candidate or office-holder. This includes: (a) donations, gifts, or loans of funds, assets or property which are made by employees or third persons, such as agents, or consultants, who are reimbursed in any way by the Company; (b) the uncompensated use of Company services, facilities, or property; and (c) loans, loan guarantees or other extensions of credit.

V. CONSULTANTS AND REPRESENTATIVES

Consultants and representatives shall only be retained for proper commercial purposes and in accordance with Company policy. Compensation for consultants and representatives shall be comparable to that customarily paid in the locale and commensurate with the nature and scope of the service.

VI. PROPER ACCOUNTING

Compliance with accepted accounting rules and internal accounting controls is required at all times. The books and accounts, documentation supporting the disbursement of funds, and all other Company financial records must accurately and fairly reflect all transactions.

VII. ADMINISTRATION AND INTERPRETATION

Considering the complexity of this Business Conduct Policy, and the determination of the Company's management and Board of Directors to comply with both the letter and spirit of all applicable laws and regulations, it is recognized that questions of interpretation will arise. All questions relating to these policies are to be addressed to your direct supervisor who shall consult with other officers, as appropriate.

VIII. COMPLIANCE LINE

Employees of all Thermo Electron companies, subsidiaries, and divisions who observe or suspect a violation of law, regulation, or Thermo Electron Policies and Procedures, may contact Thermo Electron's Compliance Line. Specific information related to the Compliance Line may be found in the Compliance Line Policy attached to this Policy as Appendix A.

4

Appendix A

THERMO ELECTRON COMPLIANCE LINE

Policy

Thermo Electron is committed to compliance with the laws that affect the conduct of our business and to the highest standards of business ethics and integrity. In order to help ensure compliance with the law and Company policies, Thermo Electron has instituted a "hot-line" for employees of all Thermo Electron companies to use to report conduct that might involve illegality or other violations of the Thermo Electron Policies and Procedures.

Scope

This policy applies to employees of all Thermo Electron Corporation and all of its worldwide divisions, subsidiaries, and affiliated companies.

Procedures

If an employee observes or suspects a violation of a law or regulation or other elements of the Thermo Electron Policies and Procedures, the employee may contact the Compliance Line. The Compliance Line may be reached by telephone toll-free in the United States at 1-888-267-5255. For employees located outside of the U.S., the telephone number for the Compliance Line is 781-622-1226. The Compliance Line staff will take your calls between 9 a.m. and 5 p.m. Eastern Time. After normal business hours, you may leave a voice mail message at the same numbers and the Compliance Line staff will return your call. If you prefer to contact the Compliance Line in writing, the address is:

Thermo Electron Corporation Attn: Compliance Line P.O. Box 9046 81 Wyman Street Waltham, MA 02454-9046

All calls will be documented by the Compliance Line staff, and then the subject is referred to Thermo Electron's Legal Department, which determines whether an investigation is appropriate. Callers may remain anonymous. Calls will be treated confidentially to the extent it is legally permissible to do so.

Callers to the Compliance Line should be prepared to describe the situation as completely as they can, including dates, names, facilities and/or departments involved, and names of other employees who would provide additional information. Callers should contact the Compliance Line even if they do not have all of the


facts or if they are unsure if there is a problem. The Compliance Line staff, in conjunction with the Thermo Electron Legal Department, will look into the information provided, attempt to verify it, and take appropriate action.

Contact the Compliance Line to report possible violations related to, among other things:

Environmental Laws
Health and Safety Laws Antitrust Laws
Export/Import Laws
Food and Drug Laws
Government Contracts Laws Theft, Bribes, and Kickbacks Fraudulent Transactions Conflicts of Interest Insider Trading and Other Securities Laws Improper Political Contributions Violations of the Thermo Electron Policies and Procedures, Including the Business Conduct Policy

Because each company, subsidiary, and division already has extensive compliance procedures for employment issues relating to age, race, color, national origin, religion, sex, and handicap, it is not expected that the Compliance Line will normally be used to resolve such issues. The Compliance Line should not be contacted in lieu of an employee's local human resources department for employment-based issues.


July 16, 1999

All Employees of Thermo Electron Corporation and Subsidiaries

Re: Thermo Electron Business Conduct Policy

Since its organization in 1956, Thermo Electron Corporation has required the highest standards of business ethics and integrity of its employees. Our adherence to strict ethical standards has contributed directly to the success of our Company.

Thermo Electron has grown significantly, both through internal expansion and through the addition of acquired companies. This growth means that large numbers of new employees are joining us who may be unfamiliar with the conduct expected of all Thermo Electron employees.

It is necessary, therefore, to emphasize from time to time the ethical standards that we strive to maintain. These standards are reflected in this Business Conduct Policy. I ask you to read the Policy carefully and to review the rules that it sets forth, not as impediments to your job, but as necessary components of your success as an employee and Thermo Electron's success as a company. The simple fact is that only people and companies that do the right thing do well in business over the long run.

Please remember that no set of rules can cover all possible situations. Nor can we foresee future changes, in our business or in society. The Business Conduct Policy is intended as a guide in the performance of your job. But, in the end, we rely on you to apply these guidelines in good faith to the best of your ability.

It is my practice to maintain an "open door" for any employee who has concerns about Company practices that the employee is unable to resolve with his or her supervisors. We have established a "Compliance Line" where employees with concerns about possible improper behavior may call toll free. The Compliance Line Policy is attached to the Business Conduct Policy as Appendix A. Despite the existence of the Compliance Line, please feel free to communicate with your Company President or me in writing, on an anonymous basis if you wish, to discuss any matter pertaining to the Business Conduct Policy. Let me conclude by reiterating that I strongly believe that high ethical standards are an absolute necessity for success and that I appreciate in advance your help in making sure we follow that approach.

Sincerely,

/S/

Richard F. Syron
President and Chief Executive Officer


Exhibit G

Thermo Electron Corporation [logo]

THERMO ELECTRON CORPORATION

POLICY ON DRUGS AND ALCOHOL IN THE WORKPLACE

We wish to alert employees to the dangers of drug and alcohol abuse in the workplace. These include the potential for workplace accidents and failures that can pose a serious threat to the health and safety of the employee and others. Drug and alcohol abuse affects an employee's reliability, stability, and good judgement necessary for the safe performance of work for the Company. Improper use of alcohol, controlled substances, or illegal drugs increases the possibility of workplace thefts and of outside pressure and coercion that can pose a serious risk to an employee's health, safety, and financial security. Problems of productivity, reliability, and absenteeism can reduce an employee's work effectiveness and result in job loss.

POLICY ON DRUGS AND ALCOHOL IN THE WORK PLACE

It is the Company's policy to maintain a productive and safe workplace free from the influence of alcohol, controlled substances, or illegal drugs. A drug and alcohol awareness program will be conducted periodically to inform employees about the dangers of workplace drug and alcohol abuse, the terms of the Company's policy, the availability of counseling and rehabilitation services, and the penalties that may be imposed on employees for drug or alcohol abuse violations. Employees who perform work on government contracts or pursuant to government grants are required to sign a statement that they have received a copy of the Company's policy and that they will abide by its terms.

REHABILITATION PROGRAMS

Drug and alcohol abuse rehabilitation and assistance programs are available through the Company's medical insurance program. Employees with drug or alcohol abuse problems are strongly encouraged to participate in these programs.

DISCIPLINE AND DISCHARGE

In accordance with federal funding and contracting requirements, the Company strictly prohibits the unlawful manufacture, distribution, dispensation, possession, or use of alcohol by any employee on Company premises or vehicles during working hours. Use of alcohol, illegal drugs, or controlled substances that affects workplace performance or conduct is likewise prohibited.

Violation of this policy will result in appropriate discipline, up to and including immediate discharge. Employees are cautioned that discipline under this policy may include participation in a drug or alcohol rehabilitation or assistance program as a condition of continued employment.


NOTICE OF CONVICTION

Any employee who is convicted of violating criminal drug statute for conduct occurring in or near the workplace must notify the Company no later that five days after conviction. Failure to notify the Company in a timely manner will result in discharge.

We regret the necessity of these types of precautions, but the protection of our employees, property, and general public certainly warrants such action.


Exhibit 10.31

Amendments to Certain Stock Option Plans

Effective as of February 7, 2002, all frozen stock option plans of Thermo Electron Corporation (the "Company") and all stock option plans of the Company's subsidiaries assumed by the Company were amended as follows:

- to clarify the language regarding restricted stock awards to provide that any dividends received on restricted stock would also be subject to the restrictions of the restricted stock;

- to delete all provisions permitting the Company to make a loan to an optionee in order to fund the purchase of shares upon the exercise of the option;

- to provide that options can only be exercised in accordance with the instructions established by the plan administrator;

- to provide that obligations to pay any federal, state or local taxes required to be withheld in accordance with the plan administrator's instructions;

- amended to provide that stock purchased on the exercise of an option be paid for in accordance with the plan administrator's instructions;

- to include a list of adjustments the Board may make upon recapitalizations, mergers and the like to the "adjustments in the event of certain transactions" provision; and

- to make the "administration" provision consistent with that of the Company's 2001 Equity Incentive Plan, as amended.


Exhibit 4.2

RIGHTS AGREEMENT

dated as of October 29, 2001

by and between

THERMO ELECTRON CORPORATION

and

AMERICAN STOCK TRANSFER & TRUST COMPANY

as Rights Agent


RIGHTS AGREEMENT, dated as of October 29, 2001 (the "Agreement"), between Thermo Electron Corporation, a Delaware corporation (the "Company"), and American Stock Transfer & Trust Company, a New York corporation, as Rights Agent (the "Rights Agent").

W I T N E S S E T H

WHEREAS, on January 19, 1996, the Board of Directors of the Company (the "Board") authorized and declared a dividend distribution of one Right for each share of Common Stock (as hereinafter defined) of the Company outstanding at the close of business on January 29, 1996 (the "Record Date"), and authorized the issuance of one Right (as such number may hereinafter be adjusted pursuant to the provisions of Section 11(i) or Section 11(p) hereof) for each share of Common Stock of the Company issued between the Record Date (whether originally issued or delivered from the Company's treasury) and the earlier of the Distribution Date or the Expiration Date, each Right initially representing the right to purchase one ten-thousandth of a share of Series B Junior Participating Preferred Stock of the Company having the rights, powers and preferences set forth in the form of Certificate of Designations attached hereto as Exhibit A, upon the terms and subject to the conditions hereinafter set forth (the "Rights");

NOW, THEREFORE, in consideration of the premises and the mutual agreements herein set forth, the parties hereby agree as follows:

Section 1. Certain Definitions. For purposes of this Agreement, the following terms have the meanings indicated:

(a) "Acquiring Person" shall mean any Person who or which, together with all Affiliates and Associates of such Person, shall be the Beneficial Owner of 15% or more of the shares of Common Stock then outstanding, but shall not include (i) the Company, (ii) any Subsidiary of the Company, (iii) any employee benefit plan of the Company or of any Subsidiary of the Company, (iv) any Person organized, appointed or established by the Company for or pursuant to the terms of any such plan, or (v) the Exempted Person. Notwithstanding the foregoing, (x) no Person shall become an "Acquiring Person" as the result of an acquisition of Common Stock by the Company that, by reducing the number of shares outstanding, increases the proportionate number of shares beneficially owned by such Person to 15% or more of the shares of Common Stock of the Company then outstanding; provided, however, that if a Person shall become the Beneficial Owner of 15% or more of the shares of Common Stock of the Company then outstanding as the result of an acquisition of Common Stock by the Company and shall, following written notice from, or public disclosure by the Company of such share purchases by the Company become the Beneficial Owner of any additional Common Stock of the Company and shall then beneficially own 15% or more of the shares of Common Stock then outstanding, then such Person shall be deemed to be an "Acquiring Person" and (y) if the Board determines in good faith that a Person who would otherwise be an "Acquiring Person," as defined pursuant to the foregoing provisions of this paragraph (a), has become such inadvertently, and such Person divests as promptly as practicable (as determined in good faith by the Board of Directors), but in any event within 15 Business Days, following receipt of written notice from the Company of such event, of Beneficial Ownership of a sufficient number of shares of Common Stock so that such Person would no longer be an "Acquiring Person," as defined pursuant to the foregoing provisions of


this paragraph (a), then such Person shall not be deemed to be an "Acquiring Person" for any purposes of this Agreement unless and until such Person shall again become an "Acquiring Person."

(b) "Act" shall mean the Securities Act of 1933, as amended.

(c) "Affiliate" and "Associate" shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as in effect on the date of this Agreement.

(d) "Adjustment Shares" shall have the meaning set forth in Section 11(a)(ii).

(e) A Person shall be deemed the "Beneficial Owner" of, and shall be deemed to "beneficially own," any securities:

(i) that such Person or any of such Person's Affiliates or Associates, directly or indirectly, owns or has the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities), whether or not in writing, or upon the exercise of conversion rights, exchange rights, other rights, warrants or options, or otherwise; provided, however, that a -------- ------- Person shall not be deemed the "Beneficial Owner" of, or to "beneficially own," (A) securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person's Affiliates or Associates until such tendered securities are accepted for purchase or exchange, or (B) securities issuable upon exercise of Rights at any time prior to the occurrence of a Triggering Event, or (C) securities issuable upon exercise of Rights from and after the occurrence of a Triggering Event which Rights were acquired by such Person or any of such Person's Affiliates or Associates prior to the Distribution Date or pursuant to Section 3(a) or Section 22 hereof (the "Original Rights") or pursuant to Section 11(i) hereof in connection with an adjustment made with respect to any Original Rights;

(ii) that such Person or any of such Person's Affiliates or Associates, directly or indirectly, has the right to vote or dispose of or has "beneficial ownership" of (as determined pursuant to Rule 13d-3 of the General Rules and Regulations under the Exchange Act, or any comparable or successor rule), including pursuant to any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities), whether or not in writing; provided, however, that a Person shall not -------- ------- be deemed the "Beneficial Owner" of, or to "beneficially own," any security under this subparagraph (ii) as a result of an agreement, arrangement or understanding to vote such security if such agreement, arrangement or understanding: (A) arises solely from a revocable proxy or consent given in response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable provisions of the General Rules and Regulations under the Exchange Act, and

2

(B) is not then reportable by such Person on Schedule 13D under the Exchange Act (or any comparable or successor report); or

(iii) that are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person (or any of such Person's Affiliates or Associates) has any agreement, arrangement or understanding (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) whether or not in writing, for the purpose of acquiring, holding, voting (except pursuant to a revocable proxy or consent as described in the proviso to subparagraph (ii) of this paragraph
(e)) or disposing of any voting securities of the Company.

For all purposes of this Agreement, any calculation of the number of shares of Common Stock outstanding at any particular time, including for purposes of determining the particular percentage of such outstanding shares of Common Stock of which any Person is the Beneficial Owner, shall be made in accordance with the last sentence of Rule 13d-3(d)(l)(i) of the General Rules and Regulations under the Exchange Act.

(f) "Board" shall have the meaning set forth in the WHEREAS clause at the beginning of this Agreement.

(g) "Business Day" shall mean any day other than a Saturday, Sunday or a day on which banking institutions in the State of New York are authorized or obligated by law or executive order to close.

(h) "Close of business" on any given date shall mean 5:00 p.m., New York time, on such date; provided, however, that if such date is not a Business Day it shall mean 5:00 p.m., New York time, on the next succeeding Business Day.

(i) "Common Stock" shall mean the common stock, $1.00 par value, of the Company, except that "Common Stock" when used with reference to any Person other than the Company shall mean the capital stock of such Person with the greatest voting power, or the equity securities or other equity interest having power to control or direct the management, of such Person.

(j) "Common stock equivalents" shall have the meaning set forth in Section 11(a)(iii) hereof.

(k) "Company" shall have the meaning set forth in the introductory paragraph hereof.

(l) "Current market price" shall have the meaning set forth in Section 11(d)(i) hereof.

(m) "Current Value" shall have the meaning set forth in Section 11(a)(iii) hereof.

3

(n) "Distribution Date" shall have the meaning set forth in Section 3(a) hereof.

(o) "Equivalent Preferred Stock" shall have the meaning set forth in
Section 11(b) hereof.

(p) "Exchange Act" shall have the meaning set forth in Section 1(c) hereof.

(q) "Exchange Ratio" shall have the meaning set forth in Section 24(a) hereof.

(r) "Expiration Date" shall have the meaning set forth in Section 7(a) hereof.

(s) "Final Expiration Date" shall mean the close of business on January 29, 2006.

(t) "Permitted Offer" shall mean a tender offer or an exchange offer for all outstanding shares of Common Stock at a price and on terms determined, prior to the consummation of such tender offer or exchange offer, by directors constituting at least 75% of all of the members of the Board, after receiving advice from a nationally recognized investment banking firm selected by the Board, to be (a) at a price that is fair to stockholders (taking into account all factors that such members of the Board deem relevant including, without limitation, prices that could reasonably be achieved if the Company or its assets were sold on an orderly basis designed to realize maximum value) and (b) otherwise in the best interests of the Company and its stockholders.

(u) "Person" shall mean any individual, firm, corporation, partnership, trust, association, limited liability company or other entity.

(v) "Preferred Stock" shall mean shares of Series B Junior Participating Preferred Stock, $100 par value, of the Company having the rights and preferences set forth in the form of Certificate of Designations attached to this Agreement as Exhibit A and, to the extent that there is not a sufficient number of shares of Series B Junior Participating Preferred Stock authorized to permit the full exercise of the Rights, any other series of Preferred Stock, $100 par value, of the Company designated for such purpose containing terms substantially similar to the terms of the Series B Junior Participating Preferred Stock.

(w) "Principal Party" shall have the meaning set forth in Section 13(b) hereof.

(x) "Purchase Price" shall have the meaning set forth in Section 4(a) hereof.

(y) "Record Date" shall have the meaning set forth in the WHEREAS clause at the beginning of this Agreement.

(z) "Redemption Date" shall have the meaning set forth in Section 7(a) hereof.

(aa) "Redemption Price" shall have the meaning set forth in Section 23(a) hereof.

4

(bb) "Rights" shall have the meaning set forth in the WHEREAS clause at the beginning of this Agreement.

(cc) "Rights Agent" shall have the meaning set forth in the introductory paragraph hereof.

(dd) "Rights Certificates" shall have the meaning set forth in Section 3(a) hereof.

(ee) "Section 11(a)(ii) Event" shall mean an acquisition of Common Stock described in the first sentence of Section 11(a)(ii) hereof.

(ff) "Section 11(a)(ii) Trigger Date" shall have the meaning set forth in
Section 11(a)(iii) hereof.

(gg) Section 13 Event" shall mean any event described in clauses (x), (y) or (z) of Section 13(a) hereof.

(hh) "Spread" shall have the meaning set forth in Section 11(a)(iii) hereof.

(ii) "Stock Acquisition Date" shall mean the first date of public announcement (which, for purposes of this definition, shall include, without limitation, a report filed pursuant to Section 13(d) under the Exchange Act) by the Company or an Acquiring Person that an Acquiring Person has become such; provided, however, that, if such Person is deemed not to be an Acquiring Person pursuant to clause (y) of Section 1(a) hereof, no Stock Acquisition Date shall be deemed to have occurred.

(jj) "Subsidiary" shall mean, with reference to any Person, any corporation or other entity of which an amount of voting securities sufficient to elect at least a majority of the directors (or comparable body) of such corporation or other entity is beneficially owned, directly or indirectly, by such Person, or otherwise controlled by such Person.

(kk) "Substitution Period" shall have the meaning set forth in Section 11(a)(iii) hereof.

(ll) "Trading Day" shall have the meaning set forth in Section 11(d)(i) hereof.

(mm) "Triggering Event" shall mean any Section 11(a)(ii) Event or any

Section 13 Event.

Section 2. Appointment of Rights Agent. The Company hereby appoints the Rights Agent to act as agent for the Company and the holders of the Rights (who, in accordance with Section 3 hereof, shall prior to the Distribution Date also be the holders of the Common Stock) in accordance with the terms and conditions hereof, and the Rights Agent hereby accepts such appointment. The Company may from time to time appoint such Co-Rights Agents as it may deem necessary or desirable upon ten (10) days' prior written notice to the Rights Agent. The Rights Agent shall have no duty to supervise, and shall in no event be liable for, the acts or omissions of any such co-Rights Agent.

5

Section 3. Issuance of Rights.

(a) Until the earlier of (i) the close of business on the tenth Business Day after the Stock Acquisition Date (or, if the tenth Business Day after the Stock Acquisition Date occurs before the Record Date, the close of business on the Record Date), or (ii) the close of business on the tenth Business Day (or such later date as may be determined by action of the Board) after the date that a tender or exchange offer by any Person (other than the Company, any Subsidiary of the Company, any employee benefit plan of the Company or of any Subsidiary of the Company, or any Person organized, appointed or established by the Company for or pursuant to the terms of any such plan) is first published or sent or given within the meaning of Rule 14d-2 of the General Rules and Regulations under the Exchange Act, if upon consummation thereof, such Person would be the Beneficial Owner of 15% or more of the shares of Common Stock then outstanding, in either instance other than pursuant to a Permitted Offer (the earlier of (i) and (ii) being herein referred to as the "Distribution Date"), (x) the Rights will be evidenced by the certificates for the Common Stock registered in the names of the holders of the Common Stock (which certificates for Common Stock shall be deemed also to be certificates for Rights) and not by separate certificates, and (y) the Rights will be transferable only in connection with the transfer of the underlying shares of Common Stock (including a transfer to the Company). As soon as practicable after the Distribution Date, the Rights Agent will send by first-class, insured, postage prepaid mail, to each record holder of the Common Stock as of the close of business on the Distribution Date, at the address of such holder shown on the records of the Company, one or more rights certificates, in substantially the form of Exhibit B hereto (the "Rights Certificates"), evidencing one Right for each share of Common Stock so held, subject to adjustment as provided herein. With respect to certificates for the Common Stock outstanding as of the close of business on the Record Date, until the Distribution Date, the Rights will be evidenced by such certificates for the Common Stock and the registered holders of the Common Stock shall also be the registered holders of the associated Rights. In addition, in connection with the issuance or sale of shares of Common Stock following the Distribution Date and prior to the redemption or expiration of the Rights, the Company (i) shall, with respect to shares of Common Stock so issued or sold pursuant to the exercise of stock options or under any employee benefit plan or arrangement, or upon the exercise, conversion or exchange of securities granted or issued by the Company prior to the Distribution Date, and (ii) may, in any other case, if deemed necessary or appropriate by the Board, issue Rights Certificates representing the appropriate number of Rights in connection with such issuance or sale; provided, however, that (x) no such Rights Certificate shall be issued if, and to the extent that, the Company shall be advised by counsel that such issuance would create a significant risk of material adverse tax consequences to the Company or the Person to whom such Rights Certificate would be issued, and (y) no such Rights Certificate shall be issued if, and to the extent that, appropriate adjustment shall otherwise have been made in lieu of the issuance thereof. In the event that an adjustment in the number of Rights per share of Common Stock has been made pursuant to Sections 11(i) or 11(p) hereof, at the time of distribution of the Rights Certificates, the Company shall make the necessary and appropriate rounding adjustments (in accordance with Section 14(a) hereof) so that Rights Certificates representing only whole numbers of Rights are distributed and cash is paid in lieu of any fractional Rights. As of and after the Distribution Date, the Rights will be evidenced solely by such Rights Certificates.

6

(b) As promptly as practicable following the Record Date, the Company will send a copy of a Summary of Rights to Purchase Preferred Stock, in substantially the form attached hereto as Exhibit C, by first-class, postage-prepaid mail, to each record holder of the Common Stock as of the close of business on the Record Date, at the address of such holder shown on the records of the Company. The failure to send a copy of the Summary of Rights shall not affect the enforceability of any part of this Rights Agreement or the rights of any holder of the Rights.

(c) Rights shall be issued (i) in respect of all shares of Common Stock that are issued (either as an original issuance or from the Company's treasury) after the Record Date but prior to the earlier of the Distribution Date or the Expiration Date and (ii) in connection with the issuance or sale of shares of Common Stock following the Distribution Date and prior to the redemption or expiration of the Rights (x) with respect to shares of Common Stock so issued or sold pursuant to the exercise of stock options or under any employee benefit plan or arrangement, or upon the exercise, conversion or exchange of securities, granted or issued by the Company prior to the Distribution Date and (y) with respect to shares of Common Stock so issued or sold in any other case, if deemed necessary or appropriate by the Board. Certificates representing such shares of Common Stock (including, without limitation, certificates issued upon transfer or exchange of Common Stock) shall also be deemed to be certificates for Rights, and shall bear the following legend:

This certificate also evidences and entitles the holder hereof to certain Rights as set forth in the Rights Agreement between Thermo Electron Corporation (the "Company") and American Stock Transfer & Trust Company (the "Rights Agent") as such Agreement may be amended from time to time (the "Rights Agreement"), the terms of which are hereby incorporated herein by reference and a copy of which is on file at the principal offices of the Company. Under certain circumstances, as set forth in the Rights Agreement, such Rights will be evidenced by separate certificates and will no longer be evidenced by this certificate. The Company will mail to the holder of this Certificate a copy of the Rights Agreement, as in effect on the date of mailing, without charge promptly after receipt of a written request therefor. Under certain circumstances set forth in the Rights Agreement, Rights issued to, or held by, any Person who is, was or becomes an Acquiring Person or any Affiliate or Associate thereof (as such terms are defined in the Rights Agreement), whether currently held by or on behalf of such Person or by any subsequent holder, may become null and void.

With respect to such certificates containing the foregoing legend, until the earlier of (i) the Distribution Date and (ii) the Expiration Date, the Rights associated with the Common Stock represented by such certificates shall be evidenced by such certificates alone and registered holders of Common Stock shall also be the registered holders of the associated Rights. Notwithstanding this Section 3(c), the omission of a legend shall not affect the enforceability of any part of this Rights Agreement or the rights of any holder of the Rights.

7

(d) Until the earlier of the Distribution Date and the Expiration Date, the transfer of any certificates representing shares of Common Stock in respect of which Rights have been issued shall also constitute the transfer of the Rights associated with such shares of Common Stock. In the event that the Company purchases or acquires any shares of Common Stock after the Record Date but prior to the Distribution Date, any Rights associated with such shares of Common Stock shall be deemed cancelled and retired so that the Company shall not be entitled to exercise any Rights associated with the shares of Common Stock that are no longer outstanding.

Section 4. Form of Rights Certificates.

(a) The Rights Certificates (and the forms of election to purchase, certification and assignment to be printed on the reverse thereof) shall each be substantially in the form set forth in Exhibit B hereto and may have such marks of identification or designation and such legends, summaries or endorsements printed thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply with any applicable law or with any rule or regulation made pursuant thereto or with any rule or regulation of any stock exchange or over-the-counter market on which the Rights may from time to time be listed, or to conform to usage. Subject to the provisions of Sections 7, 11 and 22 hereof, the Rights Certificates, whenever distributed, shall entitle the holders thereof to purchase such number of one ten-thousandths of a share of Preferred Stock as shall be set forth therein at the price set forth therein (such exercise price per one ten-thousandth of a share, the "Purchase Price"), but the amount and type of securities purchasable upon the exercise of each Right and the Purchase Price thereof shall be subject to adjustment as provided herein.

(b) Any Rights Certificate issued pursuant to Section 3, Section 11(i) or
Section 22 hereof that represents Rights beneficially owned by persons known to be: (i) an Acquiring Person or an Associate or Affiliate of an Acquiring Person,
(ii) a transferee of an Acquiring Person (or of any such Associate or Affiliate) who becomes a transferee after the Acquiring Person becomes such, or (iii) a transferee of an Acquiring Person (or of any such Associate or Affiliate) who becomes a transferee prior to or concurrently with the Acquiring Person becoming such and receives such Rights pursuant to either (A) a transfer (whether or not for consideration) from the Acquiring Person to holders of equity interests in such Acquiring Person or to any Person with whom such Acquiring Person has any continuing agreement, arrangement or understanding (whether or not in writing) regarding the transferred Rights or (B) a transfer that the Board has determined is part of a plan, arrangement or understanding (whether or not in writing) that has as a primary purpose or effect avoidance of Section 7(e) hereof, and any Rights Certificate issued pursuant to Section 6 or Section 11 hereof upon transfer, exchange, replacement or adjustment of any other Rights Certificate referred to in this sentence, shall contain (to the extent feasible) the following legend:

The Rights represented by this Rights Certificate are or were beneficially owned by a Person who was or became an Acquiring Person or an Affiliate or Associate of an Acquiring Person (as such terms are defined in the Rights Agreement). Accordingly, this Rights Certificate and the

8

Rights represented hereby may become null and void in the circumstances specified in Section 7(e) of such Agreement.

The provisions of Section 7(e) hereof shall be operative whether or not the foregoing legend is contained on any such Rights Certificate.

Section 5. Countersignature and Registration.

(a) The Rights Certificates shall be executed on behalf of the Company by its Chairman of the Board, President or any Vice President, either manually or by facsimile signature, and shall have affixed thereto the Company's seal or a facsimile thereof, which shall be attested by the Secretary or an Assistant Secretary of the Company, either manually or by facsimile signature. The Rights Certificates shall be manually countersigned by the Rights Agent and shall not be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed any of the Rights Certificates shall cease to be such officer of the Company before countersignature by the Rights Agent and issuance and delivery by the Company, such Rights Certificates, nevertheless, may be countersigned by the Rights Agent and issued and delivered by the Company with the same force and effect as though the person who signed such Rights Certificates had not ceased to be such officer of the Company; and any Rights Certificates may be signed on behalf of the Company by any person who, at the actual date of the execution of such Rights Certificate, shall be a proper officer of the Company to sign such Rights Certificate, although at the date of the execution of this Rights Agreement any such person was not such an officer.

(b) Following the Distribution Date, the Rights Agent shall keep or cause to be kept, at its office designated as the appropriate place for surrender of Rights Certificates upon exercise or transfer, books for registration and transfer of the Rights Certificates issued hereunder. Such books shall show the names and addresses of the respective holders of the Rights Certificates, the number of Rights evidenced on its face by each of the Rights Certificates, the Rights Certificate number and the date of each of the Rights Certificates.

Section 6. Transfer, Split Up, Combination and Exchange of Rights Certificates; Mutilated, Destroyed, Lost or Stolen Rights Certificates.

(a) Subject to the provisions of Section 4(b), Section 7(e) and Section 14 hereof, at any time after the close of business on the Distribution Date, and at or prior to the close of business on the Expiration Date, any Rights Certificate or Certificates (other than Rights Certificates representing Rights that have become void pursuant to Section 7(e) hereof or that have been exchanged pursuant to Section 24 hereof) may be transferred, split up, combined or exchanged for another Rights Certificate or Certificates, entitling the registered holder to purchase a like number of one ten-thousandths of a share of Preferred Stock (or, following a Triggering Event, Common Stock, other securities, cash or other assets, as the case may be) as the Rights Certificate or Certificates surrendered then entitled such holder (or former holder in the case of a transfer) to purchase. Any registered holder desiring to transfer, split up, combine or exchange any Rights Certificate or Certificates shall make such request in writing delivered to the Rights Agent, and shall surrender the Rights Certificate or Certificates to be transferred, split up, combined or exchanged, with the form of assignment and certificate appropriately executed, at the

9

office of the Rights Agent designated for such purpose. Neither the Rights Agent nor the Company shall be obligated to take any action whatsoever with respect to the transfer of any such surrendered Rights Certificate until the registered holder shall have completed and signed the certificate contained in the form of assignment on the reverse side of such Rights Certificate and shall have provided such additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or Affiliates or Associates thereof as the Company shall reasonably request. Thereupon the Rights Agent shall, subject to Section
4(b), Section 7(e) and Section 14 hereof, countersign and deliver to the Person entitled thereto a Rights Certificate or Rights Certificates, as the case may be, as so requested. The Company may require payment of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer, split up, combination or exchange of Rights Certificates.

(b) Upon receipt by the Company and the Rights Agent of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of a Rights Certificate, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to them, and reimbursement to the Company and the Rights Agent of all reasonable expenses incidental thereto, and upon surrender to the Rights Agent and cancellation of the Rights Certificate if mutilated, the Company will execute and deliver a new Rights Certificate of like tenor to the Rights Agent for countersignature and delivery to the registered owner in lieu of the Rights Certificate so lost, stolen, destroyed or mutilated.

Section 7. Exercise of Rights; Purchase Price; Expiration Date of Rights.

(a) Subject to Section 7(e) hereof, the registered holder of any Rights Certificate may exercise the Rights evidenced thereby (except as otherwise provided herein including, without limitation, the restrictions on exercisability set forth in Section 9(c), Section 11(a)(iii) and Section 23 hereof) in whole or in part at any time after the Distribution Date upon surrender of the Rights Certificate, with the form of election to purchase and the certificate on the reverse side thereof duly executed, to the Rights Agent at the office of the Rights Agent designated for such purpose, together with payment of the aggregate Purchase Price with respect to the total number of one ten-thousandths of a share of Preferred Stock (or other shares, securities, cash or other assets, as the case may be) as to which such surrendered Rights are then exercisable, at or prior to the earliest of (i) the Final Expiration Date,
(ii) the time at which the Rights expire as provided in Section 13(d) hereof,
(iii) the time at which the Rights are redeemed as provided in Section 23 hereof (the "Redemption Date") and (iv) the time at which such Rights are exchanged as provided in Section 24 hereof (the earliest of (i), (ii), (iii) and (iv) being herein referred to as the "Expiration Date").

(b) The Purchase Price for each one ten-thousandth of a share of Preferred Stock pursuant to the exercise of a Right shall initially be $250.00 and shall be subject to adjustment from time to time as provided in Sections 11 and 13(a) hereof and shall be payable in lawful money of the United States of America in accordance with paragraph (c) below.

(c) Upon receipt of a Rights Certificate representing exercisable Rights, with the form of election to purchase and the certificate duly executed, accompanied by payment, with respect to each Right so exercised, of the Purchase Price per one ten-thousandth of a share of Preferred Stock (or other shares, securities, cash or other assets, as the case may be) to be purchased and an

10

amount equal to any applicable transfer tax, the Rights Agent shall, subject to
Section 20(k) hereof, thereupon promptly (i) (A) requisition from any transfer agent of the shares of Preferred Stock (or make available, if the Rights Agent is the transfer agent for such shares) certificates for the total number of one ten-thousandths of a share of Preferred Stock to be purchased and the Company hereby authorizes its transfer agent to comply with such requests, or (B) if the Company shall have elected to deposit the total number of shares of Preferred Stock issuable upon exercise of the Rights hereunder with a depositary agent, requisition from the depositary agent depositary receipts representing such number of one ten-thousandths of a share of Preferred Stock as are to be purchased (in which case certificates for the shares of Preferred Stock represented by such receipts shall be deposited by the transfer agent with the depositary agent) and the Company hereby directs the depositary agent to comply with such requests, (ii) requisition from the Company the amount of cash, if any, to be paid in lieu of fractional shares in accordance with Section 14 hereof, (iii) after receipt of such certificates or depositary receipts, cause the same to be delivered to or upon the order of the registered holder of such Rights Certificate, registered in such name or names as may be designated by such holder, and (iv) after receipt thereof, deliver such cash, if any, to or upon the order of the registered holder of such Rights Certificate. The payment of the Purchase Price (as such amount may be reduced pursuant to Section 11(a)(iii) hereof) may be made in cash or by certified bank check or money order payable to the order of the Company. In the event that the Company is obligated to issue other securities (including Common Stock) of the Company, pay cash and/or distribute other property pursuant to Section 11(a) hereof, the Company shall make all arrangements necessary so that such other securities, cash and/or other property are available for distribution by the Rights Agent, if and when appropriate.

(d) In case the registered holder of any Rights Certificate shall exercise less than all the Rights evidenced thereby, a new Rights Certificate evidencing Rights equivalent to the Rights remaining unexercised shall be issued by the Rights Agent and delivered to, or upon the order of, the registered holder of such Rights Certificate, registered in such name or names as may be designated by such holder, subject to the provisions of Section 14 hereof.

(e) Notwithstanding anything in this Agreement to the contrary, from and after the first occurrence of a Section 11(a)(ii) Event, any Rights beneficially owned by (i) an Acquiring Person or an Associate or Affiliate of an Acquiring Person, (ii) a transferee of an Acquiring Person (or of any such Associate or Affiliate) who becomes a transferee after the Acquiring Person becomes such, or
(iii) a transferee of an Acquiring Person (or of any such Associate or Affiliate) who becomes a transferee prior to or concurrently with the Acquiring Person becoming such and receives such Rights pursuant to either (A) a transfer (whether or not for consideration) from the Acquiring Person to holders of equity interests in such Acquiring Person or to any Person with whom the Acquiring Person has any continuing agreement, arrangement or understanding (whether or not in writing) regarding the transferred Rights or (B) a transfer that the Board has determined is part of a plan, arrangement or understanding (whether or not in writing) that has as a primary purpose or effect avoidance of this Section 7(e), shall become null and void without any further action and no holder of such Rights shall have any rights whatsoever with respect to such Rights, whether under any provision of this Agreement or otherwise. No Rights Certificate shall be issued at any time upon the transfer of any Rights to an Acquiring Person whose Rights would be void pursuant to the preceding sentence or any Associate or Affiliate thereof or to any nominee of such Acquiring

11

Person, Associate or Affiliate; and any Rights Certificate delivered to the Rights Agent for transfer to an Acquiring Person whose Rights would be void pursuant to the preceding sentence shall be cancelled. The Company shall use all reasonable efforts to insure that the provisions of this Section 7(e) and
Section 4(b) hereof are complied with, but shall have no liability to any holder of Rights Certificates or other Person as a result of its failure to make any determinations with respect to an Acquiring Person or its Affiliates, Associates or transferees hereunder.

(f) Notwithstanding anything in this Agreement to the contrary, neither the Rights Agent nor the Company shall be obligated to undertake any action with respect to a registered holder upon the occurrence of any purported transfer or exercise as set forth in this Section 7 unless such registered holder shall have
(i) completed and signed the certificate following the form of assignment or election to purchase set forth on the reverse side of the Rights Certificate surrendered for such assignment or exercise, and (ii) provided such additional evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or any Affiliates or Associates thereof as the Company shall reasonably request.

Section 8. Cancellation and Destruction of Rights Certificates. All Rights Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered to the Company or any of its agents, be delivered to the Rights Agent for cancellation or in cancelled form, or, if surrendered to the Rights Agent, shall be cancelled by it, and no Rights Certificates shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Agreement. The Company shall deliver to the Rights Agent for cancellation and retirement, and the Rights Agent shall so cancel and retire, any other Rights Certificate purchased or acquired by the Company otherwise than upon the exercise thereof. The Rights Agent shall deliver all cancelled Rights Certificates to the Company, or shall, at the written request of the Company, destroy such cancelled Rights Certificates, and in such case shall deliver a certificate of destruction thereof to the Company.

Section 9. Reservation and Availability of Capital Stock.

(a) The Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Preferred Stock (and, following the occurrence of a Triggering Event, out of its authorized and unissued shares of Common Stock and/or other securities or out of its authorized and issued shares held in its treasury), the number of shares of Preferred Stock (and, following the occurrence of a Triggering Event, Common Stock and/or other securities) that, as provided in this Agreement including Section 11(a)(iii) hereof, will be sufficient to permit the exercise in full of all outstanding Rights.

(b) So long as the shares of Preferred Stock (and, following the occurrence of a Section 11(a)(ii) Event, Common Stock and/or other securities) issuable and deliverable upon the exercise of the Rights may be listed on any national securities exchange or automated quotation system, the Company shall use its best efforts to cause, from and after such time as the Rights become exercisable, all shares reserved for such issuance to be so listed upon official notice of issuance upon such exercise.

(c) The Company shall use its best efforts to (i) file, as soon as practicable following the earliest date after the first occurrence of a Section
11(a)(ii) Event on which the consideration to be delivered by the Company upon

12

exercise of the Rights has been determined in accordance with Section 11(a)(iii) hereof, or as soon as is required by law following the Distribution Date, as the case may be, a registration statement under the Act, with respect to the securities purchasable upon exercise of the Rights on an appropriate form, (ii) cause such registration statement to become effective as soon as practicable after such filing, (iii) cause such registration statement to remain effective (with a prospectus at all times meeting the requirements of the Act) until the earlier of (A) the date as of which the Rights are no longer exercisable for such securities, and (B) the Expiration Date, and (iv) obtain such regulatory approvals as may be necessary for it to issue securities purchasable upon the exercise of the Rights. The Company will also take such action as may be appropriate under, or to ensure compliance with, the securities or "blue sky" laws of the various states in connection with the exercisability of the Rights. The Company may temporarily suspend, for a period of time not to exceed 90 days after the date set forth in clause (i) of the first sentence of this Section
9(c), the exercisability of the Rights in order to prepare and file such registration statement and permit it to become effective or to obtain any other required regulatory approval in connection with the exercisability of the Rights. Upon any such suspension, the Company shall issue a public announcement stating that the exercisability of the Rights has been temporarily suspended, as well as a public announcement at such time as the suspension is no longer in effect. Notwithstanding any provision of this Agreement to the contrary, the Rights shall not be exercisable in any jurisdiction unless the requisite registration or qualification in such jurisdiction shall have been effected or obtained.

(d) The Company covenants and agrees that it will take all such action as may be necessary to ensure that all one ten-thousandths of a share of Preferred Stock (and, following the occurrence of a Triggering Event, Common Stock and/or other securities) delivered upon exercise of Rights shall, at the time of delivery of the certificates for such shares (subject to payment of the Purchase Price), be duly and validly authorized and issued and fully paid and nonassessable.

(e) The Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges that may be payable in respect of the issuance or delivery of the Rights Certificates and of any certificates for a number of one ten-thousandths of a share of Preferred Stock (or Common Stock and/or other securities, as the case may be) upon the exercise of Rights. The Company shall not, however, be required (i) to pay any transfer tax that may be payable in respect of any transfer or delivery of Rights Certificates to a Person other than, or the issuance or delivery of a number of one ten-thousandths of a share of Preferred Stock (or Common Stock and/or other securities, as the case may be) in respect of a name other than that of, the registered holder of the Rights Certificate evidencing Rights surrendered for exercise or (ii) to issue or deliver any certificates for a number of one ten-thousandths of a share of Preferred Stock (or Common Stock and/or other securities, as the case may be) in a name other than that of the registered holder upon the exercise of any Rights until such tax shall have been paid (any such tax being payable by the holder of such Rights Certificate at the time of surrender) or until it has been established to the Company's satisfaction that no such tax is due.

Section 10. Preferred Stock Record Date. Each Person in whose name any certificate for a number of one ten-thousandths of a share of Preferred Stock (or Common Stock and/or other securities, as the case may be) is issued upon the

13

exercise of Rights shall for all purposes be deemed to have become the holder of record of such fractional shares of Preferred Stock (or Common Stock and/or other securities, as the case may be) represented thereby on, and such certificate shall be dated, the date upon which the Rights Certificate evidencing such Rights was duly surrendered with the forms of election and certification duly executed and payment of the Purchase Price (and all applicable transfer taxes) was made; provided, however, that if the date of such surrender and payment is a date upon which the Preferred Stock (or Common Stock and/or other securities, as the case may be) transfer books of the Company are closed, such Person shall be deemed to have become the record holder of such shares (fractional or otherwise) on, and such certificate shall be dated, the next succeeding Business Day on which the Preferred Stock (or Common Stock and/or other securities, as the case may be) transfer books of the Company are open. Prior to the exercise of the Rights evidenced thereby, the holder of a Rights Certificate, as such, shall not be entitled to any rights of a stockholder of the Company with respect to securities for which the Rights shall be exercisable, including, without limitation, the right to vote, to receive dividends or other distributions or to exercise any preemptive rights, and shall not be entitled to receive any notice of any proceedings of the Company, except as provided herein.

Section 11. Adjustment of Purchase Price, Number and Kind of Shares or Number of Rights. The Purchase Price, the number and kind of shares covered by each Right and the number of Rights outstanding are subject to adjustment from time to time as provided in this Section 11.

(a) (i) In the event the Company shall at any time after the date of this Agreement (A) declare a dividend on the Preferred Stock payable in shares of Preferred Stock, (B) subdivide the outstanding Preferred Stock, (C) combine the outstanding Preferred Stock into a smaller number of shares, or (D) issue any shares of its capital stock in a reclassification of the Preferred Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing or surviving corporation), except as otherwise provided in this Section 11(a) and Section 7(e) hereof, the Purchase Price in effect at the time of the record date for such dividend or of the effective date of such subdivision, combination or reclassification, and the number and kind of shares of Preferred Stock or capital stock, as the case may be, issuable on such date, shall be proportionately adjusted so that the holder of any Right exercised after such time shall be entitled to receive, upon payment of the Purchase Price then in effect, the aggregate number and kind of shares of Preferred Stock or capital stock, as the case may be, that, if such Right had been exercised immediately prior to such date and at a time when the Preferred Stock transfer books of the Company were open, he would have owned upon such exercise and been entitled to receive by virtue of such dividend, subdivision, combination or reclassification. If an event occurs that would require an adjustment under both this
Section 11(a)(i) and Section 11(a)(ii) hereof, the adjustment provided for in this Section 11(a)(i) shall be in addition to, and shall be made prior to, any adjustment required pursuant to Section 11(a)(ii) hereof.

14

(ii) Subject to Section 24 of this Agreement, in the event that any Person, alone or together with its Affiliates or Associates, becomes an Acquiring Person (other than pursuant to a Permitted Offer), then, promptly following the first occurrence of such event, proper provision shall be made so that each holder of a Right (except as provided below and in Section 7(e) hereof) shall thereafter have the right to receive (subject to the last sentence of Section 23(a)), upon exercise thereof at the then current Purchase Price in accordance with the terms of this Agreement, in lieu of a number of one ten-thousandths of a share of Preferred Stock, such number of shares of Common Stock of the Company that equals the result obtained by (x) multiplying the then current Purchase Price by the then number of one ten-thousandths of a share of Preferred Stock for which a Right was exercisable immediately prior to the first occurrence of a Section
11(a)(ii) Event, and (y) dividing that product (which, following such first occurrence, shall thereafter be referred to as the "Purchase Price" for each Right and for all purposes of this Agreement) by 50% of the current market price (determined pursuant to Section 11(d) hereof) per share of Common Stock on the date of such first occurrence (such number of shares, the "Adjustment Shares").

(iii) In the event that the number of shares of Common Stock that are authorized by the Company's Certificate of Incorporation but not outstanding or reserved for issuance for purposes other than upon exercise of the Rights are not sufficient to permit the exercise in full of the Rights in accordance with the foregoing subparagraph (ii) of this Section 11(a), the Company shall: (A) determine the excess of
(1) the value of the Adjustment Shares issuable upon the exercise of a Right (the "Current Value") over (2) the Purchase Price (such excess, the "Spread"), and (B) with respect to each Right, make adequate provision to substitute for the Adjustment Shares, upon payment of the applicable Purchase Price, (1) cash, (2) a reduction in the Purchase Price, (3) Common Stock or other equity securities of the Company (including, without limitation, shares, or units of shares, of preferred stock that the Board has deemed to have the same value as shares of Common Stock (such shares of preferred stock, "common stock equivalents")), (4) debt securities of the Company, (5) other assets, or (6) any combination of the foregoing, having an aggregate value equal to the Current Value, where such aggregate value has been determined by the Board based upon the advice of a nationally recognized investment banking firm selected by the Board; provided, however, if the Company shall not have made adequate provision to deliver value pursuant to clause (B) above within 30 days following the later of (x) the first occurrence of a Section 11(a)(ii) Event and

15

(y) the date on which the Company's right of redemption pursuant to
Section 23(a) expires (the later of (x) and (y) being referred to herein as the "Section 11(a)(ii) Trigger Date"), then the Company shall be obligated to deliver, upon the surrender for exercise of a Right and without requiring payment of the Purchase Price, shares of Common Stock (to the extent available) and then, if necessary, cash, which shares and/or cash have an aggregate value equal to the Spread. If the Board shall determine in good faith that it is likely that sufficient additional shares of Common Stock could be authorized for issuance upon exercise in full of the Rights, the 30 day period set forth above may be extended to the extent necessary, but not more than 90 days after the Section 11(a)(ii) Trigger Date, in order that the Company may seek stockholder approval for the authorization of such additional shares (such period, as it may be extended, the "Substitution Period"). To the extent that the Company determines that some action need be taken pursuant to the first and/or second sentences of this Section 11(a)(iii), the Company (x) shall provide, subject to Section 7(e) hereof, that such action shall apply uniformly to all outstanding Rights, and (y) may suspend the exercisability of the Rights until the expiration of the Substitution Period in order to seek any authorization of additional shares and/or to decide the appropriate form of distribution to be made pursuant to such first sentence and to determine the value thereof. In the event of any such suspension, the Company shall issue a public announcement stating that the exercisability of the Rights has been temporarily suspended, as well as a public announcement at such time as the suspension is no longer in effect. For purposes of this Section 11(a)(iii), the value of the Common Stock shall be the current market price (as determined pursuant to Section 11(d) hereof) per share of the Common Stock on the
Section 11(a)(ii) Trigger Date and the value of any "common stock equivalent" shall be deemed to have the same value as the Common Stock on such date.

(b) In case the Company shall fix a record date for the issuance of rights, options or warrants to all holders of Preferred Stock entitling them to subscribe for or purchase (for a period expiring within 45 calendar days after such record date) Preferred Stock (or shares having the same rights, privileges and preferences as the shares of Preferred Stock ("equivalent preferred stock")) or securities convertible into Preferred Stock or equivalent preferred stock at a price per share of Preferred Stock or per share of equivalent preferred stock (or having a conversion price per share, if a security convertible into Preferred Stock or equivalent preferred stock) less than the current market price (as determined pursuant to Section 11(d) hereof) per share of Preferred Stock on such record date, the Purchase Price to be in effect after such record date shall be determined by multiplying the Purchase Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the number of shares of Preferred Stock outstanding on such record date, plus the number of shares of Preferred Stock that the aggregate offering price of the total number of shares of Preferred Stock and/or equivalent preferred stock so to be offered (and/or the aggregate initial conversion price of the convertible securities so to be offered) would purchase at such current market price, and the denominator of which shall be the number of shares of Preferred Stock outstanding on such record date, plus the number of additional shares of Preferred Stock and/or equivalent preferred stock to be offered for subscription or purchase (or into which the convertible securities so to be offered are initially convertible). In case such subscription price may be paid by delivery of consideration part or all of which may be in a form other than cash, the value of such consideration shall be as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes. Shares of Preferred Stock owned by or held for the account of the Company shall not be deemed outstanding for the purpose of any such computation. Such adjustment shall be made successively whenever such a record date is fixed, and in the event that such rights, options or warrants are not so issued, the Purchase Price shall be adjusted to be the Purchase Price that would then be in effect if such record date had not been fixed.

16

(c) In case the Company shall fix a record date for a distribution to all holders of Preferred Stock (including any such distribution made in connection with a consolidation or merger in which the Company is the continuing corporation) of evidences of indebtedness, cash (other than a regular quarterly cash dividend out of the earnings or retained earnings of the Company), assets (other than a dividend payable in Preferred Stock, but including any dividend payable in stock other than Preferred Stock) or subscription rights or warrants (excluding those referred to in Section 11(b) hereof), the Purchase Price to be in effect after such record date shall be determined by multiplying the Purchase Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the current market price (as determined pursuant to
Section 11(d) hereof) per share of Preferred Stock on such record date, less the fair market value (as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes) of the portion of the cash, assets or evidences of indebtedness so to be distributed or of such subscription rights or warrants applicable to a share of Preferred Stock and the denominator of which shall be such current market price (as determined pursuant to Section 11(d) hereof) per share of Preferred Stock on such record date. Such adjustments shall be made successively whenever such a record date is fixed, and in the event that such distribution is not so made, the Purchase Price shall be adjusted to be the Purchase Price that would have been in effect if such record date had not been fixed.

(d) (i) For the purpose of any computation hereunder, other than computations made pursuant to Section 11(a)(iii) hereof, the "current market price" per share of Common Stock on any date shall be deemed to be the average of the daily closing prices per share of such Common Stock for the 30 consecutive Trading Days (as such term is hereinafter defined) immediately prior to such date, and for purposes of computations made pursuant to Section 11(a)(iii) hereof, the "current market price" per share of Common Stock on any date shall be deemed to be the average of the daily closing prices per share of such Common Stock for the ten (10) consecutive Trading Days immediately following such date; provided, however, that in the event that the current market price per share of the Common Stock is determined during a period following the announcement by the issuer of such Common Stock of (A) a dividend or distribution on such Common Stock payable in shares of such Common Stock or securities convertible into shares of such Common Stock (other than the Rights), or (B) any subdivision, combination or reclassification of such Common Stock, and prior to the expiration of the requisite 30 Trading Day or ten (10) Trading Day period, as set forth above, after the ex-dividend date for such dividend or distribution, or the record date for such subdivision, combination or reclassification occurs, then, and in each such case, the "current market price" shall be properly adjusted to take into account ex-dividend or post record date trading. The closing price for each day shall be the last sale price, regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on the principal national securities exchange on which the shares of Common Stock are listed or admitted to trading or, if the shares of Common Stock are not listed or admitted to trading on any national securities exchange, the last quoted price or, if not so quoted, the average of the high bid and the low asked prices in the over-the-counter market, as reported by The Nasdaq Stock

17

Market, Inc. ("Nasdaq") or such other system then in use, or, if on any such date the shares of Common Stock are not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the Common Stock selected by the Board. All references in this Section to closing prices, last quoted prices or other stock prices mean prices during regular trading hours, without giving effect to any after-hours or extended hours trading. If on any such date no market maker is making a market in the Common Stock, the fair value of such shares on such date shall be as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes. The term "Trading Day" shall mean a day on which Nasdaq or any national securities exchange on which the shares of Common Stock are listed or admitted to trading is open for the transaction of business or, if the shares of Common Stock are not listed or admitted to trading on Nasdaq or any national securities exchange, a Business Day. If the Common Stock is not publicly held or not so listed or traded, "current market price" per share shall mean the fair value per share as determined in good faith by the Board, whose determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes.

(ii) For the purpose of any computation hereunder, the "current market price" per share of Preferred Stock shall be determined in the same manner as set forth above for the Common Stock in clause (i) of this Section 11(d) (other than the last sentence thereof). If the current market price per share of Preferred Stock cannot be determined in the manner provided above or if the Preferred Stock is not publicly held or listed or traded in a manner described in clause (i) of this
Section 11(d), the "current market price" per share of Preferred Stock shall be conclusively deemed to be an amount equal to 10,000 (as such number may be appropriately adjusted for such events as stock splits, stock dividends and recapitalizations with respect to the Common Stock occurring after the date of this Agreement) multiplied by the current market price per share of the Common Stock. If neither the Common Stock nor the Preferred Stock is publicly held or so listed or traded, "current market price" per share of the Preferred Stock shall mean the fair value per share as determined in good faith by the Board, which determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes. For all purposes of this Agreement, the "current market price" of one ten-thousandth of a share of Preferred Stock shall be equal to the "current market price" of one share of Preferred Stock divided by 10,000.

(e) Anything herein to the contrary notwithstanding, no adjustment in the Purchase Price shall be required unless such adjustment would require an increase or decrease of at least one percent (1%) in the Purchase Price; provided, however, that any adjustments that by reason of this Section 11(e) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this Section 11 shall be made to the nearest cent or to the nearest ten-millionth of a share of Preferred Stock, or hundred-thousandth of a share of Common Stock or other security, as the case may be. Notwithstanding the first sentence of this Section 11(e), any adjustment

18

required by this Section 11 shall be made no later than the earlier of (i) three years from the date of the transaction that mandates such adjustment, or (ii) the Expiration Date.

(f) If as a result of an adjustment made pursuant to Section 11(a)(ii) or
Section 13(a) hereof, the holder of any Right thereafter exercised shall become entitled to receive any securities other than Preferred Stock, thereafter the number of such other securities so receivable upon exercise of any Right and the Purchase Price thereof shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Preferred Stock contained in Sections 11(a), (b), (c), (e), (g),
(h), (i), (j), (k) and (m), and the provisions of Sections 7, 9, 10, 13 and 14 hereof with respect to the Preferred Stock shall apply on like terms to any such other securities; provided, however, that the Company shall not be liable for its inability to reserve and keep available for issuance upon exercise of the Rights pursuant to Section 11(a)(ii) a number of shares of Common Stock greater than the number then authorized by the Company's Certificate of Incorporation but not outstanding or reserved for other purposes.

(g) All Rights originally issued by the Company subsequent to any adjustment made to the Purchase Price hereunder shall evidence the right to purchase, at the adjusted Purchase Price, the number of one ten-thousandths of a share of Preferred Stock purchasable from time to time hereunder upon exercise of the Rights, all subject to further adjustment as provided herein.

(h) Unless the Company shall have exercised its election as provided in
Section 11(i), upon each adjustment of the Purchase Price as a result of the calculations made in Sections 11(b) and (c), each Right outstanding immediately prior to the making of such adjustment shall thereafter evidence the right to purchase, at the adjusted Purchase Price, that number of one ten-thousandths of a share of Preferred Stock (calculated to the nearest ten-millionth) obtained by
(i) multiplying (x) the number of one ten-thousandths of a share covered by a Right immediately prior to this adjustment, by (y) the Purchase Price in effect immediately prior to such adjustment of the Purchase Price, and (ii) dividing the product so obtained by the Purchase Price in effect immediately after such adjustment of the Purchase Price.

(i) The Company may elect on or after the date of any adjustment of the Purchase Price to adjust the number of Rights, in lieu of any adjustment in the number of one ten-thousandths of a share of Preferred Stock purchasable upon the exercise of a Right. Each of the Rights outstanding after the adjustment in the number of Rights shall be exercisable for the number of one ten-thousandths of a share of Preferred Stock for which a Right was exercisable immediately prior to such adjustment. Each Right held of record prior to such adjustment of the number of Rights shall become that number of Rights (calculated to the nearest one-hundred- thousandth) obtained by dividing the Purchase Price in effect immediately prior to adjustment of the Purchase Price by the Purchase Price in effect immediately after adjustment of the Purchase Price. The Company shall make a public announcement of its election to adjust the number of Rights, indicating the record date for the adjustment, and, if known at the time, the amount of the adjustment to be made. This record date may be the date on which the Purchase Price is adjusted or any day thereafter, but, if the Rights Certificates have been issued, shall be at least ten (10) days later than the date of the public announcement. If Rights Certificates have been issued, upon

19

each adjustment of the number of Rights pursuant to this Section 11(i), the Company shall, as promptly as practicable, cause to be distributed to holders of record of Rights Certificates on such record date Rights Certificates evidencing, subject to Section 14 hereof, the additional Rights to which such holders shall be entitled as a result of such adjustment, or, at the option of the Company, shall cause to be distributed to such holders of record in substitution and replacement for the Rights Certificates held by such holders prior to the date of adjustment, and upon surrender thereof, if required by the Company, new Rights Certificates evidencing all the Rights to which such holders shall be entitled after such adjustment. Rights Certificates so to be distributed shall be issued, executed and countersigned in the manner provided for herein (and may bear, at the option of the Company, the adjusted Purchase Price) and shall be registered in the names of the holders of record of Rights Certificates on the record date specified in the public announcement.

(j) Irrespective of any adjustment or change in the Purchase Price or the number of one ten-thousandth of a share of Preferred Stock issuable upon the exercise of the Rights, the Rights Certificates theretofore and thereafter issued may continue to express the Purchase Price per one ten-thousandth of a share and the number of one ten-thousandths of a share that were expressed in the initial Rights Certificates issued hereunder.

(k) Before taking any action that would cause an adjustment reducing the Purchase Price below the then par value, if any, of the number of one ten-thousandths of a share of Preferred Stock issuable upon exercise of the Rights, the Company shall take any corporate action that may, in the opinion of its counsel, be necessary in order that the Company may validly and legally issue such number of one ten-thousandths of a share of fully paid and nonassessable Preferred Stock at such adjusted Purchase Price.

(l) In any case in which this Section 11 shall require that an adjustment in the Purchase Price be made effective as of a record date for a specified event, the Company may elect to defer until the occurrence of such event the issuance to the holder of any Right exercised after such record date the number of one ten-thousandths of a share of Preferred Stock and other capital stock or securities of the Company, if any, issuable upon such exercise over and above the number of one ten-thousandths of a share of Preferred Stock and other capital stock or securities of the Company, if any, issuable upon such exercise on the basis of the Purchase Price in effect prior to such adjustment; provided, however, that the Company shall deliver to such holder a due bill or other appropriate instrument evidencing such holder's right to receive such additional shares (fractional or otherwise) or securities upon the occurrence of the event requiring such adjustment.

(m) Anything in this Section 11 to the contrary notwithstanding, the Company shall be entitled to make such reductions in the Purchase Price, in addition to those adjustments expressly required by this Section 11, as and to the extent that in their good faith judgment the Board shall determine to be advisable in order that any (i) consolidation or subdivision of the Preferred Stock, (ii) issuance wholly for cash of any shares of Preferred Stock at less than the current market price, (iii) issuance wholly for cash of shares of Preferred Stock or securities that by their terms are convertible into or exchangeable for shares of Preferred Stock, (iv) stock dividends or (v) issuance of rights, options or warrants referred to in this Section 11, hereafter made by the Company to holders of its Preferred Stock shall not be taxable to such stockholders.

20

(n) The Company covenants and agrees that it shall not, at any time after the Distribution Date, (i) consolidate with any other Person (other than a Subsidiary of the Company in a transaction that complies with Section 11(o) hereof), (ii) merge with or into any other Person (other than a Subsidiary of the Company in a transaction that complies with Section 11(o) hereof), or (iii) sell or transfer (or permit any Subsidiary to sell or transfer), in one transaction, or a series of related transactions, assets or earning power aggregating more than 50% of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to any other Person or Persons (other than the Company and/or any of its Subsidiaries in one or more transactions each of which complies with Section 11(o) hereof), if (x) at the time of or immediately after such consolidation, merger or sale there are any charter or bylaw provisions or any rights, warrants or other instruments or securities outstanding or agreements in effect that would substantially diminish or otherwise eliminate the benefits intended to be afforded by the Rights or (y) prior to, simultaneously with or immediately after such consolidation, merger or sale, the stockholders of the Person who constitutes, or would constitute, the "Principal Party" for purposes of Section 13(a) hereof shall have received a distribution of Rights previously owned by such Person or any of its Affiliates or Associates. The Company shall not consummate any consolidation, merger, sale or transfer described in clause (i), (ii) or (iii) of the prior sentence unless prior thereto the Company and such other Person shall have executed and delivered to the Rights Agent a supplemental agreement evidencing compliance with this Section 11(n).

(o) The Company covenants and agrees that, after the Distribution Date, it will not, except as permitted by Section 23, Section 24 or Section 27 hereof, take (or permit any Subsidiary to take) any action if at the time such action is taken it is reasonably foreseeable that such action will diminish substantially or otherwise eliminate the benefits intended to be afforded by the Rights.

(p) Anything in this Agreement to the contrary notwithstanding, in the event that the Company shall at any time after the Record Date and prior to the Distribution Date (i) declare or pay any dividend on the outstanding shares of Common Stock payable in shares of Common Stock, (ii) subdivide the outstanding shares of Common Stock, or (iii) combine the outstanding shares of Common Stock into a smaller number of shares, the number of Rights associated with each share of Common Stock then outstanding, or issued or delivered thereafter but prior to the Distribution Date, shall be proportionately adjusted so that the number of Rights thereafter associated with each share of Common Stock following any such event shall equal the result obtained by multiplying the number of Rights associated with each share of Common Stock immediately prior to such event by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to the occurrence of such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately following the occurrence of such event.

Section 12. Certificate of Adjusted Purchase Price or Number of Shares. Whenever an adjustment is made as provided in Section 11 or Section 13 hereof, the Company shall promptly (a) prepare a certificate setting forth such adjustment and a brief statement of the facts accounting for such adjustment, (b) file with the Rights Agent, and with each transfer agent for the Preferred Stock and the Common Stock, a copy of such certificate, and (c) mail a brief summary thereof to each holder of a Rights Certificate (or, if prior to the Distribution Date, to each holder of a certificate representing shares of Common Stock) in accordance with Section 26 hereof. The Rights Agent shall be fully protected in

21

relying on any such certificate and on any adjustment therein contained and shall not be deemed to have knowledge of any adjustment unless and until it shall have received such certificate.

Section 13. Consolidation, Merger or Sale or Transfer of Assets or Earning Power.

(a) In the event that, at any time after a Person has become an Acquiring Person, (x) the Company shall consolidate with, or merge with and into, any other Person (other than a Subsidiary of the Company in a transaction that complies with Section 11(o) hereof), and the Company shall not be the continuing or surviving corporation of such consolidation or merger, (y) any Person (other than a Subsidiary of the Company in a transaction that complies with Section 11(o) hereof) shall consolidate with, or merge with or into, the Company, and the Company shall be the continuing or surviving corporation of such consolidation or merger and, in connection with such consolidation or merger, all or part of the outstanding shares of Common Stock shall be changed into or exchanged for stock or other securities of any other Person or cash or any other property, or (z) the Company shall sell or otherwise transfer (or one or more of its Subsidiaries shall sell or otherwise transfer), in one transaction or a series of related transactions, assets or earning power aggregating more than 50% of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to any Person or Persons (other than the Company or any Subsidiary of the Company in one or more transactions each of which complies with Section 11(o) hereof), then, and in each such case and except as contemplated by Section 13(d) hereof, proper provision shall be made so that: (i) each holder of a Right, except as provided in Section 7(e) hereof, shall thereafter have the right to receive, upon the exercise thereof at the then current Purchase Price in accordance with the terms of this Agreement, such number of validly authorized and issued, fully paid, non-assessable and freely tradeable shares of Common Stock of the Principal Party (as such term is hereinafter defined), which shall not be subject to any liens, encumbrances, rights of first refusal or other adverse claims, as shall be equal to the result obtained by (1) multiplying the then current Purchase Price by the number of one ten-thousandths of a share of Preferred Stock for which a Right is exercisable immediately prior to the first occurrence of a Section 13 Event (or, if a Section 11(a)(ii) Event has occurred prior to the first occurrence of a Section 13 Event, multiplying the number of such one ten-thousandths of a share for which a Right was exercisable immediately prior to the first occurrence of a Section 11(a)(ii) Event by the Purchase Price in effect immediately prior to such first occurrence), and (2) dividing that product (which, following the first occurrence of a Section 13 Event, shall be referred to as the "Purchase Price" for each Right and for all purposes of this Agreement) by 50% of the current market price (determined pursuant to Section 11(d)(i) hereof) per share of the Common Stock of such Principal Party on the date of consummation of such Section 13 Event; (ii) such Principal Party shall thereafter be liable for, and shall assume, by virtue of such Section 13 Event, all the obligations and duties of the Company pursuant to this Agreement; (iii) the term "Company" shall thereafter be deemed to refer to such Principal Party, it being specifically intended that, subject to clause (v) below, the provisions of Section 11 hereof shall apply only to such Principal Party following the first occurrence of a
Section 13 Event; (iv) such Principal Party shall take such steps (including, but not limited to, the reservation of a sufficient number of shares of its Common Stock) in connection with the consummation of any such transaction as may be necessary to assure that the provisions hereof shall thereafter be applicable, as nearly as reasonably may be, in relation to its shares of Common Stock thereafter deliverable upon the exercise of the Rights; and (v) the

22

provisions of Section 11(a)(ii) hereof shall be of no effect following the first occurrence of any Section 13 Event.

(b) "Principal Party" shall mean

(i) in the case of any transaction described in clause (x) or (y) of the first sentence of Section 13(a), the Person that is the issuer of any securities into which shares of Common Stock of the Company are converted in such merger or consolidation, and if no securities are so issued, the Person that is the other party to such merger or consolidation; and

(ii) in the case of any transaction described in clause (z) of the first sentence of Section 13(a), the Person that is the party receiving the greatest portion of the assets or earning power transferred pursuant to such transaction or transactions;

provided, however, that in any such case, (1) if the Common Stock of such Person is not at such time and has not been continuously over the preceding twelve (12) month period registered under Section 12 of the Exchange Act, and such Person is a direct or indirect Subsidiary of another Person the Common Stock of which is and has been so registered, "Principal Party" shall refer to such other Person;
(2) in case such Person is a Subsidiary, directly or indirectly, of more than one Person, the Common Stocks of two or more of which are and have been so registered, "Principal Party" shall refer to whichever of such Persons is the issuer of the Common Stock having the greatest aggregate market value; and (3) in case such Person is owned, directly or indirectly, by a joint venture formed by two or more Persons that are not owned, directly or indirectly, by the same Person, the rules set forth in (1) and (2) above shall apply to each of the chains of ownership having an interest in such joint venture as if such party were a "Subsidiary" of both or all of such joint ventures and the Principal Parties in each such chain shall bear the obligations set forth in this Section 13 in the same ratio as their direct or indirect interests in such Person bear to the total of such interests.

(c) The Company shall not consummate any such consolidation, merger, sale or transfer unless the Principal Party shall have a sufficient number of authorized shares of its Common Stock that have not been issued or reserved for issuance to permit the exercise in full of the Rights in accordance with this
Section 13 and unless prior thereto the Company and such Principal Party shall have executed and delivered to the Rights Agent a supplemental agreement providing for the terms set forth in paragraphs (a) and (b) of this Section 13 and further providing that, as soon as practicable after the date of any consolidation, merger or sale of assets mentioned in paragraph (a) of this
Section 13, the Principal Party will

(i) prepare and file a registration statement under the Act, with respect to the Rights and the securities purchasable upon exercise of the Rights on an appropriate form, and will use its best efforts to cause such registration statement to (A) become effective as soon as practicable after such filing and (B) remain effective (with a prospectus at all times meeting the requirements of the Act) until the Expiration Date;

23

(ii) use its best efforts to qualify or register the Rights and the securities purchasable upon exercise of the Rights under the blue sky laws of such jurisdictions as may be necessary or appropriate; and

(iii) deliver to holders of the Rights historical financial statements for the Principal Party and each of its Affiliates that comply in all respects with the requirements for registration on Form 10 under the Exchange Act.

The provisions of this Section 13 shall similarly apply to successive mergers or consolidations or sales or other transfers. In the event that a Section 13 Event shall occur at the same time as, or at any time after, the occurrence of a
Section 11(a)(ii) Event, the Rights that have not theretofore been exercised shall thereafter become exercisable in the manner described in Section 13(a).

(d) Notwithstanding anything in this Agreement to the contrary, Section 13 shall not be applicable to a transaction described in subparagraphs (x) and (y) of Section 13(a) if (i) such transaction is consummated with a Person or Persons (or a wholly owned subsidiary of any such Person or Persons) who acquired shares of Common Stock pursuant to a Permitted Offer, (ii) the price per share of Common Stock paid in such transaction is not less than the price per share of Common Stock paid to all holders of shares of Common Stock whose shares were purchased pursuant to such Permitted Offer, and (iii) the form of consideration paid in such transaction is the same as the form of consideration paid pursuant to such Permitted Offer. Upon consummation of any such transaction contemplated by this Section 13(d), all Rights hereunder shall expire.

Section 14. Fractional Rights and Fractional Shares.

(a) The Company shall not be required to issue fractions of Rights, except prior to the Distribution Date as provided in Section 11(i) or (p) hereof, or to distribute Rights Certificates that evidence fractional Rights. In lieu of such fractional Rights, there shall be paid to the registered holders of the Rights Certificates with regard to which such fractional Rights would otherwise be issuable, an amount in cash equal to the same fraction of the current market value of a whole Right. For purposes of this Section 14(a), the current market value of a whole Right shall be the closing price of the Rights for the Trading Day immediately prior to the date on which such fractional Rights would have been otherwise issuable. The closing price of the Rights for any day shall be the last sale price, regular way, or, in case no such sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case as reported in the principal consolidated transaction reporting system with respect to securities listed or admitted to trading on the principal national securities exchange on which the Rights are listed or admitted to trading, or if the Rights are not listed or admitted to trading on any national securities exchange, the last quoted price or, if not so quoted, the average of the high bid and the low asked prices in the over-the-counter market, as reported by Nasdaq or such other system then in use or, if on any such date the Rights are not quoted by any such organization, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the Rights selected by the Board. All references in this Section to closing prices, last quoted prices or other stock prices means prices during regular trading hours, without giving effect to any after-hours or extended hours trading. If on any such date no such market maker is making a market in the Rights, the fair value of the Rights on such date as determined in good faith by the Board shall be

24

used, which determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes.

(b) The Company shall not be required to issue fractions of shares of Preferred Stock (other than fractions that are integral multiples of one ten-thousandth of a share of Preferred Stock) upon exercise of the Rights or to distribute certificates that evidence fractional shares of Preferred Stock (other than fractions that are integral multiples of one ten-thousandth of a share of Preferred Stock). Fractional shares of Preferred Stock in integral multiples of one ten-thousandth of a share of Preferred Stock may, at the election of the Company, be evidenced by depositary receipts; provided, however, that holders of such depositary receipts shall have all of the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions to which they are entitled as beneficial owners of the shares of Preferred Stock represented by such depositary receipts. In lieu of fractional shares of Preferred Stock (other than fractions that are integral multiples of one ten-thousandth of a share of Preferred Stock), the Company shall pay to the registered holders of Rights Certificates at the time such Rights are exercised as herein provided an amount in cash equal to the same fraction of the current market value of one ten-thousandth of a share of Preferred Stock. For purposes of this Section 14(b), the current market value of one ten-thousandth of a share of Preferred Stock shall be one ten-thousandth of the closing price of a share of Preferred Stock (as determined pursuant to Section 11(d)(ii) hereof) for the Trading Day immediately prior to the date of such exercise.

(c) Following the occurrence of a Triggering Event, the Company shall not be required to issue fractions of shares of Common Stock upon exercise of the Rights or to distribute certificates that evidence fractional shares of Common Stock. In lieu of fractional shares of Common Stock, the Company shall pay to the registered holders of Rights Certificates at the time such Rights are exercised as herein provided an amount in cash equal to the same fraction of the current market price of one (1) share of Common Stock (as determined pursuant to
Section 11(d)(i) hereof) for the Trading Day immediately prior to the date of such exercise.

(d) The holder of a Right by the acceptance of such Right expressly waives his right to receive any fractional Rights or any fractional shares upon exercise of a Right, except as permitted by this Section 14.

Section 15. Rights of Action. All rights of action in respect of this Agreement, except the rights of action expressly given to the Rights Agent in Section 18 hereof, are vested in the respective registered holders of the Rights Certificates (and, prior to the Distribution Date, the registered holders of the Common Stock); and any registered holder of any Rights Certificate (or, prior to the Distribution Date, of the Common Stock), without the consent of the Rights Agent or of the holder of any other Rights Certificate (or, prior to the Distribution Date, of the Common Stock), may, in his own behalf and for his own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company to enforce, or otherwise act in respect of, his right to exercise the Rights evidenced by such Rights Certificate in the manner provided in such Rights Certificate and in this Agreement. Without limiting the foregoing or any remedies available to the holders of Rights, it is specifically acknowledged that the holders of Rights would not have an adequate remedy at law for any breach of this Agreement and shall be entitled to specific performance

25

of the obligations hereunder and injunctive relief against actual or threatened violations of the obligations hereunder of any Person subject to this Agreement.

Section 16. Agreement of Rights Holders. Every holder of a Right by accepting the same consents and agrees with the Company and the Rights Agent and with every other holder of a Right that:

(a) prior to the Distribution Date, the Rights will be transferable only in connection with the transfer of Common Stock;

(b) after the Distribution Date, the Rights Certificates are transferable only on the registry books of the Rights Agent if surrendered at the office of the Rights Agent designated for such purposes, duly endorsed or accompanied by a proper instrument of transfer and with the appropriate forms and certificates duly completed and fully executed;

(c) subject to Section 6(a) and Section 7(f) hereof, the Company and the Rights Agent may deem and treat the person in whose name a Rights Certificate (or, prior to the Distribution Date, the associated Common Stock certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any notations of ownership or writing on the Rights Certificates or the associated Common Stock certificate made by anyone other than the Company or the Rights Agent) for all purposes whatsoever, and neither the Company nor the Rights Agent, subject to the penultimate sentence of Section 7(e) hereof, shall be required to be affected by any notice to the contrary; and

(d) notwithstanding anything in this Agreement to the contrary, neither the Company nor the Rights Agent shall have any liability to any holder of a Right or other Person as a result of its inability to perform any of its obligations under this Agreement by reason of any preliminary or permanent injunction or other order, decree or ruling issued by a court of competent jurisdiction or by a governmental, regulatory or administrative agency or commission, or any statute, rule, regulation or executive order promulgated or enacted by any governmental authority, prohibiting or otherwise restraining performance of such obligation; provided, however, the Company must use its best efforts to prevent the issuance of any such order, decree or ruling and to have any such order, decree or ruling lifted or otherwise overturned as soon as possible.

Section 17. Rights Certificate Holder Not Deemed a Stockholder. No holder, as such, of any Rights Certificate shall be entitled to vote, receive dividends or be deemed for any purpose the holder of the number of one ten-thousandths of a share of Preferred Stock or any other securities of the Company that may at any time be issuable on the exercise of the Rights represented thereby, nor shall anything contained herein or in any Rights Certificate be construed to confer upon the holder of any Rights Certificate, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting stockholders (except as provided in Section 25 hereof), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by such Rights Certificate shall have been exercised in accordance with the provisions hereof.

26

Section 18. Concerning the Rights Agent.

(a) The Company agrees to pay to the Rights Agent reasonable compensation for all services rendered by it hereunder and, from time to time, on demand of the Rights Agent, its reasonable expenses and counsel fees and disbursements and other disbursements incurred in the administration and execution of this Agreement and the exercise and performance of its duties hereunder. The Company also agrees to indemnify the Rights Agent for, and to hold it harmless against, any loss, liability or expense, incurred without gross negligence, bad faith or willful misconduct on the part of the Rights Agent, for anything done or omitted by the Rights Agent in connection with the acceptance and administration of this Agreement, including the costs and expenses of defending against any claim of liability in the premises.

(b) The Rights Agent shall be protected and shall incur no liability for or in respect of any action taken, suffered or omitted by it in connection with its administration of this Agreement in reliance upon any Rights Certificate or certificate for Common Stock or for other securities of the Company, instrument of assignment or transfer, power of attorney, endorsement, affidavit, letter, notice, direction, consent, certificate, statement, or other paper or document believed by it to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or Persons, or otherwise upon the advice of counsel as set forth in Section 20 hereof.

Section 19. Merger or Consolidation or Change of Name of Rights Agent.

(a) Any corporation into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or any corporation resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any corporation succeeding to the corporate trust business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided, however, that such corporation would be eligible for appointment as a successor Rights Agent under the provisions of Section 21 hereof. In case at the time such successor Rights Agent shall succeed to the agency created by this Agreement, any of the Rights Certificates shall have been countersigned but not delivered, any such successor Rights Agent may adopt the countersignature of a predecessor Rights Agent and deliver such Rights Certificates so countersigned; and in case at that time any of the Rights Certificates shall not have been countersigned, any successor Rights Agent may countersign such Rights Certificates either in the name of the predecessor or in the name of the successor Rights Agent; and in all such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.

(b) In case at any time the name of the Rights Agent shall be changed and at such time any of the Rights Certificates shall have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Rights Certificates so countersigned; and in case at that time any of the Rights Certificates shall not have been countersigned, the Rights Agent may countersign such Rights Certificates either in its prior name or in its changed name; and in all such cases such Rights Certificates shall have the full force provided in the Rights Certificates and in this Agreement.

27

Section 20. Duties of Rights Agent. The Rights Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, by all of which the Company and the holders of Rights Certificates, by their acceptance thereof, shall be bound:

(a) The Rights Agent may consult with legal counsel (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete authorization and protection to the Rights Agent as to any action taken or omitted by it in good faith and in accordance with such opinion.

(b) Whenever in the performance of its duties under this Agreement the Rights Agent shall deem it necessary or desirable that any fact or matter (including, without limitation, the identity of any Acquiring Person and the determination of "current market price") be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chairman of the Board, the President, any Vice President, the Treasurer, any Assistant Treasurer, the Secretary or any Assistant Secretary of the Company and delivered to the Rights Agent; and such certificate shall be full authorization to the Rights Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.

(c) The Rights Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct.

(d) The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement or in the Rights Certificates or be required to verify the same (except as to its countersignature on such Rights Certificates), but all such statements and recitals are and shall be deemed to have been made by the Company only.

(e) The Rights Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Rights Agent) or in respect of the validity or execution of any Rights Certificate (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Rights Certificate; nor shall it be responsible for any adjustment required under the provisions of Section 11,
Section 13 or Section 24 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment (except with respect to the exercise of Rights evidenced by Rights Certificates after receipt of a certificate describing any such adjustment, delivered pursuant to Section 12); nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock or Preferred Stock to be issued pursuant to this Agreement or any Rights Certificate or as to whether any shares of Common Stock or Preferred Stock will, when so issued, be validly authorized and issued, fully paid and nonassessable.

(f) The Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.

28

(g) The Rights Agent is hereby authorized and directed to accept instructions with respect to the performance of its duties hereunder from the Chairman of the Board, the President, any Vice President, the Secretary, any Assistant Secretary, the Treasurer or any Assistant Treasurer of the Company, and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable for any action taken or suffered to be taken by it in good faith in accordance with instructions of any such officer. Any application by the Rights Agent for written instructions from the Company may, at the option of the Rights Agent, set forth in writing any action proposed to be taken or omitted by the Rights Agent with respect to its duties or obligations under this Rights Agreement and the date on and/or after which such action shall be taken or omitted and the Rights Agent shall not be liable for any action taken or omitted in accordance with a proposal included in any such application on or after the date specified therein (which date shall not be less than five Business Days after the date any such officer actually receives such application, unless any such officer shall have consented in writing to an earlier date) unless, prior to taking or omitting any such action, the Rights Agent has received written instructions in response to such application specifying the action to be taken or omitted.

(h) The Rights Agent and any stockholder, director, officer or employee of the Rights Agent may buy, sell or deal in any of the Rights or other securities of the Company or become pecuniarily interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Rights Agent under this Agreement. Nothing herein shall preclude the Rights Agent from acting in any other capacity for the Company or for any other legal entity.

(i) The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company resulting from any such act, default, neglect or misconduct; provided, however, reasonable care was exercised in the selection and continued employment thereof.

(j) No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.

(k) If, with respect to any Rights Certificate surrendered to the Rights Agent for exercise or transfer, the certificate attached to the form of assignment or form of election to purchase, as the case may be, has not been completed, the Company and the Rights Agent will deem the beneficial owner of the rights evidenced by such Rights Certificate to be an Acquiring Person or an Affiliate or Associate thereof and such assignment or election to purchase will not be honored.

Section 21. Change of Rights Agent. The Rights Agent or any successor Rights Agent may resign and be discharged from its duties under this Agreement upon 30 days' notice in writing mailed to the Company, and to each transfer agent of the Common Stock and Preferred Stock, by registered or certified mail, and to the

29

holders of the Rights Certificates by first-class mail. The Company may remove the Rights Agent or any successor Rights Agent upon 30 days' notice in writing, mailed to the Rights Agent or successor Rights Agent, as the case may be, and to each transfer agent of the Common Stock and Preferred Stock, by registered or certified mail, and to the holders of the Rights Certificates by first-class mail. If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Rights Agent. If the Company shall fail to make such appointment within a period of 30 days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of a Rights Certificate (who shall, with such notice, submit his Rights Certificate for inspection by the Company), then any registered holder of any Rights Certificate may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be (a) a corporation organized and doing business under the laws of the United States (or of any state of the United States) in good standing, which is authorized under such laws to exercise corporate trust or stock transfer powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment as Rights Agent a combined capital and surplus of at least $50,000,000 or (b) an affiliate of a corporation described in clause (a) of this sentence. After appointment, the successor Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent of the Common Stock and the Preferred Stock, and mail a notice thereof in writing to the registered holders of the Rights Certificates. Failure to give any notice provided for in this Section 21, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be.

Section 22. Issuance of New Rights Certificates. Notwithstanding any of the provisions of this Agreement or of the Rights to the contrary, the Company may, at its option, issue new Rights Certificates evidencing Rights in such form as may be approved by the Board to reflect any adjustment or change in the Purchase Price and the number or kind or class of shares or other securities or property purchasable under the Rights Certificates made in accordance with the provisions of this Agreement.

Section 23. Redemption.

(a) The Board of Directors of the Company may, at its option, at any time prior to the earlier of (i) the close of business on the tenth day following the Stock Acquisition Date (or, if the Stock Acquisition Date shall have occurred prior to the Record Date, the close of business on the tenth day following the Record Date), or (ii) the Final Expiration Date, redeem all but not less than all the then outstanding Rights at a redemption price of $.01 per Right, as such amount may be appropriately adjusted to reflect any stock split, stock dividend or similar transaction occurring after the date hereof (such redemption price being hereinafter referred to as the "Redemption Price") and the Company may, at its option, pay the Redemption Price either in shares of Common Stock (based on

30

the "current market price," as defined in Section 11(d)(i) hereof, of the shares of Common Stock at the time of redemption) or cash; provided, however, that notwithstanding the foregoing if, following the occurrence of a Stock Acquisition Date and following the expiration of the right of redemption set forth above in this Section 23(a), either (i)(A) a Person who is an Acquiring Person shall have transferred or otherwise disposed of a number of shares of Common Stock in one transaction or series of transactions, not directly or indirectly involving the Company or any of its Subsidiaries, such that such Person is thereafter a Beneficial Owner of 10% or less of the outstanding shares of Common Stock, and (B) there are no other Persons, immediately following the occurrence of the event described in clause (A), who are Acquiring Persons, and
(C) a majority of the members of the Board of Directors approve the reinstatement of the right of redemption pursuant to this Section 23, or (ii)(A) the Board Immediately upon the action of the Board ordering the redemption of the Rights, evidence of which shall have been filed with the Rights Agent and without any further action and without any notice, the right to exercise the Rights shall terminate and the only right thereafter of the holders of Rights shall be to receive the Redemption Price for each Right so held. Promptly after the action of the Board ordering the redemption of the Rights, the Company shall give notice of such redemption to the Rights Agent and the holders of the then outstanding Rights by mailing such notice to all such holders at each holder's last address as it appears upon the registry books of the Rights Agent or, prior to the Distribution Date, on the registry books of the Transfer Agent for the Common Stock. Any notice that is mailed in the manner herein provided shall be deemed given, whether or not the holder receives the notice. Each such notice of redemption will state the method by which the payment of the Redemption Price will be made.

(b) In the event of a redemption of the Rights in accordance with this Agreement, the Company may, at its option, discharge all of its obligations with respect to the Rights by (i) issuing a press release announcing the manner of redemption of the Rights in accordance with this Agreement and (ii) mailing payment of the Redemption Price to the registered holders of the Rights at their last addresses as they appear on the registry books of the Rights Agent or, prior to the Distribution Date, on the registry books of the Transfer Agent of the Common Stock, and upon such action, all outstanding Rights and Right Certificates shall be null and void without any further action by the Company.

Section 24. Exchange.

(a) The Board may, at its option, at any time after a Section 11(a)(ii) Event, exchange all or part of the then outstanding and exercisable Rights (which (i) shall not include Rights that have become void pursuant to the provisions of Section 7(e) hereof, and (ii) shall include, without limitation, any Rights issued after the Distribution Date) for shares of Common Stock at an exchange ratio of one share of Common Stock per Right, appropriately adjusted to reflect any stock split, stock dividend or similar transaction occurring after the date hereof (such exchange ratio being hereinafter referred to as the "Exchange Ratio"). Notwithstanding the foregoing, the Board shall not be empowered to effect such exchange at any time after any Person (other than the Company, any Subsidiary of the Company, any employee benefit plan of the Company or any such Subsidiary, or any entity holding Common Stock for or pursuant to the terms of any such plan), together with all Affiliates and Associates of such Person, becomes the Beneficial Owner of 50% or more of the shares of Common Stock then outstanding.

31

(b) Immediately upon the action of the Board ordering the exchange of any Rights pursuant to subsection (a) of this Section 24, evidence of which shall have been filed with the Rights Agent, and without any further action and without any notice, the right to exercise such Rights shall terminate and the only right thereafter of a holder of such Rights shall be to receive that number of shares of Common Stock equal to the number of such Rights held by such holder multiplied by the Exchange Ratio. The Company shall promptly give public notice of any such exchange; provided, however, that the failure to give, or any defect in, such notice shall not affect the validity of such exchange. The Company promptly shall mail a notice of any such exchange to all of the holders of such Rights at their last addresses as they appear upon the registry books of the Rights Agent. Any notice that is mailed in the manner herein provided shall be deemed given, whether or not the holder receives the notice. Each such notice of exchange shall state the method by which the exchange of shares of Common Stock for Rights will be effected and, in the event of any partial exchange, the number of Rights that will be exchanged. Any partial exchange shall be effected pro rata based on the number of Rights (other than Rights that have become void pursuant to the provisions of Section 7(e) hereof) held by each holder of Rights.

(c) In any exchange pursuant to this Section 24, the Company, at its option, may substitute Preferred Stock (or equivalent preferred stock, as such term is defined in Section 11(b) hereof) for shares of Common Stock exchangeable for Rights, at the initial rate of one ten-thousandth of a share of Preferred Stock (or equivalent preferred stock) for each share of Common Stock, as appropriately adjusted to reflect adjustments in the voting rights of the Preferred Stock pursuant to Section 3(A) of the Certificate of Designations attached hereto as Exhibit A, so that the fraction of a share of Preferred Stock (or equivalent preferred stock) delivered in lieu of each share of Common Stock shall have the same voting rights as one share of Common Stock.

(d) In the event that there shall not be sufficient shares of Common Stock or Preferred Stock issued but not outstanding or authorized but unissued to permit any exchange of Rights as contemplated in accordance with this Section 24, the Company shall take all such action as may be necessary to authorize additional shares of Common Stock or Preferred Stock for issuance upon exchange of the Rights.

(e) The Company shall not be required to issue fractions of shares of Common Stock or to distribute certificates that evidence fractional shares of Common Stock. In lieu of such fractional shares of Common Stock, there shall be paid to the registered holders of the Right Certificates with regard to which such fractional shares of Common Stock would otherwise be issuable, an amount in cash equal to the same fraction of the current market value of a whole share of Common Stock. For the purposes of this subsection (e), the current market value of a whole share of Common Stock shall be the closing price per share of Common Stock (as determined pursuant to the second sentence of Section 11(d)(i) hereof) for the Trading Day immediately prior to the date of exchange pursuant to this
Section 24.

Section 25. Notice of Certain Events.

(a) In case the Company shall propose, at any time after the Distribution Date, (i) to pay any dividend payable in stock of any class to the holders of Preferred Stock or to make any other distribution to the holders of Preferred

32

Stock (other than a regular quarterly cash dividend out of earnings or retained earnings of the Company), or (ii) to offer to the holders of Preferred Stock rights or warrants to subscribe for or to purchase any additional shares of Preferred Stock or shares of stock of any class or any other securities, rights or options, or (iii) to effect any reclassification of its Preferred Stock (other than a reclassification involving only the subdivision of outstanding shares of Preferred Stock), or (iv) to effect any consolidation or merger into or with any other Person (other than a Subsidiary of the Company in a transaction that complies with Section 11(o) hereof), or to effect any sale or other transfer (or to permit one or more of its Subsidiaries to effect any sale or other transfer), in one transaction or a series of related transactions, of more than 50% of the assets or earning power of the Company and its Subsidiaries (taken as a whole) to any other Person or Persons (other than the Company and/or any of its Subsidiaries in one or more transactions each of which complies with
Section 11(o) hereof), or (v) to effect the liquidation, dissolution or winding up of the Company, then, in each such case, the Company shall give to each holder of a Rights Certificate, to the extent feasible and in accordance with
Section 26 hereof, a notice of such proposed action, which shall specify the record date for the purposes of such stock dividend, distribution of rights or warrants, or the date on which such reclassification, consolidation, merger, sale, transfer, liquidation, dissolution, or winding up is to take place and the date of participation therein by the holders of the shares of Preferred Stock, if any such date is to be fixed, and such notice shall be so given in the case of any action covered by clause (i) or (ii) above at least 20 days prior to the record date for determining holders of the shares of Preferred Stock for purposes of such action, and in the case of any such other action, at least 20 days prior to the date of the taking of such proposed action or the date of participation therein by the holders of the shares of Preferred Stock, whichever shall be the earlier.

(b) In case a Section 11(a)(ii) Event shall occur, then, in any such case,
(i) the Company shall as soon as practicable thereafter give to each holder of a Rights Certificate, to the extent feasible and in accordance with Section 26 hereof, a notice of the occurrence of such event, which shall specify the event and the consequences of the event to holders of Rights under Section 11(a)(ii) hereof, and (ii) all references in the preceding paragraph to Preferred Stock shall be deemed thereafter to refer also to Common Stock and/or, if appropriate, other securities; provided that the failure to give such notice shall not affect the validity of such consent.

Section 26. Notices. Notices or demands authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Rights Certificate to or on the Company shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed (until another address is filed in writing with the Rights Agent) as follows:

Thermo Electron Corporation 81 Wyman Street Waltham, Massachusetts 02454 Attention: Corporate Secretary

Subject to the provisions of Section 21, any notice or demand authorized by this Agreement to be given or made by the Company or by the holder of any Rights Certificate to or on the Rights Agent shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed (until another address is filed in writing with the Company) as follows:

33

American Stock Transfer & Trust Company 59 Maiden Lane New York, NY 10038 Attention: Corporate Trust Department

Notices or demands authorized by this Agreement to be given or made by the Company or the Rights Agent to the holder of any Rights Certificate (or, if prior to the Distribution Date, to the holder of certificates representing shares of Common Stock) shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company.

Section 27. Supplements and Amendments. Except as provided in the penultimate sentence of this Section 27, for so long as the Rights are then redeemable, the Company may, in its sole and absolute discretion, and the Rights Agent shall, if the Company so directs, supplement or amend any provision of this Agreement in any respect without the approval of any holders of the Rights. At any time when the Rights are no longer redeemable, except as provided in the penultimate sentence of this Section 27, the Company may, by approval of at least 75% of the members of the Board, and the Rights Agent shall, if the Company so directs, supplement or amend this Agreement without the approval of any holders of Rights in order (i) to cure any ambiguity or (ii) to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein, provided that no such supplement or amendment shall adversely affect the interests of the holders of Rights as such (other than an Acquiring Person or an Affiliate or Associate of an Acquiring Person). Upon the delivery of a certificate from an appropriate officer of the Company that states that the proposed supplement or amendment is in compliance with the terms of this Section 27, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything contained in this Agreement to the contrary, no supplement or amendment shall be made that changes the Redemption Price. Prior to the Distribution Date, the interests of the holders of Rights shall be deemed coincident with the interests of the holders of Common Stock.

Section 28. Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective successors and assigns hereunder.

Section 29. Actions by the Board, etc. The Board shall have the exclusive power and authority to administer this Agreement and to exercise all rights and powers specifically granted to the Board or to the Company, or as may be necessary or advisable in the administration of this Agreement, including, without limitation, the right and power to (i) interpret the provisions of this Agreement, and (ii) make all determinations deemed necessary or advisable for the administration of this Agreement (including a determination to redeem or not redeem the Rights or to amend this Agreement). All such actions, calculations, interpretations and determinations (including, for purposes of clause (y) below, all omissions with respect to the foregoing) that are done or made by the Board in good faith, shall (x) be final, conclusive and binding on the Company, the Rights Agent, the holders of the Rights and all other parties, and (y) not subject the Board to any liability to the holders of the Rights.

34

Section 30. Benefits of this Agreement. Nothing in this Agreement shall be construed to give to any Person other than the Company, the Rights Agent and the registered holders of the Rights Certificates (and, prior to the Distribution Date, registered holders of the Common Stock) any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the sole and exclusive benefit of the Company, the Rights Agent and the registered holders of the Rights Certificates (and, prior to the Distribution Date, registered holders of the Common Stock).

Section 31. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated; provided, however, that notwithstanding anything in this Agreement to the contrary, if any such term, provision, covenant or restriction is held by such court or authority to be invalid, void or unenforceable and the Board determines in its good faith judgment that severing the invalid, void or unenforceable language from this Agreement would adversely affect the purpose or effect of this Agreement, the right of redemption set forth in Section 23 hereof shall be reinstated and shall not expire until the close of business on the tenth day following the date of such determination by the Board.

Section 32. Governing Law. This Agreement, each Right and each Rights Certificate issued hereunder shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of Delaware applicable to contracts made and to be performed entirely within Delaware.

Section 33. Counterparts. This Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

Section 34. Descriptive Headings. Descriptive headings of the several Sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

35

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and their respective corporate seals to be hereunto affixed and attested, all as of the day and year first above written.

Attest:                                 THERMO ELECTRON CORPORATION



By:                                     By:
   ------------------------                      -------------------------------
Name:                                   Name:
      ---------------------                      -------------------------------
Title:                                  Title:
      ---------------------                      -------------------------------


Attest:                                 AMERICAN STOCK TRANSFER & TRUST COMPANY



By:                                     By:
   ------------------------                      -------------------------------
Name:                                   Name:
      ---------------------                      -------------------------------
Title:                                  Title:
      ---------------------                      -------------------------------

36

EXHIBIT A

FORM OF

CERTIFICATE OF DESIGNATIONS

OF

SERIES B JUNIOR PARTICIPATING PREFERRED STOCK

OF

THERMO ELECTRON CORPORATION


Thermo Electron Corporation, a corporation organized and existing under the laws of the State of Delaware (hereinafter called the "Corporation"), hereby certifies that the following resolution was adopted by the Board of Directors of the Corporation at a meeting duly called and held on January 19, 1996:

RESOLVED:          That pursuant to the authority  granted to and vested in the
                   Board of Directors of the  Corporation  (hereinafter  called
                   the  "Board")  in  accordance  with  the  provisions  of the
                   Certificate of Incorporation,  as amended,  the Board hereby
                   creates a series of  Preferred  Stock,  $100 par value  (the
                   "Preferred Stock"), of the Corporation and hereby states the
                   designation  and  number of shares,  and fixes the  relative

rights, preferences and limitations thereof as follows:

Series B Junior Participating Preferred Stock:

Section 1. Designation and Amount. The shares of such series shall be designated as "Series B Junior Participating Preferred Stock" (the "Series B Preferred Stock") and the number of shares constituting the Series B Preferred Stock shall be Forty Thousand (40,000). Such number of shares may be increased or decreased by resolution of the Board prior to issuance; provided, that no decrease shall reduce the number of shares of Series B Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Corporation convertible into Series B Preferred Stock.

Section 2. Dividends and Distributions.

(A) Subject to the rights of the holders of any shares of any series of Preferred Stock (or any similar stock) ranking prior and superior to the Series B Preferred Stock with respect to dividends, the holders of shares of Series B Preferred Stock, in preference to the holders of Common Stock, par value $1.00 per share (the "Common Stock"), of the Corporation, and of any other junior stock, shall be entitled to receive, when, as and if declared by the Board out of funds of the Corporation legally available for the payment of dividends, quarterly dividends payable in cash on March 31, June 30, September 30 and December 31 in each year (each such date being referred to herein as a

A-1

"Quarterly Dividend Payment Date"), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of Series B Preferred Stock, in an amount per share (rounded to the nearest cent) equal to the greater of (a) $100 or (b) subject to the provision for adjustment hereinafter set forth, 10,000 times the aggregate per share amount of all cash dividends, and 10,000 times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions, other than a dividend payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series B Preferred Stock. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the amount to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event under clause (b) of the preceding sentence shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. In the event the Corporation shall at any time declare or pay any dividend on the Series B Preferred Stock payable in shares of Series B Preferred Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Series B Preferred Stock (by reclassification or otherwise than by payment of a dividend in shares of Series B Preferred Stock) into a greater or lesser number of shares of Series B Preferred Stock, then in each such case the amount to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event under clause (b) of the first sentence of this
Section 2(A) shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Series B Preferred Stock that were outstanding immediately prior to such event and the denominator of which is the number of shares of Series B Preferred Stock outstanding immediately after such event.

(B) The Corporation shall declare a dividend or distribution on the Series B Preferred Stock as provided in paragraph (A) of this Section immediately after it declares a dividend or distribution on the Common Stock (other than a dividend payable in shares of Common Stock) and the Corporation shall pay such dividend or distribution on the Series B Preferred Stock before the dividend or distribution declared on the Common Stock is paid or set apart; provided that, in the event no dividend or distribution shall have been declared on the Common Stock during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date, a dividend of $100 per share on the Series B Preferred Stock shall nevertheless be payable on such subsequent Quarterly Dividend Payment Date.

(C) Dividends shall begin to accrue and be cumulative on outstanding shares of Series B Preferred Stock from the Quarterly Dividend Payment Date next preceding the date of issue of such shares, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of shares of Series B Preferred Stock entitled to receive a quarterly dividend

A-2

and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue and be cumulative from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends paid on the shares of Series B Preferred Stock in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share-by-share basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of shares of Series B Preferred Stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall be not more than 60 days prior to the date fixed for the payment thereof.

Section 3. Voting Rights. The holders of shares of Series B Preferred Stock shall have the following voting rights:

(A) Subject to the provision for adjustment hereinafter set forth, each share of Series B Preferred Stock shall entitle the holder thereof to 10,000 votes on all matters submitted to a vote of the stockholders of the Corporation. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the number of votes per share to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event shall be adjusted by multiplying such number by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. In the event the Corporation shall at any time declare or pay any dividend on the Series B Preferred Stock payable in shares of Series B Preferred Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Series B Preferred Stock (by reclassification or otherwise than by payment of a dividend in shares of Series B Preferred Stock) into a greater or lesser number of shares of Series B Preferred Stock, then in each such case the number of votes per share to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Series B Preferred Stock that were outstanding immediately prior to such event and the denominator of which is the number of shares of Series B Preferred Stock outstanding immediately after such event.

(B) Except as otherwise provided herein, the holders of shares of Series B Preferred Stock and the holders of shares of Common Stock and any other capital stock of the Corporation having general voting rights shall vote together as one class on all matters submitted to a vote of stockholders of the Corporation.

(C) (i) If at any time dividends on any Series B Preferred Stock shall be in arrears in an amount equal to six quarterly dividends thereon, the holders of the Series B Preferred Stock, voting as a separate series from all other series of Preferred Stock and classes of capital stock, shall be entitled to elect two members of the Board in addition to any Directors elected by any other series, class or classes of securities and the authorized number of Directors will automatically be increased by two. Promptly thereafter, the Board of Directors of this Corporation shall, as soon as may be practicable, call a special meeting of holders of Series B Preferred Stock for the purpose of electing such members

A-3

of the Board of Directors. Said special meeting shall in any event be held within 45 days of the occurrence of such arrearage.

(ii) During any period when the holders of Series B Preferred Stock, voting as a separate series, shall be entitled and shall have exercised their right to elect two Directors, then, and during such time as such right continues, (a) the then authorized number of Directors shall be increased by two, and the holders of Series B Preferred Stock, voting as a separate series, shall be entitled to elect the additional Directors so provided for, and (b) each such additional Director shall not be a member of any existing class of the Board of Directors, but shall serve until the next annual meeting of stockholders for the election of Directors, or until his or her successor shall be elected and shall qualify, or until his or her right to hold such office terminates pursuant to the provisions of this Section 3(C).

(iii) A Director elected pursuant to the terms hereof may be removed with or without cause by the holders of Series B Preferred Stock entitled to vote in an election of such Director.

(iv) If, during any interval between annual meetings of stockholders for the election of Directors and while the holders of Series B Preferred Stock shall be entitled to elect two Directors, there is no such Director in office by reason of resignation, death or removal, then, promptly thereafter, the Board shall call a special meeting of the holders of Series B Preferred Stock for the purpose of filling such vacancy and such vacancy shall be filled at such special meeting. Such special meeting shall in any event be held within 45 days of the occurrence of such vacancy.

(v) At such time as the arrearage is fully cured, and all dividends accumulated and unpaid on any shares of Series B Preferred Stock outstanding are paid, and, in addition thereto, at least one regular dividend has been paid subsequent to curing such arrearage, the term of office of any Director elected pursuant to this Section 3(C), or his or her successor, shall automatically terminate, and the authorized number of Directors shall automatically decrease by two, the rights of the holders of the shares of the Series B Preferred Stock to vote as provided in this Section 3(C) shall cease, subject to renewal from time to time upon the same terms and conditions, and the holders of shares of the Series B Preferred Stock shall have only the limited voting rights elsewhere herein set forth.

(D) Except as set forth herein, or as otherwise provided by law, holders of Series B Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for taking any corporate action.

Section 4. Certain Restrictions.

(A) Whenever quarterly dividends or other dividends or distributions payable on the Series B Preferred Stock as provided in Section 2 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on shares of Series B Preferred Stock outstanding shall have been paid in full, the Corporation shall not:

A-4

(i) declare or pay dividends, or make any other distributions, on any shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series B Preferred Stock;

(ii) declare or pay dividends, or make any other distributions, on any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series B Preferred Stock, except dividends paid ratably on the Series B Preferred Stock and all such parity stock on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled;

(iii) redeem or purchase or otherwise acquire for consideration shares of any stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series B Preferred Stock, provided that the Corporation may at any time redeem, purchase or otherwise acquire shares of any such junior stock in exchange for shares of any stock of the Corporation ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series B Preferred Stock; or

(iv) redeem or purchase or otherwise acquire for consideration any shares of Series B Preferred Stock, or any shares of stock ranking on a parity with the Series B Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board) to all holders of such shares upon such terms as the Board, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and equitable treatment among the respective series or classes.

(B) The Corporation shall not permit any subsidiary of the Corporation to purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under paragraph (A) of this Section 4, purchase or otherwise acquire such shares at such time and in such manner.

Section 5. Reacquired Shares. Any shares of Series B Preferred Stock purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and cancelled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock subject to the conditions and restrictions on issuance set forth herein or in any other Certificate of Designation creating a series of Preferred Stock or any similar stock or as otherwise required by law.

Section 6. Liquidation, Dissolution or Winding Up.

(A) Upon any liquidation, dissolution or winding up of the Corporation, no distribution shall be made (1) to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series B Preferred Stock unless, prior thereto, the holders of shares of Series B Preferred Stock shall have received $100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment, provided that the holders of shares of Series B Preferred Stock shall be entitled to receive an aggregate amount per share,

A-5

subject to the provision for adjustment hereinafter set forth, equal to 10,000 times the aggregate amount to be distributed per share to holders of shares of Common Stock, or (2) to the holders of shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series B Preferred Stock, except distributions made ratably on the Series B Preferred Stock and all such parity stock in proportion to the total amounts to which the holders of all such shares are entitled upon such liquidation, dissolution or winding up.

(B) Neither the consolidation, merger or other business combination of the Corporation with or into any other corporation nor the sale, lease, exchange or conveyance of all or any part of the property, assets or business of the Corporation shall be deemed to be a liquidation, dissolution or winding up of the Corporation for purposes of this Section 6.

(C) In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the aggregate amount to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event under the proviso in clause (1) of paragraph (A) of this Section 6 shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. In the event the Corporation shall at any time declare or pay any dividend on the Series B Preferred Stock payable in shares of Series B Preferred Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Series B Preferred Stock (by reclassification or otherwise than by payment of a dividend in shares of Series B Preferred Stock) into a greater or lesser number of shares of Series B Preferred Stock, then in each such case the aggregate amount to which holders of shares of Series B Preferred Stock were entitled immediately prior to such event under the proviso in clause (1) of paragraph (A) of this Section 6 shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Series B Preferred Stock that were outstanding immediately prior to such event and the denominator of which is the number of shares of Series B Preferred Stock outstanding immediately after such event.

Section 7. Consolidation, Merger, etc. Notwithstanding anything to the contrary contained herein, in case the Corporation shall enter into any consolidation, merger, combination or other transaction in which the shares of Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case each share of Series B Preferred Stock shall at the same time be similarly exchanged or changed into an amount per share, subject to the provision for adjustment hereinafter set forth, equal to 10,000 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, into which or for which each share of Common Stock is changed or exchanged. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the amount set forth in the preceding sentence with respect to the exchange or change of shares of Series B Preferred Stock shall be adjusted by multiplying such amount by a fraction, the

A-6

numerator of which is the number of shares of Common Stock outstanding immediately after such event and the denominator of which is the number of shares of Common Stock that were outstanding immediately prior to such event. In the event the Corporation shall at any time declare or pay any dividend on the Series B Preferred Stock payable in shares of Series B Preferred Stock, or effect a subdivision, combination or consolidation of the outstanding shares of Series B Preferred Stock (by reclassification or otherwise than by payment of a dividend in shares of Series B Preferred Stock) into a greater or lesser number of shares of Series B Preferred Stock, then in each such case the amount set forth in the first sentence of this Section 7 with respect to the exchange or change of shares of Series B Preferred Stock shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of shares of Series B Preferred Stock that were outstanding immediately prior to such event and the denominator of which is the number of shares of Series B Preferred Stock outstanding immediately after such event.

Section 8. No Redemption. The shares of Series B Preferred Stock shall not be redeemable.

Section 9. Rank. The Series B Preferred Stock shall rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of the Preferred Stock issued either before or after the issuance of the Series B Preferred Stock, unless the terms of any such series shall provide otherwise.

Section 10. Amendment. The Certificate of Incorporation, as amended, of the Corporation shall not be amended in any manner that would materially alter or change the powers, preferences or special rights of the Series B Preferred Stock so as to affect them adversely without the affirmative vote of the holders of at least two-thirds of the outstanding shares of Series B Preferred Stock, voting together as a single class.

Section 11. Fractional Shares. Series B Preferred Stock may be issued in fractions of a share that shall entitle the holder, in proportion to such holder's fractional shares, to exercise voting rights, receive dividends, participate in distributions and have the benefit of all other rights of holders of Series B Preferred Stock.

IN WITNESS WHEREOF, this Certificate of Designations is executed on behalf of the Corporation by its President and Chief Executive Officer this 19th day of January, 1996.

THERMO ELECTRON CORPORATION

By:     /s/ George N. Hatsopoulos
        --------------------------------------
        George N. Hatsopoulos
        Chairman of the Board and President


EXHIBIT B
[Form of Rights Certificate]

Certificate No. R- ______ Rights

NOT EXERCISABLE AFTER JANUARY 29, 2006 OR EARLIER IF REDEEMED OR EXCHANGED BY THE COMPANY. THE RIGHTS ARE SUBJECT TO REDEMPTION AT $.01 PER RIGHT AND TO EXCHANGE ON THE TERMS SET FORTH IN THE RIGHTS AGREEMENT. UNDER CERTAIN CIRCUMSTANCES, RIGHTS BENEFICIALLY OWNED BY AN ACQUIRING PERSON (AS SUCH TERM IS DEFINED IN THE RIGHTS AGREEMENT) AND ANY SUBSEQUENT HOLDER OF SUCH RIGHTS MAY BECOME NULL AND VOID. [THE RIGHTS REPRESENTED BY THIS RIGHTS CERTIFICATE ARE OR WERE BENEFICIALLY OWNED BY A PERSON WHO WAS OR BECAME AN ACQUIRING PERSON OR AN AFFILIATE OR ASSOCIATE OF AN ACQUIRING PERSON (AS SUCH TERMS ARE DEFINED IN THE RIGHTS AGREEMENT). ACCORDINGLY, THIS RIGHTS CERTIFICATE AND THE RIGHTS REPRESENTED HEREBY MAY BECOME NULL AND VOID IN THE CIRCUMSTANCES SPECIFIED IN
SECTION 7(e) OF SUCH AGREEMENT.]*

Rights Certificate

THERMO ELECTRON CORPORATION

This certifies that , or registered assigns, is the registered owner of the number of Rights set forth above, each of which entitles the owner thereof, subject to the terms, provisions and conditions of the Rights Agreement, dated as of January 19, 1996 (as amended, the "Rights Agreement"), between Thermo Electron Corporation, a Delaware corporation (the "Company"), and American Stock Transfer & Trust Company (the "Rights Agent"), to purchase from the Company after the Distribution Date (as such term is defined on the Rights Agreement) and at any time prior to 5:00 P.M. (Boston time) on January 29, 2006 at the office of the Rights Agent designated for such purpose, or its successors as Rights Agent, one ten-thousandth of a fully paid, non-assessable share of Series B Junior Participating Preferred Stock (the "Preferred Stock") of the Company, $100 par value per share, at a purchase price of $250.00 in cash per one ten-thousandth of a share (the "Purchase Price"), upon presentation and surrender of this Rights Certificate with the Form of Election to Purchase and related Certificate duly executed. The number of Rights evidenced by this Rights Certificate (and the number of one ten-thousandths of a share of Preferred Stock which may be purchased upon exercise hereof) set forth above, and the Purchase Price set forth above, are the number and Purchase Price as of the close of business on January 29, 1996, based on the Preferred Stock as constituted at

* The portion of the legend in brackets shall be inserted only if applicable and shall replace the preceding sentence.

B-1

such date. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Rights Agreement.

Upon the occurrence of a Section 11(a)(ii) Event, if the Rights evidenced by this Rights Certificate are beneficially owned by (i) an Acquiring Person or an Affiliate or Associate of any such Acquiring Person (as such terms are defined in the Rights Agreement), (ii) a transferee of any such Acquiring Person, Associate or Affiliate who becomes a transferee after the Acquiring Person becomes an Acquiring Person, or (iii) under certain circumstances specified in the Rights Agreement, a transferee of a person who, concurrently with or after such transfer, became an Acquiring Person, or an Affiliate or Associate of an Acquiring Person, such Rights shall become null and void and no holder hereof shall have any right with respect to such Rights from and after the occurrence of such Section 11(a)(ii) Event.

As provided in the Rights Agreement, the Purchase Price and the number and kind of shares of Preferred Stock or other securities which may be purchased upon the exercise of the Rights evidenced by this Rights Certificate are subject to modification and adjustment upon the happening of certain events, including
Section 11(a)(ii) Events.

This Rights Certificate is subject to all of the terms, provisions and conditions of the Rights Agreement, which terms, provisions and conditions are hereby incorporated herein by reference and made a part hereof and to which Rights Agreement reference is hereby made for a full description of the rights, limitations of rights, obligations, duties and immunities hereunder of the Rights Agent, the Company and the holders of the Rights Certificates, which limitations of rights include the temporary suspension of the exercisability of such Rights under the specific circumstances set forth in the Rights Agreement. Copies of the Rights Agreement are on file at the principal offices of the Company and are available upon written request to the Company.

This Rights Certificate, with or without other Rights Certificates, upon surrender at the office of the Rights Agent designated for such purpose, with the Form of Election and Certificate set forth on the reverse side duly executed, may be exchanged for another Rights Certificate or Rights Certificates of like tenor and date evidencing Rights entitling the holder to purchase a like aggregate number of one ten-thousandths of a share of Preferred Stock as the Rights evidenced by the Rights Certificate or Rights Certificates surrendered shall have entitled such holder to purchase. If this Rights Certificate shall be exercised in part, the holder shall be entitled to receive upon surrender hereof another Rights Certificate or Rights Certificates for the number of whole Rights not exercised.

Subject to the provisions of the Rights Agreement, the Rights evidenced by this Certificate may be redeemed by the Company at its option at a redemption price of $.01 per Right at any time prior to the earlier of the close of business on (i) the tenth day following the Stock Acquisition Date (as such time period may be extended pursuant to the Rights Agreement), and (ii) the Final Expiration Date.

Subject to the provisions of the Rights Agreement, the Company may, at its option, at any time after a Section 11(a)(ii) Event, exchange all or part of the Rights evidenced by this Certificate for shares of the Company's Common Stock or for Preferred Stock (or shares of a class or series of the Company's preferred stock having the same rights, privileges and preferences as the Preferred Stock).

B-2

No fractional shares of Preferred Stock will be issued upon the exercise of any Right or Rights evidenced hereby (other than fractions which are integral multiples of one ten-thousandth of a share of Preferred Stock, which may, at the election of the Company, be evidenced by depositary receipts), but in lieu thereof a cash payment will be made, as provided in the Rights Agreement.

No holder of this Rights Certificate, as such, shall be entitled to vote or receive dividends or be deemed for any purpose the holder of shares of Preferred Stock or of any other securities of the Company which may at any time be issuable on the exercise hereof, nor shall anything contained in the Rights Agreement or herein be construed to confer upon the holder hereof, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action, or to receive notice of meetings or other actions affecting stockholders (except as provided in the Rights Agreement), or to receive dividends or subscription rights, or otherwise, until the Right or Rights evidenced by this Rights Certificate shall have been exercised as provided in the Rights Agreement.

This Rights Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the Rights Agent.

WITNESS the facsimile signature of the proper officers of the Company and its corporate seal.

Dated as of _______________, _____

ATTEST: THERMO ELECTRON CORPORATION

By:

Secretary Title:

COUNTERSIGNED:

American Stock Transfer & Trust Company, as Rights Agent

By:

Authorized Signature

B-3

FORM OF ELECTION TO PURCHASE

(To be executed if holder desires to exercise Rights represented by the Rights Certificate)

To: American Stock Transfer & Trust Company

The undersigned hereby irrevocably elects to exercise ________ Rights represented by this Rights Certificate to purchase the shares of Preferred Stock issuable upon the exercise of the Rights (or such other securities of the Company or of any other person which may be issuable upon the exercise of the Rights) and requests that certificates for such shares be issued in the name of and delivered to:

Please insert social security ___________________________________ or other identifying number _____________________________________


(Please print name and address)

If such number of Rights shall not be all the Rights evidenced by this Rights Certificate, a new Rights Certificate for the balance of such Rights shall be registered in the name of and delivered to:

Please insert social security ___________________________________ or other identifying number______________________________________


(Please print name and address)

Dated:


Signature

Signature Guaranteed:

B-4

Certificate

The undersigned hereby certifies by checking the appropriate boxes that:

(1) the Rights evidenced by this Rights Certificate [ ] are [ ] are not being exercised by or on behalf of a Person who is or was an Acquiring Person or an Affiliate or Associate thereof (as such terms are defined pursuant to the Rights Agreement);

(2) after due inquiry and to the best knowledge of the undersigned, it [ ] did [ ] did not acquire the Rights evidenced by this Rights Certificate from any Person who is, was or became an Acquiring Person or an Affiliate or Associate thereof.

Dated: ______________, __


Signature

Signature Guaranteed:

NOTICE

The signature to the foregoing Election to Purchase and Certificate must correspond to the name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever.

B-5

[Form of Reverse Side of Rights Certificate]

FORM OF ASSIGNMENT

(To be executed by the registered holder if such holder desires to transfer the Rights Certificate)

FOR VALUE RECEIVED_______________________________________________
hereby sells, assigns and transfers unto_________________________

(Please print name and address of transferee)

this Rights Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and appoint _________________ Attorney, to transfer the within Rights Certificate on the books of the within-named Company, with full power of substitution.

Dated: __________________, ____


Signature

Signature Guaranteed:

Certificate

The undersigned hereby certifies that the Rights evidenced by this Rights Certificate are not beneficially owned by an Acquiring Person or an Affiliate or Associate thereof (as such terms are defined in the Rights Agreement).

Dated: ___________, ____


Signature

Signature Guaranteed:

B-6

EXHIBIT C

SUMMARY OF RIGHTS TO PURCHASE PREFERRED STOCK

On January 19, 1996, the Board of Directors of Thermo Electron Corporation (the "Company") declared a dividend distribution of one Right for each outstanding share of the Company's Common Stock to stockholders of record at the close of business on January 29, 1996. Each Right entitles the registered holder to purchase from the Company a unit consisting of one ten-thousandth of a share (a "Unit") of Series B Junior Participating Preferred Stock, $100 par value (the "Preferred Stock") at a Purchase Price of $250.00 in cash per Unit, subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement (as amended, the "Rights Agreement") between the Company and American Stock Transfer & Trust Company, as Rights Agent.

Initially, the Rights will be attached to all Common Stock certificates representing shares then outstanding, and no separate Rights Certificates will be distributed. The Rights will separate from the Common Stock and a Distribution Date will occur upon the earlier of (i) 10 days following a public announcement that a person or group of affiliated or associated persons (an "Acquiring Person") has acquired, or obtained the right to acquire, beneficial ownership of 15% or more of the outstanding shares of Common Stock (the "Stock Acquisition Date"), or (ii) 10 business days following the commencement of a tender offer or exchange offer that would result in a person or group beneficially owning 15% or more of such outstanding shares of Common Stock. Until the Distribution Date, (i) the Rights will be evidenced by the Common Stock certificates and will be transferred with and only with such Common Stock certificates, (ii) new Common Stock certificates will contain a notation incorporating the Rights Agreement by reference and (iii) the surrender for transfer of any certificates for Common Stock outstanding will also constitute the transfer of the Rights associated with the Common Stock represented by such certificate.

The Rights are not exercisable until the Distribution Date and will expire at the close of business on January 29, 2006, unless earlier redeemed or exchanged by the Company as described below.

As soon as practicable after the Distribution Date, Rights Certificates will be mailed to holders of record of the Common Stock as of the close of business on the Distribution Date and, thereafter, the separate Rights Certificates alone will represent the Rights. Except as otherwise determined by the Board of Directors and except in connection with shares of Common Stock issued upon the exercise of employee stock options, issuances under other employee stock benefit plans or issuances upon the exercise, conversion or exchange of securities issued prior to the Distribution Date, only shares of Common Stock issued prior to the Distribution Date will be issued with Rights.

In the event that a Person becomes the beneficial owner of 15% or more of the then outstanding shares of Common Stock, except pursuant to an offer for all outstanding shares of Common Stock that at least a majority of the Board of

C-1

Directors determines to be fair to, and otherwise in the best interests of, stockholders, each holder of a Right will thereafter have the right to receive, upon exercise, that number of shares of Common Stock (or, in certain circumstances, cash, property or other securities of the Company) which equals the exercise price of the Right divided by one-half of the current market price (as defined in the Rights Agreement) of the Common Stock at the date of the occurrence of the event. However, Rights are not exercisable following the event set forth above until such time as the Rights are no longer redeemable by the Company as set forth below. Notwithstanding any of the foregoing, following the occurrence of such event, all Rights that are, or (under certain circumstances specified in the Rights Agreement) were, beneficially owned by any Acquiring Person will be null and void. The event set forth in this paragraph is referred to as a "Section 11(a)(ii) Event."

For example, at an exercise price of $250.00 per Right, each Right not owned by an Acquiring Person (or by certain related parties) following an event set forth in the preceding paragraph would entitle its holder to purchase for $250.00 such number of shares of Common Stock (or other consideration, as noted above) as equals $250.00 divided by one-half of the current market price (as defined in the Rights Agreement) of the Common Stock. Assuming that the Common Stock had a per share value of $50.00 at such time, the holder of each valid Right would be entitled to purchase ten shares of Common Stock for $250.00.

In the event that, at any time after any person has become an Acquiring Person, (i) the Company is acquired in a merger or other business combination transaction in which the Company is not the surviving corporation or its Common Stock is changed or exchanged (other than a merger which follows an offer determined by the Board of Directors to be fair as described in the first sentence of the second preceding paragraph), or (ii) 50% or more of the Company's assets or earning power is sold or transferred, each holder of a Right (except Rights which previously have been voided as set forth above) shall thereafter have the right to receive, upon exercise, that number of shares of common stock of the acquiring company which equals the exercise price of the Right divided by one-half of the current market price of such common stock at the date of the occurrence of the event.

For example, at an exercise price of $250.00 per Right, each Right following an event set forth in the preceding paragraph would entitle its holder to purchase for $250.00 such number of shares of common stock of the acquiring company as equals $250.00 divided by one-half of the current market price (as defined in the Rights Agreement) of such common stock. Assuming that such common stock had a per share value of $100.00 at such time, the holder of each valid Right would be entitled to purchase five shares of common stock of the acquiring company for $250.00.

At any time after the occurrence of a Section 11(a)(ii) Event, the Board of Directors of the Company may exchange the Rights (other than Rights owned by such Acquiring Person that have become void), in whole or in part, at an exchange ratio of one share of Common Stock, or one ten-thousandth of a share of Preferred Stock (or of a share of a class or series of the Company's preferred

C-2

stock having equivalent rights, preferences and privileges), per Right (subject to adjustment).

The Purchase Price payable, and the number of Units of Preferred Stock or other securities or property issuable, upon exercise of the Rights are subject to adjustment from time to time to prevent dilution (i) in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Preferred Stock, (ii) if holders of the Preferred Stock are granted certain rights or warrants to subscribe for Preferred Stock or convertible securities at less than the current market price of the Preferred Stock, or (iii) upon the distribution to holders of the Preferred Stock of evidences of indebtedness or assets (excluding regular quarterly cash dividends) or of subscription rights or warrants (other than those referred to above).

The number of Rights associated with each share of Common Stock is also subject to adjustment in the event of a stock split of the Common Stock or a stock dividend on the Common Stock payable in Common Stock or subdivisions, consolidations or combinations of Common Stock occurring, in any such case, prior to the Distribution Date. As a result of the Company's three-for-two stock split in the form of a 50% stock dividend in 1996, the number of Rights associated with each share of Common Stock has been reduced from one Right per share of Common Stock to two-thirds of a Right per share of Common Stock.

Preferred Stock purchasable upon exercise of the Rights will not be redeemable. Each share of Preferred Stock will be entitled to a minimum preferential quarterly dividend payment of $100 per share and will be entitled to an aggregate dividend of 10,000 times the dividend declared per share of Common Stock. In the event of liquidation, the holders of the Preferred Stock will be entitled to a minimum preferential liquidating payment of $100 per share and will be entitled to an aggregate payment of 10,000 times the payment made per share of Common Stock. Each share of Preferred Stock will have 10,000 votes, voting together with the Common Stock. Finally, in the event of any merger, consolidation or other transaction in which Common Stock is changed or exchanged, each share of Preferred Stock will be entitled to receive 10,000 times the amount received per share of Common Stock. These rights are protected by customary antidilution provisions and, in accordance therewith, in light of the Company's stock dividend in 1996, currently provide for (i) an aggregate dividend per share of Preferred Stock of 15,000 times the dividend declared per share of Common Stock, (ii) an aggregate payment per share of Preferred Stock, in the event of liquidation, of 15,000 times the payment made per share of Common Stock and (iii) 15,000 votes per share of Preferred Stock, voting together with the Common Stock.

Because of the nature of the Preferred Stock's dividend, liquidation and voting rights, the value of one ten-thousandth of a share of Preferred Stock purchasable upon exercise of each Right should approximate the value of one share of Common Stock. With certain exceptions, no adjustment in the Purchase Price will be required until cumulative adjustments amount to at least 1% of the Purchase Price. No fractional Units will be issued and, in lieu thereof, an adjustment in cash will be made based on the market price of the Preferred Stock on the last trading date prior to the date of exercise.

C-3

At any time until ten days following the Stock Acquisition Date, the Company may redeem the Rights in whole, but not in part, at a price of $.01 per Right (payable in cash or stock). Immediately upon the action of the Board of Directors ordering redemption of the Rights, the Rights will terminate and the only right of the holders of Rights will be to receive the $.01 redemption price. The Rights may also be redeemable following certain other circumstances specified in the Rights Agreement.

Until a Right is exercised, the holder thereof, as such, will have no rights as a stockholder of the Company, including, without limitation, the right to vote or to receive dividends. While the distribution of the Rights will not be taxable to stockholders or to the Company, stockholders may, depending upon the circumstances, recognize taxable income in the event that the Rights become exercisable for Common Stock (or other consideration) of the Company or for common stock of the acquiring company as set forth above.

Prior to the Distribution Date, the terms of the Rights are subject to amendment by the Board of Directors without the consent of the holders of the Rights, except that the redemption price of the Rights is not subject to amendment. After the Distribution Date, only limited terms of the Rights are subject to amendment by the Board.

As long as the Rights are attached to the Common Stock, one Right (as such number may be adjusted pursuant to the provisions of the Rights Agreement) shall be deemed to be delivered for each share of Common Stock issued or delivered by the Company, except that following the Distribution Date and prior to the expiration or redemption of the Rights, the Company (a) shall issue Rights only in respect of shares of common stock issued upon the exercise of stock options or under any employee plan or arrangement, or upon the exercise, conversion or exchange of securities issued before the Distribution Date and (b) may otherwise issue Rights when it issues Common Stock only if the Board of Directors deems it to be necessary or appropriate; provided that no Rights will be issued if the Company is advised by counsel that such issuance would create a significant risk of material adverse tax consequences to the Company or the recipient of the Rights.

A copy of the Rights Agreement has been filed with the Securities and Exchange Commission as an Exhibit to a Registration Statement on Form 8-A dated January 25, 1996, as amended. A copy of the Rights Agreement is available free of charge from the Company. This summary description of the Rights does not purport to be complete and is qualified in its entirety by reference to the Rights Agreement.

C-4

Exhibit 4.3

THERMO ELECTRON CORPORATION

Amendment No. 1 to Rights Agreement

THIS AMENDMENT NO. 1, executed as of February 7, 2002, is made to the RIGHTS AGREEMENT, dated as of October 29, 2001 (the "Agreement"), between Thermo Electron Corporation, a Delaware corporation (the "Company"), and American Stock Transfer & Trust Company, a New York banking corporation, as Rights Agent (the "Rights Agent").

In accordance with the provisions of Section 27 of the Agreement, the Agreement is hereby amended as follows:

1. Section 23 is amended by adding the following new subparagraph (d) at the end thereof:

"(d) The Shareholder Rights Plan Committee of the Company's Board of Directors shall review this Agreement in order to consider whether the maintenance of this Agreement continues to be in the best interests of the Company and its stockholders. The committee shall conduct such review periodically when, as and in such manner as the committee deems appropriate, after giving due regard to all relevant circumstances; provided, however, that the committee shall take such action at least once every three years. Following each such review, the committee will report its conclusions to the Board of Directors of the Company, including any recommendation in light thereof as to whether this Agreement should be modified or the Rights should be redeemed. The committee is authorized to retain such legal counsel, financial advisors and other advisors as the committee deems appropriate in order to assist the committee in carrying out its foregoing responsibilities under this Agreement. The committee shall consist of directors who are eligible to serve on the committee in accordance with the Company's bylaws."

2. Except as amended hereby, the Agreement shall remain unchanged and shall remain in full force and effect.

3. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written.

Attest:                                 THERMO ELECTRON CORPORATION



By:                                       By:
Name:                                    Name:
Title:                                  Title:



Attest:                                 AMERICAN STOCK TRANSFER & TRUST COMPANY

By: By:
Name: Name:
Title: Title:


Exhibit 10.10
THERMO ELECTRON CORPORATION

EQUITY INCENTIVE PLAN

As amended and restated effective as of February 7, 2002

1. Purpose

The purpose of this Equity Incentive Plan (the "Plan") is to secure for Thermo Electron Corporation (the "Company") and its Stockholders the benefits arising from capital stock ownership by employees and directors of, and consultants to, the Company and its subsidiaries or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries. The Plan is intended to accomplish these goals by enabling the Company to offer such persons equity-based interests, equity-based incentives or performance-based stock incentives in the Company, or any combination thereof ("Awards").

2. Administration

The Plan will be administered by the Board of Directors of the Company (the "Board"). The Board shall have full power to interpret and administer the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan and Awards, and full authority to select the persons to whom Awards will be granted ("Participants"), determine the type and amount of Awards to be granted to Participants (including any combination of Awards), determine the terms and conditions of Awards granted under the Plan (including terms and conditions relating to events of merger, consolidation, dissolution and liquidation, change of control, vesting, forfeiture, restrictions, dividends and interest, if any, on deferred amounts), waive compliance by a participant with any obligation to be performed by him or her under an Award, waive any term or condition of an Award, cancel an existing Award in whole or in part with the consent of a Participant, grant replacement Awards, accelerate the vesting or lapse of any restrictions of any Award, correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award and adopt the form of instruments evidencing Awards under the Plan and change such forms from time to time. Any interpretation by the Board of the terms and provisions of the Plan or any Award thereunder and the administration thereof, and all action taken by the Board, shall be final, binding and conclusive on all parties and any person claiming under or through any party. No Director shall be liable for any action or determination made in good faith. The Board may, to the full extent permitted by law, delegate any or all of its responsibilities under the Plan to a committee (the "Committee") appointed by the Board and consisting of members of the Board. All references in the Plan to the "Board" shall mean the Board or a Committee of the Board to the extent that the Board's powers or authority under the Plan have been delegated to such Committee.

3. Effective Date

The Plan shall be effective as of the date first approved by the Board of Directors, subject to the approval of the Plan by the Corporation's

1

Stockholders. Grants of Awards under the Plan made prior to such approval shall be effective when made (unless otherwise specified by the Board at the time of grant), but shall be conditioned on and subject to such approval of the Plan.

4. Shares Subject to the Plan

Subject to adjustment as provided in Section 10.6, the total number of shares of common stock of the Company, par value $1.00 per share ("Common Stock"), reserved and available for distribution under the Plan shall be 15,575,000 shares. Such shares may consist, in whole or in part, of authorized and unissued shares or treasury shares.

If any Award of shares of Common Stock requiring exercise by the Participant for delivery of such shares expires or terminates without having been exercised in full, is forfeited or is otherwise terminated without a payment being made to the Participant in the form of Common Stock, or if any shares of Common Stock subject to restrictions are repurchased by the Company pursuant to the terms of any Award or are otherwise reacquired by the Company to satisfy obligations arising by virtue of any Award, such shares shall be available for distribution in connection with future Awards under the Plan.

5. Eligibility

Employees and Directors of, and consultants to, the Company and its subsidiaries, or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries shall be eligible to receive Awards under the Plan. The Board, or other appropriate committee or person to the extent permitted pursuant to the last sentence of Section 2, shall from time to time select from among such eligible persons those who will receive Awards under the Plan.

6. Types of Awards

The Board may offer Awards under the Plan in any form of equity-based interest, equity-based incentive or performance-based stock incentive in Common Stock of the Company or any combination thereof. The type, terms and conditions and restrictions of an Award shall be determined by the Board at the time such Award is made to a Participant; provided however that the maximum number of shares permitted to be granted under any Award or combination of Awards to any Participant during any one calendar year may not exceed 1,500,000 shares of Common Stock.

An Award shall be made at the time specified by the Board and shall be subject to such conditions or restrictions as may be imposed by the Board and shall conform to the general rules applicable under the Plan as well as any special rules then applicable under federal tax laws or regulations or the federal securities laws relating to the type of Award granted.

Without limiting the foregoing, Awards may take the following forms and shall be subject to the following rules and conditions:

2

6.1 Options

An option is an Award that entitles the holder on exercise thereof to purchase Common Stock at a specified exercise price. Options granted under the Plan may be either incentive stock options ("incentive stock options") that meet the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), or options that are not intended to meet the requirements of
Section 422 ("non-statutory options").

6.1.1 Option Price. The price at which Common Stock may be purchased upon exercise of an option shall be determined by the Board, provided however, the exercise price shall not be less than 85% of the fair market value per share of Common Stock as of the date of grant. The Board shall not have the authority to reprice outstanding stock options granted to directors or executive officers of the Company, except to the extent permitted under Section 10.6 of the Plan in connection with adjustments in the event of certain transactions.

6.1.2 Option Grants. The granting of an option shall take place at the time specified by the Board. Options shall be evidenced by option agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including but not limited to vesting and forfeiture provisions, acceleration, change of control, protection in the event of merger, consolidations, dissolutions and liquidations) as the Board shall deem advisable. Option agreements shall expressly state whether an option grant is intended to qualify as an incentive stock option or non-statutory option.

6.1.3 Option Period. An option will become exercisable at such time or times (which may be immediately or in such installments as the Board shall determine) and on such terms and conditions as the Board shall specify. The option agreements shall specify the terms and conditions applicable in the event of an option holder's termination of employment during the option's term.

Any exercise of an option must be in accordance with the instructions described in "The Guide for Employees of Thermo Electron Corporation Stock Option Plans," as may be amended from time to time (the "Guide").

6.1.4 Payment of Exercise Price. Stock purchased on exercise of an option shall be paid for in accordance with the instructions described in the Guide.

6.1.5 Buyout Provision. The Board may at any time offer to buy out for a payment in cash, shares of Common Stock, deferred stock or restricted stock, an option previously granted, based on such terms and conditions as the Board shall establish and communicate to the option holder at the time that such offer is made.

6.1.6 Special Rules for Incentive Stock Options. Each provision of the Plan and each option agreement evidencing an incentive stock option shall be construed so that each incentive stock option shall be an incentive stock option as defined in Section 422 of the Code or any statutory provision that may replace such Section, and any provisions thereof that cannot be so construed shall be disregarded. Instruments evidencing incentive stock options shall

3

contain such provisions as are required under applicable provisions of the Code. Incentive stock options may be granted only to employees of the Company and its subsidiaries. The exercise price of an incentive stock option shall not be less than 100% (110% in the case of an incentive stock option granted to a more than ten percent stockholder of the Company) of the fair market value of the Common Stock on the date of grant, as determined by the Board. An incentive stock option may not be granted after the tenth anniversary of the date on which the Plan was adopted by the Board and the latest date on which an incentive stock option may be exercised shall be the tenth anniversary (fifth anniversary, in the case of any incentive stock option granted to a more than ten percent stockholder of the Company) of the date of grant, as determined by the Board.

6.2 Restricted and Unrestricted Stock

An Award of restricted stock entitles the recipient thereof to acquire shares of Common Stock upon payment of the purchase price subject to restrictions specified in the instrument evidencing the Award.

6.2.1 Restricted Stock Awards. Awards of restricted stock shall be evidenced by restricted stock agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including restriction and forfeiture provisions, change of control, protection in the event of mergers, consolidations, dissolutions and liquidations) as the Board shall deem advisable.

6.2.2 Restrictions. Until the restrictions specified in a restricted stock agreement shall lapse, restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of, and upon certain conditions specified in the restricted stock agreement, must be resold to the Company for the price, if any, specified in such agreement. The restrictions shall lapse at such time or times, and on such conditions, as the Board may specify. The Board may at any time accelerate the time at which the restrictions on all or any part of the shares shall lapse.

6.2.3 Rights as a Stockholder. A Participant who acquires shares of restricted stock will have all of the rights of a stockholder of the Company with respect to such shares except as otherwise limited pursuant to the Participant's restricted stock agreement. Unless the Board otherwise determines, certificates evidencing shares of restricted stock will remain in the possession of the Company until such shares are free of all restrictions under the Plan.

6.2.4 Purchase Price. The purchase price of shares of restricted stock shall be determined by the Board, in its sole discretion.

6.2.5 Other Awards Settled With Restricted Stock. The Board may provide that any or all the Common Stock delivered pursuant to an Award will be restricted stock.

6.2.6 Unrestricted Stock. The Board may, in its sole discretion, sell to any Participant shares of Common Stock free of restrictions under the Plan for a price determined by the Board, but which may not be less than the par value per share of the Common Stock.

4

6.3 Deferred Stock

6.3.1 Deferred Stock Award. A deferred stock Award entitles the recipient to receive shares of deferred stock, which is Common Stock to be delivered in the future. Delivery of the Common Stock will take place at such time or times, and on such conditions, as the Board may specify. The Board may at any time accelerate the time at which delivery of all or any part of the Common Stock will take place.

6.3.2 Other Awards Settled with Deferred Stock. The Board may, at the time any Award described in this Section 6 is granted, provide that, at the time Common Stock would otherwise be delivered pursuant to the Award, the Participant will instead receive an instrument evidencing the right to future delivery of deferred stock.

6.4 Performance Awards

6.4.1 Performance Awards. A performance Award entitles the recipient to receive, without payment, an amount, in cash or Common Stock or a combination thereof (such form to be determined by the Board), following the attainment of performance goals. Performance goals may be related to personal performance, corporate performance, departmental performance or any other category of performance deemed by the Board to be important to the success of the Company. The Board will determine the performance goals, the period or periods during which performance is to be measured and all other terms and conditions applicable to the Award.

6.4.2 Other Awards Subject to Performance Conditions. The Board may, at the time any Award described in this Section 6 is granted, impose the condition (in addition to any conditions specified or authorized in this Section 6 of the Plan) that performance goals be met prior to the Participant's realization of any payment or benefit under the Award.

7. Purchase Price and Payment

Except as otherwise provided in the Plan, the purchase price of Common Stock to be acquired pursuant to an Award shall be the price determined by the Board, provided that such price shall not be less than the par value of the Common Stock. Except as otherwise provided in the Plan, the Board may determine the method of payment of the exercise price or purchase price of an Award granted under the Plan and the form of payment. The Board may determine that all or any part of the purchase price of Common Stock pursuant to an Award has been satisfied by past services rendered by the Participant. The Board may agree at any time, upon request of the Participant, to defer the date on which any payment under an Award will be made.

5

8. Intentionally Omitted

9. Change in Control

9.1 Impact of Event

In the event of a "Change in Control" as defined in Section 9.2, the following provisions shall apply, unless the agreement evidencing the Award otherwise provides (by specific explicit reference to Section 9.2 below). If a Change in Control occurs while any Awards are outstanding, then, effective upon the Change in Control, (i) each outstanding stock option or other stock-based Award awarded under the Plan that was not previously exercisable and vested shall become immediately exercisable in full and will no longer be subject to a right of repurchase by the Company, (ii) each outstanding restricted stock award or other stock-based Award subject to restrictions and to the extent not fully vested, shall be deemed to be fully vested, free of restrictions and no longer subject to a right of repurchase by the Company, and (iii) deferral limitations and conditions that relate solely to the passage of time, continued employment or affiliation will be waived and removed as to deferred stock Awards and performance Awards; performance of other conditions (other than conditions relating solely to the passage of time, continued employment or affiliation) will continue to apply unless otherwise provided in the agreement evidencing the Award or in any other agreement between the Participant and the Company or unless otherwise agreed by the Board.

9.2 Definition of "Change in Control"

"Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of beneficial ownership of any capital stock of Thermo Electron Corporation ("Thermo Electron") if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of Thermo Electron (the "Outstanding TMO Common Stock") or (ii) the combined voting power of the then-outstanding securities of Thermo Electron entitled to vote generally in the election of directors (the "Outstanding TMO Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by Thermo Electron, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Thermo Electron or any corporation controlled by Thermo Electron, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this definition; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board of Directors of Thermo Electron (the "Thermo Board") (or, if applicable, the Board of Directors of a successor corporation to Thermo Electron), where the term "Continuing Director" means at any date a

6

member of the Thermo Board (i) who was a member of the Thermo Board as of July 1, 1999 or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Thermo Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Thermo Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving Thermo Electron or a sale or other disposition of all or substantially all of the assets of Thermo Electron in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns Thermo Electron or substantially all of Thermo Electron's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by Thermo Electron or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of Thermo Electron of a complete liquidation or dissolution of Thermo Electron.

10. General Provisions

10.1 Documentation of Awards

Awards will be evidenced by written instruments, which may differ among Participants, prescribed by the Board from time to time. Such instruments may be in the form of agreements to be executed by both the Participant and the Company or certificates, letters or similar instruments which need not be executed by the participant but acceptance of which will evidence agreement to the terms thereof. Such instruments shall conform to the requirements of the Plan and may contain such other provisions (including provisions relating to events of merger, consolidation, dissolution and liquidations, change of control

7

and restrictions affecting either the agreement or the Common Stock issued thereunder), as the Board deems advisable.

10.2 Rights as a Stockholder

Except as specifically provided by the Plan or the instrument evidencing the Award, the receipt of an Award will not give a Participant rights as a stockholder of the Company with respect to any shares covered by an Award until the date of issue of a stock certificate to the participant for such shares.

10.3 Conditions on Delivery of Stock

The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove any restriction from shares previously delivered under the Plan (a) until all conditions of the Award have been satisfied or removed, (b) until, in the opinion of the Company's counsel, all applicable federal and state laws and regulations have been complied with, (c) if the outstanding Common Stock is at the time listed on any stock exchange, until the shares have been listed or authorized to be listed on such exchange upon official notice of issuance, and (d) until all other legal matters in connection with the issuance and delivery of such shares have been approved by the Company's counsel. If the sale of Common Stock has not been registered under the Securities Act of 1933, as amended, the Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of such act and may require that the certificates evidencing such Common Stock bear an appropriate legend restricting transfer.

If an Award is exercised by the participant's legal representative, the Company will be under no obligation to deliver Common Stock pursuant to such exercise until the Company is satisfied as to the authority of such representative.

10.4 Tax Withholding

The Company will withhold from any cash payment made pursuant to an Award an amount sufficient to satisfy all federal, state and local withholding tax requirements (the "withholding requirements").

In the case of an Award pursuant to which Common Stock may be delivered, the Board will have the right to require that the participant or other appropriate person remit to the Company an amount sufficient to satisfy the withholding requirements, or make other arrangements satisfactory to the Board with regard to such requirements, prior to the delivery of any Common Stock. If and to the extent that such withholding is required, the Board may permit the participant or such other person to elect at such time and in such manner as the Board provides to have the Company hold back from the shares to be delivered, or to deliver to the Company, Common Stock having a value calculated to satisfy the withholding requirement.

10.5 Transferability of Awards

Except as may be authorized by the Board, in its sole discretion, no Award (other than an Award in the form of an outright transfer of cash or Common

8

Stock not subject to any restrictions) may be transferred other than by will or the laws of descent and distribution, and during a Participant's lifetime an Award requiring exercise may be exercised only by him or her (or in the event of incapacity, the person or persons properly appointed to act on his or her behalf). The Board may, in its discretion, determine the extent to which Awards granted to a Participant shall be transferable, and such provisions permitting or acknowledging transfer shall be set forth in the written agreement evidencing the Award executed and delivered by or on behalf of the Company and the Participant.

10.6 Adjustments in the Event of Certain Transactions

(a) In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the Board will make (i) appropriate adjustments to the maximum number of shares that may be delivered under the Plan under Section 4 above, and (ii) appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise prices relating to Awards and any other provisions of Awards affected by such change.

(b) In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Board, the Board in its discretion may make appropriate adjustments to outstanding Awards, including, without limitation: (i) accelerate the exercisability of the Option, or (ii) adjust the terms of the Option (whether or not in a manner that complies with the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended (the "Code")), or (iii) if there is a survivor or acquiror entity, provide for the assumption of the Option by such survivor or acquiror or an affiliate thereof or for the grant of one or more replacement options by such survivor or acquiror or an affiliate thereof, in each case on such terms (which may, but need not, comply with the requirements of Section 424(a) of the Code) as the Board may determine, or (iv) terminate the Option (provided, that if the Board terminates the Option, it shall, in connection therewith, either (A) accelerate the exercisability of the Option prior to such termination, or (B) provide for a payment to the holder of the Option of cash or other property or a combination of cash or other property in an amount reasonably determined by the Board to approximate the value of the Option assuming an exercise immediately prior to the transaction, or (C) if there is a survivor or acquiror entity, provide for the grant of one or more replacement options pursuant to clause (iii) above), or (v) provide for none of, or any combination of, the foregoing.

(c) No fraction of a share or fractional shares shall be purchasable or deliverable pursuant to this Section 10.6.

10.7 Employment Rights

Neither the adoption of the Plan nor the grant of Awards will confer upon any person any right to continued employment with the Company or any

9

subsidiary or interfere in any way with the right of the Company or subsidiary to terminate any employment relationship at any time or to increase or decrease the compensation of such person. Except as specifically provided by the Board in any particular case, the loss of existing or potential profit in Awards granted under the Plan will not constitute an element of damages in the event of termination of an employment relationship even if the termination is in violation of an obligation of the Company to the employee.

Whether an authorized leave of absence, or absence in military or government service, shall constitute termination of employment shall be determined by the Board at the time. For purposes of this Plan, transfer of employment between the Company and its subsidiaries shall not be deemed termination of employment.

10.8 Other Employee Benefits

The value of an Award granted to a Participant who is an employee, and the amount of any compensation deemed to be received by an employee as a result of any exercise or purchase of Common Stock pursuant to an Award or sale of shares received under the Plan, will not constitute "earnings" or "compensation" with respect to which any other employee benefits of such employee are determined, including without limitation benefits under any pension, stock ownership, stock purchase, life insurance, medical, health, disability or salary continuation plan.

10.9 Legal Holidays

If any day on or before which action under the Plan must be taken falls on a Saturday, Sunday or legal holiday, such action may be taken on the next succeeding day not a Saturday, Sunday or legal holiday.

10.10 Foreign Nationals

Without amending the Plan, Awards may be granted to persons who are foreign nationals or employed outside the United States or both, on such terms and conditions different from those specified in the Plan, as may, in the judgment of the Board, be necessary or desirable to further the purpose of the Plan.

11. Termination and Amendment

The Plan shall remain in full force and effect until terminated by the Board. Subject to the last sentence of this Section 11, the Board may at any time or times amend the Plan or any outstanding Award for any purpose that may at the time be permitted by law, or may at any time terminate the Plan as to any further grants of Awards. No amendment of the Plan or any agreement evidencing Awards under the Plan may adversely affect the rights of any participant under any Award previously granted without such participant's consent.

10

Exhibit 10.11
THERMO ELECTRON CORPORATION

2001 EQUITY INCENTIVE PLAN

As amended and restated as of February 7, 2002

1. Purpose

The purpose of this 2001 Equity Incentive Plan (the "Plan") is to secure for Thermo Electron Corporation (the "Company") and its Stockholders the benefits arising from capital stock ownership by employees and directors of, and consultants to, the Company and its subsidiaries or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries. The Plan is intended to accomplish these goals by enabling the Company to offer such persons equity-based interests, equity-based incentives or performance-based stock incentives in the Company, or any combination thereof ("Awards").

2. Administration

The Plan will be administered by the Board of Directors of the Company (the "Board"). The Board shall have full power to interpret and administer the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan and Awards, and full authority to select the persons to whom Awards will be granted ("Participants"), determine the type and amount of Awards to be granted to Participants (including any combination of Awards), determine the terms and conditions of Awards granted under the Plan (including terms and conditions relating to events of merger, consolidation, dissolution and liquidation, change of control, vesting, forfeiture, restrictions, dividends and interest, if any, on deferred amounts), waive compliance by a participant with any obligation to be performed by him or her under an Award, waive any term or condition of an Award, cancel an existing Award in whole or in part with the consent of a Participant, grant replacement Awards, accelerate the vesting or lapse of any restrictions of any Award, correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award and adopt the form of instruments evidencing Awards under the Plan and change such forms from time to time. Any interpretation by the Board of the terms and provisions of the Plan or any Award thereunder and the administration thereof, and all action taken by the Board, shall be final, binding and conclusive on all parties and any person claiming under or through any party. No Director shall be liable for any action or determination made in good faith. The Board may, to the full extent permitted by law, delegate any or all of its responsibilities under the Plan to a committee (the "Committee") appointed by the Board and consisting of members of the Board. All references in the Plan to the "Board" shall mean the Board or a Committee of the Board to the extent that the Board's powers or authority under the Plan have been delegated to such Committee.

-1-

3. Effective Date

The Plan shall be effective as of the date first approved by the Board, subject to the approval of the Plan by the Corporation's Stockholders. Grants of Awards under the Plan made prior to such approval shall be effective when made (unless otherwise specified by the Board at the time of grant), but shall be conditioned on and subject to such approval of the Plan.

     4. Shares Subject to the Plan

     Subject to  adjustment  as provided in Section  10.6,  the total  number of
shares of  common  stock of the  Company,  par  value  $1.00 per share  ("Common

Stock"), reserved and available for distribution under the Plan shall be five million shares. Such shares may consist, in whole or in part, of authorized and unissued shares or treasury shares.

If any Award of shares of Common Stock requiring exercise by the Participant for delivery of such shares expires or terminates without having been exercised in full, is forfeited or is otherwise terminated without a payment being made to the Participant in the form of Common Stock, or if any shares of Common Stock subject to restrictions are repurchased by the Company pursuant to the terms of any Award or are otherwise reacquired by the Company to satisfy obligations arising by virtue of any Award, such shares shall be available for distribution in connection with future Awards under the Plan.

5. Eligibility

Employees and Directors of, and consultants to, the Company and its subsidiaries, or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries shall be eligible to receive Awards under the Plan. The Board, or other appropriate committee or person to the extent permitted pursuant to the last sentence of Section 2, shall from time to time select from among such eligible persons those who will receive Awards under the Plan.

6. Types of Awards

The Board may offer Awards under the Plan in any form of equity-based interest, equity-based incentive or performance-based stock incentive in Common Stock of the Company or any combination thereof. The type, terms and conditions and restrictions of an Award shall be determined by the Board at the time such Award is made to a Participant; provided however that the maximum number of shares permitted to be granted under any Award or combination of Awards to any Participant during any one calendar year may not exceed 1,500,000 shares of Common Stock. In addition, the maximum number of shares of Common Stock that may be issued pursuant to all Awards that are not stock options, including without limitation restricted stock Awards, may not exceed 500,000 shares of Common Stock in any calendar year. Further, the number of restricted stock awards or other non-option awards granted under the Plan that are not subject to a restriction on resale that lapses in equal annual installments over three years

-2-

(or such longer period as the Board may specify) shall not exceed 10% of the number of shares authorized to be issued under the Plan.

An Award shall be made at the time specified by the Board and shall be subject to such conditions or restrictions as may be imposed by the Board and shall conform to the general rules applicable under the Plan as well as any special rules then applicable under federal tax laws or regulations or the federal securities laws relating to the type of Award granted.

Without limiting the foregoing, Awards may take the following forms and shall be subject to the following rules and conditions:

6.1 Options

An option is an Award that entitles the holder on exercise thereof to purchase Common Stock at a specified exercise price. Options granted under the Plan may be either incentive stock options ("incentive stock options") that meet the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), or options that are not intended to meet the requirements of
Section 422 ("non-statutory options").

6.1.1 Option Price. The price at which Common Stock may be purchased upon exercise of an option shall be determined by the Board, provided however, the exercise price shall not be less than 100% of the fair market value per share of Common Stock as of the date of grant. The Board shall not have the authority to adjust the exercise price of any outstanding stock options granted under this plan to an exercise price that is lower than the original exercise price (a "repricing"), except to the extent permitted under Section 10.6 of the Plan in connection with adjustments in the event of certain transactions.

6.1.2 Option Grants. The granting of an option shall take place at the time specified by the Board. Options shall be evidenced by option agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including but not limited to vesting and forfeiture provisions, acceleration, change of control, protection in the event of merger, consolidations, dissolutions and liquidations) as the Board shall deem advisable. Option agreements shall expressly state whether an option grant is intended to qualify as an incentive stock option or non-statutory option.

6.1.3 Option Period. An option will become exercisable at such time or times (which may be immediately or in such installments as the Board shall determine) and on such terms and conditions as the Board shall specify; provided however that the term of an option during which it may be exercisable may not exceed ten years. The option agreements shall specify the terms and conditions applicable in the event of an option holder's termination of employment during the option's term.

-3-

Any exercise of an option must be in accordance with the instructions described in "The Guide for Employees of Thermo Electron Corporation Stock Option Plans," as may be amended from time to time (the "Guide").

6.1.4 Payment of Exercise Price. Stock purchased on exercise of an option shall be paid for in accordance with the instructions described in the Guide.

6.1.5 Buyout Provision. The Board may at any time offer to buy out for a payment in cash, shares of Common Stock, deferred stock or restricted stock, an option previously granted, based on such terms and conditions as the Board shall establish and communicate to the option holder at the time that such offer is made.

6.1.6 Special Rules for Incentive Stock Options. Each provision of the Plan and each option agreement evidencing an incentive stock option shall be construed so that each incentive stock option shall be an incentive stock option as defined in Section 422 of the Code or any statutory provision that may replace such Section, and any provisions thereof that cannot be so construed shall be disregarded. Instruments evidencing incentive stock options shall contain such provisions as are required under applicable provisions of the Code. Incentive stock options may be granted only to employees of the Company and its subsidiaries. The exercise price of an incentive stock option shall not be less than 100% (110% in the case of an incentive stock option granted to a more than ten percent stockholder of the Company) of the fair market value of the Common Stock on the date of grant, as determined by the Board. An incentive stock option may not be granted after the tenth anniversary of the date on which the Plan was adopted by the Board and the latest date on which an incentive stock option may be exercised shall be the tenth anniversary (fifth anniversary, in the case of any incentive stock option granted to a more than ten percent stockholder of the Company) of the date of grant, as determined by the Board.

6.2 Restricted Stock

An Award of restricted stock entitles the recipient thereof to acquire shares of Common Stock upon payment of the purchase price subject to restrictions specified in the instrument evidencing the Award.

6.2.1 Restricted Stock Awards. Awards of restricted stock shall be evidenced by restricted stock agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including restriction and forfeiture provisions, change of control, protection in the event of mergers, consolidations, dissolutions and liquidations) as the Board shall deem advisable.

6.2.2 Restrictions. Until the restrictions specified in a restricted stock agreement shall lapse, restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of, and upon certain conditions specified in the restricted stock agreement, must be resold to the Company for the price, if any, specified in such agreement. The restrictions shall lapse in equal annual installments over three years, unless the Board specifies a longer restriction period, provided however, that the Board may grant a restricted

-4-

stock Award that does not conform to the restriction period stated herein, provided that the aggregate number of shares underlying all such non-conforming Award granted under the Plan may not exceed 10% of the number of shares authorized to be issued under the Plan. The Board may at any time accelerate the time at which the restrictions on all or any part of the shares shall lapse.

6.2.3 Rights as a Stockholder. A Participant who acquires shares of restricted stock will have all of the rights of a stockholder of the Company with respect to such shares except as otherwise limited pursuant to the Participant's restricted stock agreement. Unless the Board otherwise determines, certificates evidencing shares of restricted stock will remain in the possession of the Company until such shares are free of all restrictions under the Plan.

6.2.4 Purchase Price. The purchase price of shares of restricted stock shall be determined by the Board, in its sole discretion

6.2.5 Other Awards Settled With Restricted Stock. The Board may provide that any or all the Common Stock delivered pursuant to an Award will be restricted stock.

6.3 Deferred Stock

6.3.1 Deferred Stock Award. A deferred stock Award entitles the recipient to receive shares of deferred stock, which is Common Stock to be delivered in the future. Delivery of the Common Stock will take place at such time or times, and on such conditions, as the Board may specify. The Board may at any time accelerate the time at which delivery of all or any part of the Common Stock will take place.

6.3.2 Other Awards Settled with Deferred Stock. The Board may, at the time any Award described in this Section 6 is granted, provide that, at the time Common Stock would otherwise be delivered pursuant to the Award, the Participant will instead receive an instrument evidencing the right to future delivery of deferred stock.

6.4 Performance Awards

6.4.1 Performance Awards. A performance Award entitles the recipient to receive, without payment, an amount, in cash or Common Stock or a combination thereof (such form to be determined by the Board), following the attainment of performance goals. Performance goals may be related to personal performance, corporate performance, departmental performance or any other category of performance deemed by the Board to be important to the success of the Company. The Board will determine the performance goals, the period or periods during which performance is to be measured and all other terms and conditions applicable to the Award.

6.4.2 Other Awards Subject to Performance Conditions. The Board may, at the time any Award described in this Section 6 is granted, impose the condition (in addition to any conditions specified or authorized in this Section 6 of the Plan) that performance goals be met prior to the Participant's realization of any payment or benefit under the Award.

5

7. Purchase Price and Payment

Except as otherwise provided in the Plan, the purchase price of Common Stock to be acquired pursuant to an Award shall be the price determined by the Board, provided that such price shall not be less than the par value of the Common Stock. Except as otherwise provided in the Plan, the Board may determine the method of payment of the exercise price or purchase price of an Award granted under the Plan and the form of payment. The Board may determine that all or any part of the purchase price of Common Stock pursuant to an Award has been satisfied by past services rendered by the Participant. The Board may agree at any time, upon request of the Participant, to defer the date on which any payment under an Award will be made.

8. Intentionally Omitted

9. Change in Control

9.1 Impact of Event

In the event of a "Change in Control" as defined in Section 9.2, the following provisions shall apply, unless the agreement evidencing the Award otherwise provides (by specific explicit reference to Section 9.2 below). If a Change in Control occurs while any Awards are outstanding, then, effective upon the Change in Control, (i) each outstanding stock option or other stock-based Award awarded under the Plan that was not previously exercisable and vested shall become immediately exercisable in full and will no longer be subject to a right of repurchase by the Company, (ii) each outstanding restricted stock award or other stock-based Award subject to restrictions and to the extent not fully vested, shall be deemed to be fully vested, free of restrictions and no longer subject to a right of repurchase by the Company, and (iii) deferral limitations and conditions that relate solely to the passage of time, continued employment or affiliation will be waived and removed as to deferred stock Awards and performance Awards; performance of other conditions (other than conditions relating solely to the passage of time, continued employment or affiliation) will continue to apply unless otherwise provided in the agreement evidencing the Award or in any other agreement between the Participant and the Company or unless otherwise agreed by the Board.

9.2 Definition of "Change in Control"

"Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

-6-

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of beneficial ownership of any capital stock of Thermo Electron Corporation ("Thermo Electron") if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either
(i) the then-outstanding shares of common stock of Thermo Electron (the "Outstanding TMO Common Stock") or (ii) the combined voting power of the then-outstanding securities of Thermo Electron entitled to vote generally in the election of directors (the "Outstanding TMO Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by Thermo Electron, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Thermo Electron or any corporation controlled by Thermo Electron, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this definition; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board of Directors of Thermo Electron (the "Thermo Board") (or, if applicable, the Board of Directors of a successor corporation to Thermo Electron), where the term "Continuing Director" means at any date a member of the Thermo Board (i) who was a member of the Thermo Board as of July 1, 1999 or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Thermo Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Thermo Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving Thermo Electron or a sale or other disposition of all or substantially all of the assets of Thermo Electron in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns Thermo Electron or substantially all of Thermo Electron's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities, respectively; and (ii) no Person

-7-

(excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by Thermo Electron or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of Thermo Electron of a complete liquidation or dissolution of Thermo Electron.

10. General Provisions

10.1 Documentation of Awards

Awards will be evidenced by written instruments, which may differ among Participants, prescribed by the Board from time to time. Such instruments may be in the form of agreements to be executed by both the Participant and the Company or certificates, letters or similar instruments which need not be executed by the participant but acceptance of which will evidence agreement to the terms thereof. Such instruments shall conform to the requirements of the Plan and may contain such other provisions (including provisions relating to events of merger, consolidation, dissolution and liquidations, change of control and restrictions affecting either the agreement or the Common Stock issued thereunder), as the Board deems advisable.

10.2 Rights as a Stockholder

Except as specifically provided by the Plan or the instrument evidencing the Award, the receipt of an Award will not give a Participant rights as a stockholder of the Company with respect to any shares covered by an Award until the date of issue of a stock certificate to the participant for such shares.

10.3 Conditions on Delivery of Stock

The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove any restriction from shares previously delivered under the Plan (a) until all conditions of the Award have been satisfied or removed, (b) until, in the opinion of the Company's counsel, all applicable federal and state laws and regulations have been complied with, (c) if the outstanding Common Stock is at the time listed on any stock exchange, until the shares have been listed or authorized to be listed on such exchange upon official notice of issuance, and (d) until all other legal matters in connection with the issuance and delivery of such shares have been approved by the Company's counsel. If the sale of Common Stock has not been registered under the Securities Act of 1933, as amended, the Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of such act and may require that the certificates evidencing such Common Stock bear an appropriate legend restricting transfer.

-8-

If an Award is exercised by the participant's legal representative, the Company will be under no obligation to deliver Common Stock pursuant to such exercise until the Company is satisfied as to the authority of such representative.

10.4 Tax Withholding

The Company will withhold from any cash payment made pursuant to an Award an amount sufficient to satisfy all federal, state and local withholding tax requirements (the "withholding requirements").

In the case of an Award pursuant to which Common Stock may be delivered, the Board will have the right to require that the participant or other appropriate person remit to the Company an amount sufficient to satisfy the withholding requirements, or make other arrangements satisfactory to the Board with regard to such requirements, prior to the delivery of any Common Stock. If and to the extent that such withholding is required, the Board may permit the participant or such other person to elect at such time and in such manner as the Board provides to have the Company hold back from the shares to be delivered, or to deliver to the Company, Common Stock having a value calculated to satisfy the withholding requirement.

10.5 Transferability of Awards

Except as may be authorized by the Board, in its sole discretion, no Award (other than an Award in the form of an outright transfer of cash or Common Stock not subject to any restrictions) may be transferred other than by will or the laws of descent and distribution, and during a Participant's lifetime an Award requiring exercise may be exercised only by him or her (or in the event of incapacity, the person or persons properly appointed to act on his or her behalf). The Board may, in its discretion, determine the extent to which Awards granted to a Participant shall be transferable, and such provisions permitting or acknowledging transfer shall be set forth in the written agreement evidencing the Award executed and delivered by or on behalf of the Company and the Participant.

10.6 Adjustments in the Event of Certain Transactions

(a) In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the Board will make (i) appropriate adjustments to the maximum number of shares that may be delivered under the Plan under Section 4 above and the participant limit set forth in Section 6 above, and (ii) appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise prices relating to Awards and any other provisions of Awards affected by such change.

-9-

(b) In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Board, the Board in its discretion may make appropriate adjustments to outstanding Awards, including, without limitation: (i) accelerate the exercisability of the Option, or (ii) adjust the terms of the Option (whether or not in a manner that complies with the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended (the "Code")), or (iii) if there is a survivor or acquiror entity, provide for the assumption of the Option by such survivor or acquiror or an affiliate thereof or for the grant of one or more replacement options by such survivor or acquiror or an affiliate thereof, in each case on such terms (which may, but need not, comply with the requirements of Section 424(a) of the Code) as the Board may determine, or (iv) terminate the Option (provided, that if the Board terminates the Option, it shall, in connection therewith, either (A) accelerate the exercisability of the Option prior to such termination, or (B) provide for a payment to the holder of the Option of cash or other property or a combination of cash or other property in an amount reasonably determined by the Board to approximate the value of the Option assuming an exercise immediately prior to the transaction, or (C) if there is a survivor or acquiror entity, provide for the grant of one or more replacement options pursuant to clause (iii) above), or (v) provide for none of, or any combination of, the foregoing.

(c) No fraction of a share or fractional shares shall be purchasable or deliverable pursuant to this Section 10.6.

10.7 Employment Rights

Neither the adoption of the Plan nor the grant of Awards will confer upon any person any right to continued employment with the Company or any subsidiary or interfere in any way with the right of the Company or subsidiary to terminate any employment relationship at any time or to increase or decrease the compensation of such person. Except as specifically provided by the Board in any particular case, the loss of existing or potential profit in Awards granted under the Plan will not constitute an element of damages in the event of termination of an employment relationship even if the termination is in violation of an obligation of the Company to the employee.

Whether an authorized leave of absence, or absence in military or government service, shall constitute termination of employment shall be determined by the Board at the time. For purposes of this Plan, transfer of employment between the Company and its subsidiaries shall not be deemed termination of employment.

10.8 Other Employee Benefits

The value of an Award granted to a Participant who is an employee, and the amount of any compensation deemed to be received by an employee as a result of any exercise or purchase of Common Stock pursuant to an Award or sale of shares received under the Plan, will not constitute "earnings" or "compensation" with respect to which any other employee benefits of such employee are determined,

-10-

including without limitation benefits under any pension, stock ownership, stock purchase, life insurance, medical, health, disability or salary continuation plan.

10.9 Legal Holidays

If any day on or before which action under the Plan must be taken falls on a Saturday, Sunday or legal holiday, such action may be taken on the next succeeding day not a Saturday, Sunday or legal holiday.

10.10 Foreign Nationals

Without amending the Plan, Awards may be granted to persons who are foreign nationals or employed outside the United States or both, on such terms and conditions different from those specified in the Plan, as may, in the judgment of the Board, be necessary or desirable to further the purpose of the Plan.

11. Termination and Amendment

The Plan shall remain in full force and effect until terminated by the Board. Subject to the last sentence of this Section 11, the Board may at any time or times amend the Plan or any outstanding Award for any purpose that may at the time be permitted by law, or may at any time terminate the Plan as to any further grants of Awards; provided that, to the extent required by law or deemed necessary by the Board, any amendment that would (i) materially increase the benefits accruing to participants under the Plan, (ii) materially increase the number of shares under the Plan or (iii) materially modify the requirements for eligibility under the Plan, shall be subject to Stockholder approval. No amendment of the Plan or any agreement evidencing Awards under the Plan may adversely affect the rights of any participant under any Award previously granted without such participant's consent.

-11-

Exhibit 10.13

Thermo Electron Corporation
Deferred Compensation Plan
Master Plan Document

Effective November 1, 2001

Copyright (C) 2001

By Clark/Bardes Consulting - Compensation Resource Group, A division of Clark/Bardes, Inc. All Rights Reserved


Thermo Electron Corporation
Deferred Compensation Plan
Master Plan Document

TABLE OF CONTENTS

Purpose        1


ARTICLE 1           Definitions....................................................................................1


ARTICLE 2           Selection, Enrollment, Eligibility.............................................................6

           2.1      Selection by Committee.........................................................................6
           2.2      Enrollment Requirements........................................................................6
           2.3      Eligibility; Commencement of Participation.....................................................6
           2.4      Termination of Participation and/or Deferrals..................................................6

ARTICLE 3           Deferral Commitments/Company Contribution/Crediting/Taxes......................................7

           3.1      Minimum Deferrals..............................................................................7
           3.2      Maximum Deferral...............................................................................7
           3.3      Election to Defer; Effect of Election Form.....................................................7
           3.4      Withholding of Annual Deferral Amounts.........................................................8
           3.5      Annual Company Contribution Amount.............................................................8
           3.6      Investment of Trust Assets.....................................................................8
           3.7      Vesting........................................................................................8
           3.8      Crediting/Debiting of Account Balances.........................................................9
           3.9      FICA and Other Taxes..........................................................................10

ARTICLE 4           Short-Term Payout; Unforeseeable Financial Emergencies; Withdrawal Election...................11

           4.1      Short-Term Payout.............................................................................11
           4.2      Other Benefits Take Precedence Over Short-Term................................................11
           4.3      Withdrawal Payout/Suspensions for Unforeseeable Financial Emergencies.........................11
           4.4      Withdrawal Election...........................................................................11

ARTICLE 5           Retirement Benefit............................................................................12

           5.1      Retirement Benefit............................................................................12
           5.2      Payment of Retirement Benefit.................................................................12
           5.3      Death Prior to Completion of Retirement Benefit...............................................12

ARTICLE 6           Pre-Retirement Survivor Benefit...............................................................12

           6.1      Pre-Retirement Survivor Benefit...............................................................12
           6.2      Payment of Pre-Retirement Survivor Benefit....................................................12

                                      -i-

ARTICLE 7           Termination Benefit...........................................................................13

           7.1      Termination Benefit...........................................................................13
           7.2      Payment of Termination Benefit................................................................13

ARTICLE 8           Disability Waiver and Benefit.................................................................13

           8.1      Disability Waiver.............................................................................13
           8.2      Continued Eligibility; Disability Benefit.....................................................13

ARTICLE 9           Beneficiary Designation.......................................................................14

           9.1      Beneficiary...................................................................................14
           9.2      Beneficiary Designation; Change...............................................................14
           9.3      Acknowledgement...............................................................................14
           9.4      No Beneficiary Designation....................................................................14
           9.5      Doubt as to Beneficiary.......................................................................14
           9.6      Discharge of Obligations......................................................................14

ARTICLE 10          Leave of Absence..............................................................................15

           10.1     Paid Leave of Absence.........................................................................15
           10.2     Unpaid Leave of Absence.......................................................................15

ARTICLE 11          Termination, Amendment or Modification........................................................15

           11.1     Termination...................................................................................15
           11.2     Amendment.....................................................................................15
           11.3     Plan Agreement................................................................................16
           11.4     Effect of Payment.............................................................................16

ARTICLE 12          Administration................................................................................16

           12.1     Committee Duties..............................................................................16
           12.2     Administration Upon Change In Control.........................................................16
           12.3     Agents........................................................................................17
           12.4     Binding Effect of Decisions...................................................................17
           12.5     Indemnity of Committee........................................................................17
           12.6     Employer Information..........................................................................17

ARTICLE 13          Other Benefits and Agreements.................................................................17

           13.1     Coordination with Other Benefits..............................................................17

ARTICLE 14          Claims Procedures.............................................................................17
                                      -ii-

           14.1     Presentation of Claim.........................................................................17
           14.2     Notification of Decision......................................................................18
           14.3     Review of a Denied Claim......................................................................18
           14.4     Decision on Review............................................................................18
           14.5     Legal Action..................................................................................19

ARTICLE 15          Trust.........................................................................................19

           15.1     Establishment of the Trust....................................................................19
           15.2     Interrelationship of the Plan and the Trust...................................................19
           15.3     Distributions From the Trust..................................................................19

ARTICLE 16          Miscellaneous.................................................................................19

           16.1     Status of Plan................................................................................19
           16.2     Unsecured General Creditor....................................................................19
           16.3     Employer's Liability..........................................................................19
           16.4     Nonassignability..............................................................................20
           16.5     Not a Contract of Employment..................................................................20
           16.6     Furnishing Information........................................................................20
           16.7     Terms.........................................................................................20
           16.8     Captions......................................................................................20
           16.9     Governing Law.................................................................................20
           16.10    Notice........................................................................................20
           16.11    Successors....................................................................................21
           16.12    Spouse's Interest.............................................................................21
           16.13    Validity......................................................................................21
           16.14    Incompetent...................................................................................21
           16.15    Court Order...................................................................................21
           16.16    Distribution in the Event of Taxation.........................................................21
           16.17    Insurance.....................................................................................22
                                     -iii-


Thermo Electron Corporation
Deferred Compensation Plan
Master Plan Document

THERMO ELECTRON CORPORATION
DEFERRED COMPENSATION PLAN
Effective November 1, 2001

Purpose

The purpose of this Plan is to provide specified benefits to a select group of management or highly compensated Employees who contribute materially to the continued growth, development and future business success of Thermo Electron Corporation, a Delaware corporation, and its subsidiaries. This Plan shall be unfunded for tax purposes and for purposes of Title I of ERISA.

ARTICLE 1
Definitions

For the purposes of this Plan, unless otherwise clearly apparent from the context, the following phrases or terms shall have the following indicated meanings:

1.1 "Account Balance" shall mean, with respect to a Participant, a credit on the records of the Employer equal to the sum of (i) the Deferral Account balance and (ii) the Company Contribution Account balance. The Account Balance, and each other specified account balance, shall be a bookkeeping entry only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant, or his or her designated Beneficiary, pursuant to this Plan.

1.2 "Annual Company Contribution Amount" shall mean, for any one Plan Year, the amount determined in accordance with Section 3.5.

1.3 "Annual Deferral Amount" shall mean that portion of a Participant's Base Salary and Annual Incentive that a Participant elects to have and is deferred in accordance with Article 3 for any one Plan Year. In the event of a Participant's Retirement, Disability (if deferrals cease in accordance with Section 8.1), death or a Termination of Employment prior to the end of a Plan Year, such year's Annual Deferral Amount shall be the actual amount withheld prior to such event.

1.4 "Annual Incentive" shall mean any compensation, in addition to Base Salary relating to services performed during any calendar year, whether or not paid in such calendar year or included on the Federal Income Tax Form W-2 for such calendar year, payable to a Participant as an Employee under any Employer's annual bonus and cash incentive plans, or any other bonus arrangement designated by the Committee, excluding stock options and restricted stock.

1.5 "Annual Installment Method" shall be an annual installment payment over the number of years selected by the Participant in accordance with this Plan, calculated as follows: the vested Account Balance of the Participant shall be calculated as of the close of business on the last business day of the year. The annual installment shall be calculated by multiplying this balance by a fraction, the numerator of which is one and the denominator of which is the remaining number of annual payments due the Participant. By way of example, if the Participant elects a ten (10) year Annual

1

Installment Method, the first payment shall be 1/10 of the vested Account Balance, calculated as described in this definition. The following year, the payment shall be 1/9 of the vested Account Balance, calculated as described in this definition. Each annual installment shall be paid no later than sixty (60) days after the last business day of the applicable year.

1.6 "Base Salary" shall mean the annual cash compensation relating to services performed during any calendar year, whether or not paid in such calendar year or included on the Federal Income Tax Form W-2 for such calendar year, excluding bonuses, commissions, overtime, fringe benefits, stock options, restricted stock, relocation expenses, Annual Incentive, non-monetary awards, directors fees and other fees, and automobile and other allowances paid to a Participant for employment services rendered (whether or not such allowances are included in the Employee's gross income). Base Salary shall be calculated before reduction for compensation voluntarily deferred or contributed by the Participant pursuant to all qualified or non-qualified plans of any Employer and shall be calculated to include amounts not otherwise included in the Participant's gross income under Code Sections 125, 402(e)(3), 402(h), or 403(b) pursuant to plans established by any Employer; provided, however, that all such amounts will be included in compensation only to the extent that had there been no such plan, the amount would have been payable in cash to the Employee.

1.7 "Beneficiary" shall mean one or more persons, trusts, estates or other entities, designated in accordance with Article 9, that are entitled to receive benefits under this Plan upon the death of a Participant.

1.8 "Beneficiary Designation Form" shall mean the form established from time to time by the Committee that a Participant completes, signs and returns to the Committee to designate one or more Beneficiaries.

1.9 "Board" shall mean the board of directors of the Company.

1.10 "Change in Control" shall mean an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) The acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the

2

Company, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.10; or

(b) Such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the board of directors of a successor corporation to the Company), where the term "Continuing Director" means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Plan document or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c) The consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) Approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.11 "Claimant" shall have the meaning set forth in Section 14.1.

1.12 "Code" shall mean the Internal Revenue Code of 1986, as it may be amended from time to time.

3

1.13 "Committee" shall mean the committee described in Article 12.

1.14 "Company" shall mean Thermo Electron Corporation, a Delaware corporation, and any successor to all or substantially all of the Company's assets or business.

1.15 "Company Contribution Account" shall mean (i) the sum of the Participant's Annual Company Contribution Amounts, plus (ii) amounts credited or debited in accordance with all the applicable crediting and debiting provisions of this Plan that relate to the Participant's Company Contribution Account, less (iii) all distributions made to the Participant or his or her Beneficiary pursuant to this Plan that relate to the Participant's Company Contribution Account.

1.16 "Deduction Limitation" shall mean the following described limitation on a benefit that may otherwise be distributable pursuant to the provisions of this Plan. Except as otherwise provided, this limitation shall be applied to all distributions that are "subject to the Deduction Limitation" under this Plan. If an Employer determines in good faith prior to a Change in Control that there is a reasonable likelihood that any compensation paid to a Participant for a taxable year of the Employer would not be deductible by the Employer solely by reason of the limitation under Code Section 162(m), then to the extent deemed necessary by the Employer to ensure that the entire amount of any distribution to the Participant pursuant to this Plan prior to the Change in Control is deductible, the Employer may defer all or any portion of a distribution under this Plan. Any amounts deferred pursuant to this limitation shall continue to be credited/debited with additional amounts in accordance with Section 3.8 below, even if such amount is being paid out in installments. The amounts so deferred and amounts credited thereon shall be distributed to the Participant or his or her Beneficiary (in the event of the Participant's death) at the earliest possible date, as determined by the Employer in good faith, on which the deductibility of compensation paid or payable to the Participant for the taxable year of the Employer during which the distribution is made will not be limited by Section 162(m) or, if earlier, the effective date of a Change in Control. Notwithstanding anything to the contrary in this Plan, the Deduction Limitation shall not apply to any distributions made after a Change in Control.

1.17 "Deferral Account" shall mean (i) the sum of all of a Participant's Annual Deferral Amounts, plus (ii) amounts credited in accordance with all the applicable crediting and debiting provisions of this Plan that relate to the Participant's Deferral Account, less (iii) all distributions made to the Participant or his or her Beneficiary pursuant to this Plan that relate to his or her Deferral Account.

1.18 "Disability" shall mean a period of disability during which a Participant qualifies for disability benefits under the Participant's Employer's long-term disability plan, or, if a Participant does not participate in such a plan, a period of disability during which the Participant would have qualified for disability benefits under such a plan had the Participant been a participant in such a plan, as determined in the sole discretion of the Committee. If the Participant's Employer does not sponsor such a plan, or discontinues to sponsor such a plan, Disability shall be determined by the Committee in its sole discretion.

1.19 "Disability Benefit" shall mean the benefit set forth in Article 8.

4

1.20 "Election Form" shall mean the form established from time to time by the Committee that a Participant completes, signs and returns to the Committee to make an election under the Plan.

1.21 "Employee" shall mean a person who is an employee of any Employer.

1.22 "Employer(s)" shall mean the Company and/or any of its subsidiaries (now in existence or hereafter formed or acquired) that have been selected by the Board to participate in the Plan.

1.23 "ERISA" shall mean the Employee Retirement Income Security Act of 1974, as it may be amended from time to time.

1.24 "First Plan Year" shall mean the period beginning January 1, 2002 and ending December 31, 2002.

1.25 "Participant" shall mean any Employee (i) who is selected to participate in the Plan, (ii) who elects to participate in the Plan, (iii) who signs a Plan Agreement, an Election Form and a Beneficiary Designation Form, (iv) whose signed Plan Agreement, Election Form and Beneficiary Designation Form are accepted by the Committee, (v) who commences participation in the Plan, and (vi) whose Plan Agreement has not terminated. A spouse or former spouse of a Participant shall not be treated as a Participant in the Plan or have an account balance under the Plan, even if he or she has an interest in the Participant's benefits under the Plan as a result of applicable law or property settlements resulting from legal separation or divorce.

1.26 "Plan" shall mean the Company's Deferred Compensation Plan, which shall be evidenced by this instrument and by each Plan Agreement, as they may be amended from time to time.

1.27 "Plan Agreement" shall mean a written agreement, as may be amended from time to time, which is entered into by and between an Employer and a Participant. Each Plan Agreement executed by a Participant and the Participant's Employer shall provide for the entire benefit to which such Participant is entitled under the Plan; should there be more than one Plan Agreement, the Plan Agreement bearing the latest date of acceptance by the Employer shall supersede all previous Plan Agreements in their entirety and shall govern such entitlement. The terms of any Plan Agreement may be different for any Participant, and any Plan Agreement may provide additional benefits not set forth in the Plan or limit the benefits otherwise provided under the Plan; provided, however, that any such additional benefits or benefit limitations must be agreed to by both the Employer and the Participant.

1.28 "Plan Year" shall mean a period beginning on January 1 of each calendar year and continuing through December 31 of such calendar year, beginning with the First Plan Year.

1.29 "Pre-Retirement Survivor Benefit" shall mean the benefit set forth in Article 6.

1.30 "Retirement", "Retire(s)" or "Retired" shall mean, with respect to an Employee, severance from employment from all Employers for any reason other than a leave of absence, death or Disability on or after the earlier of the attainment of (a) age sixty-five (65) or (b) age fifty-five (55) with ten
(10) Years of Service.

1.31 "Retirement Benefit" shall mean the benefit set forth in Article 5.

1.32 "Short-Term Payout" shall mean the payout set forth in Section 4.1.

5

1.33 "Termination Benefit" shall mean the benefit set forth in Article 7.

1.34 "Termination of Employment" shall mean the severing of employment with all Employers, voluntarily or involuntarily, for any reason other than Retirement, Disability, death or an authorized leave of absence.

1.35 "Trust" shall mean one or more trusts established pursuant to that certain Master Trust Agreement, dated as of November 1, 2001 between the Company and the trustee named therein, as amended from time to time.

1.36 "Unforeseeable Financial Emergency" shall mean an unanticipated emergency that is caused by an event beyond the control of the Participant that would result in severe financial hardship to the Participant resulting from (i) a sudden and unexpected illness or accident of the Participant or a dependent of the Participant, (ii) a loss of the Participant's property due to casualty, or (iii) such other extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant, all as determined in the sole discretion of the Committee.

1.37 "Years of Service" shall mean the total number of full years in which a Participant has been employed by one or more Employers. For purposes of this definition, a year of employment shall be a 365 day period (or 366 day period in the case of a leap year) that, for the first year of employment, commences on the Employee's date of hiring and that, for any subsequent year, commences on an anniversary of that hiring date. Any partial year of employment shall not be counted.

ARTICLE 2
Selection, Enrollment, Eligibility

2.1 Selection by Committee. Participation in the Plan shall be limited to a select group of management and highly compensated Employees of the Employers, as determined by the Committee in its sole discretion. From that group, the Committee shall select, in its sole discretion, Employees to participate in the Plan.

2.2 Enrollment Requirements. As a condition to participation, each selected Employee shall complete, execute and return to the Committee a Plan Agreement, an Election Form and a Beneficiary Designation Form, all within thirty (30) days after he or she is selected to participate in the Plan. In addition, the Committee shall establish from time to time such other enrollment requirements as it determines in its sole discretion are necessary.

2.3 Eligibility; Commencement of Participation. Provided an Employee selected to participate in the Plan has met all enrollment requirements set forth in this Plan and required by the Committee, including returning all required documents to the Committee within the specified time period, that Employee shall commence participation in the Plan on the first day of the month following the month in which the Employee completes all enrollment requirements. If an Employee fails to meet all such requirements within the period required, in accordance with Section 2.2, that Employee shall not be eligible to participate in the Plan until the first day of the Plan Year following the delivery to and acceptance by the Committee of the required documents.

6

2.4 Termination of Participation and/or Deferrals. If the Committee determines in good faith that a Participant no longer qualifies as a member of a select group of management or highly compensated employees, as membership in such group is determined in accordance with Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA, the Committee shall have the right, in its sole discretion, to (i) terminate any deferral election the Participant has made for the remainder of the Plan Year in which the Participant's membership status changes, (ii) prevent the Participant from making future deferral elections and/or (iii) immediately distribute the Participant's then vested Account Balance as a Termination Benefit and terminate the Participant's participation in the Plan.

ARTICLE 3
Deferral Commitments/Company Contribution/Crediting/Taxes

3.1 Minimum Deferrals.

(a) Base Salary and Annual Incentive. For each Plan Year, a Participant may elect to defer, as his or her Annual Deferral Amount, an aggregate minimum of $5,000 of Base Salary and/or Annual Incentive. If an election is made for less than the stated minimum amounts, or if no election is made, the amount deferred shall be zero.

(b) Short Plan Year. Notwithstanding the foregoing, if a Participant first becomes a Participant after the first day of a Plan Year, the minimum Annual Deferral Amount shall be an amount equal to the minimum set forth above, multiplied by a fraction, the numerator of which is the number of complete months remaining in the Plan Year and the denominator of which is 12.

3.2 Maximum Deferral.

(a) Base Salary and Annual Incentive. For each Plan Year, a Participant may elect to defer, as his or her Annual Deferral Amount, Base Salary and/or Annual Incentive up to the following maximum percentages for each deferral elected:

-------------------------------------- ----------------------------------
            Deferral                       Maximum Amount
-------------------------------------- ----------------------------------
          Base Salary                           90%
-------------------------------------- ----------------------------------
-------------------------------------- ----------------------------------
        Annual Incentive                       100%
-------------------------------------- ----------------------------------

(b) Short Plan Year. Notwithstanding the foregoing, if a Participant first becomes a Participant after the first day of a Plan Year, the maximum Annual Deferral Amount, with respect to Base Salary and Annual Incentive shall be limited to the amount of compensation not yet earned by the Participant as of the date the Participant submits a Plan Agreement and Election Form to the Committee for acceptance.

3.3 Election to Defer; Effect of Election Form.

(a) First Plan Year. In connection with a Participant's commencement of participation in the Plan, the Participant shall make an irrevocable deferral election for the Plan Year in which the Participant commences

7

participation in the Plan, along with such other elections as the Committee deems necessary or desirable under the Plan. For these elections to be valid, the Election Form must be completed and signed by the Participant, timely delivered to the Committee (in accordance with Section 2.2 above) and accepted by the Committee.

(b) Subsequent Plan Years. For each succeeding Plan Year, an irrevocable deferral election for that Plan Year, and such other elections as the Committee deems necessary or desirable under the Plan, shall be made by timely delivering to the Committee, in accordance with its rules and procedures, before the end of the Plan Year preceding the Plan Year for which the election is made, a new Election Form. If no such Election Form is timely delivered for a Plan Year, the Annual Deferral Amount shall be zero for that Plan Year.

3.4 Withholding of Annual Deferral Amounts. For each Plan Year, the Base Salary portion of the Annual Deferral Amount shall be withheld from each regularly scheduled Base Salary payroll in equal amounts, as adjusted from time to time for increases and decreases in Base Salary. The Annual Incentive portion of the Annual Deferral Amount shall be withheld at the time the Annual Incentive is or otherwise would be paid to the Participant, whether or not this occurs during the Plan Year itself.

3.5 Annual Company Contribution Amount. For each Plan Year, an Employer, in its sole discretion, may, but is not required to, credit any amount it desires to any Participant's Company Contribution Account under this Plan, which amount shall be for that Participant the Annual Company Contribution Amount for that Plan Year. The amount so credited to a Participant may be smaller or larger than the amount credited to any other Participant, and the amount credited to any Participant for a Plan Year may be zero, even though one or more other Participants receive an Annual Company Contribution Amount for that Plan Year. The Annual Company Contribution Amount, if any, shall be credited as of the last day of the Plan Year. If a Participant is not employed by an Employer as of the last day of a Plan Year other than by reason of his or her Retirement or death while employed, the Annual Company Contribution Amount for that Plan Year shall be zero.

3.6 Investment of Trust Assets. The Trustee of the Trust shall be authorized, upon written instructions received from the Committee or investment manager appointed by the Committee, to invest and reinvest the assets of the Trust in accordance with the applicable Trust Agreement, including the disposition of stock and reinvestment of the proceeds in one or more investment vehicles designated by the Committee.

3.7 Vesting.

(a) A Participant shall at all times be 100% vested in his or her Deferral Account.

(b) The Committee, in its sole discretion, will determine over what period of time and in what percentage increments a Participant shall vest in his or her Company Contribution Account. The Committee may credit some Participants with larger or smaller vesting percentages than other Participants, and the vesting percentage credited to any Participant

8

for a Plan Year may be zero, even though one or more other Participants have a greater vesting percentage credited to them for that Plan Year.

(c) Notwithstanding anything to the contrary contained in this Section 3.7, in the event of a Change in Control and/or a Participant's Retirement, a Participant's Company Contribution Account shall immediately become 100% vested (if it is not already vested in accordance with the above vesting schedules).

(d) Notwithstanding subsection (c), the vesting schedule for a Participant's Company Contribution Account shall not be accelerated to the extent that the Committee determines that such acceleration would cause the deduction limitations of Section 280G of the Code to become effective. In the event that all of a Participant's Company Contribution Account is not vested pursuant to such a determination, the Participant may request independent verification of the Committee's calculations with respect to the application of Section 280G. In such case, the Committee must provide to the Participant within 15 business days of such a request an opinion from a nationally recognized accounting firm selected by the Participant (the "Accounting Firm"). The opinion shall state the Accounting Firm's opinion that any limitation in the vested percentage hereunder is necessary to avoid the limits of Section 280G and contain supporting calculations. The cost of such opinion shall be paid for by the Company.

3.8 Crediting/Debiting of Account Balances. In accordance with, and subject to, the rules and procedures that are established from time to time by the Committee, in its sole discretion, amounts shall be credited or debited to a Participant's Account Balance in accordance with the following rules:

(a) Election of Measurement Funds. A Participant, in connection with his or her initial deferral election in accordance with Section 3.3(a) above, shall elect, on the Election Form, one or more Measurement Fund(s) (as described in Section 3.8(c) below) to be used to determine the amounts to be credited or debited to his or her Account Balance. The Participant may (but is not required to) elect, by submitting an Election Form to the Committee that is accepted by the Committee, to add or delete one or more Measurement Fund(s) to be used to determine the amounts to be credited or debited to his or her Account Balance, or to change the portion of his or her Account Balance allocated to each previously or newly elected Measurement Fund. If an election is made in accordance with the previous sentence, it shall apply as of the first business day deemed reasonably practicable by the Committee, in its sole discretion, and continue thereafter for each subsequent day in which the Participant participates in the Plan, unless changed in accordance with the previous sentence. The Participant may make no more than four (4) such elections in any Plan Year.

(b) Proportionate Allocation. In making any election described in Section 3.8(a) above, the Participant shall specify on the Election Form, in increments of five percentage points (5%), the percentage of his or her Account Balance to be allocated to a Measurement Fund (as if the Participant was making an investment in that Measurement Fund with that portion of his or her Account Balance).

9

(c) Measurement Funds. A Participant may elect one or more of the measurement funds selected by the Committee in its sole discretion (the "Measurement Funds"), based on certain mutual funds, for the purpose of crediting or debiting additional amounts to his or her Account Balance. As necessary, the Committee may, in its sole discretion, discontinue, substitute or add a Measurement Fund. Each such action will take effect as of the first day of the calendar quarter that follows by thirty (30) days the day on which the Committee gives Participants advance written notice of such change.

(d) Crediting or Debiting Method. The performance of each elected Measurement Fund (either positive or negative) will be determined by the Committee, in its reasonable discretion, based on the performance of the Measurement Funds themselves. A Participant's Account Balance shall be credited or debited on a daily basis based on the performance of each Measurement Fund selected by the Participant, such performance being determined by the Committee in its sole discretion.

(e) No Actual Investment. Notwithstanding any other provision of this Plan that may be interpreted to the contrary, the Measurement Funds are to be used for measurement purposes only, and a Participant's election of any such Measurement Fund, the allocation to his or her Account Balance thereto, the calculation of additional amounts and the crediting or debiting of such amounts to a Participant's Account Balance shall not be considered or construed in any manner as an actual investment of his or her Account Balance in any such Measurement Fund. In the event that the Company or the Trustee (as that term is defined in the Trust), in its own discretion, decides to invest funds in any or all of the Measurement Funds, no Participant shall have any rights in or to such investments themselves. Without limiting the foregoing, a Participant's Account Balance shall at all times be a bookkeeping entry only and shall not represent any investment made on his or her behalf by the Company or the Trust; the Participant shall at all times remain an unsecured creditor of the Company.

3.9 FICA and Other Taxes.

(a) Annual Deferral Amounts. For each Plan Year in which an Annual Deferral Amount is being withheld from a Participant, the Participant's Employer(s) shall withhold from that portion of the Participant's Base Salary and Annual Incentive that is not being deferred, in a manner determined by the Employer(s), the Participant's share of FICA and other employment taxes on such Annual Deferral Amount. If necessary, the Committee may reduce the Annual Deferral Amount in order to comply with this Section 3.9.

(b) Company Contribution Amounts. When a participant becomes vested in a portion of his or her Company Contribution Account, the Participant's Employer(s) shall withhold from the Participant's Base Salary and/or Annual Incentive that is not deferred, in a manner determined by the Employer(s), the Participant's share of FICA and other employment taxes. If necessary, the Committee may reduce the vested portion of the Participant's Company Contribution Account in order to comply with this Section 3.9.

10

(c) Distributions. The Participant's Employer(s), or the trustee of the Trust, shall withhold from any payments made to a Participant under this Plan all federal, state and local income, employment and other taxes required to be withheld by the Employer(s), or the trustee of the Trust, in connection with such payments, in amounts and in a manner to be determined in the sole discretion of the Employer(s) and the trustee of the Trust.

ARTICLE 4

Short-Term Payout; Unforeseeable Financial Emergencies; Withdrawal Election

4.1 Short-Term Payout. In connection with each election to defer an Annual Deferral Amount, a Participant may irrevocably elect to receive a future "Short-Term Payout" from the Plan with respect to all or a portion of such Annual Deferral Amount, including amounts credited or debited in the manner provided in Section 3.8 above on that amount. Subject to the Deduction Limitation, the Short-Term Payout shall be a lump sum payment in an amount that is equal to the portion of the Annual Deferral Amount the Participant elected to have distributed to him or her as a Short-Term Payout plus amounts credited or debited in the manner provided in Section 3.8 above on that amount, determined at the time that the Short-Term Payout becomes payable. Subject to the Deduction Limitation and the other terms and conditions of this Plan, each Short-Term Payout elected shall be paid out during a sixty (60) day period commencing immediately after the last day of any Plan Year designated by the Participant that is at least three Plan Years after the Plan Year in which the Annual Deferral Amount is actually deferred. By way of example, if a three year Short-Term Payout is elected for Annual Deferral Amounts that are deferred in the Plan Year commencing January 1, 2002, the three year Short-Term Payout would become payable during a sixty (60) day period commencing January 1, 2006.

4.2 Other Benefits Take Precedence Over Short-Term. Should an event occur that triggers a benefit under Article 5, 6, 7 or 8, any Annual Deferral Amount, plus amounts credited or debited thereon, that is subject to a Short-Term Payout election under Section 4.1 shall not be paid in accordance with
Section 4.1 but shall be paid in accordance with the other applicable Article.

4.3 Withdrawal Payout/Suspensions for Unforeseeable Financial Emergencies. If the Participant experiences an Unforeseeable Financial Emergency, the Participant may petition the Committee to (i) suspend any deferrals required to be made by a Participant and/or (ii) receive a partial or full payout from the Plan. The payout shall not exceed the lesser of the Participant's vested Account Balance, calculated as if such Participant were receiving a Termination Benefit, or the amount reasonably needed to satisfy the Unforeseeable Financial Emergency. If, subject to the sole discretion of the Committee, the petition for a suspension and/or payout is approved, suspension shall take effect upon the date of approval and any payout shall be made within sixty (60) days of the date of approval. The payment of any amount under this Section 4.3 shall not be subject to the Deduction Limitation.

4.4 Withdrawal Election. Provided a Participant's vested Account Balance is $25,000 or greater, a Participant (or, after a Participant's death, his or her Beneficiary) may elect, at any time, to withdraw all of his or her vested Account Balance, calculated as if there had occurred a Termination

11

of Employment as of the day of the election, less a withdrawal penalty equal to 10% of such amount (the net amount shall be referred to as the "Withdrawal Amount"). A Participant (or, after a Participant's death, his or her Beneficiary) may also elect, at any time, to withdraw a minimum of $25,000 or a larger portion of his or her vested Account Balance, calculated as if there had occurred a Termination of Employment as of the day of the election, less a withdrawal penalty equal to 10% of such amount (the net amount shall be referred to as the "Withdrawal Amount"). This election can be made at any time, before or after Retirement, Disability, death or Termination of Employment, and whether or not the Participant (or Beneficiary) is in the process of being paid pursuant to an installment payment schedule. The Participant (or his or her Beneficiary) shall make this election by giving the Committee advance written notice of the election in a form determined from time to time by the Committee. The Participant (or his or her Beneficiary) shall be paid the Withdrawal Amount within sixty (60) days of his or her election. Once the Withdrawal Amount is paid, the Participant's participation in the Plan shall be suspended for the remainder of the Plan Year in which the withdrawal is elected. The payment of this Withdrawal Amount shall not be subject to the Deduction Limitation.

ARTICLE 5
Retirement Benefit

5.1 Retirement Benefit. Subject to the Deduction Limitation, a Participant who Retires shall receive, as a Retirement Benefit, his or her vested Account Balance.

5.2 Payment of Retirement Benefit. A Participant, in connection with his or her commencement of participation in the Plan, shall elect on an Election Form to receive the Retirement Benefit in a lump sum or pursuant to an Annual Installment Method of 5, 10 or 15 years. The Participant may annually change his or her election to an allowable alternative payout period by submitting a new Election Form to the Committee, provided that any such Election Form is submitted at least 13 months prior to the Participant's Retirement and is accepted by the Committee in its sole discretion. The Election Form most recently accepted by the Committee shall govern the payout of the Retirement Benefit. If a Participant does not make any election with respect to the payment of the Retirement Benefit, then such benefit shall be payable in a lump sum. The lump sum payment shall be made, or installment payments shall commence, no later than sixty (60) days after the earlier of (i) the March 1st immediately following the Participant's Retirement, or (ii) the September 1st immediately following the Participant's Retirement. Any payment made shall be subject to the Deduction Limitation.

5.3 Death Prior to Completion of Retirement Benefit. If a Participant dies after Retirement but before the Retirement Benefit is paid in full, the Participant's Beneficiary shall receive a lump sum payment that is equal to the Participant's unpaid remaining vested Account Balance.

12

ARTICLE 6
Pre-Retirement Survivor Benefit

6.1 Pre-Retirement Survivor Benefit. Subject to the Deduction Limitation, the Participant's Beneficiary shall receive a Pre-Retirement Survivor Benefit equal to the Participant's vested Account Balance if the Participant dies before he or she Retires, experiences a Termination of Employment or suffers a Disability.

6.2 Payment of Pre-Retirement Survivor Benefit. If a Participant dies before he or she Retires, experiences a Termination of Employment or suffers a Disability, the Pre-Retirement Survivor Benefit shall be paid to the Participant's Beneficiary in a lump sum payment no later than sixty (60) days after the last day of the Plan Year in which the Committee is provided with proof that is satisfactory to the Committee of the Participant's death. Any payment made shall be subject to the Deduction Limitation.

ARTICLE 7
Termination Benefit

7.1 Termination Benefit. Subject to the Deduction Limitation, the Participant shall receive a Termination Benefit, which shall be equal to the Participant's vested Account Balance if a Participant experiences a Termination of Employment prior to his or her Retirement, death or Disability.

7.2 Payment of Termination Benefit. The Participant's Termination Benefit shall be paid in a lump sum payment; provided, however, that the Committee, in its sole discretion, may pay a Participant's Termination Benefit pursuant to an Annual Installment Method, over a number of years to be determined by the Committee, but not to exceed five (5) years. The lump sum payment shall be made, or installment payments shall commence, no later than sixty (60) days after the last day of the Plan Year in which the Participant experiences the Termination of Employment. Any payment made shall be subject to the Deduction Limitation.

13

ARTICLE 8
Disability Waiver and Benefit

8.1 Disability Waiver.

(a) Waiver of Deferral. A Participant who is determined by the Committee to be suffering from a Disability shall be excused from fulfilling that portion of the Annual Deferral Amount commitment that would otherwise have been withheld from a Participant's Base Salary and/or Annual Incentive for the Plan Year during which the Participant first suffers a Disability. During the period of Disability, the Participant shall not be allowed to make any additional deferral elections, but will continue to be considered a Participant for all other purposes of this Plan.

(b) Return to Work. If a Participant returns to employment with an Employer after a Disability ceases, the Participant may elect to defer an Annual Deferral Amount for the Plan Year following his or her return to employment or service and for every Plan Year thereafter while a Participant in the Plan; provided such deferral elections are otherwise allowed and an Election Form is delivered to and accepted by the Committee for each such election in accordance with Section 3.3 above.

8.2 Continued Eligibility; Disability Benefit. A Participant suffering a Disability shall, for benefit purposes under this Plan, continue to be considered to be employed and shall be eligible for the benefits provided for in Articles 4, 5, 6 or 7 in accordance with the provisions of those Articles. Notwithstanding the above, the Committee shall have the right to, in its sole and absolute discretion and for purposes of this Plan only, and must in the case of a Participant who is otherwise eligible to Retire, deem the Participant to have experienced a Termination of Employment, or in the case of a Participant who is eligible to Retire, to have Retired, at any time (or in the case of a Participant who is eligible to Retire, as soon as practicable) after such Participant is determined to be suffering a Disability, in which case the Participant shall receive a Disability Benefit equal to his or her vested Account Balance at the time of the Committee's determination; provided, however, that should the Participant otherwise have been eligible to Retire, he or she shall be paid in accordance with Article 5. The Disability Benefit shall be paid in a lump sum within sixty (60) days of the Committee's exercise of such right. Any payment made shall be subject to the Deduction Limitation.

ARTICLE 9
Beneficiary Designation

9.1 Beneficiary. Each Participant shall have the right, at any time, to designate his or her Beneficiary(ies) (both primary as well as contingent) to receive any benefits payable under the Plan to a beneficiary upon the death of a Participant. The Beneficiary designated under this Plan may be the same as or different from the Beneficiary designation under any other plan of an Employer in which the Participant participates.

14

9.2 Beneficiary Designation; Change. A Participant shall designate his or her Beneficiary by completing and signing the Beneficiary Designation Form, and returning it to the Committee or its designated agent. A Participant shall have the right to change a Beneficiary by completing, signing and otherwise complying with the terms of the Beneficiary Designation Form and the Committee's rules and procedures, as in effect from time to time. Upon the acceptance by the Committee of a new Beneficiary Designation Form, all Beneficiary designations previously filed shall be canceled. The Committee shall be entitled to rely on the last Beneficiary Designation Form filed by the Participant and accepted by the Committee prior to his or her death.

9.3 Acknowledgment. No designation or change in designation of a Beneficiary shall be effective until received and acknowledged in writing by the Committee or its designated agent.

9.4 No Beneficiary Designation. If a Participant fails to designate a Beneficiary as provided in Sections 9.1, 9.2 and 9.3 above or, if all designated Beneficiaries predecease the Participant or die prior to complete distribution of the Participant's benefits, then the Participant's designated Beneficiary shall be deemed to be his or her surviving spouse. If the Participant has no surviving spouse, the benefits remaining under the Plan to be paid to a Beneficiary shall be payable to the executor or personal representative of the Participant's estate.

9.5 Doubt as to Beneficiary. If the Committee has any doubt as to the proper Beneficiary to receive payments pursuant to this Plan, the Committee shall have the right, exercisable in its discretion, to cause the Participant's Employer to withhold such payments until this matter is resolved to the Committee's satisfaction.

9.6 Discharge of Obligations. The payment of benefits under the Plan to a Beneficiary shall fully and completely discharge all Employers and the Committee from all further obligations under this Plan with respect to the Participant, and that Participant's Plan Agreement shall terminate upon such full payment of benefits.

ARTICLE 10
Leave of Absence

10.1 Paid Leave of Absence. If a Participant is authorized by the Participant's Employer for any reason to take a paid leave of absence from the employment of the Employer, the Participant shall continue to be considered employed by the Employer and the Annual Deferral Amount shall continue to be withheld during such paid leave of absence in accordance with Section 3.3.

10.2 Unpaid Leave of Absence. If a Participant is authorized by the Participant's Employer for any reason to take an unpaid leave of absence from the employment of the Employer, the Participant shall continue to be considered employed by the Employer and the Participant shall be excused from making deferrals until the earlier of the date the leave of absence expires or the Participant returns to a paid employment status. Upon such expiration or return, deferrals shall resume for the remaining portion of the Plan Year in which the expiration or return occurs, based on the deferral election, if any, made for that Plan Year. If no election was made for that Plan Year, no deferral shall be withheld.

15

ARTICLE 11
Termination, Amendment or Modification

11.1 Termination. Although each Employer anticipates that it will continue the Plan for an indefinite period of time, there is no guarantee that any Employer will continue the Plan or will not terminate the Plan at any time in the future. Accordingly, each Employer reserves the right to discontinue its sponsorship of the Plan and/or to terminate the Plan at any time with respect to any or all of its participating Employees. Upon the termination of the Plan with respect to any Employer, the Plan Agreements of the affected Participants who are employed by that Employer shall terminate and their Account Balances determined (i) as if they had experienced a Termination of Employment on the date of Plan termination; or (ii) if Plan termination occurs after the date upon which a Participant was eligible to Retire, then with respect to that Participant as if he or she had Retired on the date of Plan termination. Such benefits shall be paid to the Participants as follows: (i) prior to a Change in Control, an Employer shall have the right, in its sole discretion, and notwithstanding any elections made by the Participant, to pay such benefits in a lump sum or pursuant to an Annual Installment Method of up to five (5) years, with amounts credited and debited during the installment period as provided herein; or (ii) after a Change in Control, the Employer shall be required to pay such benefits in a lump sum. The termination of the Plan shall not adversely affect any Participant or Beneficiary who has become entitled to the payment of any benefits under the Plan as of the date of termination; provided however, that the Employer shall have the right to accelerate installment payments without a premium or prepayment penalty by paying the vested Account Balance in a lump sum or pursuant to an Annual Installment Method using fewer years.

11.2 Amendment. Any Employer may, at any time, amend or modify the Plan in whole or in part with respect to that Employer; provided, however, that: (i) no amendment or modification shall be effective to decrease or restrict the value of a Participant's vested Account Balance in existence at the time the amendment or modification is made, calculated as if the Participant had experienced a Termination of Employment as of the effective date of the amendment or modification or, if the amendment or modification occurs after the date upon which the Participant was eligible to Retire, the Participant had Retired as of the effective date of the amendment or modification, and
(ii) no amendment or modification of this Section 11.2 or Section 12.2 of the Plan shall be effective. The amendment or modification of the Plan shall not affect any Participant or Beneficiary who has become entitled to the payment of benefits under the Plan as of the date of the amendment or modification; provided, however, that the Employer shall have the right to accelerate installment payments by paying the vested Account Balance in a lump sum or pursuant to an Annual Installment Method using fewer years.

11.3 Plan Agreement. Despite the provisions of Sections 11.1 and 11.2 above, if a Participant's Plan Agreement contains benefits or limitations that are not in this Plan document, the Employer may only amend or terminate such provisions with the consent of the Participant.

11.4 Effect of Payment. The full payment of the applicable benefit under Articles 4, 5, 6, 7 or 8 of the Plan shall completely discharge all obligations to a Participant and his or her designated Beneficiaries under this Plan and the Participant's Plan Agreement shall terminate.

16

ARTICLE 12
Administration

12.1 Committee Duties. Except as otherwise provided in this Article 12, this Plan shall be administered by a Committee which shall consist of the Board, or such other person(s) as the Board shall appoint. Members of the Committee may be Participants under this Plan. The Committee shall also have the discretion and authority to (i) make, amend, interpret, and enforce all appropriate rules and regulations for the administration of this Plan and (ii) decide or resolve any and all questions including interpretations of this Plan, as may arise in connection with the Plan. Any individual serving on the Committee who is a Participant shall not vote or act on any matter relating solely to himself or herself. When making a determination or calculation, the Committee shall be entitled to rely on information furnished by a Participant or the Company.

12.2 Administration Upon Change In Control. For purposes of this Plan, the Company shall be the "Administrator" at all times prior to the occurrence of a Change in Control. Upon and after the occurrence of a Change in Control, the "Administrator" shall be an independent third party selected by the Trustee and approved by the individual who, immediately prior to such event, was the Company's Chief Executive Officer or, if not so identified, the Company's highest ranking officer (the "Ex-CEO"). The Administrator shall have the discretionary power to determine all questions arising in connection with the administration of the Plan and the interpretation of the Plan and Trust including, but not limited to benefit entitlement determinations; provided, however, upon and after the occurrence of a Change in Control, the Administrator shall have no power to direct the investment of Plan or Trust assets or select any investment manager or custodial firm for the Plan or Trust. Upon and after the occurrence of a Change in Control, the Company must: (1) pay all reasonable administrative expenses and fees of the Administrator; (2) indemnify the Administrator against any costs, expenses and liabilities including, without limitation, attorney's fees and expenses arising in connection with the performance of the Administrator hereunder, except with respect to matters resulting from the gross negligence or willful misconduct of the Administrator or its employees or agents; and (3) supply full and timely information to the Administrator on all matters relating to the Plan, the Trust, the Participants and their Beneficiaries, the Account Balances of the Participants, the date of circumstances of the Retirement, Disability, death or Termination of Employment of the Participants, and such other pertinent information as the Administrator may reasonably require. Upon and after a Change in Control, the Administrator may be terminated (and a replacement appointed) by the Trustee only with the approval of the Ex-CEO. Upon and after a Change in Control, the Administrator may not be terminated by the Company.

12.3 Agents. In the administration of this Plan, the Committee may, from time to time, employ agents and delegate to them such administrative duties as it sees fit (including acting through a duly appointed representative) and may from time to time consult with counsel who may be counsel to any Employer.

12.4 Binding Effect of Decisions. The decision or action of the Administrator with respect to any question arising out of or in connection with the

17

administration, interpretation and application of the Plan and the rules and regulations promulgated hereunder shall be final and conclusive and binding upon all persons having any interest in the Plan.

12.5 Indemnity of Committee. The Company shall indemnify and hold harmless the members of the Committee, any Employee to whom the duties of the Committee may be delegated, and the Administrator against any and all claims, losses, damages, expenses or liabilities arising from any action or failure to act with respect to this Plan, except in the case of willful misconduct by the Committee, any of its members, any such Employee or the Administrator.

12.6 Employer Information. To enable the Committee and/or Administrator to perform its functions, the Company and each Employer shall supply full and timely information to the Committee and/or Administrator, as the case may be, on all matters relating to the compensation of its Participants, the date and circumstances of the Retirement, Disability, death or Termination of Employment of its Participants, and such other pertinent information as the Committee or Administrator may reasonably require.

ARTICLE 13
Other Benefits and Agreements

13.1 Coordination with Other Benefits. The benefits provided for a Participant and Participant's Beneficiary under the Plan are in addition to any other benefits available to such Participant under any other plan or program for employees of the Participant's Employer. The Plan shall supplement and shall not supersede, modify or amend any other such plan or program except as may otherwise be expressly provided.

ARTICLE 14
Claims Procedures

14.1 Presentation of Claim. Any Participant or Beneficiary of a deceased Participant (such Participant or Beneficiary being referred to below as a "Claimant") may deliver to the Committee a written claim for a determination with respect to the amounts distributable to such Claimant from the Plan. If such a claim relates to the contents of a notice received by the Claimant, the claim must be made within sixty (60) days after such notice was received by the Claimant. All other claims must be made within 180 days of the date on which the event that caused the claim to arise occurred. The claim must state with particularity the determination desired by the Claimant.

14.2 Notification of Decision. The Committee shall consider a Claimant's claim within a reasonable time, and shall notify the Claimant in writing:

(a) that the Claimant's requested determination has been made, and that the claim has been allowed in full; or

(b) that the Committee has reached a conclusion contrary, in whole or in part, to the Claimant's requested determination, and such notice must set forth in a manner calculated to be understood by the Claimant:

18

(i) the specific reason(s) for the denial of the claim, or any part of it;

(ii) specific reference(s) to pertinent provisions of the Plan upon which such denial was based;

(iii)a description of any additional material or information necessary for the Claimant to perfect the claim, and an explanation of why such material or information is necessary; and

(iv) an explanation of the claim review procedure set forth in Section 14.3 below.

14.3 Review of a Denied Claim. Within sixty (60) days after receiving a notice from the Committee that a claim has been denied, in whole or in part, a Claimant (or the Claimant's duly authorized representative) may file with the Committee a written request for a review of the denial of the claim. Thereafter, but not later than thirty (30) days after the review procedure began, the Claimant (or the Claimant's duly authorized representative):

(a) may review pertinent documents;

(b) may submit written comments or other documents; and/or

(c) may request a hearing, which the Committee, in its sole discretion, may grant.

14.4 Decision on Review. The Committee shall render its decision on review promptly, and not later than sixty (60) days after the filing of a written request for review of the denial, unless a hearing is held or other special circumstances require additional time, in which case the Committee's decision must be rendered within 120 days after such date. Such decision must be written in a manner calculated to be understood by the Claimant, and it must contain:

(a) specific reasons for the decision;

(b) specific reference(s) to the pertinent Plan provisions upon which the decision was based; and

(c) such other matters as the Committee deems relevant.

14.5 Legal Action. A Claimant's compliance with the foregoing provisions of this Article 14 is a mandatory prerequisite to a Claimant's right to commence any legal action with respect to any claim for benefits under this Plan.

ARTICLE 15
Trust

15.1 Establishment of the Trust. The Company shall establish the Trust, and each Employer shall at least annually transfer over to the Trust such assets as the Employer determines, in its sole discretion, are necessary to provide, on a present value basis, for its respective future liabilities created with respect to the Annual Deferral Amounts and Annual Company Contribution Amounts for such Employer's Participants for all periods prior to the transfer, as well as any debits and credits to the Participants' Account Balances for all periods prior to the transfer, taking into consideration the value of the assets in the trust at the time of the transfer.

19

15.2 Interrelationship of the Plan and the Trust. The provisions of the Plan and the Plan Agreement shall govern the rights of a Participant to receive distributions pursuant to the Plan. The provisions of the Trust shall govern the rights of the Employers, Participants and the creditors of the Employers to the assets transferred to the Trust. Each Employer shall at all times remain liable to carry out its obligations under the Plan.

15.3 Distributions From the Trust. Each Employer's obligations under the Plan may be satisfied with Trust assets distributed pursuant to the terms of the Trust, and any such distribution shall reduce the Employer's obligations under this Plan.

ARTICLE 16
Miscellaneous

16.1 Status of Plan. The Plan is intended to be a plan that is not qualified within the meaning of Code Section 401(a) and that "is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employee" within the meaning of ERISA Sections 201(2), 301(a)(3) and
401(a)(1). The Plan shall be administered and interpreted to the extent possible in a manner consistent with that intent.

16.2 Unsecured General Creditor. Participants and their Beneficiaries, heirs, successors and assigns shall have no legal or equitable rights, interests or claims in any property or assets of an Employer. For purposes of the payment of benefits under this Plan, any and all of an Employer's assets shall be, and remain, the general, unpledged unrestricted assets of the Employer. An Employer's obligation under the Plan shall be merely that of an unfunded and unsecured promise to pay money in the future.

16.3 Employer's Liability. An Employer's liability for the payment of benefits shall be defined only by the Plan and the Plan Agreement, as entered into between the Employer and a Participant. An Employer shall have no obligation to a Participant under the Plan except as expressly provided in the Plan and his or her Plan Agreement.

16.4 Nonassignability. Neither a Participant nor any other person shall have any right to commute, sell, assign, transfer, pledge, anticipate, mortgage or otherwise encumber, transfer, hypothecate, alienate or convey in advance of actual receipt, the amounts, if any, payable hereunder, or any part thereof, which are, and all rights to which are expressly declared to be, unassignable and non-transferable. No part of the amounts payable shall, prior to actual payment, be subject to seizure, attachment, garnishment or sequestration for the payment of any debts, judgments, alimony or separate maintenance owed by a Participant or any other person, be transferable by operation of law in the event of a Participant's or any other person's bankruptcy or insolvency or be transferable to a spouse as a result of a property settlement or otherwise.

16.5 Not a Contract of Employment. The terms and conditions of this Plan shall not be deemed to constitute a contract of employment between any Employer and the Participant. Such employment is hereby acknowledged to be an "at will" employment relationship that can be terminated at any time for any reason, or no reason, with or without cause, and with or without notice,

20

unless expressly provided in a written employment agreement. Nothing in this Plan shall be deemed to give a Participant the right to be retained in the service of any Employer, or to interfere with the right of any Employer to discipline or discharge the Participant at any time.

16.6 Furnishing Information. A Participant or his or her Beneficiary will cooperate with the Committee by furnishing any and all information requested by the Committee and take such other actions as may be requested in order to facilitate the administration of the Plan and the payments of benefits hereunder, including but not limited to taking such physical examinations as the Committee may deem necessary.

16.7 Terms. Whenever any words are used herein in the masculine, they shall be construed as though they were in the feminine in all cases where they would so apply; and whenever any words are used herein in the singular or in the plural, they shall be construed as though they were used in the plural or the singular, as the case may be, in all cases where they would so apply.

16.8 Captions. The captions of the articles, sections and paragraphs of this Plan are for convenience only and shall not control or affect the meaning or construction of any of its provisions.

16.9 Governing Law. Subject to ERISA, the provisions of this Plan shall be construed and interpreted according to the internal laws of the Commonwealth of Massachusetts without regard to its conflicts of laws principles.

16.10Notice. Any notice or filing required or permitted to be given to the Committee under this Plan shall be sufficient if in writing and hand-delivered, or sent by registered or certified mail, to the address below:

Deferred Compensation Plan Committee

Thermo Electron Corporation

81 Wyman Street

Waltham, MA 02454

or such other address as the Company indicates by notice to the Participants.

Such notice shall be deemed given as of the date of delivery or, if delivery is made by mail, as of the date shown on the postmark on the receipt for registration or certification.

Any notice or filing required or permitted to be given to a Participant under this Plan shall be sufficient if in writing and hand-delivered, or sent by mail, to the last known address of the Participant.

16.11Successors. The provisions of this Plan shall bind and inure to the benefit of the Participant's Employer and its successors and assigns and the Participant and the Participant's designated Beneficiaries.

16.12Spouse's Interest. The interest in the benefits hereunder of a spouse of a Participant who has predeceased the Participant shall automatically pass to the Participant and shall not be transferable by such spouse in any manner, including but not limited to such spouse's will, nor shall such interest pass under the laws of intestate succession.

21

16.13Validity. In case any provision of this Plan shall be illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts hereof, but this Plan shall be construed and enforced as if such illegal or invalid provision had never been inserted herein.

16.14Incompetent. If the Committee determines in its discretion that a benefit under this Plan is to be paid to a minor, a person declared incompetent or to a person incapable of handling the disposition of that person's property, the Committee may direct payment of such benefit to the guardian, legal representative or person having the care and custody of such minor, incompetent or incapable person. The Committee may require proof of minority, incompetence, incapacity or guardianship, as it may deem appropriate prior to distribution of the benefit. Any payment of a benefit shall be a payment for the account of the Participant and the Participant's Beneficiary, as the case may be, and shall be a complete discharge of any liability under the Plan for such payment amount.

16.15Court Order. The Committee is authorized to make any payments directed by court order in any action in which the Plan or the Committee has been named as a party. In addition, if a court determines that a spouse or former spouse of a Participant has an interest in the Participant's benefits under the Plan in connection with a property settlement or otherwise, the Committee, in its sole discretion, shall have the right, notwithstanding any election made by a Participant, to immediately distribute the spouse's or former spouse's interest in the Participant's benefits under the Plan to that spouse or former spouse.

16.16 Distribution in the Event of Taxation.

(a) In General. If, for any reason, all or any portion of a Participant's benefits under this Plan becomes taxable to the Participant prior to receipt, a Participant may petition the Committee before a Change in Control, or the trustee of the Trust after a Change in Control, for a distribution of that portion of his or her benefit that has become taxable. Upon the grant of such a petition, which grant shall not be unreasonably withheld (and, after a Change in Control, shall be granted), a Participant's Employer shall distribute to the Participant immediately available funds in an amount equal to the taxable portion of his or her benefit (which amount shall not exceed a Participant's unpaid vested Account Balance under the Plan). If the petition is granted, the tax liability distribution shall be made within 90 days of the date when the Participant's petition is granted. Such a distribution shall affect and reduce the benefits to be paid under this Plan.

(b) Trust. If the Trust terminates in accordance with its terms and benefits are distributed from the Trust to a Participant in accordance therewith, the Participant's benefits under this Plan shall be reduced to the extent of such distributions.

16.17Insurance. The Employers, on their own behalf or on behalf of the trustee of the Trust, and, in their sole discretion, may apply for and procure insurance on the life of the Participant, in such amounts and in such forms as the Employers may choose. The Employers or the trustee of the Trust, as the case may be, shall be the sole owner and beneficiary of any such insurance. The Participant shall have no interest whatsoever in any such policy or policies, and at the request of the Employers shall submit to medical examinations and supply such information and execute such documents as may be required by the insurance company or companies to whom the Employers have applied for insurance.

22

IN WITNESS WHEREOF, the Company has signed this Plan document as of November 1, 2001.

"Company"
Thermo Electron Corporation, a Delaware corporation

By:
Title:

23

Exhibit 10.3
THERMO ELECTRON CORPORATION

EXECUTIVE SEVERANCE AGREEMENT

THIS AGREEMENT by and between THERMO ELECTRON CORPORATION, a Delaware corporation (the "Company"), and Theo Melas-Kyriazi (the "Executive") is made as of January 27, 2000 (the "Effective Date").

WHEREAS, the Company recognizes that the uncertainty regarding the future employment prospects for key personnel may result in the departure or distraction of key personnel to the detriment of the Company and its stockholders;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the Company's key personnel without distraction from such uncertainty and related events and circumstances; and

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in its employ, the Company agrees that the Executive shall receive the severance benefits set forth in this Agreement in the event the Executive's employment with the Company is terminated under the circumstances described below.

1. Key Definitions.

As used herein, the following terms shall have the following respective meanings:

1.1 "Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.1; or


(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term "Continuing Director" means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.2 "Cause" means the Executive's willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company. For purposes of this Section 1.2, no act or failure to act by the Executive shall be considered "willful" unless it is done, or omitted to be


done, in bad faith and without reasonable belief that the Executive's action or omission was in the best interests of the Company.

2. Term of Agreement. This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) or
(b) the fulfillment by the Company of all of its obligations under Sections 4 and 5.2 if the Executive's employment with the Company terminates prior to the expiration of the Term. "Term" shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2002.

3. Not an Employment Contract. The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time.

4. Benefits to Executive.

4.1 Compensation.

(a) Termination Without Cause. If the Executive's employment with the Company is terminated by the Company (other than for Cause) then the Executive shall be entitled to the following benefits:

(i) the Company shall pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts:

(1) the sum of (A) two times the Executive's annual base salary as in effect immediately prior to the date of termination, and (B) the amount of any cash compensation previously deferred by the Executive (together with any accrued interest or earnings thereon) and any accrued vacation pay, in each case to the extent not previously paid; and

(ii) for two years after the date of termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue to provide benefits to the Executive and the Executive's family at least equal to those which would have been provided to them if the Executive's employment had not been terminated, in accordance with the applicable benefit plans in effect on the date of termination or, if more favorable to the Executive and the Executive's family, in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies; provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., health insurance benefits) from such employer on terms at least as favorable to the Executive and the Executive's family as


those being provided by the Company, then the Company shall no longer be required to provide those particular benefits to the Executive and the Executive's family;

(iii) to the extent not previously paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"); and

(iv) for purposes of determining eligibility (but not the time of commencement of benefits) of the Executive for retiree benefits to which the Executive is entitled, the Executive shall be considered to have remained employed by the Company until two years after the date of termination.

(b) Termination for Cause. If the Company terminates the Executive's employment with the Company for Cause, then the Company shall (i) pay the Executive, in a lump sum in cash within 30 days after the date of termination, the sum of (A) the Executive's base salary through the date of termination and (B) the amount of any cash compensation previously deferred by the Executive, in each case to the extent not previously paid and (ii) timely pay or provide to the Executive the Other Benefits.

4.2 Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in this Section 4 by seeking other employment or otherwise. Further, except as provided in Section 4.1(a)(ii), the amount of any payment or benefits provided for in this Section 4 shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

5. Disputes.

5.1 Settlement of Disputes; Arbitration. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board of Directors of the Company and shall be in writing. Any denial by the Board of Directors of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board of Directors shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim. Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

5.2 Expenses. The Company agrees to pay as incurred, to the full extent permitted by law, all legal, accounting and other fees and expenses which


the Executive may reasonably incur as a result of any claim or contest (regardless of the outcome thereof) by the Company, the Executive or others regarding the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Internal Revenue Code.

6. Successors.

6.1 Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

6.2 Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or the Executive's family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

7. Notice. All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 81 Wyman Street, Waltham, Massachusetts and to the Executive at the Executive's principal residence as currently reflected on the Company's records (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.


8. Miscellaneous.

8.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

8.2 Injunctive Relief. The Company and the Executive agree that any breach of this Agreement by the Company is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

8.3 Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.4 Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

8.5 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

8.6 Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

8.7 Entire Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein, and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled, except as provided in the next sentence. Notwithstanding the foregoing sentence, if the Executive is party to an agreement with the Company providing for the payment of benefits in the event employment is terminated after a Change in Control (a "Change in Control Agreement"), such Change in Control Agreement shall not be terminated or cancelled by this Agreement and such Change in Control Agreement shall survive and remain in effect in accordance with its own terms. In the event the Executive actually receives benefits under the Change in Control Agreement, the Executive shall not also be entitled to receive benefits under this Agreement.

8.8 Amendments. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

THERMO ELECTRON CORPORATION

By:     /s/ Anne Pol
        ------------------------------------
        Anne Pol
        Senior Vice President, Human Resources

EXECUTIVE:

/s/ Theo Melas-Kyriazi
-----------------------------------
Theo Melas-Kyriazi


Exhibit 10.7

THERMO ELECTRON CORPORATION

DIRECTORS STOCK OPTION PLAN

As amended and restated effective as of February 7, 2002

1. Purpose

The purpose of this Directors Stock Option Plan (the "Plan") of Thermo Electron Corporation (the "Company") is to encourage ownership in the Company by outside directors of the Company whose services are considered essential to the Company's growth and progress and to provide them with a further incentive to become directors and to continue as directors of the Company. The Plan is intended to be a nonstatutory stock option plan.

2. Administration

The Board of Directors, or a Committee (the "Committee") consisting of one or more directors of the Company appointed by the Board of Directors, shall supervise and administer the Plan. Grants of stock options under the Plan and the amount and nature of the options to be granted shall be automatic in accordance with Section 5. However, all questions of interpretation of the Plan or of any stock options granted under it shall be determined by the Board of Directors or the Committee and such determination shall be final and binding upon all persons having an interest in the Plan.

3. Participation in the Plan

Directors of the Company who are not employees of the Company or any subsidiary or parent of the Company shall be eligible to participate in the Plan. Directors who receive grants of stock options in accordance with this Plan are sometimes referred to herein as "Optionees."

4. Stock Subject to the Plan

The maximum number of shares that may be issued under the Plan shall be 675,000 shares of the Company's Common Stock (the "Common Stock"), subject to adjustment as provided in Section 9. Shares to be issued upon the exercise of options granted under the Plan may be either authorized but unissued shares or shares held by the Company in its treasury. If any option expires or terminates for any reason without having been exercised in full, the unpurchased shares subject thereto shall again be available for options thereafter to be granted.

5. Terms and Conditions

A. Annual Stock Option Grants

Each Director of the Company who meets the requirements of Section 3 and who is holding office immediately following the Annual Meeting of Stockholders commencing with the Annual Meeting of Stockholders held in calendar year 1993, shall be granted an option to purchase 1,000 shares of Common Stock at the close

1

of business on the date of such Annual Meeting.

B. General Terms and Conditions Applicable to All Grants.

1. Options shall be immediately exercisable at any time from and after the grant date and prior to the date which is the earliest of:

(a) seven years after the grant date, (b) three years after the Optionee ceases to serve as a director of the Company, or any subsidiary of the Company (one year in the event the Optionee ceases to meet the requirements of this Subsection by reason of his or her death), or (c) the date of dissolution or liquidation of the Company.

2. The exercise price at which Options are granted hereunder shall be the average of the closing prices reported by the national securities exchange on which the Common Stock is principally traded for the five trading days immediately preceding and including the date the option is granted or, if such security is not traded on an exchange, the average last reported sale price for the five-day period on the NASDAQ National Market List, or the average of the closing bid prices for the five-day period last quoted by an established quotation service for over-the-counter securities, or if none of the above shall apply, the last price paid for shares of the Common Stock by independent investors in a private placement.

3. All options shall be evidenced by a written agreement substantially in such form as shall be approved by the Board of Directors or Committee, containing terms and conditions consistent with the provisions of this Plan.

6. Exercise of Options

A. Exercise/Consideration

An option may be exercised in accordance with the instructions described in "The Guide for Employees of Thermo Electron Stock Option Plans" and any supplement thereto as they may be amended from time to time (the "Guide"). Upon exercise of the option in accordance with the aforementioned instructions, the Company shall deliver or cause to be delivered to the Optionee the number of shares then being purchased, registered in the name of the Optionee or other person exercising the option. If any law or applicable regulation of the Securities and Exchange Commission or other body having jurisdiction in the premises shall require the Company or the Director to take any action in connection with shares being purchased upon exercise of the option, exercise of the option and delivery of the certificate or certificates for such shares shall be postponed until completion of the necessary action, which shall be taken at the Company's expense.

2

B. Tax Withholding

No later than the date on which part or all of the value of any shares received upon the exercise of an option first becomes includible in your gross income for income tax purposes, you shall satisfy your obligations to pay any federal, state or local taxes required to be withheld with respect to such income in accordance with the provisions of the Guide. Notwithstanding the foregoing, no election to use shares for the payment of withholding taxes shall be effective unless made in compliance with any applicable requirements of Rule 16b-3.

7. Transferability

Except as may be authorized by the Board, in its sole discretion, no Option may be transferred other than by will or the laws of descent and distribution, and during an Optionee's lifetime an Option may be exercised only by him or her (or in the event of incapacity, the person or persons properly appointed to act on his or her behalf). The Board may, in its discretion, determine the extent to which Options granted to an Optionee shall be transferable, and such provisions permitting or acknowledging transfer shall be set forth in the written agreement evidencing the Option executed and delivered by or on behalf of the Company and the Optionee.

8. Limitation of Rights to Continue as a Director

Neither the Plan, nor the quantity of shares subject to options granted under the Plan, nor any other action taken pursuant to the Plan, shall constitute or be evidence of any agreement or understanding, express or implied, that the Company will retain a Director for any period of time, or at any particular rate of compensation.

9. Adjustments in the Event of Certain Transactions

(a) In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the Board will make (i) appropriate adjustments to the maximum number of shares that may be delivered under the Plan under Section 4 above, and
(ii) appropriate adjustments to the number and kind of shares of stock or securities subject to Options then outstanding or subsequently granted, any exercise prices relating to Options and any other provisions of Options affected by such change.

(b) In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Board, the Board in its discretion may make appropriate adjustments to outstanding Awards, including, without limitation: (i) accelerate the exercisability of the Option, or (ii) adjust the terms of the Option (whether or not in a manner that complies with the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended (the "Code")), or (iii) if there is a survivor or acquiror entity, provide for the assumption of the Option by such survivor or acquiror or an affiliate thereof or for the grant of one or more replacement options by such survivor or acquiror or an affiliate thereof, in each case on such terms (which may, but need not, comply with the requirements

3

of Section 424(a) of the Code) as the Board may determine, or (iv) terminate the Option (provided, that if the Board terminates the Option, it shall, in connection therewith, either (A) accelerate the exercisability of the Option prior to such termination, or (B) provide for a payment to the holder of the Option of cash or other property or a combination of cash or other property in an amount reasonably determined by the Board to approximate the value of the Option assuming an exercise immediately prior to the transaction, or (C) if there is a survivor or acquiror entity, provide for the grant of one or more replacement options pursuant to clause (iii) above), or (v) provide for none of, or any combination of, the foregoing.

(c) No fraction of a share or fractional shares shall be purchasable or deliverable pursuant to this Section 9.

10. Limitation of Rights in Option Stock

The Optionee shall have no rights as a stockholder in respect of shares as to which his or her options shall not have been exercised, certificates issued and delivered and payment as herein provided made in full, and shall have no rights with respect to such shares not expressly conferred by this Plan or the written agreement evidencing options granted hereunder.

11. Stock Reserved

The Company shall at all times during the term of the options reserve and keep available such number of shares of the Common Stock as will be sufficient to permit the exercise in full of all options granted under this Plan and shall pay all other fees and expenses necessarily incurred by the Company in connection therewith.

12. Securities Laws Restrictions

A. Investment Representations.

The Company may require any person to whom an option is granted, as a condition of exercising such option, to give written assurances in substance and form satisfactory to the Company to the effect that such person is acquiring the Common Stock subject to the option for his or her own account for investment and not with any present intention of selling or otherwise distributing the same, and to such other effects as the Company deems necessary or appropriate in order to comply with federal and applicable state securities laws.

B. Compliance with Securities Laws.

Each option shall be subject to the requirement that if, at any time, counsel to the Company shall determine that the listing, registration or qualification of the shares subject to such option upon any securities exchange or under any state or federal law, or the consent or approval of any governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of shares thereunder, such option may not be exercised, in whole or in part, unless such

4

listing, registration, qualification, consent or approval, or satisfaction of such condition shall have been effected or obtained on conditions acceptable to the Board of Directors. Nothing herein shall be deemed to require the Company to apply for or to obtain such listing, registration or qualification, or to satisfy such condition.

13. Change in Control

A. Impact of Event

In the event of a "Change in Control" as defined in Section 13(A), the following provisions shall apply, unless the agreement evidencing the Award otherwise provides (by specific explicit reference to Section 13(B) below). If a Change in Control occurs while any Options are outstanding, then, effective upon the Change in Control, each outstanding Option under the Plan that was not previously exercisable and vested shall become immediately exercisable in full and will no longer be subject to a right of repurchase by the Company.

B. Definition of "Change in Control"

"Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of beneficial ownership of any capital stock of Thermo Electron Corporation ("Thermo Electron") if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either
(i) the then-outstanding shares of common stock of Thermo Electron (the "Outstanding TMO Common Stock") or (ii) the combined voting power of the then-outstanding securities of Thermo Electron entitled to vote generally in the election of directors (the "Outstanding TMO Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by Thermo Electron, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Thermo Electron or any corporation controlled by Thermo Electron, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this definition; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board of Directors of Thermo Electron (the "Thermo Board") (or, if applicable, the Board of Directors of a successor corporation to Thermo Electron), where the term "Continuing Director" means at any date a member of the Thermo Board (i) who was a member of the Thermo Board as of July 1, 1999 or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Thermo Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall

5

be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Thermo Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving Thermo Electron or a sale or other disposition of all or substantially all of the assets of Thermo Electron in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns Thermo Electron or substantially all of Thermo Electron's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by Thermo Electron or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of Thermo Electron of a complete liquidation or dissolution of Thermo Electron.

14. Amendment of the Plan

The provisions of Sections 3 and 5 of the Plan shall not be amended more than once every six months, other than to comport with changes in the Code, the Employee Retirement Income Security Act of 1974, or the rules thereunder. Subject to the foregoing, the Board of Directors may at any time, and from time to time, modify or amend the Plan in any respect, except that if at any time the approval of the Stockholders of the Company is required as to such modification or amendment under Rule 16b-3, the Board of Directors may not effect such modification or amendment without such approval.

The termination or any modification or amendment of the Plan shall not, without the consent of an Optionee, affect his or her rights under an option previously granted to him or her. With the consent of the Optionees affected, the Board of Directors may amend outstanding option agreements in a manner not inconsistent with the Plan. The Board of Directors shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding option to the extent necessary to ensure the qualification of the Plan under Rule 16b-3.

6

15. Effective Date of the Plan

The Plan shall become effective when adopted by the Board of Directors, but no option granted under the Plan shall become exercisable until six months after the Plan is approved by the Stockholders of the Company.

16. Notice

Any written notice to the Company required by any of the provisions of the Plan shall be addressed to the Secretary of the Company and shall become effective when it is received.

17. Governing Law

The Plan and all determinations made and actions taken pursuant hereto shall be governed by the laws of the State of Delaware.

7

Exhibit 3.2

As amended and effective as of February 7, 2002

THERMO ELECTRON CORPORATION

BY-LAWS

TABLE OF CONTENTS

Title                                                                                                   Page
-------------------------------------------------------------------------------------------------------------
Article I - Stockholders                                                                                 1
         Section 1.        Annual Meeting                                                                1
         Section 2.        Special Meetings                                                              1
         Section 3.        Notice of Meetings                                                            1
         Section 4.        Quorum; Adjournments                                                          1
         Section 5.        Voting; Proxies                                                               2
         Section 6         Inspectors of Elections                                                       2
         Section 7.        Presiding Officer and Secretary                                               2
         Section 8.        List of Stockholders                                                          3
         Section 9.        Advance Notice of Stockholder Nominations and Proposals                       3
         Section 10.       Action Without Meeting                                                        5


Article II- Directors                                                                                    6
         Section 1.        General Powers                                                                6
         Section 2.        Number and Qualification                                                      6
         Section 3.        Classes of Directors                                                          6
         Section 4.        Terms of Office                                                               6
         Section 5.        Vacancies                                                                     7
         Section 6.        Resignations                                                                  7
         Section 7.        Meetings                                                                      7
         Section 8.        Notice of Meetings                                                            7
         Section 9.        Quorum                                                                        7
         Section 10.       Action at Meeting                                                             7
         Section 11.       Action by Consent                                                             8
         Section 12.       Meetings by Telephone Conference Call                                         8
         Section 13.       Compensation of Directors                                                     8
         Section 14.       Committees                                                                    8




                                      (i)

Title                                                                                                 Page
-------------------------------------------------------------------------------------------------------------
Article III - Officers                                                                                   9
         Section 1.        General Provisions; Qualification                                             9
         Section 2.        Election                                                                      9
         Section 3.        Tenure                                                                        9
         Section 4.        Resignation and Removal                                                       9
         Section 5.        Vacancies                                                                     9
         Section 6.        The Chief Executive Officer                                                   9
         Section 7.        The President                                                                 9
         Section 8.        Vice Presidents                                                              10
         Section 9.        Chief Financial Officer                                                      10
         Section 10.       General Counsel                                                              10
         Section 11.       The Treasurer                                                                10
         Section 12.       The Secretary                                                                10
         Section 13.       Assistant Treasurers                                                         10
         Section 14.       Assistant Secretaries                                                        11
         Section 15.       Other Officers                                                               11
         Section 16.       Delegation of Duties                                                         11
         Section 17.       Salaries                                                                     11


Article IV - Capital Stock 11
         Section 1.        Certificates for Shares                                                      11
         Section 2.        Transfer of Shares of Stock                                                  11
         Section 3.        Lost, Stolen or Destroyed Certificates                                       11
         Section 4.        Record Date                                                                  11
         Section 5.        Regulations                                                                  12


Article V - General Provisions                                                                          13
         Section 1.        Fiscal Year                                                                  13
         Section 2.        Corporate Seal                                                               13
         Section 3.        Waiver of Notice                                                             13
         Section 4.        Voting of Securities                                                         13
         Section 5.        Evidence of Authority                                                        13
         Section 6.        Certificate of Incorporation                                                 13
         Section 7.        Transactions with Interested Parties                                         13
         Section 8.        Severability                                                                 14
         Section 9.        Limitation on Stock Option Repricing                                         14

Article VI - Amendments    14
         Section 1.        By the Board of Directors                                                    14
         Section 2.        By the Stockholders                                                          14
         Section 3.        Certain Provisions                                                           15

(ii)

THERMO ELECTRON CORPORATION

BY-LAWS

ARTICLE I - STOCKHOLDERS

Section 1. Annual Meeting. The annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors may each year fix.

Section 2. Special Meetings. Special meetings of stockholders may be called only by the Board of Directors, the Chairman of the Board of Directors, or the Chief Executive Officer. Special meetings may be held at such place, on such date, and at such time as the person(s) calling the meeting may specify. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. The Board of Directors may postpone or reschedule any previously scheduled special meeting.

Section 3. Notice of Meetings. Written notice of the place, date, and time of all meetings of the stockholders shall be given, not less than ten (10) nor more than sixty (60) days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise required by the Delaware General Corporation Law (meaning, here and hereinafter, the General Corporation Law of the State of Delaware, as amended and in effect from time to time, the "Delaware General Corporation Law").

Section 4. Quorum; Adjournments. At any meeting of the stockholders, the holders of a majority of all of the shares of the stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by the Certificate of Incorporation or the Delaware General Corporation Law. Where a separate vote by a class or classes or series is required, a majority of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter.

If a quorum shall fail to attend any meeting, the presiding officer may adjourn the meeting to another place, date, or time. When a meeting is adjourned to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted that could have been transacted at the original meeting.


Section 5. Voting; Proxies. Each stockholder shall have one vote for each share of stock entitled to vote held of record by such stockholder unless otherwise provided by the Delaware General Corporation Law or the Certificate of Incorporation. Each stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing without a meeting, may vote or express such consent or dissent in person or may authorize another person or persons to vote or act for the stockholder by written proxy executed by the stockholder or the stockholder's authorized agent and delivered to the Secretary of the Corporation. No such proxy shall be voted or acted upon after three years from the date of its execution, unless the proxy expressly provides for a longer period.

When a quorum is present at any meeting, the affirmative vote of holders of a majority of the stock present or represented and entitled to vote and voting affirmatively or negatively on a matter (or if there are two or more classes or series of stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority of the stock of that class present or represented and voting affirmatively or negatively on a matter) shall constitute stockholder action on any matter to be voted upon by the stockholders at such meeting, except when a different vote is required by the Delaware General Corporation Law, the Certificate of Incorporation or these By-laws. Except as may be otherwise required by the Certificate of Incorporation, any election by stockholders of directors shall be determined by a plurality of the votes cast by the stockholders entitled to vote at the election.

Section 6. Inspectors of Elections. The Corporation may, and to the extent required by the Delaware General Corporation Law, shall, in advance of any meeting of the stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof and perform the other duties of inspectors at meetings of stockholders as set forth in the Delaware General Corporation Law. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by the Certificate of Incorporation or the Delaware General Corporation Law, shall, appoint one or more persons to act at the meeting. Each inspector, before entering the discharge of the inspector's duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of the inspector's ability.

Section 7. Presiding Officer and Secretary. The Chairman of the Board, or in the Chairman's absence, the Chief Executive Officer, or in the Chief Executive Officer's absence, the President, or in the President's absence, the Chief Financial Officer, in such order, shall call meetings of the stockholders to order, and shall act as presiding officer of such meeting. The presiding officer shall determine the order of business and the procedure at meetings, including such regulation of the manner of voting and the conduct of discussion as seem to the presiding officer in order. The presiding officer shall have the power to adjourn meetings to another place, date, and time. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. The Secretary of the Corporation, or in the Secretary's absence, any Assistant Secretary, shall act as the secretary at all meetings of the stockholders, but in the absence of the Secretary and any Assistant Secretary, the presiding officer may appoint any person to act as secretary of the meeting.

2

Section 8. List of Stockholders. The Secretary shall prepare, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least 10 days prior to the meeting, at a place within the city where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time of the meeting, and may be inspected by any stockholder who is present.

Section 9. Advance Notice of Stockholder Nominations and Proposals.

1. Nominations of persons for election to the Board of Directors and the proposal of business to be transacted by the stockholders may be made at an annual meeting of stockholders (a) pursuant to the Corporation's notice with respect to such meeting, (b) by or at the direction of the Board or (c) by any stockholder of record of the Corporation who was a stockholder of record at the time of the giving of the notice provided for in the following paragraph, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 9.

2. For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (c) of the foregoing paragraph, (1) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (2) such business must be a proper matter for stockholder action under the Delaware General Corporation Law, (3) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in subclause (c)(iii) of this paragraph, such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation's voting shares required under the Delaware General Corporation Law to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation's voting shares reasonably believed by such stockholder or beneficial holder to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice, and (4) if no Solicitation Notice relating thereto has been timely provided pursuant to this Section 9, the stockholder or beneficial owner proposing such business or nomination must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section 9. To be timely, a stockholder's notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than 60 or more than 75 days prior to the first anniversary (the "Anniversary") of the date on which the Corporation first mailed its proxy materials for the preceding year's annual meeting of stockholders; provided, however, that if the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year's annual meeting, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (i) the 90th day prior to such annual meeting or (ii) the 10th day following the day on which public announcement of the date of such meeting is first made. Such stockholder's notice shall set forth (a) as to each person whom the

3

stockholder proposes to nominate for election or reelection as a director all information relating to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees as directors pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and such person's written consent to serve as a director if elected; (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of such business, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the nomination or proposal is made; (c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made (i) the name and address of such stockholder, as they appear on the Corporation's books, and of such beneficial owner, (ii) the class and number of shares of the Corporation that are owned beneficially and of record by such stockholder and such beneficial owner, and (iii) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation's voting shares required under the Delaware General Corporation Law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation's voting shares to elect such nominee or nominees (an affirmative statement of such intent, a "Solicitation Notice").

3. Notwithstanding anything in the second sentence of the second paragraph of this Section 9 to the contrary, in the event that the number of directors to be elected to the Board is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board made by the Corporation at least 70 days prior to the Anniversary, a stockholder's notice required by this By-law shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.

4. Only persons nominated in accordance with the procedures set forth in this Section 9 shall be eligible to serve as directors and only such business shall be conducted at an annual meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this
Section 9. The presiding officer of the meeting shall have the power and the duty to determine whether a nomination or any business proposed to be brought before the meeting has been made in accordance with the procedures set forth in these By-laws and, if any proposed nomination or business is not in compliance with these By-laws, to declare that such defective proposed business or nomination shall not be presented for stockholder action at the meeting and shall be disregarded.

5. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation's notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of meeting (a) by or at the direction of the Board or (b) by any stockholder of record of the Corporation who is a stockholder of record at the time of giving of notice provided for in this paragraph, who shall be entitled to vote at the meeting and who complies with the procedures set forth in this Section 9, including, without limitation,

4

the procedures regarding Solicitation Notices. Nominations by stockholders of persons for election to the Board may be made at such a special meeting of stockholders if the stockholder's notice required by the second paragraph of this Section 9 shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the 90th day prior to such special meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting.

For purposes of this Section 9, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

Notwithstanding the foregoing provisions of this Section 9, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this
Section 9. Nothing in this Section 9 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act.

Section 10. Action Without Meeting. Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by stockholders for or in connection with any corporate action may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Deliveries made to the Corporation's registered office in Delaware shall be by hand or certified or registered mail, return receipt requested. Each such written consent shall bear the date of signature of each stockholder who signs the consent. No written consent shall be effective to take the corporate action referred to therein unless written consents signed by a number of stockholders sufficient to take such action are delivered to the Corporation in the manner specified in this paragraph within sixty (60) days of the earliest dated consent so delivered.

If action is taken by consent of stockholders and in accordance with the foregoing, there shall be filed with the records of the meetings of stockholders the writing or writings comprising such consent.

If action is taken by less than unanimous consent of stockholders, prompt notice of the taking of such action without a meeting shall be given to those who have not consented in writing and a certificate signed and attested to by the Secretary of the Corporation that such notice was given shall be filed with the records of the meetings of stockholders.

In the event that the action consented to is such as would have required the filing of a certificate under any provision of the Delaware General

5

Corporation Law, if such action had been voted upon by the stockholders at a meeting thereof, the certificate filed under such provision shall state, in lieu of any statement required by such provision concerning a vote of stockholders, that written consent has been given under Section 228 of the Delaware General Corporation Law.

ARTICLE II - DIRECTORS

Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of a Board of Directors, who may exercise all of the powers of the Corporation except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law. In the event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, may exercise the powers of the full Board of Directors until the vacancy is filled. The Board of Directors may appoint a Chairman of the Board. The Chairman of the Board shall preside at all meetings of the Board of Directors and shall perform such duties and possess such powers as are assigned to the Chairman by the Board of Directors.

Section 2. Number and Qualification. Except as otherwise required by the Certificate of Incorporation, the number of directors that shall constitute the whole Board of Directors shall be determined by resolution of the Board of Directors, but in no event shall be less than three (3). The number of directors may be increased at any time by resolution of the Board of Directors. The number of directors may be decreased at any time and from time to time by a majority of the directors then in office, but only to eliminate vacancies existing by reason of the death, resignation, removal or expiration of the term of one or more directors. A majority of the Board of Directors shall be comprised of directors who are outside directors within the meaning of Treasury Regulation of ss.1/162-27 as in effect on January 1, 2002.

Section 3. Classes of Directors. The Board of Directors shall be divided into three classes as nearly as equal in number as possible. If the number of directors is changed, any increase or decrease shall be apportioned among the classes so as to maintain the number of directors in each class as nearly as equal as possible. Such classes shall consist of one class of directors who shall be elected for a three-year term expiring at the annual meeting of stockholders held in 1986; a second class of directors who shall be elected for a three-year term expiring at the annual meeting of stockholders held in 1987; and a third class of directors who shall be elected for a three-year term expiring at the annual meeting of stockholders held in 1988. At each annual meeting of stockholders beginning in 1986, the successors of the class of directors whose term expires at that annual meeting shall be elected for a three-year term.

Section 4. Terms of Office. Subject to Section 5 of this Article II, each director shall serve for a term ending on the date of the third annual meeting following the annual meeting at which such director was elected; provided that the term of each director shall be subject to the election and qualification of such director's successor and to such director's earlier death, resignation or removal.

6

Section 5. Vacancies. Except as otherwise required by the Certificate of Incorporation or the Delaware General Corporation Law, any vacancy in the Board of Directors, however occurring, or any newly-created directorship resulting from an enlargement of the size of the Board of Directors, shall be filled only by vote of a majority of the directors then in office, even if less than a quorum, or by the sole remaining director and not by the stockholders. A director elected to fill a vacancy shall be elected for the unexpired term of such director's predecessor in office, and a director chosen to fill a newly created directorship shall hold office until the next election of the class for which such director shall have been chosen, subject in each case to the election and qualification of the director's successor and to the director's earlier death, resignation or removal.

Section 6. Resignations. Any director may resign by delivering a written resignation to the Corporation at its principal office or to the Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.

Section 7. Meetings. Regular meetings of the Board of Directors may be held without notice at such time and place, either within or without the State of Delaware, as shall be determined from time to time by the Board of Directors. A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders. Special meetings of the Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer, a majority of the total number of the whole Board of Directors, or by one director in the event that there is only a single director in office and may held at any time and place, within or without the State of Delaware, as specified by the person(s) calling the meeting.

Section 8. Notice of Meetings. No notice of the annual or other regular meetings of the Board of Directors need be given. Notice of any special meeting of directors shall be given to each director by the Secretary. Notice to each director shall be duly given by mailing the same not later than the second business day before the meeting, or by giving notice in person, by fax, by telephone, or by any other electronic means not later than four hours before the meeting. No notice of a meeting need be given if all directors are present in person. Any business may be transacted at any meeting of the Board of Directors, whether or not specified in a notice of the meeting.

Section 9. Quorum. A majority of the total number of the whole Board of Directors shall constitute a quorum at all meetings of the Board of Directors. In the absence of a quorum at any such meeting, a majority of the directors present may adjourn the meeting from time to time to a different date, place, or time without further notice (or waiver of notice) other than announcement at the meeting, until a quorum shall be present.

Section 10. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a majority of the directors present shall be sufficient to take any action, unless a different vote is specified by the Delaware General Corporation Law, the Certificate of Incorporation or these By-laws.

7

Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee of the Board of Directors may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent to the action in writing, and the written consents are filed with the minutes of proceedings of the Board of Directors or committee.

Section 12. Meetings by Telephone Conference Call. Directors or any members of any committee designated by the directors may participate in a meeting of the Board of Directors or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such means shall constitute presence in person at such meeting.

Section 13. Compensation of Directors. Directors may be paid such compensation for their services and such reimbursement for expenses of attendance at meetings of the Board of Directors or committees of the Board of Directors as the Board of Directors or any committee to which the Board has delegated responsibility for establishing director compensation may from time to time determine. No such payment shall preclude any director from serving the Corporation or any of its parent, subsidiary, or affiliate corporations in any other capacity and receiving compensation for such service.

Section 14. Committees. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. "In addition to other committees that the Board may designate from time to time, the Board shall designate a Human Resources Committee, an Audit Committee, a Nominating and Corporate Governance Committee and a Shareholder Rights Plan Committee, each of which shall be, as of January 1, 2003, comprised only of directors of the Corporation who shall have been determined by the Board of Directors to be outside directors within the meaning of Treasury Regulation ss.1.162-27 as in effect on January 1, 2002." The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not disqualified from voting, whether or not the member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors and subject to the provisions of the Delaware General Corporation Law, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it. Each such committee shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-laws for the Board of Directors. A majority of the members of a committee shall constitute a quorum unless the committee consist of one or two members, in which event, one member shall constitute a quorum. All matters shall be determined by a majority vote of the committee members present.

8

ARTICLE III - OFFICERS

Section 1. General Provisions; Qualification. The officers of the Corporation shall be a Chief Executive Officer, a President, a Chief Financial Officer, a General Counsel, a Treasurer and a Secretary, and may include one or more Vice Presidents, one or more Assistant Treasurers and one or more Assistant Secretaries and such other officers as the Board of Directors may deem appropriate. Any two or more offices may be held by the same person.

Section 2. Election. The Chief Executive Officer, the President, the Chief Financial Officer, the General Counsel, the Treasurer and Secretary shall be elected annually by the Board of Directors at its first meeting following the annual meeting of stockholders. Other officers may be appointed by the Board of Directors at such meeting or at any other meeting.

Section 3. Tenure. Except as otherwise provided by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, each officer shall hold office until such officer's successor is elected and qualified, unless a different term is specified in the vote choosing or appointing such officer, or until such officer's earlier death, resignation or removal.

Section 4. Resignation and Removal. Any officer may resign by delivering a written resignation to the Corporation at its principal office or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. Any officer may be removed at any time, with or without cause by vote of the Board of Directors.

Section 5. Vacancies. The Board of Directors may at any time fill any vacancy occurring in any office for any reason. Each such successor shall hold office for the unexpired term of such successor's predecessor and until such successor's successor is elected and qualified, or until such successor's earlier death, resignation or removal.

Section 6. The Chief Executive Officer. The Chief Executive Officer shall be the principal executive officer of the Corporation. Subject to the control of the Board of Directors, the Chief Executive Officer shall have general charge of the business and affairs of the Corporation. The Chief Executive Officer shall employ and discharge employees and agents of the Corporation, except such as shall hold their offices by appointment of the Board of Directors, but the Chief Executive Officer may delegate these powers to other officers as to employees under their immediate supervision. The Chief Executive Officer shall have such other powers and perform such other duties as may be prescribed by the Board of Directors.

Section 7. The President. The Board of Directors may appoint an officer of the Corporation to serve as the President of the Corporation. The President shall perform such of the duties of the Chief Executive Officer of the Corporation on behalf of the Corporation as may be assigned to the President from time to time by the Board of Directors or the Chief Executive Officer. In the absence or inability of the Chief Executive Officer to act, the President shall have and possess all of the powers and discharge all of the duties of the Chief Executive Officer, subject to the control of the Board of Directors.

9

Section 8. Vice Presidents. Each Vice President shall have such powers and perform such duties as the Board of Directors, the Chief Executive Officer, or the President may from time to time prescribe.

Section 9. Chief Financial Officer. The Board of Directors shall appoint an officer to serve as the Chief Financial Officer of the Corporation. The Chief Financial Officer shall be responsible for the Corporation's public financial reporting obligations and shall have such further powers and duties as are incident to the position of Chief Financial Officer, subject to the direction of the Chief Executive Officer and the Board of Directors.

Section 10. General Counsel. The Board of Directors shall appoint an officer to serve as the General Counsel of the Corporation. The General Counsel shall be the chief legal officer of the Corporation and shall be responsible for all legal affairs of the Corporation, and shall have such further powers and duties as are incident to the position of General Counsel.

Section 11. The Treasurer. The Treasurer shall perform such duties and shall have such powers as may from time to time be assigned to the Treasurer by the Board of Directors or the Chief Executive Officer. In addition, subject to the direction of the Board of Directors, the Treasurer shall perform such duties and have such powers as are incident to the office of treasurer, including, without limitation, the duty and power to keep and be responsible for all funds and securities of the Corporation, to deposit funds of the Corporation in depositories, to disburse such funds, to make proper accounts of such funds, and to render statements of all such transactions and of the financial condition of the Corporation. The Treasurer shall report directly to the Chief Executive Officer.

Section 12. The Secretary. The Secretary shall keep the minutes of all meetings of the Board of Directors and of the stockholders and shall attend to the giving and serving of all notices of the Corporation. The Secretary shall have custody of the seal of the Corporation and shall affix the seal to all certificates of shares of stock of the Corporation and to such other papers or documents as may be proper and, when the seal is so affixed, the Secretary shall attest the same by the Secretary's signature wherever required. The Secretary shall have charge of the stock certificate book, transfer book, and stock ledger, and such other books and papers as the Board of Directors may direct. The Secretary shall, in general, perform all the duties of secretary, subject to the control of the Board of Directors.

Section 13. Assistant Treasurers. In the absence or inability of the Treasurer to act, any Assistant Treasurer may perform all the duties and exercise all of the powers of the Treasurer, subject to the control of the Board of Directors. An Assistant Treasurer shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Treasurer may from time to time prescribe.

10

Section 14. Assistant Secretaries. In the absence or inability of the Secretary to act, any Assistant Secretary may perform all the duties and exercise all the powers of the Secretary, subject to the control of the Board of Directors. An Assistant Secretary shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Secretary may from time to time prescribe.

Section 15. Other Officers. Other officers shall perform such duties and have such powers as may from time to time be assigned to them by the Board of Directors.

Section 16. Delegation of Duties. In case of the absence of any officer of the Corporation, or for any other reason that the Board of Directors may deem sufficient, the Board of Directors may confer, for the time being, the powers or duties, or any of them, of such officer upon any other officer, or upon any director.

Section 17. Salaries. Officers of the Corporation shall be entitled to such salaries, compensation, or reimbursement as shall be fixed or allowed from time to time by the Board of Directors.

ARTICLE IV - CAPITAL STOCK

Section 1. Certificates for Shares. Each stockholder shall be entitled to a certificate signed by, or in the name of the Corporation by, the Chairman of the Board, the Chief Executive Officer, or the President or a Vice President, and by the Secretary or an Assistant Secretary, or Treasurer or an Assistant Treasurer, certifying the class and number of shares of record owned by such stockholder. Any or all of the signatures may be a facsimile.

Section 2. Transfer of Shares of Stock. Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with Section 3 of this Article IV of these By-laws, an outstanding certificate for the number of shares involved shall be surrendered for cancellation before a new certificate is issued therefor.

Section 3. Lost, Stolen or Destroyed Certificates. In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors or transfer agent may establish concerning proof of such loss, theft, or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.

Section 4. Record Date.

(a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders, or to receive payment of any dividend or other distribution or allotment of any rights or to exercise any rights in respect of any change, conversion, or exchange of stock or for the purpose of any other lawful action, the Board of Directors may, except as otherwise required by the Delaware General Corporation Law, fix a record date, which record date shall not precede the date on which the resolution fixing the record date is adopted and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of any meeting of stockholders, nor more than sixty (60) days prior to the time for such other action as

11

hereinbefore described; provided, however, that if no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held, and, for determining stockholders entitled to receive payment of any dividend or other distribution or allotment of rights or to exercise any rights of change, conversion, or exchange of stock or for any other purpose, the record date shall be at the close of business on the day on which the Board of Directors adopts a resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

(b) In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary of the Corporation, request the Board of Directors to fix a record date. The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such a request is received by the Secretary, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within ten (10) days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or any officer or agent of the Corporation having custody of the book in which proceeding of meetings of stockholders are recorded. Delivery made to the Corporation's registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.

Section 5. Regulations. The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.

ARTICLE V - General Provisions

Section 1. Fiscal Year. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the Corporation shall end on the Saturday closest to December 31.

12

Section 2. Corporate Seal. The corporate seal shall be in such form as may be approved by the Board of Directors. The corporate seal may be altered from time to time by the Board. Section 3. Waiver of Notice. Whenever any notice whatsoever is required to be given by the Delaware General Corporation Law, by the Certificate of Incorporation or by these By-laws, a written waiver of such notice signed by the person entitled to such notice or such person's duly authorized attorney, whether before or after the time of the event for which notice is to be given shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. The appearance of such person at such meeting in person or by proxy, shall constitute waiver of notice except attendance for the sole purpose of objecting to the timeliness or lack of notice.

Section 4. Voting of Securities. Subject always to the specific directions of the Board of Directors, any officer of the Corporation may waive notice of, and act as, or appoint any person or persons to act as, proxy or attorney-in-fact for this Corporation (with or without power of substitution) at, any meeting of stockholders or shareholders of any other corporation or organization, the securities of which may be held by this Corporation. The Board of Directors, by resolution from time to time, may confer like powers upon any other person or persons.

Section 5. Evidence of Authority. A certificate by the Secretary, or an Assistant Secretary as to any action taken by the stockholders, directors, a committee or any officer or representative of the Corporation shall as to all persons who rely on the certificate in good faith be conclusive evidence of such action.

Section 6. Certificate of Incorporation. All references in these By-laws to the Certificate of Incorporation shall be deemed to refer to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended, restated and in effect from time to time.

Section 7. Transactions with Interested Parties. No contract or transaction between the Corporation and one or more of the directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or a committee of the Board of Directors that authorizes the contract or transaction or solely because the interested directors' votes are counted for such purpose, if:

(1) The material facts as to the director's or officer's relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum;

(2) The material facts as to the director's or officer's relationship or interest and as to the contract or transaction are

13

disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or

(3) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee of the Board of Directors, or the stockholders.

Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.

Section 8. Severability. Any determination that any provision of these By-laws is for any reason inapplicable, illegal, or ineffective shall not affect or invalidate any other provision of these By-laws.

Section 9. Limitation on Stock Option Repricing. No stock option granted to an officer or director of the Corporation shall, after issuance, be repriced to a lower exercise price (other than adjustments for stock splits, stock dividends, spinoffs, recapitalizations and like events), without the prior affirmative vote of the holders of a majority of the shares of capital stock of the Corporation present at a stockholders meeting in person or by proxy and entitled to vote thereon."

ARTICLE VI - AMENDMENTS

Section 1. By the Board of Directors. In furtherance and not in limitation of the powers conferred by the Delaware General Corporation Law and the Certificate of Incorporation, the Board of Directors is expressly authorized to alter, amend or repeal any provision of these By-laws or make new by-laws.

Section 2. By the Stockholders. Except as otherwise provided in Section 3 of this Article VI, the stockholders of the Corporation shall have the power to alter, amend or repeal any provision of these By-laws or make new by-laws by affirmative vote of the holders of a majority of the shares of capital stock of the Corporation issued and outstanding and entitled to vote, voting together as a single class; provided, however, that the power of the stockholders to, alter, amend or repeal any provision of these By-laws or make any new by-laws is further subject to any affirmative vote of the holders of any particular class or series of capital stock of the Corporation as may be required by the Delaware General Corporation Law, the Certificate of Incorporation, or these By-laws.

14

Section 3. Certain Provisions. Notwithstanding any other provision of the Delaware General Corporation Law, the Certificate of Incorporation, or these By-laws (including Section 2 of this Article VI), the affirmative vote of the holders of at least sixty-six and two-thirds percent (66 2/3%) of the shares of capital stock of the Corporation issued and outstanding and entitled to vote shall be required to alter, amend or repeal, or make any new by-laws inconsistent with, Article II or this Article VI of these By-laws. This Section 3 is not intended to abrogate or otherwise affect the power of the Board of Directors to amend Article II or Article VI pursuant to Section 1 of this Article VI.

15

Exhibit 13

Thermo Electron Corporation

Consolidated Financial Statements

2001


Thermo Electron Corporation                                                           2001 Financial Statements

                                      Consolidated Statement of Operations


(In thousands except per share amounts)                                          2001         2000         1999
---------------------------------------------------------------------------------------------------------------

Revenues (Notes 3 and 16)                                                  $2,188,210   $2,280,522   $2,294,620
                                                                           ----------   ----------   ----------

Costs and Operating Expenses:
 Cost of revenues (Note 15)                                                 1,229,588    1,258,686    1,245,773
 Selling, general, and administrative expenses                                620,104      646,920      658,297
 Research and development expenses                                            171,614      176,756      171,100
 Restructuring and other unusual costs (income), net (Note 15)                132,702      (67,855)      37,346
                                                                           ----------   ----------   ----------

                                                                            2,154,008    2,014,507    2,112,516
                                                                           ----------   ----------   ----------

Operating Income                                                               34,202      266,015      182,104
Other Income (Expense), Net (Notes 4 and 15)                                   36,479      (81,184)     (57,345)
                                                                           ----------   ----------   ----------

Income from Continuing Operations Before Provision for Income Taxes,
 Minority Interest, Extraordinary Item, and Cumulative Effect of
 Change in Accounting Principle                                                70,681      184,831      124,759
Provision for Income Taxes (Note 6)                                           (26,929)    (112,217)     (64,428)
Minority Interest Income (Expense)                                              5,840      (10,567)     (23,048)
                                                                           ----------   ----------   ----------

Income from Continuing Operations Before Extraordinary Item and
 Cumulative Effect of Change in Accounting Principle                           49,592       62,047       37,283
Income (Loss) from Discontinued Operations (net of income tax provision
 (benefit) and minority interest of $12,249 and $(107,089); Note 17)                -       14,228     (163,325)
Provision for Loss on Disposal of Discontinued Operations, Net (net of
 income tax provision (benefit) of $(22,741), $(104,000), and $174,000;
 Note 17)                                                                     (50,440)    (100,000)     (50,000)
                                                                           ----------   ----------   ----------

Loss Before Extraordinary Item and Cumulative Effect of Change in
 Accounting Principle                                                            (848)     (23,725)    (176,042)
Extraordinary Item (net of income tax provision and minority interest of
 $637, $333, and $900; Note 10)                                                 1,061          532        1,469
                                                                           ----------   ----------   ----------

Income (Loss) Before Cumulative Effect of Change in Accounting Principle          213      (23,193)    (174,573)
Cumulative Effect of Change in Accounting Principle (net of income
 tax benefit and minority interest of $663 and $8,986; Notes 1 and 16)           (994)     (12,918)           -
                                                                           ----------   ----------   ----------

Net Loss                                                                   $     (781)  $  (36,111)  $ (174,573)
                                                                           ==========   ==========   ==========

Earnings per Share from Continuing Operations Before Extraordinary
 Item and Cumulative Effect of Change in Accounting Principle (Note 7)
   Basic                                                                   $      .27   $      .37   $      .24
                                                                           ==========   ==========   ==========
   Diluted                                                                 $      .27   $      .36   $      .22
                                                                           ==========   ==========   ==========

Loss per Share (Note 7)
   Basic                                                                   $        -   $     (.22)  $    (1.10)
                                                                           ==========   ==========   ==========
   Diluted                                                                 $        -   $     (.22)  $    (1.12)
                                                                           ==========   ==========   ==========

Weighted Average Shares (Note 7)
   Basic                                                                      180,560      167,462      157,987
                                                                           ==========   ==========   ==========
   Diluted                                                                    183,916      170,519      158,223
                                                                           ==========   ==========   ==========


The accompanying notes are an integral part of these consolidated financial statements.

<

2

>

Thermo Electron Corporation                                                      2001 Financial Statements

                                      Consolidated Balance Sheet

(In thousands)                                                                           2001         2000
----------------------------------------------------------------------------------------------------------

Assets
Current Assets:
 Cash and cash equivalents                                                         $  297,557   $  505,524
 Short-term available-for-sale investments, at quoted market value
   (amortized cost of $697,757 and $510,312; Notes 9 and 15)                          744,321      521,329
 Accounts receivable, less allowances of $26,525 and $30,593                          410,960      431,476
 Unbilled contract costs and fees                                                      24,071       18,520
 Inventories (Note 15)                                                                337,041      394,152
 Deferred tax asset (Note 6)                                                           82,766      148,051
 Other current assets                                                                  68,494       75,007
 Net assets of discontinued operations (Note 17)                                            -      371,470
                                                                                   ----------   ----------

                                                                                    1,965,210    2,465,529
                                                                                   ----------   ----------

Property, Plant, and Equipment, at Cost, Net (Note 15)                                270,712      285,878
                                                                                   ----------   ----------

Long-term Available-for-sale Investments, at Quoted Market Value
 (amortized cost of $5,729 and $9,883; Notes 9 and 15)                                  9,360       17,110
                                                                                   ----------   ----------

Other Assets (Notes 2 and 15)                                                         231,395      183,974
                                                                                   ----------   ----------

Goodwill (Notes 2, 6, and 15)                                                       1,348,393    1,378,663
                                                                                   ----------   ----------

Long-term Net Assets of Discontinued Operations (Note 17)                                   -      531,823
                                                                                   ----------   ----------


                                                                                   $3,825,070   $4,862,977
                                                                                   ==========   ==========



<
                                       3

>


Thermo Electron Corporation                                                      2001 Financial Statements



                                  Consolidated Balance Sheet (continued)

(In thousands except share amounts)                                                      2001         2000
----------------------------------------------------------------------------------------------------------

Liabilities and Shareholders' Investment
Current Liabilities:
 Short-term obligations and current maturities of long-term
   obligations (Notes 10 and 19)                                                   $  528,988   $  103,356
 Advance payable to affiliates (Note 10)                                                    -       16,088
 Accounts payable                                                                     111,950      139,662
 Accrued payroll and employee benefits                                                 79,403       78,483
 Accrued income taxes                                                                  30,797       95,344
 Deferred revenue                                                                      48,166       50,341
 Accrued installation and warranty costs                                               33,024       37,058
 Accrued restructuring costs (Note 15)                                                 60,685       21,024
 Other accrued expenses (Note 2)                                                      183,610      187,195
 Net liabilities of discontinued operations (Note 17)                                  65,416            -
                                                                                   ----------   ----------

                                                                                    1,142,039      728,551
                                                                                   ----------   ----------

Deferred Income Taxes (Note 6)                                                          7,907       10,691
                                                                                   ----------   ----------

Other Deferred Items                                                                   32,579       36,539
                                                                                   ----------   ----------

Long-term Obligations (Notes 10 and 19):
 Senior convertible obligations                                                       145,414      172,500
 Senior notes                                                                         128,725      150,000
 Subordinated convertible obligations                                                 445,377    1,177,565
 Other                                                                                  7,986       28,418
                                                                                   ----------   ----------

                                                                                      727,502    1,528,483
                                                                                   ----------   ----------

Minority Interest (Note 17)                                                             6,901       24,737
                                                                                   ----------   ----------

Commitments and Contingencies (Note 11)

Shareholders' Investment (Notes 5 and 12):
 Preferred stock, $100 par value, 50,000 shares authorized; none issued Common
 stock, $1 par value, 350,000,000 shares authorized; 199,816,264 and
   195,877,421 shares issued                                                          199,816      195,877
 Capital in excess of par value                                                     1,758,567    1,681,452
 Retained earnings (Note 17)                                                          509,681    1,005,857
 Treasury stock at cost, 23,458,555 and 13,708,863 shares                            (457,475)    (246,228)
 Deferred compensation                                                                 (3,157)      (6,640)
 Accumulated other comprehensive items (Note 8)                                       (99,290)     (96,342)
                                                                                   ----------   ----------

                                                                                    1,908,142    2,533,976
                                                                                   ----------   ----------

                                                                                   $3,825,070   $4,862,977
                                                                                   ==========   ==========



The accompanying notes are an integral part of these consolidated financial statements.

<

4

>

Thermo Electron Corporation                                                      2001 Financial Statements

                                  Consolidated Statement of Cash Flows


(In thousands)                                                             2001         2000         1999
---------------------------------------------------------------------------------------------------------

Operating Activities
 Net loss                                                             $    (781)   $ (36,111)   $(174,573)
 Adjustments to reconcile net loss to income from
   continuing operations:
     (Income) loss from discontinued operations (Note 17)                     -      (14,228)     163,325
     Provision for loss on disposal of discontinued
       operations, net (Note 17)                                         50,440      100,000       50,000
                                                                      ---------    ---------    ---------

 Income from continuing operations                                       49,659       49,661       38,752

 Adjustments to reconcile income from continuing operations
   to net cash provided by operating activities:
     Depreciation and amortization                                       98,521       97,486       91,429
     Noncash restructuring and other unusual costs, net (Note 15)        41,144       22,865       30,214
     Provision for losses on accounts receivable                          6,316        9,264        8,614
     Minority interest (income) expense                                  (5,840)      10,567       23,048
     Equity in (earnings) loss of unconsolidated subsidiaries
       (Note 15)                                                         (4,699)      47,315        7,274
     Cumulative effect of change in accounting principle, net
       of income taxes and minority interest (Notes 1 and 16)               994       12,918            -
     Change in deferred income taxes                                    (16,751)     (39,700)     (28,378)
     Loss (gain) on sale of businesses (Notes 2 and 15)                  10,943     (126,330)           -
     Gain on investments, net (Notes 9 and 15)                          (35,579)      (6,849)      (3,662)
     Extraordinary item, net of income taxes and minority
       interest (Note 10)                                                (1,061)        (532)      (1,469)
     Other noncash items, net                                            34,264       29,213       17,675
     Other unusual income                                                  (511)      (4,372)           -
     Changes in current accounts, excluding the effects
       of acquisitions and dispositions:
        Accounts receivable                                             (19,041)     (27,395)     (19,737)
        Inventories                                                       7,724      (77,356)      14,260
        Other current assets                                            (13,097)      (4,710)      (8,800)
        Accounts payable                                                (19,082)      17,742        2,012
        Other current liabilities                                        50,472       47,982       17,499
                                                                      ---------    ---------    ---------

          Net cash provided by continuing operations                    184,376       57,769      188,731
          Net cash provided by discontinued operations                    4,025      142,152      148,390
                                                                      ---------    ---------    ---------

          Net cash provided by operating activities                     188,401      199,921      337,121
                                                                      ---------    ---------    ---------

Investing Activities
 Purchases of available-for-sale investments                           (969,267)    (473,576)    (554,870)
 Proceeds from sale of available-for-sale investments                   536,966      113,220      281,451
 Proceeds from maturities of available-for-sale investments             250,345      403,134      794,288
 Proceeds from sale of other investments                                 43,255        6,367        3,775
 Purchases of property, plant, and equipment                            (84,799)     (74,039)     (61,238)
 Proceeds from sale of property, plant, and equipment                    11,638       21,828        9,604


<
                                       5

>



Thermo Electron Corporation                                                      2001 Financial Statements



                              Consolidated Statement of Cash Flows (continued)

(In thousands)                                                             2001         2000         1999
---------------------------------------------------------------------------------------------------------

Investing Activities (continued)
 Acquisitions, net of cash acquired (Note 2)                          $ (14,130)   $ (15,808)   $(344,615)
 Acquisition of minority interests of subsidiaries (Note 17)           (69,528)    (307,166)     (43,176)
 Proceeds from sale of businesses, net of cash divested (Note 2)         46,767      253,583           61
 Advance (to) from affiliates                                           (16,088)     (96,434)       8,633
 Refund of acquisition purchase price                                         -            -        8,969
 Increase in other assets                                                (5,077)      (3,954)      (4,797)
 Other                                                                   (1,580)       7,826        2,181
                                                                      ---------    ---------    ---------

          Net cash provided by (used in) continuing operations         (271,498)    (165,019)     100,266
          Net cash provided by (used in) discontinued operations        447,654      394,596     (173,834)
                                                                      ---------    ---------    ---------

          Net cash provided by (used in) investing activities           176,156      229,577      (73,568)
                                                                      ---------    ---------    ---------

Financing Activities
 Purchases and redemption of Company and subsidiary common
   stock and subordinated convertible debentures (Note 10)             (511,393)     (43,787)    (190,412)
 Net proceeds from issuance of Company and subsidiary
   common stock (Notes 5 and 12)                                         69,873       58,466       14,896
 Repayment of long-term obligations                                     (43,129)    (161,191)     (40,283)
 Net proceeds from issuance of long-term obligations                        249       14,577       16,813
 Increase (decrease) in short-term notes payable                        (16,870)     (19,183)      25,373
 Other                                                                   (1,760)      (4,377)      (6,669)
                                                                      ---------    ---------    ---------

          Net cash used in continuing operations                       (503,030)    (155,495)    (180,282)
          Net cash provided by (used in) discontinued operations       (193,283)      17,914     (106,601)
                                                                      ---------    ---------    ---------

          Net cash used in financing activities                        (696,313)    (137,581)    (286,883)
                                                                      ---------    ---------    ---------

Exchange Rate Effect on Cash of Continuing Operations                    (3,760)      (2,883)     (12,242)
Exchange Rate Effect on Cash of Discontinued Operations                   4,464       (9,997)      (3,883)
                                                                      ---------    ---------    ---------

Increase (Decrease) in Cash and Cash Equivalents                       (331,052)     279,037      (39,455)
Cash and Cash Equivalents at Beginning of Year                          636,252      357,215      396,670
                                                                      ---------    ---------    ---------

                                                                        305,200      636,252      357,215
Cash and Cash Equivalents of Discontinued Operations at
 End of Year                                                             (7,643)    (130,728)    (119,371)
                                                                      ---------    ---------    ---------

Cash and Cash Equivalents at End of Year                              $ 297,557    $ 505,524    $ 237,844
                                                                      =========    =========    =========

See Note 14 for supplemental cash flow information.


The accompanying notes are an integral part of these consolidated financial statements.



<
                                       6

>


Thermo Electron Corporation                                                      2001 Financial Statements



                Consolidated Statement of Comprehensive Loss and Shareholders' Investment


(In thousands)                                                              2001         2000         1999
----------------------------------------------------------------------------------------------------------

Comprehensive Loss
Net Loss                                                              $     (781)  $  (36,111)  $ (174,573)
                                                                      ----------   ----------   ----------

Other Comprehensive Items (Note 8):
 Currency translation adjustment                                         (24,606)     (44,975)     (50,979)
 Unrealized gains on available-for-sale investments, net of
   reclassification adjustment                                            20,320        4,558        4,651
 Unrealized gains on hedging instruments, net of
   reclassification adjustment                                             1,338            -            -
                                                                      ----------   ----------   ----------

                                                                          (2,948)     (40,417)     (46,328)
 Minority interest                                                           (81)       5,188        9,439
                                                                      ----------   ----------   ----------

                                                                          (3,029)     (35,229)     (36,889)
                                                                      ----------   ----------   ----------

                                                                      $   (3,810)  $  (71,340)  $ (211,462)
                                                                      ==========   ==========   ==========

Shareholders' Investment
Common Stock, $1 Par Value:
 Balance at beginning of year                                         $  195,877   $  167,433   $  166,971
 Acquisition of minority interests of subsidiaries (Note 17)                   -       22,553            -
 Issuance of stock under employees' and directors' stock plans             3,939        5,891          462
                                                                      ----------   ----------   ----------

 Balance at end of year                                                  199,816      195,877      167,433
                                                                      ----------   ----------   ----------

Capital in Excess of Par Value:
 Balance at beginning of year                                          1,681,452    1,052,837    1,033,799
 Acquisition of minority interests of subsidiaries (Note 17)                   -      541,434            -
 Activity under employees' and directors' stock plans                     56,542       84,840        4,093
 Tax benefit related to employees' and directors' stock plans              9,461       18,000        1,645
 Effect of subsidiaries' equity transactions                              11,112      (15,659)      13,300
                                                                      ----------   ----------   ----------

 Balance at end of year                                                1,758,567    1,681,452    1,052,837
                                                                      ----------   ----------   ----------

Retained Earnings:
 Balance at beginning of year                                          1,005,857    1,041,968    1,216,541
 Distribution of Kadant and Viasys Healthcare subsidiaries
   to shareholders (Note 17)                                            (495,395)           -            -
 Net loss                                                                   (781)     (36,111)    (174,573)
                                                                      ----------   ----------   ----------

 Balance at end of year                                               $  509,681   $1,005,857   $1,041,968
                                                                      ----------   ----------   ----------



<
                                       7

>


Thermo Electron Corporation                                                      2001 Financial Statements



          Consolidated Statement of Comprehensive Loss and Shareholders' Investment (continued)

(In thousands)                                                              2001         2000         1999
----------------------------------------------------------------------------------------------------------

Treasury Stock:
 Balance at beginning of year                                         $ (246,228)  $ (189,646)  $ (151,643)
 Purchases of Company common stock                                      (196,544)     (22,826)     (44,758)
 Activity under employees' and directors' stock plans                    (12,305)     (26,590)       6,755
 Receipt of Company common stock as repayment of notes receivable         (2,398)      (6,155)           -
 Receipt of Company common stock in connection with sale of
   business                                                                    -       (1,011)           -
                                                                      ----------   ----------   ----------

 Balance at end of year                                                 (457,475)    (246,228)    (189,646)
                                                                      ----------   ----------   ----------

Deferred Compensation (Note 5):
 Balance at beginning of year                                             (6,640)      (3,149)           -
 Awards under employees' stock plans                                        (429)      (7,818)      (4,061)
 Amortization of deferred compensation                                     3,700        3,725          912
 Forfeitures under employees' stock plans                                    212          602            -
                                                                      ----------   ----------   ----------

 Balance at end of year                                                   (3,157)      (6,640)      (3,149)
                                                                      ----------   ----------   ----------

Accumulated Other Comprehensive Items (Note 8):
 Balance at beginning of year                                            (96,342)     (55,925)      (9,597)
 Other comprehensive items                                                (2,948)     (40,417)     (46,328)
                                                                      ----------   ----------   ----------

 Balance at end of year                                                  (99,290)     (96,342)     (55,925)
                                                                      ----------   ----------   ----------

                                                                      $1,908,142   $2,533,976   $2,013,518
                                                                      ==========   ==========   ==========


The accompanying notes are an integral part of these consolidated financial statements.


<

8

>

Thermo Electron Corporation 2001 Financial Statements

Notes to Consolidated Financial Statements

1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations
Thermo Electron Corporation (the Company) is a global leader in the development, manufacture, and sale of technology-based instrument systems, components, and solutions used in virtually every industry to monitor, collect, and analyze data to provide knowledge for the user. For example, the Company's powerful analysis technologies help biotech researchers sift through data to make the discoveries that will fight disease or prolong life; allow telecommunications equipment manufacturers to fabricate components required to increase the speed and quality of communications; and monitor and control industrial processes on-line to ensure that critical quality standards are met efficiently and safely.

Principles of Consolidation
The accompanying financial statements include the accounts of the Company and its majority- and wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated. The Company accounts for investments in businesses in which it owns between 20% and 50% using the equity method.

Presentation
During 2000 and 2001, the Company completed the principal aspects of a major corporate reorganization. As part of this reorganization, the Company spun off two businesses and sold a number of operating units. In addition, the Company has taken private all of its majority-owned subsidiaries in its continuing operations including Spectra-Physics, Inc. (formerly Spectra-Physics Lasers, Inc.), which was effected in February 2002 (Note 19). The results of operations of certain major lines of business that have been spun off or that have been or will be sold have been classified as discontinued operations in the accompanying financial statements (Note 17).

Fiscal Year
The Company has adopted a fiscal year ending the Saturday nearest December
31. References to 2001, 2000, and 1999 are for the fiscal years ended December 29, 2001, December 30, 2000, and January 1, 2000, respectively.

Revenue Recognition
Prior to 2000, the Company generally recognized revenues upon shipment of its products. During the fourth quarter of 2000, effective as of January 2, 2000, the Company adopted Securities and Exchange Commission (SEC) Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition in Financial Statements." Under SAB No. 101, when the terms of sale include customer acceptance provisions, and compliance with those provisions can not be demonstrated until customer use, revenues are recognized upon acceptance. Revenues for products that require installation for which the installation is essential to functionality or is not deemed inconsequential or perfunctory are recognized upon completion of installation. Revenues for products sold where installation is not essential to functionality and is deemed inconsequential or perfunctory are recognized upon shipment with estimated installation costs accrued (Note 16).
In restating quarterly results for 2000 to comply with SAB No. 101, the Company included adjustments to record amounts billed to customers for shipping and handling costs as revenues with the associated costs reported as cost of revenues. Previously, amounts billed to customers for shipping and handling had generally been reported as an offset to the related cost. Periods prior to 2000 were not restated for shipping and handling costs due to immateriality.
The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay amounts due. The Company provides a reserve for its estimate of warranty costs at the time revenue is recognized. Deferred revenue in the accompanying balance sheet consists primarily of unearned revenue on service contracts. Substantially all of the deferred revenue in the accompanying 2001 balance sheet will be recognized within one year.

<

9

>
Thermo Electron Corporation 2001 Financial Statements

Notes to Consolidated Financial Statements

1. Nature of Operations and Summary of Significant Accounting Policies
(continued)

Stock-based Compensation Plans
The Company applies Accounting Principles Board Opinion (APB) No. 25, "Accounting for Stock Issued to Employees" and related interpretations in accounting for its stock-based compensation plans (Note 5). Accordingly, no accounting recognition is given to stock options granted at fair market value until they are exercised. Upon exercise, net proceeds, including tax benefits realized, are credited to shareholders' investment.

Income Taxes
In accordance with Statement of Financial Accounting Standards (SFAS) No. 109, "Accounting for Income Taxes," the Company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return.

Earnings (Loss) per Share
Basic earnings (loss) per share has been computed by dividing net income
(loss) by the weighted average number of shares outstanding during the year. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share has been computed assuming the conversion of convertible obligations and the elimination of the related interest expense, and the exercise of stock options, as well as their related income tax effects (Note 7).

Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper, and other marketable securities purchased with an original maturity of three months or less. These investments are carried at cost, which approximates market value.

Available-for-sale Investments
The Company's marketable debt and equity securities are considered available-for-sale investments in the accompanying balance sheet and are carried at market value, with the difference between cost and market value, net of related tax effects, recorded in the "Accumulated other comprehensive items" component of shareholders' investment (Note 9).

Inventories
Inventories are stated at the lower of cost (on a first-in, first-out or weighted average basis) or net realizable value and include materials, labor, and manufacturing overhead. The components of inventories are as follows:

(In thousands)                                                                           2001         2000
----------------------------------------------------------------------------------------------------------

Raw Materials and Supplies                                                           $137,622     $169,885
Work in Progress                                                                       60,220       65,625
Finished Goods (includes $14,918 and $33,605 at customer locations)                   139,199      158,642
                                                                                     --------     --------

                                                                                     $337,041     $394,152
                                                                                     ========     ========

      The Company periodically reviews its quantities of inventories on hand and
compares these amounts to expected usage of each particular product or product
line. The Company records as a charge to cost of revenues any amounts required
to reduce the carrying value of inventories to net realizable value (Note 15).

<
                                       10

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


1.    Nature of Operations and Summary of Significant Accounting Policies
     (continued)
--------------------------------------------------------------------------------

Property, Plant, and Equipment
      The costs of additions and improvements are capitalized, while maintenance
and repairs are charged to expense as incurred. The Company provides for
depreciation and amortization using the straight-line method over the estimated
useful lives of the property as follows: buildings and improvements, 2 to 40
years; machinery and equipment, 1 to 15 years; and leasehold improvements, the
shorter of the term of the lease or the life of the asset. Property, plant, and
equipment consists of the following:

(In thousands)                                                                           2001         2000
----------------------------------------------------------------------------------------------------------

Land                                                                                 $ 33,099     $ 40,292
Buildings and Improvements                                                            142,697      143,012
Machinery, Equipment, and Leasehold Improvements                                      306,590      301,251
                                                                                     --------     --------

                                                                                      482,386      484,555
Less:  Accumulated Depreciation and Amortization                                      211,674      198,677
                                                                                     --------     --------

                                                                                     $270,712     $285,878
                                                                                     ========     ========

Other Assets
      Other assets in the accompanying balance sheet includes intangible assets,
notes receivable, deferred debt expense, prepaid pension costs, an equity method
investment in FLIR Systems, Inc., and other assets. Intangible assets include
the costs of acquired trademarks, patents, product technology, and other
specifically identifiable intangible assets and are being amortized using the
straight-line method over their estimated useful lives, which range from 2 to 20
years. Intangible assets were $40.1 million and $46.8 million, net of
accumulated amortization of $43.0 million and $36.1 million, at year-end 2001
and 2000, respectively.

Goodwill
      Goodwill was amortized through December 29, 2001, using the straight-line
method over periods ranging from 5 to 40 years. Accumulated amortization was
$233.0 million and $192.8 million at year-end 2001 and 2000, respectively. The
Company assesses the future useful life of this and other noncurrent assets
whenever events or changes in circumstances indicate that the current useful
life has diminished. Such events or circumstances generally include the
occurrence of operating losses or a significant decline in earnings associated
with the acquired business or asset. The Company considers the future
undiscounted cash flows of the acquired companies in assessing the
recoverability of this asset. The Company assesses cash flows before interest
charges, and when impairment is indicated, writes the asset down to fair value.
If quoted market values are not available, the Company estimates fair value by
calculating the present value of future cash flows. If impairment has occurred,
any excess of carrying value over fair value is recorded as a loss (Note 15).
      In July 2001, the Financial Accounting Standards Board (FASB) issued SFAS
No. 142, "Goodwill and Other Intangible Assets." The Company will adopt the
requirements of SFAS No. 142 effective December 30, 2001. SFAS No. 142 requires
companies to test all goodwill for impairment by June 29, 2002, and to cease
amortization of this asset in 2002. The provisions of SFAS No. 142 apply to all
goodwill regardless of when it was acquired. While the Company is in the process
of completing its testing of goodwill for impairment, it does not expect a
material charge for impairment based on its preliminary review. Amortization of
goodwill totaled $40.2 million, $37.9 million, and $34.4 million in 2001, 2000,
and 1999, respectively.



<
                                       11

>
Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


1.    Nature of Operations and Summary of Significant Accounting Policies
      (continued)
--------------------------------------------------------------------------------

Currency Translation
      All assets and liabilities of the Company's non-U.S. subsidiaries are
translated at year-end exchange rates, and revenues and expenses are translated
at average exchange rates for the year in accordance with SFAS No. 52, "Foreign
Currency Translation." Resulting translation adjustments are reflected in the
"Accumulated other comprehensive items" component of shareholders' investment.
Currency transaction gains and losses are included in the accompanying statement
of operations and are not material for the three years presented.

Forward Contracts
      Effective in the first quarter of 2001, the Company adopted SFAS No. 133,
"Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133, as
amended, requires that all derivatives, including forward currency exchange
contracts, be recognized on the balance sheet at fair value. Derivatives that
are not hedges must be recorded at fair value through earnings. If a derivative
is a hedge, depending on the nature of the hedge, changes in the fair value of
the derivative are either offset against the change in fair value of the hedged
item through earnings or recognized in other comprehensive income until the
hedged item is recognized in earnings. The Company immediately records in
earnings the extent to which a hedge is not effective in achieving offsetting
changes in fair value or cash flows. Adoption of SFAS No. 133 in the first
quarter of 2001 resulted in the deferral of a gain of $1.0 million, net of tax
and minority interest, and a corresponding loss on periods prior to 2001, which
was classified as "Cumulative effect of the change in accounting principle" in
the accompanying 2001 statement of operations. This deferred gain related to
forward currency exchange contracts that were marked to market through earnings
prior to the adoption of SFAS No. 133. The entire deferred gain recorded upon
adoption was reclassified into earnings during 2001 as the underlying hedged
transactions occurred.
      Forward currency exchange contracts are used by the Company primarily to
hedge certain operational (cash-flow hedges) and balance sheet (fair-value
hedges) exposures resulting from changes in currency exchange rates. Such
exposures result from sales that are denominated in currencies other than the
functional currencies of the respective operations. These contracts principally
hedge transactions denominated in U.S. dollars, Euros, British pounds sterling,
Japanese yen, French francs, Swiss francs, German marks, Swedish krona, and
Netherland guilders. The Company enters into these currency exchange contracts
to hedge anticipated product sales and recorded accounts receivable made in the
normal course of business and, accordingly, the hedges are not speculative in
nature. As part of the Company's overall strategy to manage the level of
exposure to the risk of currency exchange fluctuations, certain operating units
enter into cash-flow hedges for a portion of their currency exposures
anticipated over the ensuing 12-month period, using exchange contracts that have
maturities of 12 months or less. The Company does not hold or engage in
transactions involving derivative instruments for purposes other than risk
management.
      The Company records its forward currency exchange contracts at fair value
in its balance sheet as other current assets or other accrued expenses and, for
cash-flow hedges, the related gains or losses on these contracts are deferred as
a component of other comprehensive items in the accompanying balance sheet.
These deferred gains and losses are recognized in income in the period in which
the underlying hedged transaction occurs. At December 29, 2001, the Company had
deferred gains, net of income taxes, relating to currency exchange contracts of
approximately $1.3 million, substantially all of which is expected to be
recognized as income over the next 12 months when the hedged transactions,
principally anticipated sales, transpire. Unrealized gains and losses resulting
from the impact of currency exchange rate movements on fair value hedges are
recognized in earnings in the period in which the exchange rates change and
offset the currency gains and losses on the underlying exposure being hedged.
The ineffective portion of the gain or loss on derivative instruments is
recorded in other income (expense), net, in the accompanying 2001 statement of
operations and is not material.
      See Note 15 for the effect in 1999 and 2000 of a majority-owned
subsidiary's early adoption of SFAS No. 133.
      Prior to adoption of SFAS No. 133, gains and losses arising from forward
currency exchange contracts were recognized as offsets to gains and losses
resulting from the transactions being hedged.


<
                                       12

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


1.    Nature of Operations and Summary of Significant Accounting Policies
      (continued)
--------------------------------------------------------------------------------

Recent Accounting Pronouncements
      In October 2001, the FASB issued SFAS No. 144, "Accounting for the
Impairment or Disposal of Long-lived Assets."  Adoption of the standard is
required in the first quarter of 2002.  The Company does not expect adoption of
SFAS No. 144 to materially affect its financial statements.

Use of Estimates
      The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. In addition, significant estimates were made in determining
the loss on disposition of the Company's discontinued operations (Note 17), in
estimating future cash flows to quantify impairment of assets, and in
determining the ultimate loss from abandoning leases at facilities being exited
(Note 15). Actual results could differ from those estimates.

2.    Acquisitions and Dispositions
--------------------------------------------------------------------------------

Acquisitions
      In 2001 and 2000, the Company made several acquisitions for $14.1 million
and $15.8 million in cash, net of cash acquired, respectively.
      In February 1999, the Company acquired 17,494,684 shares (or approximately
99%) of Spectra-Physics AB, a Stockholm Stock Exchange-listed company, for
approximately 160 Swedish krona per share (approximately $20 per share) in
completion of the Company's cash tender offer to acquire all of the outstanding
shares of Spectra-Physics AB. In March 2000, the Company completed the
acquisition of the remaining Spectra-Physics AB shares outstanding pursuant to
the compulsory acquisition rules applicable to Swedish companies. As part of the
acquisition of Spectra-Physics AB, the Company acquired Spectra-Physics AB's
majority-owned public subsidiary, Spectra-Physics, Inc. The aggregate purchase
price was approximately $351.5 million, including related expenses. On the date
of acquisition, Spectra-Physics AB had $39.1 million of cash, which included
$30.5 million held by Spectra-Physics. Spectra-Physics AB manufactures a wide
range of laser-based instrumentation systems, primarily for the process-control,
industrial measurement, research, commercial, and government markets.
      In connection with the acquisition of Spectra-Physics AB, the Company
acquired 4,162,000 shares of FLIR common stock. FLIR designs, manufactures, and
markets thermal imaging and broadcast camera systems that detect infrared
radiation or heat emitted directly by all objects and materials. The Company
accounts for its investment in FLIR using the equity method with a one quarter
lag to ensure the availability of FLIR's operating results in time to enable the
Company to include its pro rata share of FLIR's results with its own. During
1999, FLIR consummated a pooling-of-interests transaction that decreased the
Company's pro rata share of FLIR's equity from 34.6% to 29.4%. During 2000, the
Company recorded a charge to reflect an impairment of its investment in FLIR
that was deemed to be other than temporary (Note 15). During 2001, the Company
sold 1,150,000 shares of FLIR bringing its ownership of FLIR to 18.2% as of
December 29, 2001 (Note 15). The investment in FLIR is included in other assets
in the accompanying balance sheet.

<
                                       13

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


2.    Acquisitions and Dispositions (continued)
--------------------------------------------------------------------------------

      Summary unaudited financial information for FLIR as of and for the 12
months ended September 30, 2001 and 2000, is as follows:

(In thousands)                                                                        2001            2000
----------------------------------------------------------------------------------------------------------

Current Assets                                                                    $118,093        $114,494
Noncurrent Assets                                                                   43,903          51,439
                                                                                  --------        --------

Total Assets                                                                      $161,996        $165,933
                                                                                  ========        ========

Current Liabilities                                                               $103,804        $132,917
Noncurrent Liabilities                                                               8,948           4,251
Shareholders' Equity                                                                49,244          28,765
                                                                                  --------        --------

Total Liabilities and Shareholders' Equity                                        $161,996        $165,933
                                                                                  ========        ========


                                                                                  Twelve Months Ended
                                                                             -----------------------------
                                                                             September 30,   September 30,
(In thousands)                                                                        2001            2000
----------------------------------------------------------------------------------------------------------

Revenues                                                                          $206,573        $181,562
Cost of Revenues                                                                    95,587         114,211
                                                                                  --------        --------

Gross Profit                                                                      $110,986        $ 67,351
                                                                                  ========        ========

Net Earnings (Loss)                                                               $ 18,247        $(59,992)
                                                                                  ========        ========

      In 1999, in addition to the acquisition of Spectra-Physics AB, the Company
and its formerly majority-owned subsidiaries made several other acquisitions for
$32.2 million in cash, net of cash acquired.
      These acquisitions have been accounted for using the purchase method of
accounting, and the acquired companies' results have been included in the
accompanying financial statements from their respective dates of acquisition.
The aggregate cost of the acquisitions in 2001, 2000, and 1999 exceeded the
estimated fair value of the acquired net assets by $200.1 million, which was
amortized principally over 40 years through 2001. Allocation of the purchase
price for these acquisitions was based on estimates of the fair value of the net
assets acquired and, for acquisitions completed in 2001, is subject to
adjustment upon finalization of the purchase price allocation. The Company has
gathered no information that indicates the final purchase price allocations will
differ materially from the preliminary estimates. Pro forma data is not
presented since the acquisitions were not material to the Company's results of
operations individually or in the aggregate.
      In connection with its acquisitions, the Company has undertaken
restructuring activities at the acquired businesses. The Company's restructuring
activities, which were accounted for in accordance with Emerging Issues Task
Force Pronouncement (EITF) 95-3, have primarily included reductions in staffing
levels and the abandonment of excess facilities. In connection with these
restructuring activities, as part of the cost of the acquisitions, the Company
established reserves as detailed below, primarily for severance and excess
facilities. In accordance with EITF 95-3, the Company finalizes its
restructuring plans no later than one year from the respective dates of the
acquisitions. Accrued acquisition expenses are included in other accrued
expenses in the accompanying balance sheet.

<

14

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


2.    Acquisitions and Dispositions (continued)
--------------------------------------------------------------------------------

      A summary of the changes in accrued acquisition expenses for acquisitions
completed before and during 1999 is as follows:

                                                 1999 Acquisitions
                                      ---------------------------------------
                                                   Abandonment
                                                     of Excess                     Pre-1999
(In thousands)                        Severance     Facilities          Other  Acquisitions          Total
----------------------------------------------------------------------------------------------------------

Balance at January 2, 1999              $     -        $     -        $    -        $16,284        $16,284
 Reserves established                     9,464          1,355         3,364          3,069         17,252
 Payments                                (3,899)           (71)         (957)        (6,612)       (11,539)
 Decrease recorded as a
   reduction in goodwill                      -              -             -         (1,521)        (1,521)
 Currency translation                      (303)          (111)          (74)          (543)        (1,031)
                                        -------        -------        -------       -------        -------

Balance at January 1, 2000                5,262          1,173         2,333         10,677         19,445
 Reserves established                        90            111             -              -            201
 Payments                                (2,767)          (420)         (761)        (2,383)        (6,331)
 Decrease recorded as a
   reduction in goodwill                   (213)             -             -           (298)          (511)
 Reserves of businesses sold               (715)          (154)         (999)             -         (1,868)
 Currency translation                       189           (200)          (60)          (829)          (900)
                                        -------        -------        -------       -------        -------

Balance at December 30, 2000              1,846            510           513          7,167         10,036
 Payments                                  (467)          (291)         (358)          (747)        (1,863)
 Decrease recorded as a reduction
   in other intangible assets              (720)          (194)            -              -           (914)
 Currency translation                       (33)           (15)          (24)          (204)          (276)
                                        -------        -------        ------        -------        -------

Balance at December 29, 2001            $   626        $    10        $  131        $ 6,216        $ 6,983
                                        =======        =======        ======        =======        =======

      The principal acquisition expenses for pre-1999 acquisitions were for
severance for 601 employees across all functions and for abandoned facilities,
primarily related to the Company's acquisitions of the product-monitoring
businesses of Graseby Limited and Life Sciences International PLC. The abandoned
facilities include two operating facilities in North America with leases that
expired in 2001 and four operating facilities in England with leases expiring
through 2014.
      The principal acquisition expenses for 1999 acquisitions were for
severance for approximately 175 employees across all functions and for abandoned
facilities, primarily at Spectra-Physics AB. The abandoned facilities at
Spectra-Physics include operating facilities in Sweden, Germany, and France with
obligations that principally expired in 2001. The amounts captioned as "other"
primarily represent employee relocation, contract termination, and other exit
costs. The Company expects to pay amounts accrued for severance, abandoned
facilities, and other primarily through 2002. The Company finalized its
restructuring plans for Spectra-Physics AB and other 1999 acquisitions in 1999
and 2000. Upon finalization of restructuring plans or settlement of obligations
for less than the expected amount, any excess reserves have been reversed with a
corresponding decrease in goodwill or other intangible assets.
      The Company has not established material reserves for restructuring
businesses acquired in 2000 or 2001.

<
                                       15

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


2.    Acquisitions and Dispositions (continued)
--------------------------------------------------------------------------------

Dispositions
      In 2001, the Company's continuing operations sold several noncore
businesses for net cash proceeds of $46.8 million and recorded $10.9 million of
pretax losses on sale, which is included in restructuring and other unusual
costs (income), net, in the accompanying statement of operations.
      On July 14, 2000, the Company completed the sale of its wholly owned
Spectra Precision businesses to Trimble Navigation Limited for $208.1 million in
net cash proceeds and $80.0 million in seller debt financing at an initial
interest rate of 10%. The note from the buyer called for repayment in two equal,
annual installments beginning in July 2001, but permitted extension of maturity
under certain conditions. The buyer elected to defer payment of the portion of
the note that was due in July 2001. Trimble has advised the Company that the
terms of its senior bank debt will preclude repayment of the note at its
maturity in July 2002. The Company is in negotiation with Trimble to amend the
terms of the note. As a result, the Company has classified the note as
noncurrent in the accompanying 2001 balance sheet. Spectra Precision, formerly
part of the Measurement and Control segment, was acquired as part of
Spectra-Physics AB and provides the construction, surveying, and heavy machine
industries with precision-positioning equipment.
      In 2000, the Company's continuing operations sold several other noncore
businesses for net cash proceeds of $45.5 million. The Company realized
aggregate pretax gains of $126.3 million in 2000 from the sale of businesses,
which are included in restructuring and other unusual costs (income), net, in
the accompanying statement of operations. The businesses that were sold in 2001
and 2000 were part of an effort to focus on potentially higher-growth
opportunities in the Life Sciences and Optical Technologies segments.

3.    Business Segment and Geographical Information
--------------------------------------------------------------------------------

      The Company's businesses are managed in three segments:

      -  Life Sciences: serves the pharmaceutical and biotechnology industries
         with tools that enable drug discovery and life science research. The
         Company also serves the healthcare market with rapid point-of-care
         diagnostic tests and clinical laboratory automation products.
      -  Optical Technologies: provides photonic components and devices used in
         applications ranging from medical diagnostics and analytical
         instrumentation to scientific research, industrial manufacturing, and
         telecommunications equipment. In addition, the Company supplies
         semiconductor manufacturing and testing instruments and precision
         temperature-control systems.
      -  Measurement and Control: helps manufacturing customers increase quality
         and improve productivity with analytical tools and on-line process
         instruments. The Company's instruments also help protect workers and
         the environment.

<

16

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


3.    Business Segment and Geographical Information (continued)
--------------------------------------------------------------------------------

      During 2001, the Company moved its Thermo KeyTek unit from the Measurement
and Control segment to the Optical Technologies segment and moved its Thermo
Projects unit (the principal operating business of which was acquired in early
2001) from the Life Sciences segment to a separate segment (included as "Other"
below) due to organizational changes. Prior periods have been restated to
conform to this presentation where applicable.

(In thousands)                                                               2001        2000         1999
----------------------------------------------------------------------------------------------------------

Business Segment Information
Revenues:
   Life Sciences                                                       $  834,164  $  779,978   $  764,408
   Optical Technologies                                                   526,353     496,307      406,818
   Measurement and Control                                                831,345   1,021,040    1,148,083
   Other                                                                   12,130          41          228
   Intersegment (a)                                                       (15,782)    (16,844)     (24,917)
                                                                       ----------  ----------   ----------

                                                                      $ 2,188,210  $2,280,522  $ 2,294,620
                                                                      ===========  ==========  ===========

Income from Continuing Operations Before Provision for Income
 Taxes, Minority Interest, Extraordinary Item, and Cumulative
 Effect of Change in Accounting Principle:
   Life Sciences (b)                                                   $   82,245  $   93,207   $  118,712
   Optical Technologies (c)                                               (30,091)     36,307       25,110
   Measurement and Control (d)                                             32,892     191,611       76,922
   Other                                                                      122      (1,345)      (1,512)
                                                                       ----------  ----------   ----------

     Total Segment Income (e)                                              85,168     319,780      219,232
   Corporate/Other (f)                                                    (14,487)   (134,949)     (94,473)
                                                                       ----------  ----------   ----------

                                                                       $   70,681  $  184,831   $  124,759
                                                                       ==========  ==========   ==========

Total Assets:
   Life Sciences                                                       $1,155,286  $1,217,767   $1,150,532
   Optical Technologies                                                   649,511     624,128      514,584
   Measurement and Control                                              1,297,908   1,342,284    1,503,129
   Corporate/Other (g)                                                    722,365     775,505      444,500
   Net Assets of Discontinued Operations                                        -     903,293    1,459,012
                                                                       ----------  ----------   ----------

                                                                       $3,825,070  $4,862,977   $5,071,757
                                                                       ==========  ==========   ==========

Depreciation:
   Life Sciences                                                       $   16,504  $   16,091   $   15,669
   Optical Technologies                                                    17,712      15,055       12,558
   Measurement and Control                                                 15,039      20,579       21,892
   Corporate/Other                                                          2,173       1,189        1,231
                                                                       ----------  ----------   ----------

                                                                       $   51,428  $   52,914   $   51,350
                                                                       ==========  ==========   ==========


<
                                       17

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


3.    Business Segment and Geographical Information (continued)
--------------------------------------------------------------------------------

(In thousands)                                                               2001        2000         1999
----------------------------------------------------------------------------------------------------------

Amortization:
   Life Sciences                                                       $   22,879  $   19,418   $   14,965
   Optical Technologies                                                     7,571       6,337        4,287
   Measurement and Control                                                 16,435      18,317       19,957
   Corporate/Other                                                            208         500          870
                                                                       ----------  ----------   ----------

                                                                       $   47,093  $   44,572   $   40,079
                                                                       ==========  ==========   ==========

Capital Expenditures:
   Life Sciences                                                       $   22,849  $   18,849   $   14,493
   Optical Technologies                                                    41,378      32,209       18,737
   Measurement and Control                                                 14,474      21,378       22,183
   Corporate/Other                                                          6,098       1,603        5,825
                                                                       ----------  ----------   ----------

                                                                       $   84,799  $   74,039   $   61,238
                                                                       ==========  ==========   ==========

Geographical Information
Revenues (h):
   United States                                                       $1,480,033  $1,574,737   $1,522,610
   England                                                                315,033     311,660      339,151
   Other                                                                  677,461     712,154      779,396
   Transfers among geographical areas (a)                                (284,317)   (318,029)    (346,537)
                                                                       ----------  ----------   ----------

                                                                       $2,188,210  $2,280,522   $2,294,620
                                                                       ==========  ==========   ==========

Long-lived Assets (i):
   United States                                                       $  199,111  $  222,169   $  206,409
   Sweden                                                                     354         262       66,339
   Other                                                                   92,457      88,846      122,723
                                                                       ----------  ----------   ----------

                                                                       $  291,922  $  311,277   $  395,471
                                                                       ==========  ==========   ==========

Export Sales Included in United States Revenues Above (j)              $  386,799  $  436,378   $  435,558
                                                                       ==========  ==========   ==========

(a) Intersegment sales and transfers among geographical areas are accounted for at prices that are
    representative of transactions with unaffiliated parties.
(b) Includes restructuring and other unusual costs, net, of $30.3 million and $16.3 million in 2001 and
    2000, respectively, and restructuring and other unusual income of $0.3 million in 1999.
(c) Includes restructuring and other unusual costs of $61.5 million, $6.5 million, and $11.2 million in
    2001, 2000, and 1999, respectively.
(d) Includes restructuring and other unusual costs, net, of $55.4 million and $30.1 million in 2001 and
    1999, respectively, and restructuring and other unusual income, net, of $91.9 million in 2000.
(e) Segment income is income before corporate general and administrative expenses, other income and
    expense, minority interest expense, income taxes, extraordinary item, and cumulative effect of change
    in accounting principle.

<

18

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


3.    Business Segment and Geographical Information (continued)
--------------------------------------------------------------------------------

(f) Includes corporate general and administrative expenses and other income and expense. Includes
    restructuring and other unusual costs of $11.5 million, $20.5 million, and $5.7 million at the
    Company's corporate office in 2001, 2000, and 1999, respectively. Other income and expense includes
    $35.1 million of income in 2001 and $45.1 million and $13.4 million of charges in 2000 and 1999,
    respectively, primarily related to the Company's investment in FLIR; and other expense of $2.8 million
    and $3.6 million for impairment of investments in 2001 and 1999, respectively.
(g) Primarily cash and cash equivalents, short- and long-term investments, and property and equipment at
    the Company's corporate office.
(h) Revenues are attributed to countries based on selling location.
(i) Includes property, plant, and equipment, net, and other long-term tangible assets.
(j) In general, export revenues are denominated in U.S. dollars.

4.    Other Income (Expense), Net
--------------------------------------------------------------------------------

      The components of other income (expense), net, in the accompanying
statement of operations are as follows:

(In thousands)                                                                 2001       2000        1999
----------------------------------------------------------------------------------------------------------

Interest Income                                                            $ 68,490   $ 40,151    $ 40,837
Interest Expense                                                            (71,769)   (83,142)    (91,861)
Equity in Earnings (Loss) of Unconsolidated Subsidiaries (Note 15)            4,699    (47,315)     (7,274)
Gain on Investments, Net (Notes 9 and 15)                                    35,579      6,849       3,662
Other Items, Net                                                               (520)     2,273      (2,709)
                                                                           --------   --------    --------

                                                                           $ 36,479   $(81,184)   $(57,345)
                                                                           ========   ========    ========

5.    Employee Benefit Plans
--------------------------------------------------------------------------------

Stock-based Compensation Plans

Stock Option Plans
------------------
      The Company has stock-based compensation plans for its key employees,
directors, and others. These plans permit the grant of a variety of stock and
stock-based awards as determined by the human resources committee of the
Company's Board of Directors (the Board Committee) or by the Company's chief
executive officer in limited circumstances, including restricted stock, stock
options, stock bonus shares, or performance-based shares. Generally, options
granted prior to July 2000 under these plans are exercisable immediately, but
are subject to certain transfer restrictions and the right of the Company to
repurchase shares issued upon exercise of the options at the exercise price,
upon certain events, primarily cessation of employment. The restrictions and
repurchase rights may lapse over periods ranging from 0-10 years, depending on
the term of the option, which may range from 3-12 years. Options granted in or
after July 2000 under these plans generally vest ratably over three years,
assuming continued employment with certain exceptions. Upon a change in control
of the Company, all options, regardless of grant date, become immediately
exercisable and cease to be subject to transfer restrictions and the Company's
repurchase rights. Nonqualified options are generally granted at fair market
value, although options may be granted at a price at or above 85% of the fair
market value on the date of grant. Incentive stock options must be granted at
not less than the fair market value of the Company's stock on the date of grant.
Generally, stock options have been granted at fair market value. The Company
also has a directors' stock option plan that provides for the annual grant of
stock options of the Company to outside directors pursuant to a formula approved
by the Company's shareholders. Options awarded under this plan are immediately
exercisable and expire three to seven years after the date of grant.

<

19

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


5.    Employee Benefit Plans (continued)
--------------------------------------------------------------------------------

      In August and November 2001, the Company distributed all of its shares of
two subsidiaries to the Company's shareholders (Note 17). The intrinsic value of
the options issued under the Company's employee stock plans prior to the
spinoffs was maintained following the spinoffs in accordance with the
methodology set forth in FASB Interpretation No. 44, "Accounting for Certain
Transactions Involving Stock Compensation." The data in the accompanying tables
has been adjusted to reflect the spinoffs. Options to purchase 908,000 shares of
Company common stock held by employees of the spun off businesses were cancelled
at the spin off dates. These employees received equivalent options in stock of
the respective spunoff business.
      In 2001, 2000, and 1999, the Company awarded 17,120, 372,800, and 193,000
shares, respectively, of restricted Company common stock with an aggregate value
of $0.4 million, $7.8 million, and $3.5 million, respectively, to certain key
employees. The shares generally vest over three years, assuming continued
employment, with some exceptions. Also in 1999, some of the Company's formerly
majority-owned subsidiaries awarded shares of restricted common stock of their
respective companies. The shares of subsidiary common stock had the same terms
as the Company's restricted common stock and had an aggregate value of $0.6
million. During 2000, the restricted common stock of the Company's formerly
majority-owned subsidiaries was converted into 100,715 shares of restricted
Company common stock with the same terms. The Company has recorded the fair
value of the restricted stock as deferred compensation in the accompanying
balance sheet and is amortizing the amount over the vesting periods.
      A summary of the Company's stock option activity is as follows:

                                                       2001                2000                 1999
                                                 ----------------    ----------------    -----------------
                                                         Weighted            Weighted             Weighted
                                                 Number   Average    Number   Average    Number    Average
                                                     of  Exercise        of  Exercise        of   Exercise
(Shares in thousands)                            Shares     Price    Shares     Price    Shares      Price
----------------------------------------------------------------------------------------------------------

Options Outstanding, Beginning of Year           24,579    $16.62    15,849    $16.86    11,528     $19.24
 Granted                                          3,086     22.00     2,595     18.49     3,961      14.47
 Assumed in mergers with subsidiaries (Note 17)       -         -    16,221     14.62     1,875       9.98
 Exercised                                       (4,258)    13.16    (5,915)    13.53      (444)     10.81
 Forfeited                                       (2,836)    19.27    (4,171)    15.25    (1,071)     24.07
 Canceled due to spinoffs                          (908)    17.53         -         -         -          -
                                                 ------              ------              ------

Options Outstanding, End of Year                 19,663    $17.78    24,579    $16.62    15,849     $16.86
                                                 ======    ======    ======    ======    ======     ======

Options Exercisable                              15,612    $16.83    23,120    $16.41    15,849     $16.86
                                                 ======    ======    ======    ======    ======     ======

Options Available for Grant                       8,234               3,826               5,531
                                                 ======              ======              ======

<

20

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


5.    Employee Benefit Plans (continued)
--------------------------------------------------------------------------------

      A summary of the status of the Company's stock options at December 29,
2001, is as follows:

                                                                      Options Outstanding
                                                   ------------------------------------------------------
Range of Exercise Prices                                   Number            Weighted            Weighted
                                                               of             Average             Average
                                                           Shares           Remaining            Exercise
                                                   (In thousands)    Contractual Life               Price
---------------------------------------------------------------------------------------------------------

$ 3.36 - $ 15.84                                            8,998           6.0 years              $11.79
 15.85 -   28.33                                            8,918           5.4 years               20.39
 28.34 -   40.82                                            1,649           7.1 years               32.54
 40.83 -  195.11                                               98           7.4 years               83.34
                                                           ------

$ 3.36 - $195.11                                           19,663           5.8 years              $17.78
                                                           ======

Employee Stock Purchase Plan
----------------------------
      Qualifying employees are eligible to participate in an employee stock
purchase plan sponsored by the Company. Under this program, shares of the
Company's common stock may be purchased at 85% of the lower of the fair market
value at the beginning or end of the purchase period, and the shares purchased
are subject to a one-year resale restriction. Shares are purchased through
payroll deductions of up to 10% of each participating employee's gross wages.
Prior to the 2000 plan year, participants of employee stock purchase programs
sponsored by the Company's formerly majority-owned public subsidiaries could
also elect to purchase shares of the common stock of the subsidiary at which
they are employed under the same general terms described above. During 2001,
2000, and 1999, the Company issued 184,000 shares, 693,000 shares, and 415,000
shares, respectively, of its common stock under this plan.

<

21

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


5.    Employee Benefit Plans (continued)
----------------------------------------------------------------------------------------------------------

Pro Forma Stock-based Compensation Expense
      In October 1995, the FASB issued SFAS No. 123, "Accounting for Stock-based
Compensation," which sets forth a fair-value based method of recognizing
stock-based compensation expense. As permitted by SFAS No. 123, the Company has
elected to continue to apply APB No. 25 to account for its stock-based
compensation plans. Had compensation cost for awards granted after 1994 under
the Company's stock-based compensation plans been determined based on the fair
value at the grant dates consistent with the method set forth under SFAS No.
123, the effect on certain financial information of the Company would have been
as follows:

(In thousands except per share amounts)                                       2001        2000        1999
----------------------------------------------------------------------------------------------------------

Income from Continuing Operations Before Extraordinary Item and
 Cumulative Effect of Change in Accounting Principle:
   As reported                                                           $  49,592   $  62,047   $  37,283
   Pro forma                                                                30,159      45,965      25,281
Basic Earnings per Share from Continuing Operations Before
 Extraordinary Item and Cumulative Effect of Change in Accounting
 Principle:
   As reported                                                                 .27         .37         .24
   Pro forma                                                                   .17         .27         .16
Diluted Earnings per Share from Continuing Operations Before
 Extraordinary Item and Cumulative Effect of Change in Accounting
 Principle:
   As reported                                                                 .27         .36         .22
   Pro forma                                                                   .16         .26         .14

Net Loss:
   As reported                                                           $    (781)  $ (36,111)  $(174,573)
   Pro forma                                                               (20,214)    (52,131)   (201,186)
Basic Loss per Share:
   As reported                                                                   -        (.22)      (1.10)
   Pro forma                                                                  (.11)       (.31)      (1.27)
Diluted Loss per Share:
   As reported                                                                   -        (.22)      (1.12)
   Pro forma                                                                  (.11)       (.31)      (1.29)

      Pro forma compensation expense for options granted is reflected over the
vesting period; therefore, future pro forma compensation expense may be greater
as additional options are granted.
      The weighted average fair value per share of options granted was $9.85,
$6.58, and $4.82 in 2001, 2000, and 1999, respectively. The fair value of each
option grant was estimated on the grant date using the Black-Scholes
option-pricing model with the following weighted-average assumptions:

                                                                                2001       2000       1999
----------------------------------------------------------------------------------------------------------

Volatility                                                                       45%        35%        32%
Risk-free Interest Rate                                                         4.1%       4.9%       5.6%
Expected Life of Options                                                   5.0 years  3.9 years  3.9 years



<
                                       22

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


5.    Employee Benefit Plans (continued)
--------------------------------------------------------------------------------

      The Black-Scholes option-pricing model was developed for use in estimating
the fair value of traded options, which have no vesting restrictions and are
fully transferable. In addition, option-pricing models require the input of
highly subjective assumptions, including expected stock price volatility.
Because the Company's employee stock options have characteristics significantly
different from those of traded options, and because changes in the subjective
input assumptions can materially affect the fair value estimate, in management's
opinion, the existing models do not necessarily provide a reliable single
measure of the fair value of its employee stock options.

401(k) Savings Plan and Other Defined Contribution Plans
      The Company's 401(k) savings plan covers the majority of the Company's
eligible full-time U.S. employees. Contributions to the plan are made by both
the employee and the Company. Company contributions are based on the level of
employee contributions.
      Certain of the Company's subsidiaries offer retirement plans in lieu of
participation in the Company's principal 401(k) savings plan. Company
contributions to these plans are based on formulas determined by the Company.
      For these plans, the Company contributed and charged to expense $19.0
million, $18.0 million, and $15.2 million in 2001, 2000, and 1999, respectively.

Defined Benefit Pension Plans
      Two of the Company's German subsidiaries and one of its U.K. subsidiaries
have defined benefit pension plans covering substantially all full-time
employees at the respective subsidiaries. One of the German subsidiaries' plans
is unfunded, as permitted under the plan and applicable laws. Net periodic
benefit costs for the plans in aggregate included the following components:

(In thousands)                                                                  2001       2000       1999
----------------------------------------------------------------------------------------------------------

Service Cost                                                                 $ 2,615    $ 2,238    $ 2,639
Interest Cost on Benefit Obligation                                            3,941      3,834      3,899
Expected Return on Plan Assets                                                (4,951)    (5,793)    (5,264)
Recognized Net Actuarial Gain                                                    (19)      (180)       (34)
Amortization of Unrecognized Gain                                                  -         (2)       (23)
Amortization of Unrecognized Initial Obligation                                   35         36         41
                                                                             -------    -------    -------

                                                                             $ 1,621    $   133    $ 1,258
                                                                             =======    =======    =======

      The activity under the Company's defined benefit plans is as follows:

(In thousands)                                                                            2001        2000
----------------------------------------------------------------------------------------------------------

Change in Benefit Obligation:
 Benefit obligation, beginning of year                                                 $73,772     $71,762
 Service cost                                                                            2,615       2,238
 Interest cost                                                                           3,941       3,834
 Benefits paid                                                                          (2,212)     (1,878)
 Actuarial (gain) loss                                                                  (8,358)      3,525
 Currency translation                                                                   (2,589)     (5,709)
                                                                                       -------     -------

 Benefit obligation, end of year                                                       $67,169     $73,772
                                                                                       -------     -------


<
                                       23

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


5.    Employee Benefit Plans (continued)
--------------------------------------------------------------------------------

(In thousands)                                                                            2001        2000
----------------------------------------------------------------------------------------------------------

Change in Plan Assets:
 Fair value of plan assets, beginning of year                                          $76,579     $89,393
 Company contributions                                                                     580         518
 Benefits paid                                                                          (2,212)     (1,878)
 Actual loss on plan assets                                                            (10,064)     (4,505)
 Currency translation                                                                   (2,328)     (6,949)
                                                                                       -------     -------

 Fair value of plan assets, end of year                                                 62,555      76,579
                                                                                       -------     -------

Funded Status                                                                           (4,614)      2,807
Unrecognized Net Actuarial Loss                                                          7,126         252
Unrecognized Initial Obligation                                                             67         107
                                                                                       -------     -------

Prepaid Pension Costs                                                                  $ 2,579     $ 3,166
                                                                                       =======     =======

      The aggregate projected benefit obligation, accumulated benefit
obligation, and fair value of plan assets for the pension plans with accumulated
benefit obligations in excess of plan assets were $18.5 million, $13.9 million,
and $5.6 million, respectively, at year-end 2001 and $18.0 million, $14.2
million, and $5.7 million, respectively, at year-end 2000.
      The weighted average rates used to determine the net periodic benefit
costs were as follows:

                                                                              2001        2000        1999
----------------------------------------------------------------------------------------------------------

Discount Rate                                                                 6.1%        5.6%        5.1%
Rate of Increase in Salary Levels                                             4.4%        4.4%        4.4%
Expected Long-term Rate of Return on Assets                                   7.0%        6.9%        6.9%

6.    Income Taxes
--------------------------------------------------------------------------------

      The components of income from continuing operations before provision for
income taxes, minority interest, extraordinary item, and cumulative effect of
change in accounting principle are as follows:

(In thousands)                                                                  2001       2000       1999
----------------------------------------------------------------------------------------------------------

U.S.                                                                        $  5,745   $ 91,342   $ 39,761
Non-U.S.                                                                      64,936     93,489     84,998
                                                                            --------   --------   --------

                                                                            $ 70,681   $184,831   $124,759
                                                                            ========   ========   ========



<
                                       24

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


6.    Income Taxes (continued)
--------------------------------------------------------------------------------

      The components of the provision for income taxes of continuing operations
are as follows:

(In thousands)                                                               2001        2000         1999
----------------------------------------------------------------------------------------------------------

Currently Payable:
 Federal                                                                $  11,117   $  55,819    $  25,102
 Non-U.S.                                                                  23,572      53,586       40,417
 State                                                                      3,318       8,311        6,364
                                                                        ---------   ---------    ---------

                                                                           38,007     117,716       71,883
                                                                        ---------   ---------    ---------

Net Deferred (Prepaid):
 Federal                                                                  (12,787)       (635)      (6,197)
 Non-U.S.                                                                   2,667      (4,535)         520
 State                                                                       (958)       (329)      (1,778)
                                                                        ---------   ---------    ---------

                                                                          (11,078)     (5,499)      (7,455)
                                                                        ---------   ---------    ---------

                                                                        $  26,929   $ 112,217    $  64,428
                                                                        =========   =========    =========

      The total provision for income taxes included in the accompanying
statement of operations is as follows:

(In thousands)                                                               2001        2000         1999
----------------------------------------------------------------------------------------------------------

Continuing Operations                                                   $  26,929   $ 112,217    $  64,428
Discontinued Operations                                                         -      10,427      (54,807)
Provision for Loss on Disposal of Discontinued Operations                 (22,741)   (104,000)     174,000
Extraordinary Item                                                            637         333          900
Cumulative Effect of Change in Accounting Principle                          (663)     (8,543)           -
                                                                        ---------   ---------    ---------

                                                                        $   4,162   $  10,434    $ 184,521
                                                                        =========   =========    =========

      The Company and its formerly majority-owned subsidiaries receive a tax
deduction upon the exercise of nonqualified stock options by employees for the
difference between the exercise price and the market price of the underlying
common stock on the date of exercise. The provision for income taxes that is
currently payable does not reflect $9.5 million, $18.0 million, and $2.7 million
of such benefits of the Company and its formerly majority-owned subsidiaries
that have been allocated to capital in excess of par value, directly or through
the effect of majority-owned subsidiaries' equity transactions, in 2001, 2000,
and 1999, respectively. In addition, the provision for income taxes that is
currently payable does not reflect $19.0 million and $3.5 million of tax
benefits used to reduce goodwill in 2000 and 1999, respectively.

<
                                       25

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


6.    Income Taxes (continued)
--------------------------------------------------------------------------------

      The provision for income taxes in the accompanying statement of operations
differs from the provision calculated by applying the statutory federal income
tax rate of 35% to income from continuing operations before provision for income
taxes, minority interest, extraordinary item, and cumulative effect of change in
accounting principle due to the following:

(In thousands)                                                               2001         2000        1999
----------------------------------------------------------------------------------------------------------

Provision for Income Taxes at Statutory Rate                             $ 24,738     $ 64,691    $ 43,666
Increases (Decreases) Resulting From:
 Goodwill of businesses sold                                                    -       30,190           -
 Amortization and write off of goodwill                                    13,095       11,330      16,648
 Writedown and equity in loss of unconsolidated subsidiary                      -       12,062           -
 Foreign sales corporation                                                 (2,401)      (7,325)     (3,558)
 Federal tax credits                                                       (2,955)      (4,113)     (3,697)
 State income taxes, net of federal tax                                     1,535        5,188       2,979
 Non-U.S. tax rate and tax law differential                                (1,017)         301       6,771
 Nondeductible expenses                                                       926        1,347       2,246
 Losses not benefited in the year they occurred                            (4,687)       1,005       1,235
 Other, net                                                                (2,305)      (2,459)     (1,862)
                                                                         --------     --------    --------

                                                                         $ 26,929     $112,217    $ 64,428
                                                                         ========     ========    ========

      Net deferred tax asset in the accompanying balance sheet consists of the
following:

(In thousands)                                                                           2001         2000
----------------------------------------------------------------------------------------------------------

Deferred Tax Asset (Liability):
 Net operating loss and credit carryforwards                                         $ 46,568     $ 94,874
 Reserves and accruals                                                                 52,234       55,460
 Inventory basis difference                                                            39,246       34,322
 Accrued compensation                                                                  10,952       12,097
 Depreciation and amortization                                                         11,299       (5,621)
 Available-for-sale investments                                                       (18,114)      (8,044)
 Other, net                                                                            (2,750)       1,102
                                                                                     --------     --------

                                                                                      139,435      184,190
 Less:  Valuation allowance                                                            45,370       54,874
                                                                                     --------     --------

                                                                                     $ 94,065     $129,316
                                                                                     ========     ========

      The valuation allowance primarily relates to the uncertainty surrounding
the realization of acquired tax loss and credit carryforwards. Any tax benefit
resulting from the use of acquired loss carryforwards is used to reduce
goodwill.
      At year-end 2001, the Company had federal, state, and non-U.S. net
operating loss carryforwards of $8 million, $327 million, and $116 million,
respectively. Use of the carryforwards is limited based on the future income of
certain subsidiaries. The federal and state net operating loss carryforwards
expire in the years 2002 through 2021. Of the non-U.S. net operating loss
carryforwards, $11 million expire in the years 2002 through 2015, and the
remainder do not expire.

<

26

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements

6.    Income Taxes (continued)
--------------------------------------------------------------------------------

      A provision has not been made for U.S. or additional non-U.S. taxes on
$514 million of undistributed earnings of international subsidiaries that could
be subject to taxation if remitted to the U.S. because the Company plans to keep
these amounts permanently reinvested overseas.

7.    Earnings (Loss) per Share
--------------------------------------------------------------------------------

(In thousands except per share amounts)                                     2001         2000         1999
----------------------------------------------------------------------------------------------------------

Basic
Income from Continuing Operations Before Extraordinary Item and
 Cumulative Effect of Change in Accounting Principle                   $  49,592    $  62,047    $  37,283
Income (Loss) from Discontinued Operations                                     -       14,228     (163,325)
Provision for Loss on Disposal of Discontinued Operations, Net           (50,440)    (100,000)     (50,000)
Extraordinary Item                                                         1,061          532        1,469
Cumulative Effect of Change in Accounting Principle                         (994)     (12,918)           -
                                                                       ---------    ---------    ---------

Net Loss                                                               $    (781)   $ (36,111)   $(174,573)
                                                                       ---------    ---------    ---------

Weighted Average Shares                                                  180,560      167,462      157,987
                                                                       ---------    ---------    ---------

Basic Earnings (Loss) per Share:
 Continuing operations before extraordinary item and cumulative
   effect of change in accounting principle                            $     .27    $     .37    $     .24
 Discontinued operations                                                    (.28)        (.51)       (1.35)
 Extraordinary item                                                          .01            -          .01
 Cumulative effect of change in accounting principle                        (.01)        (.08)           -
                                                                       ---------    ---------    ---------

                                                                       $       -    $    (.22)   $   (1.10)
                                                                       =========    =========    =========



<
                                       27

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


7.    Earnings (Loss) per Share (continued)
--------------------------------------------------------------------------------

(In thousands except per share amounts)                                     2001         2000         1999
----------------------------------------------------------------------------------------------------------

Diluted
Income from Continuing Operations Before Extraordinary Item and
 Cumulative Effect of Change in Accounting Principle                   $  49,592    $  62,047    $  37,283
Income (Loss) from Discontinued Operations                                     -       14,228     (163,325)
Provision for Loss on Disposal of Discontinued Operations, Net           (50,440)    (100,000)     (50,000)
Extraordinary Item                                                         1,061          532        1,469
Cumulative Effect of Change in Accounting Principle                         (994)     (12,918)           -
                                                                       ---------    ---------    ---------

Net Loss                                                                    (781)     (36,111)    (174,573)

Effect of:
 Majority-owned subsidiaries' dilutive securities - continuing
   operations                                                                  -       (1,331)      (3,071)
 Majority-owned subsidiaries' dilutive securities - discontinued
   operations                                                                  -         (113)        (145)
                                                                       ---------    ---------    ---------

Loss Available to Common Shareholders, as Adjusted                     $    (781)   $ (37,555)   $(177,789)
                                                                       ---------    ---------    ---------

Weighted Average Shares                                                  180,560      167,462      157,987
Effect of:
 Stock options                                                             2,893        2,819          236
 Convertible obligations                                                     463          238            -
                                                                       ---------    ---------    ---------

Weighted Average Shares, as Adjusted                                     183,916      170,519      158,223
                                                                       ---------    ---------    ---------

Diluted Earnings (Loss) per Share:
 Continuing operations before extraordinary item and cumulative
   effect of change in accounting principle                            $     .27    $     .36    $     .22
 Discontinued operations                                                    (.27)        (.50)       (1.35)
 Extraordinary item                                                          .01            -          .01
 Cumulative effect of change in accounting principle                        (.01)        (.08)           -
                                                                       ---------    ---------    ---------

                                                                       $       -    $    (.22)   $   (1.12)
                                                                       =========    =========    =========

      Options to purchase 4,755,000, 4,726,000, and 12,200,000 shares of common
stock were not included in the computation of diluted earnings (loss) per share
for 2001, 2000, and 1999, respectively, because the options' exercise prices
were greater than the average market price for the common stock and their effect
would have been antidilutive.

<

28

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


7.    Earnings (Loss) per Share (continued)
--------------------------------------------------------------------------------

      During 2000, convertible obligations of some of the Company's formerly
public subsidiaries became convertible into Company common stock (Note 17). The
computation of diluted earnings (loss) per share for 2001 and 2000 excludes the
effect of assuming the conversion of the following of the Company's subordinated
convertible debentures because the effect would be antidilutive:

                                                                Conversion
                                    Principal       Interest     Price per
                                       Amount           Rate         Share
                                  ----------------------------------------
                                  (In thousands)

                                     $398,498         4 1/4%       $ 32.09
                                      231,508             4%         35.77
                                      145,414         4 1/2%         34.42
                                       78,048         3 1/4%         41.84
                                       75,168         4 3/8%        111.83
                                       69,614         4 5/8%         34.22
                                       17,650         4 7/8%         32.50
                                       11,583         2 7/8%         28.16

      The computation of diluted earnings (loss) per share for 1999 excludes the
effect of assuming the conversion of the Company's 4 1/4% subordinated
convertible debentures, convertible at $32.09 per share, because the effect
would be antidilutive. In addition, the computation of diluted earnings (loss)
per share for 1999 excludes the effect of assuming the repurchase of 2,367,000
shares of Company common stock at a weighted average exercise price of $14.06
per share in connection with put options (Note 12) because the effect would be
antidilutive.

8.    Comprehensive Loss
--------------------------------------------------------------------------------

      Comprehensive loss combines net loss and "other comprehensive items,"
which represents certain amounts that are reported as components of
shareholders' investment in the accompanying balance sheet, including currency
translation adjustments and unrealized net of tax gains and losses on
available-for-sale investments and hedging instruments.
      Accumulated other comprehensive items in the accompanying balance sheet
consists of the following:

(In thousands)                                                                           2001         2000
----------------------------------------------------------------------------------------------------------

Cumulative Translation Adjustment                                                   $(132,709)   $(108,103)
Net Unrealized Gains on Available-for-sale Investments                                 32,081       11,761
Net Unrealized Gains on Hedging Instruments                                             1,338            -
                                                                                    ---------    ---------

                                                                                    $ (99,290)   $ (96,342)
                                                                                    =========    =========

<

29

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


8.    Comprehensive Loss (continued)
--------------------------------------------------------------------------------

      The change in unrealized gains on available-for-sale investments, a
component of other comprehensive items in the accompanying statement of
comprehensive loss and shareholders' investment, includes the following:

(In thousands)                                                              2001         2000         1999
----------------------------------------------------------------------------------------------------------

Unrealized Holding Gains Arising During the Year (net of
 income tax provision of $12,136, $5,257, and $3,956)                    $21,077      $ 8,668      $ 6,848
Reclassification Adjustment for Gains Included in Net Loss
 (net of income tax provision of $505, $2,739, and $1,465)                  (757)      (4,110)      (2,197)
                                                                         -------      -------      -------

Net Unrealized Gains (net of income tax provision of $11,631,
 $2,518, and $2,491)                                                     $20,320      $ 4,558      $ 4,651
                                                                         =======      =======      =======

      The change in unrealized gains on hedging instruments, a component of
other comprehensive items in the accompanying statement of comprehensive loss
and shareholders' investment, includes the following:

(In thousands)                                                                                        2001
----------------------------------------------------------------------------------------------------------

Unrealized Holding Gains Arising During the Year (net of
 income tax provision of $2,861)                                                                   $ 4,330
Reclassification Adjustment for Gains Included in Net Loss
 (net of income tax provision of $1,995)                                                            (2,992)
                                                                                                   -------

Net Unrealized Gains (net of income tax provision of $866)                                         $ 1,338
                                                                                                   =======

9.    Available-for-sale Investments
--------------------------------------------------------------------------------

      The aggregate market value, cost basis, and gross unrealized gains and
losses of short- and long-term available-for-sale investments by major security
type are as follows:

                                                                                      Gross         Gross
                                                         Market          Cost    Unrealized    Unrealized
(In thousands)                                            Value         Basis         Gains        Losses
---------------------------------------------------------------------------------------------------------

2001
Corporate Bonds and Notes                              $682,520      $666,432      $ 16,372      $   (284)
Other                                                    71,161        37,054        34,231          (124)
                                                       --------      --------      --------      --------

                                                       $753,681      $703,486      $ 50,603      $   (408)
                                                       ========      ========      ========      ========

2000
Corporate Bonds and Notes                              $434,140      $431,553      $  2,749      $   (162)
U.S. Government-agency Securities                        42,475        42,318           222           (65)
Other                                                    61,824        46,324        17,633        (2,133)
                                                       --------      --------      --------      --------

                                                       $538,439      $520,195      $ 20,604      $ (2,360)
                                                       ========      ========      ========      ========

<

30

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


9.    Available-for-sale Investments (continued)
--------------------------------------------------------------------------------

      Short- and long-term available-for-sale investments in the accompanying
2001 balance sheet include equity securities of $54.6 million and debt
securities of $246.8 million with contractual maturities of one year or less and
$452.3 million with contractual maturities of more than one year through five
years. Actual maturities may differ from contractual maturities as a result of
the Company's intent to sell these securities prior to maturity and as a result
of put and call features of the securities that enable either the Company, the
issuer, or both to redeem these securities at an earlier date.
      The cost of available-for-sale investments that were sold was based on
specific identification in determining realized gains and losses recorded in the
accompanying statement of operations. The net gain on the sale of
available-for-sale investments resulted from gross realized gains of $5.0
million, $9.3 million, and $7.6 million and gross realized losses of $3.7
million, $2.5 million, and $3.9 million in 2001, 2000, and 1999, respectively.

10.   Long-term Obligations and Other Financing Arrangements
--------------------------------------------------------------------------------

(In thousands except per share amounts)                                                  2001         2000
----------------------------------------------------------------------------------------------------------

4 1/2% Senior Convertible Debentures, Due 2003, Convertible at $34.42 per Share    $  145,414   $  172,500
7 5/8% Senior Notes, Due 2008                                                         128,725      150,000
4 1/4% Subordinated Convertible Debentures, Due 2003, Convertible at $32.09
 per Share (called for redemption in March 2002; Note 19)                             398,498      561,563
4% Subordinated Convertible Debentures, Due 2005, Convertible at $35.77 per
 Share                                                                                231,508      247,000
3 1/4% Subordinated Convertible Debentures, Due 2007, Convertible at $41.84 per
 Share                                                                                 78,048       78,048
4 3/8% Subordinated Convertible Debentures, Due 2004, Convertible at $111.83 per
 Share                                                                                 75,168       98,310
4 5/8% Subordinated Convertible Debentures, Due 2003, Convertible at $34.22
 per Share (called for redemption in March 2002; Note 19)                              69,614      110,191
Noninterest-bearing Subordinated Convertible Debentures, Due 2003, Convertible
 at $61.67 per Share                                                                   31,420       31,565
4 7/8% Subordinated Convertible Debentures, Due 2004, Convertible at $32.50 per
 Share                                                                                 17,650       35,029
2 7/8% Subordinated Convertible Debentures, Due 2003, Convertible at $28.16 per
 Share                                                                                 11,583       15,859
2 1/2% Subordinated Convertible Debentures, Due 2001, Convertible into Shares
 of Subsidiary Common Stock                                                                 -        4,787
Noninterest-bearing Subordinated Convertible Debentures, Due 2001, Convertible
 at $26.74 per Share                                                                        -        1,680
Other                                                                                  10,303       44,361
                                                                                   ----------   ----------

                                                                                    1,197,931    1,550,893
Less:  Current Maturities                                                             470,429       22,410
                                                                                   ----------   ----------

                                                                                   $  727,502   $1,528,483
                                                                                   ==========   ==========

      As a result of the spinoffs to shareholders discussed in Note 17, the
conversion price of each of the Company's convertible debentures was reduced in
2001 to approximately 85% of the conversion price at December 30, 2000, in
accordance with the terms of the convertible debentures.

<
                                       31

>


Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements

10.   Long-term Obligations and Other Financing Arrangements (continued)
--------------------------------------------------------------------------------

      Outstanding debentures issued by subsidiaries that were taken private in
transactions in which the consideration paid to stockholders of the subsidiary
was Thermo Electron common stock have become convertible into the Company's
common stock. Outstanding debentures issued by subsidiaries that have been taken
private in transactions in which the consideration paid to stockholders of the
subsidiary was cash became convertible into an amount based on the same cash
consideration payable in the merger transactions. Holders of such debentures had
the right to cause the debentures to be redeemed 90 days following the effective
date of the merger (Note 17). The interest cost of this debt has been included
as interest expense of continuing operations in the accompanying statement of
operations. No allocation of interest expense for debt of the Company's
continuing operations has been made to discontinued operations.

      The annual requirements for long-term obligations are as follows:

(In thousands)
----------------------------------------------------------------------------------------------------------

2002                                                                                            $  470,429
2003                                                                                               190,871
2004                                                                                                93,723
2005                                                                                               232,084
2006                                                                                                   346
2007 and thereafter                                                                                210,478
                                                                                                ----------

                                                                                                $1,197,931
                                                                                                ==========

      See Note 13 for fair value information pertaining to the Company's
      long-term obligations. Short-term obligations and current maturities of
      long-term obligations in the accompanying balance
sheet includes $58.5 million and $80.9 million in 2001 and 2000, respectively,
of short-term bank borrowings and borrowings under lines of credit of certain of
the Company's subsidiaries. The weighted average interest rate for these
borrowings was 3.1% and 4.7% at year-end 2001 and 2000, respectively. Unused
lines of credit were $189 million as of year-end 2001. The unused lines of
credit generally provide for short-term unsecured borrowings outside the United
States at various interest rates.
      Repurchases of subordinated convertible debentures for less than the par
value resulted in extraordinary gains of $1.1 million, $0.5 million, and $1.5
million in 2001, 2000, and 1999, respectively. The gains are net of taxes of
$0.6 million, $0.3 million, and $0.9 million in 2001, 2000, and 1999,
respectively.
      The Company has a cash-management arrangement in which some of its
subsidiaries participate, including some operating units of discontinued
operations. Amounts invested in this arrangement by the Company's discontinued
operations were classified as "Advance payable to affiliates" in the
accompanying 2000 balance sheet.
      Long-term net assets of discontinued operations in 2000 includes $153.0
million principal amount of 4 1/2% subordinated debentures due 2004 and
convertible into shares of Kadant Inc. common stock at $60.50 per share. The net
assets of discontinued operations at year-end 2000 also reflects $17.0 million
of redeemable stock obligations of Thermo Fibergen Inc., that were redeemed in
2001. The Company remains a guarantor of the Kadant debentures following the
spin off of Kadant and its Thermo Fibergen subsidiary in August 2001 (Note 17).
      Long-term net assets of discontinued operations at year-end 2000 also
includes $54.8 million principal amount of 4 3/4% subordinated convertible
debentures of Thermo Cardiosystems Inc., due 2004. In February 2001, the Company
sold Thermo Cardiosystems to Thoratec Corporation. Under the terms of the sale,
Thermo Cardiosystems' 4 3/4% subordinated convertible debentures were assumed by
Thoratec and became convertible into shares of Thoratec common stock. The
debentures remained outstanding through March 11, 2002, when they were redeemed
by Thoratec. Thermo Electron remained a guarantor of these obligations until
redemption occurred. Thoratec had posted a bank letter of credit naming the
fiscal agent of the debentures as beneficiary to secure the Company's position
as guarantor of the obligations.

<
                                       32

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


11.   Commitments and Contingencies
--------------------------------------------------------------------------------

Operating Leases
      The Company leases portions of its office and operating facilities under
various operating lease arrangements. Income from continuing operations includes
expenses from operating leases of $43.9 million, $42.2 million, and $43.4
million in 2001, 2000, and 1999, respectively. Future minimum payments due under
noncancelable operating leases at December 29, 2001, are $36.3 million in 2002,
$32.5 million in 2003, $28.3 million in 2004, $21.6 million in 2005, $14.3
million in 2006, and $60.6 million in 2007 and thereafter. Total future minimum
lease payments are $193.6 million.

Letters of Credit
      Outstanding letters of credit, principally relating to performance bonds,
totaled $44.4 million at December 29, 2001.

Litigation and Related Contingencies

Continuing Operations
      The Company has been named a defendant, along with many other companies,
in a patent-infringement lawsuit brought by the Lemelson Medical, Education &
Research Foundation, L.P. The suit asserts that products manufactured, used, or
sold by the defendants infringe one or more patents related to methods of
machine vision or computer-image analysis. Also, Spectra-Physics and its Opto
Power subsidiary have been sued for patent infringement by Rockwell
International Corp. The suit claims that Spectra-Physics and Opto Power
infringed a patent for the manufacture of a film used in semiconductor
applications. Both the Lemelson and Rockwell actions seek damages, including
enhanced damages for alleged willful infringement and attorney's fees, and
Lemelson seeks injunctive relief.

Discontinued Operations
      The Company's Trex Medical Corporation subsidiary is a defendant in a
lawsuit brought by Fischer Imaging Corporation, which alleges that the prone
breast-biopsy systems of the Lorad division of Trex Medical infringe Fischer's
patents on a precision mammographic needle-biopsy system and a motorized
mammographic biopsy apparatus. Lorad's cumulative revenues from these products
totaled approximately $167 million through September 30, 2000. Trex Medical sold
this business in 2000 but retained this litigation as a term of the sale.
Subject to certain limitations, the Company is required to indemnify the buyer
with respect to claims by Fischer that post-closing sales of these products
infringe Fischer's patents.
      The Company's Thermo Coleman Corporation subsidiary has been named as a
defendant in a lawsuit initiated by two former employees. The suit alleges,
among other things, that Thermo Coleman violated the Federal False Claims Act in
connection with the performance of a government contract. The complaint seeks
the award of treble damages in an unspecified amount, plus other penalties. The
amount of billings under the contract activities in question were approximately
$7.6 million. Thermo Coleman sold its core business in 2000, but retained this
litigation as a term of the sale.
      The Company is a defendant in a lawsuit alleging breach of contract and
fraud in connection with the Company's sale in 2000 of its former Peek, Ltd.
subsidiary for $128 million. The suit alleges that the Company misrepresented
and concealed facts concerning Peek's earnings, assets, and liabilities, as a
result of which the plaintiffs seek damages.

      The Company intends to vigorously defend the matters in continuing and
discontinued operations described above. In the opinion of management, an
unfavorable outcome in one or more of the matters described above could
materially affect the Company's financial position as well as its results of
operations and cash flows for a particular quarter or annual period.

<
                                       33

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


11.   Commitments and Contingencies (continued)
--------------------------------------------------------------------------------

      The Company's continuing and discontinued operations are a defendant in a
number of other pending legal proceedings incidental to present and former
operations. The Company does not expect the outcome of these proceedings, either
individually or in the aggregate, to have a material adverse effect on its
financial position, results of operations, or cash flows.

12.   Common and Preferred Stock
--------------------------------------------------------------------------------

      At December 29, 2001, the Company had reserved 58,892,617 unissued shares
of its common stock for possible issuance under stock-based compensation plans
and for possible conversion of the Company's convertible debentures.
      The Company has 50,000 shares of authorized but unissued $100 par value
preferred stock.
      In 2000, the Company issued 22.6 million shares of its common stock valued
at $448.7 million to complete mergers with several of its formerly majority-
owned subsidiaries (Note 17).
      During 1998 and 1999, in a series of transactions with an institutional
counterparty, the Company sold put options and purchased call options. No cash
was exchanged as a result of these transactions. The Company had the right to
settle the put options by physical settlement of the options or by net share
settlement using shares of the Company's common stock. During 2000, the Company
purchased 1,183,500 shares of its common stock under the call options for $17.5
million. During 1999, the Company purchased 1,536,000 shares of its common stock
under the put options for $24.6 million. During 1999 and 2000, put options for
4,165,000 shares expired. No remaining obligation under the put options existed
at year-end 2000 or 2001.
      The Company has distributed rights under a shareholder rights plan adopted
by the Company's Board of Directors to holders of outstanding shares of the
Company's common stock. Each right entitles the holder to purchase one
ten-thousandth of a share (a Unit) of Series B Junior Participating Preferred
Stock, $100 par value, at a purchase price of $250 per Unit, subject to
adjustment. The rights will not be exercisable until the earlier of (i) 10 days
following a public announcement that a person or group of affiliated or
associated persons (an Acquiring Person) has acquired, or obtained the right to
acquire, beneficial ownership of 15% or more of the outstanding shares of common
stock (the Stock Acquisition Date), or (ii) 10 business days following the
commencement of a tender offer or exchange offer for 15% or more of the
outstanding shares of common stock.
      In the event that a person becomes the beneficial owner of 15% or more of
the outstanding shares of common stock, except pursuant to an offer for all
outstanding shares of common stock approved by at least a majority of the
members of the Board of Directors, each holder of a right (except for the
Acquiring Person) will thereafter have the right to receive, upon exercise, that
number of shares of common stock that equals the exercise price of the right
divided by one-half of the current market price of the common stock. In the
event that, at any time after any person has become an Acquiring Person, (i) the
Company is acquired in a merger or other business combination transaction in
which the Company is not the surviving corporation or its common stock is
changed or exchanged (other than a merger that follows an offer approved by the
Board of Directors), or (ii) 50% or more of the Company's assets or earning
power is sold or transferred, each holder of a right (except for the Acquiring
Person) shall thereafter have the right to receive, upon exercise, the number of
shares of common stock of the acquiring company that equals the exercise price
of the right divided by one half of the current market price of such common
stock.
      At any time until 10 days following the Stock Acquisition Date, the
Company may redeem the rights in whole, but not in part, at a price of $.01 per
right (payable in cash or stock). The rights expire on January 29, 2006, unless
earlier redeemed or exchanged.

<
                                       34

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


13.   Fair Value of Financial Instruments
--------------------------------------------------------------------------------

      The Company's financial instruments consist mainly of cash and cash
equivalents, available-for-sale investments, accounts receivable, short-term
obligations and current maturities of long-term obligations, advance payable to
affiliates, accounts payable, common stock subject to redemption, long-term
obligations, and forward currency exchange contracts. The carrying amounts of
cash and cash equivalents, accounts receivable, short-term obligations and
current maturities of long-term obligations (excluding convertible obligations),
advance payable to affiliates, and accounts payable approximate fair value due
to their short-term nature.
      Available-for-sale investments are carried at fair value in the
accompanying balance sheet. The fair values were determined based on quoted
market prices (Note 9).
      The carrying amount and fair value of the Company's long-term obligations,
common stock subject to redemption, and forward currency exchange contracts are
as follows:

                                                                   2001                     2000
                                                         ------------------------  -----------------------
                                                            Carrying         Fair     Carrying        Fair
(In thousands)                                                Amount        Value      Amount       Value
----------------------------------------------------------------------------------------------------------

Current Maturities of Convertible Obligations             $  468,112   $  466,720  $    6,467   $    6,450
                                                          ==========   ==========  ==========   ==========

Common Stock Subject to Redemption                        $        -   $        -  $    7,692   $    7,692
                                                          ==========   ==========  ==========   ==========

Long-term Obligations:
 Convertible obligations                                  $  590,791   $  562,264  $1,350,065   $1,283,979
 Other                                                       136,711      140,006     178,418      180,268
                                                          ----------   ----------  ----------   ----------

                                                          $  727,502   $  702,270  $1,528,483   $1,464,247
                                                          ==========   ==========  ==========   ==========

Forward Currency Exchange Contracts Receivable            $    3,585   $    3,585  $    1,936   $    2,149

      The fair value of long-term obligations was determined based on quoted
market prices and on borrowing rates available to the Company at the respective
year ends. The fair value of common stock subject to redemption was determined
based upon quoted market prices.
      The notional amounts of forward currency exchange contracts outstanding
totaled $90.1 million and $122.1 million at year-end 2001 and 2000,
respectively. The fair value of such contracts is the estimated amount that the
Company would receive upon termination of the contracts, taking into account the
change in currency exchange rates.

<

35

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


14.   Supplemental Cash Flow Information
--------------------------------------------------------------------------------

(In thousands)                                                           2001          2000           1999
----------------------------------------------------------------------------------------------------------

Cash Paid For
 Interest                                                           $  61,797     $  84,380      $  93,070
                                                                    =========     =========      =========

 Income taxes                                                       $  44,822     $  93,136      $  71,637
                                                                    =========     =========      =========

Noncash Activities
 Receipt of note in connection with sale of business (Note 2)       $       -     $  80,000      $       -
                                                                    =========     =========      =========

 Conversions of Company and subsidiary convertible
   obligations                                                      $       -     $       -      $   9,277
                                                                    =========     =========      =========

 Issuance of Company common stock in exchange for
   minority interests of subsidiaries (Note 17)                     $       -     $ 448,747      $       -
                                                                    =========     =========      =========

 Fair value of assets of acquired companies                         $  18,161     $  25,114      $ 604,114
 Cash paid for acquired companies                                     (14,834)      (17,311)      (385,260)
 Issuance of short- and long-term obligations for
   acquired company                                                         -             -        (14,852)
                                                                    ---------     ---------      ---------

     Liabilities assumed of acquired companies                      $   3,327     $   7,803      $ 204,002
                                                                    =========     =========      =========

15.   Restructuring and Other Unusual Costs (Income), Net
--------------------------------------------------------------------------------

2001
      In response to a downturn in telecommunications, semiconductor, and other
markets served by the Company's businesses and in an effort to further integrate
business units, the Company initiated restructuring actions in the second
quarter of 2001 in a number of business units to reduce costs and shed
unproductive assets. Further actions were initiated in the fourth quarter of
2001. The restructuring and related actions primarily consist of headcount
reductions, writedowns of telecommunication equipment and excess
telecommunication inventories at Spectra-Physics, discontinuing a number of
mature or unprofitable product lines, and consolidation of facilities to
streamline operations and reduce costs. During 2001, the Company recorded $158.8
million of restructuring and unusual charges primarily associated with these
actions, including $26.1 million of charges to cost of revenues. In addition,
the Company recorded $2.8 million of other nonoperating charges during 2001.
These charges are detailed by segment below. The Company expects to incur an
additional $11 million of restructuring costs in 2002 for charges associated
with these actions that cannot be recorded until incurred. The Company expects
that the restructuring actions undertaken in 2001 will be substantially
completed by the third quarter of 2002.

<

36

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

      The Company recorded charges by segment for 2001 as follows:

                                                   Optical     Measurement
(In thousands)             Life Sciences  Technologies (a)     and Control       Corporate           Total
----------------------------------------------------------------------------------------------------------

Cost of Revenues                $  4,412          $ 11,753        $  9,930        $      -        $ 26,095
Restructuring and Other
  Unusual Costs, Net              25,906            49,779          45,499          11,518         132,702
Loss on Investments                    -               801           1,983               -           2,784
                                --------          --------        --------        --------        --------

                                $ 30,318          $ 62,333        $ 57,412        $ 11,518        $161,581
                                ========          ========        ========        ========        ========

(a) Excludes a gain of $35.1 million on the sale of 1,150,000 shares of FLIR, including $14.2 million
    representing a recovery of amounts previously written down in 1999 and 2000. The gain was recorded in
    other income (expense), net, in the accompanying 2001 statement of operations.

      The components of restructuring and other unusual costs by segment are as
follows:

Life Sciences
-------------
      The Life Sciences segment recorded $30.3 million of restructuring and
unusual costs, net, in 2001. The segment recorded charges to cost of revenues of
$4.4 million, primarily for discontinued product lines, and $25.9 million of
other costs. The other restructuring and unusual costs consist of $15.1 million
of cash costs, including $11.1 million of severance for 342 employees across all
functions; $3.6 million of ongoing lease costs through 2012 for facilities
described below; and $0.4 million of other costs. A total of 128 employees were
terminated as of December 29, 2001. The charge also includes a $3.4 million
writeoff of in-process research and development costs at an acquired business,
$6.7 million of asset writedowns, and $0.7 million of noncash severance costs.
The writeoff of in-process research and development was determined through
established valuation techniques and was charged to expense upon acquisition
because technological feasibility had not been established and no future
alternative uses existed. The asset writedowns principally include $4.7 million
of goodwill for business units that were or will be closed and $2.0 million of
fixed assets at facilities being consolidated. The facility consolidations
include closure of 11 sales and service offices, including 10 in Europe and one
in the United States, and the closure of seven factories, including five in
Europe and two in the United States. The activities of these sales and service
offices and factories are being transferred to other facilities in those
regions.

Optical Technologies
--------------------
      The Optical Technologies segment recorded $61.5 million of restructuring
and unusual costs, net, in 2001. The segment recorded charges to cost of
revenues of $11.8 million, primarily for excess telecommunication inventories at
Spectra-Physics and discontinued product lines, and $49.8 million of other
costs. The excess telecommunication inventories resulted from a severe slowdown
in this market and the writedown reduced the carrying value of these and other
inventories to estimated net realizable value. The other restructuring and
unusual costs consist of $25.2 million of cash costs, including $7.6 million of
severance for 614 employees, primarily in manufacturing positions; $7.0 million
for leases on abandoned equipment; $5.9 million of loss on litigation; $1.4
million of ongoing lease costs through 2005 for facilities described below; and
$3.3 million of other cash costs. A total of 599 employees were terminated as of
December 29, 2001. The other cash costs primarily represent cancellation fees
for fixed asset purchases and termination of distributor agreements. The segment
also recorded $24.6 million of asset writedowns. The asset writedowns include
$22.0 million of fixed assets, principally equipment used in telecommunication

<
                                       37

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

manufacturing for which estimated future cash flows are not sufficient to
recover the carrying value. The asset writedowns also include $2.2 million of
goodwill to reduce the carrying value of two small business units that are held
for sale to their estimated disposal value and $0.4 million of costs associated
with an abandoned financing at Spectra-Physics. The facility consolidations
include closure of six sales and service offices, including four in Europe and
two in the United States, the closure of three factories in the United States,
and the closure of two distribution facilities in Europe. The activities of
these sales and service offices, factories, and distribution facilities are
being transferred to other facilities in those regions.
      This segment also recorded $0.8 million of other nonoperating charges in
2001 to writedown an investment to its market value due to an impairment that
the Company deemed other than temporary.

Measurement and Control
-----------------------
      The Measurement and Control segment recorded $55.4 million of
restructuring and unusual costs, net, in 2001. The segment recorded charges to
cost of revenues of $9.9 million, primarily for discontinued product lines, and
$45.5 million of other costs, net. The other restructuring and unusual costs
consist of $30.0 million of cash costs, including $19.4 million of severance for
629 employees across all functions; $8.9 million of ongoing lease costs through
2011 for facilities described below; and $1.7 million of other cash costs. A
total of 256 employees were terminated as of December 29, 2001. The charge also
includes $11.0 million, net, of loss on the sale of businesses and writedowns of
goodwill for businesses subsequently sold, $5.5 million of asset writedowns, and
$0.1 million of other costs, offset in part by $1.1 million of gain on the sale
of a building. The principal businesses that were sold that resulted in losses
included Pharos Marine, a marine navigation unit, in August 2001, and
ThermoMicroscopes, a manufacturer of scanning probe microscopes, in July 2001.
These units were noncore businesses. The asset writedowns include $4.5 million
of assets at facilities being closed, including $3.9 million of fixed assets and
$0.6 million of goodwill and other assets, and $1.0 million for impairment of a
note receivable that was a preacquisition asset of a business acquired in 1999.
The facility consolidations include closure of 15 sales and service offices, all
of which are located in Europe, and the closure of 16 factories, including 10 in
the United States, five in Europe, and one in Canada. The activities of these
sales and service offices and facilities are being transferred to other
facilities in those regions.
      This segment also recorded $2.0 million of other nonoperating charges in
2001 to writedown to its market value an available-for-sale investment that was
a preacquisition asset of a business acquired in 1999, due to an impairment that
the Company deemed other than temporary.

Corporate
---------
      The Company recorded $11.5 million of restructuring and unusual costs at
its corporate office in 2001. This amount includes $11.3 million of cash costs,
including $5.9 million of investment banking, consulting, and legal fees
associated with the Company's reorganization plan; $3.5 million of
employee-retention costs that was accrued ratably through 2001, the period
through which the employees had to work to qualify for a payment; and $1.9
million for severance for 21 employees. A total of 18 employees were terminated
as of December 29, 2001. The charge also includes $0.2 million of noncash
severance costs.

2000
      As a result of a review of existing businesses following the appointment
of a new president and chief operating officer in July 2000, the Company
commenced a restructuring of a number of business units to reduce costs and shed
unproductive assets. The restructuring primarily consisted of headcount
reductions, discontinuing a number of mature or unprofitable product lines, and
consolidation of facilities to streamline operations and reduce costs. During
2000, the Company recorded $81.4 million of restructuring and unusual charges
primarily associated with these actions, including $19.3 million of charges to
cost of revenues. These charges are detailed by segment below. In addition, the
Company recorded other unusual income, net, of $130.0 million and nonoperating
charges of $45.1 million during 2000, as detailed by segment below.


<
                                       38

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

      The Company recorded charges (income) by segment for 2000 as follows:

                                                   Optical     Measurement
(In thousands)               Life Sciences    Technologies  and Control (a)      Corporate           Total
----------------------------------------------------------------------------------------------------------

Cost of Revenues                  $  8,369        $  2,916        $  8,000        $      -        $ 19,285
Restructuring and Other
  Unusual Costs (Income), Net        7,939           3,600         (99,890)         20,496         (67,855)
Equity in Loss of
  Unconsolidated
  Subsidiaries                           -          47,421               -               -          47,421
Other Income, Net                        -          (2,281)              -               -          (2,281)
                                  --------        --------        --------        --------        --------

                                  $ 16,308        $ 51,656        $(91,890)       $ 20,496        $ (3,430)
                                  ========        ========        ========        ========        ========

(a) Excludes an operating loss of $1.7 million at the Spectra Precision businesses in the third quarter of
    2000 prior to their sale (Note 2).

      The components of restructuring and other unusual costs (income) by
segment are as follows:

Life Sciences
-------------
      The Life Sciences segment recorded $16.3 million of restructuring and
unusual costs in 2000. The segment recorded charges to cost of revenues of $8.4
million, primarily for discontinued product lines, and $7.9 million of other
costs. The other restructuring and unusual costs consisted of $6.5 million of
cash costs, including $4.0 million of severance for 78 employees across all
functions; $1.1 million for ongoing lease costs through 2003 for facilities
described below; $0.8 million of provisions for two lawsuits; and $0.6 million
for other exit costs. The segment also recorded $1.4 million of asset writedowns
in connection with the closure of a small business and the consolidation and
abandonment of facilities. The asset writedowns included $0.7 million of
goodwill and $0.7 million of fixed assets. The facility consolidations included
closure of sales offices in Spain, Belgium, and Japan and the transfer of their
activities to other offices, consolidation of two German units into one
facility, and relocation of a unit to other facilities within Colorado.

Optical Technologies
--------------------
      The Optical Technologies segment recorded $6.5 million of restructuring
and unusual costs in 2000. The segment recorded charges to cost of revenues of
$2.9 million, primarily for discontinued product lines, and $3.6 million of
other costs. The other restructuring and unusual costs consisted of a charge of
$1.5 million for in-process research and development in connection with an
acquisition; $0.9 million of asset writedowns; and $1.2 million of cash costs,
including $0.3 million of severance for 22 employees across all functions, $0.4
million for ongoing lease costs, and $0.5 million of other exit costs. The asset
writedowns primarily consisted of charges to reduce the carrying value of a
small business unit that was held for sale to estimated disposal value and
included $0.7 million of goodwill and $0.2 million of fixed assets. The lease
costs related to the closure of a facility in California with lease payments
that ceased in 2000.

<
                                       39

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

      The Optical Technologies segment also recorded a charge of $23.7 million
in 2000 to write down the carrying value of its equity method investment in FLIR
(Note 2) based on a decline in the market value of FLIR shares that the Company
deemed other than temporary. The segment also recorded other noncash charges of
$23.7 million in 2000, representing the Company's pro rata share of FLIR's
losses. Both of these charges were recorded to equity in earnings (loss) of
unconsolidated subsidiaries, a component of other income (expense), net, in the
accompanying statement of operations.
      Prior to its acquisition by the Company, Spectra-Physics elected early
adoption of SFAS No. 133. Under SFAS No. 133, Spectra-Physics is permitted under
certain conditions to enter into currency exchange contracts to hedge probable
anticipated transactions without recording gains and losses on such contracts in
income. The Company did not adopt SFAS No. 133 until 2001 and through 2000
accounted for hedging transactions under SFAS No. 52. Under SFAS No. 52, such
contracts are deemed to be speculative hedges and must be marked to market with
the resulting gain or loss reported as a component of the Company's results of
operations. During 2000, the Company recorded income on currency exchange
contracts entered into by Spectra-Physics of $2.3 million, which is included in
other income (expense), net, in the accompanying statement of operations.

Measurement and Control
-----------------------
      The Measurement and Control segment recorded $91.9 million of
restructuring and unusual income, net, in 2000. The segment recorded charges to
cost of revenues of $8.0 million, primarily for discontinued product lines, and
recorded $99.9 million of other unusual income, net. The segment had a net gain
of $126.3 million on the sale of several businesses, primarily Spectra Precision
(Note 2), Nicolet Imaging Systems (NIS), and Sierra Research and Technology Inc.
(SRT). NIS and SRT manufacture products that include imaging systems used in
assembling complex printed circuit boards and in airbag manufacturing. Spectra
Precision, NIS, and SRT had aggregate revenues and operating income of $125.7
million and $11.0 million, respectively, in 2000 through their respective
disposal dates. The segment also recorded charges of $20.6 million for asset
writedowns to reduce the carrying value of businesses held for sale to estimated
disposal value and for fixed assets unique to certain discontinued products and
$6.4 million of cash costs. The cash costs included $3.0 million of severance
for 128 employees across all functions, $2.4 million of lease costs through
2001, and $1.0 million of other exit costs, primarily employee retention and
relocation costs incurred in 2000. The lease costs included amounts for the
closure of sales offices in Norway, New Zealand, and Germany, and a
manufacturing operation in the U.K. The asset writedowns included $17.6 million
of goodwill, $2.8 million of fixed assets, and $0.2 million of other assets. The
businesses held for sale primarily included CAC Inc. and the Mid South
Companies, which provide the oil and gas industry with wellhead safety and
control products; the Test and Measurement business, which manufactures and
sells data acquisition systems, digital oscilloscopes, and recorders; and Pharos
Marine. The segment also had unusual income of $0.6 million in 2000, primarily
representing a gain on the termination of a lease.

Corporate
---------
      The Company recorded $20.5 million of restructuring and unusual costs,
net, at its corporate office in 2000. This amount included $16.1 million of
investment banking, consulting, and legal fees associated with the Company's
reorganization plan; $3.6 million of employee-retention costs that was accrued
ratably over the period through which the employees had to work to qualify for a
payment; $3.0 million of severance for 21 employees; and $1.6 million of noncash
costs. The Company also recorded unusual income of $3.8 million, representing a
gain from the sale of an office building adjacent to the Company's corporate
office.

<
                                       40

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

1999
      During 1999, the Company recorded restructuring and unusual costs of $46.8
million and other nonoperating charges of $18.4 million in connection with broad
scale restructuring actions affecting a number of business units. Restructuring
and other unusual costs, net, included $37.7 million of restructuring costs,
$0.3 million of other unusual income, net, and $9.4 million of charges to cost
of revenues. The Company also recorded $17.0 million of other nonoperating
charges and $1.4 million of income tax expense. These charges are detailed by
segment below.
      The Company recorded charges (income) by segment for 1999 as follows:

                                             Life       Optical   Measurement
(In thousands)                           Sciences  Technologies   and Control     Corporate         Total
----------------------------------------------------------------------------------------------------------

Cost of Revenues                          $     -       $ 4,072       $ 5,354       $     -       $ 9,426
Restructuring and Other Unusual
 Costs (Income), Net                         (326)        7,166        24,761         5,745        37,346
Equity in Loss of Unconsolidated
 Subsidiaries                                   -        11,066             -             -        11,066
Other Expense, Net                              -         2,316             -         3,609         5,925
Income Tax Expense                              -             -         1,409             -         1,409
                                          -------       -------       -------       -------       -------

                                          $  (326)      $24,620       $31,524       $ 9,354       $65,172
                                          =======       =======       =======       =======       =======

      The components of restructuring and unusual costs (income) by segment are
as follows:

Life Sciences
-------------
      During 1999, the Life Sciences segment settled certain severance matters
for less than had been previously accrued and, as a result, reversed $0.3
million of previously established reserves.

Optical Technologies
--------------------
      During 1999, the Optical Technologies segment recorded restructuring and
unusual costs of $11.2 million. The restructuring and unusual costs included
$6.0 million of goodwill impairment in connection with the planned sale of the
Company's power electronics and test-equipment business; $3.2 million of charges
to cost of revenues for the sale of inventories revalued at the date of
acquisition; $1.0 million of facility closing costs and severance associated
with a restructuring plan undertaken in 1998 and completed in 1999; $0.9 million
of inventory provisions that resulted from exiting and reengineering certain
product lines; and $0.1 million of other costs. The Company sold the operating
units of the power electronics and test-equipment business in 2000 and 2001
except for its Thermo KeyTek unit, which it decided to retain. The other
components of the power electronics and test-equipment business were part of the
Measurement and Control segment.
      The Optical Technologies segment also recorded $13.4 million of
nonoperating charges in 1999. During the first calendar quarter of 1999, FLIR
recorded a loss in connection with a pooling-of-interests transaction and
certain restructuring actions. The Company recorded its pro rata share of this
loss, $5.1 million, in equity in earnings (loss) of unconsolidated subsidiaries,
a component of other income (expense), net, in the accompanying statement of
operations. In addition, as a result of the pooling consummated by FLIR and
related issuance of FLIR shares in March 1999, the Company's pro rata share of
FLIR's equity decreased to 29.4% from 34.6% prior to the transaction. This
decrease totaled $6.0 million and was recorded as a loss in equity in earnings
(loss) of unconsolidated subsidiaries in the accompanying statement of
operations, pursuant to SAB No. 51, "Accounting for Sales of Stock by a
Subsidiary." In addition, during 1999, the Optical Technologies segment recorded
a loss of $2.3 million on currency exchange contracts accounted for under SFAS
No. 133 by Spectra-Physics.

<
                                       41

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

Measurement and Control
-----------------------
      During 1999, the Measurement and Control segment recorded restructuring
and unusual costs of $30.1 million and other nonoperating charges of $1.4
million. The Company recorded restructuring costs of $24.8 million and a tax
asset writeoff of $1.4 million, related to a decision to sell its power
electronics and test-equipment business. The planned sale of the power
electronics and test-equipment businesses followed a period of declining sales
and profitability in these units. These businesses are dependent on the cyclical
nature of the semiconductor industry and have lower growth prospects than other
businesses held by the Company. As a result, the Company decided to sell these
units. Restructuring costs included $22.6 million to write off related goodwill
to reduce the carrying value of the business to the estimated proceeds from its
sale. In addition, restructuring costs included a charge of $1.6 million
recorded to write off the Company's remaining net investment in a subsidiary of
the power electronics and test-equipment business, which the Company transferred
to a buyer in consideration for a release from certain contractual obligations,
primarily ongoing lease obligations. The tax writeoff represented a deferred tax
asset that was not realized as a result of exiting this business. Revenues and
operating losses, excluding restructuring and related costs, of the power
electronics and test-equipment business were $16.0 million and $1.4 million,
respectively, for 1999. The Company also recorded other unusual costs of $0.6
million, net, in 1999 at the power electronics and test-equipment business. As
of December 29, 2001, all of the principal operating units of this business had
been sold.
      The Measurement and Control segment's unusual charges also included a
charge to cost of revenues of $3.5 million relating to the sale of inventories
at some Spectra-Physics AB units that were revalued at the date of their
acquisition, and $1.9 million for inventories deemed excessive based on low
demand at the segment's quality assurance and security products business.

Corporate
---------
      During 1999, the Company recorded $5.7 million of restructuring and
unusual costs and $3.6 million of other nonoperating charges. Restructuring
costs consisted of $4.9 million for severance costs for seven senior-level
employees and $0.8 million of legal and advisory costs related to the Company's
reorganization. The Company also recorded $3.6 million of other nonoperating
charges to write down available-for-sale investments due to impairment that the
Company deemed other than temporary based upon market prices. These charges are
included in gain on investments, net, a component of other income (expense),
net, in the accompanying statement of operations.

<

42

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

      The following table summarizes the severance actions of the Company in
1999, 2000, and 2001.

                                                                                                 Number of
                                                                                                 Employees
----------------------------------------------------------------------------------------------------------

1999 Restructuring Plans
Terminations Announced in 1999                                                                          38
Terminations Occurring in 1999                                                                         (38)
                                                                                                    ------

Remaining Terminations at January 1, 2000                                                                -
                                                                                                    ======

2000 Restructuring Plans
Terminations Announced in 2000                                                                         249
Terminations Occurring in 2000                                                                        (168)
Adjustment to Plan                                                                                      (1)
                                                                                                    ------

Remaining Terminations at December 30, 2000                                                             80

Additional Terminations Announced in 2001                                                               16
Terminations Occurring in 2001                                                                         (91)
Adjustment to Plan                                                                                      (1)
                                                                                                    ------

Remaining Terminations at December 29, 2001                                                              4
                                                                                                    ======

2001 Restructuring Plans
Terminations Announced in 2001                                                                       1,606
Terminations Occurring in 2001                                                                      (1,001)
                                                                                                    ------

Remaining Terminations at December 29, 2001                                                            605
                                                                                                    ======

<

43

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

      The following table summarizes the cash components of the Company's
restructuring plans. The noncash components and other amounts reported as
restructuring and unusual costs (income), net, in the accompanying statement of
operations have been summarized in the notes to the tables.

                                                                 Abandonment
                                                                   of Excess
(In thousands)                                      Severance     Facilities          Other          Total
----------------------------------------------------------------------------------------------------------

Pre-1999 Restructuring Plans
 Balance at January 2, 1999                          $  9,281       $  1,263       $    776       $ 11,320
 Costs incurred in 1999 (b)                             1,486          1,280            652          3,418
 1999 usage                                            (7,205)        (2,046)          (838)       (10,089)
 Reserves reversed (c)                                 (2,101)          (217)             -         (2,318)
 Currency translation                                    (568)           (55)           (26)          (649)
                                                     --------       --------       --------       --------

 Balance at January 1, 2000                               893            225            564          1,682
 Costs incurred in 2000                                     -            144              -            144
 2000 usage                                              (774)          (284)             -         (1,058)
 Reserves reversed                                          -            (84)             -            (84)
 Currency translation                                     (22)            (1)           (44)           (67)
                                                     --------       --------       --------       --------

 Balance at December 30, 2000                              97              -            520            617
 2001 usage                                               (90)             -              -            (90)
 Currency translation                                      (7)             -            (14)           (21)
                                                     --------       --------       --------       --------

 Balance at December 29, 2001                        $      -       $      -       $    506       $    506
                                                     ========       ========       ========       ========

1999 Restructuring Plans
 Costs incurred in 1999 (d)                          $  3,938       $      -       $    893       $  4,831
 1999 usage                                              (195)             -           (893)        (1,088)
                                                     --------       --------       --------       --------

 Balance at January 1, 2000                             3,743              -              -          3,743
 2000 usage                                            (2,851)             -              -         (2,851)
 Reserves reversed                                         (6)             -              -             (6)
                                                     --------       --------       --------       --------

 Balance at December 30, 2000                             886              -              -            886
 2001 usage                                              (315)             -              -           (315)
                                                     --------       --------       --------       --------

 Balance at December 29, 2001                        $    571       $      -       $      -       $    571
                                                     ========       ========       ========       ========

<

44

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements

15.   Restructuring and Other Unusual Costs (Income), Net (continued)
--------------------------------------------------------------------------------

                                                                 Abandonment
                                                     Employee      of Excess
(In thousands)                       Severance  Retention (a)     Facilities         Other          Total
----------------------------------------------------------------------------------------------------------

2000 Restructuring Plans
 Costs incurred in 2000 (e)          $  10,469      $   4,116      $   3,818      $ 17,533      $  35,936
 2000 usage                             (6,488)          (830)        (1,031)       (7,958)       (16,307)
 Reserves reversed                        (205)             -              -             -           (205)
 Currency translation                       48             (3)            33            19             97
                                     ---------      ---------      ---------      --------      ---------

 Balance at December 30, 2000            3,824          3,283          2,820         9,594         19,521
 Costs incurred in 2001                    328          3,472             21         5,963          9,784
 2001 usage                             (2,415)          (468)          (909)      (14,277)       (18,069)
 Reserves reversed                        (105)             -            (21)            -           (126)
 Currency translation                      (44)             -            (45)          (80)          (169)
                                     ---------      ---------      ---------      --------      ---------

 Balance at December 29, 2001        $   1,588      $   6,287      $   1,866      $  1,200      $  10,941
                                     =========      =========      =========      ========      =========

2001 Restructuring Plans
 Costs incurred in 2001 (f)          $  40,076      $     297      $  21,058      $  5,099      $  66,530
 2001 usage                            (13,585)          (155)        (1,180)       (2,353)       (17,273)
 Reserves reversed                        (385)             -           (182)          (90)          (657)
 Currency translation                      (14)             1             69            11             67
                                     ---------      ---------      ---------      --------      ---------

 Balance at December 29, 2001        $  26,092      $     143      $  19,765      $  2,667      $  48,667
                                     =========      =========      =========      ========      =========

(a) Employee retention costs were accrued ratably over the period through which the employees had to work
    to qualify for a payment. The awards were based on specified percentages of employees' salaries and
    were generally awarded to help ensure continued employment at least through completion of the
    Company's reorganization plan in January 2002.
(b) Excludes a noncash charge of $0.1 million in the Measurement and Control segment.
(c) Reflects reversals of previously recorded restructuring costs of $0.3 million and $2.0 million
    in the Life Sciences and Measurement and Control segments, respectively, due to attrition and sale
    of businesses.
(d) Excludes noncash charges, net, of $6.0 million, $24.2 million, and $0.9 million in the Optical
    Technologies and Measurement and Control segments and at the Company's corporate office,
    respectively. Also excludes unusual costs of $0.3 million in the Measurement and Control segment.
(e) Excludes noncash charges, net, of $1.4 million and $2.4 million in the Life Sciences and Optical
    Technologies segments, respectively, and noncash income, net, of $106.3 million and $2.2 million in
    the Measurement and Control segment and at the Company's corporate office, respectively. Also,
    excludes $0.8 million of cash costs in the Life Sciences segment related to two lawsuits.
(f) Excludes noncash charges, net, of $10.8 million, $24.6 million, $15.5 million, and $0.2 million in
    the Life Sciences, Optical Technologies, and Measurement and Control segments, and at the Company's
    corporate office, respectively, and loss on litigation of $5.9 million in the Optical Technologies
    sector.

      The Company's continuing operations expect to pay accrued restructuring
costs as follows: severance, primarily in 2002; employee retention obligations,
primarily in 2002; abandoned-facility payments, over lease terms expiring
through 2012; and other costs, which primarily represent
cancellation/termination fees, in 2002.

<
                                       45

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


16.   Adoption of SAB No. 101
--------------------------------------------------------------------------------

      In December 1999, the SEC issued SAB No. 101, "Revenue Recognition in
Financial Statements," which established criteria for recording revenue when the
terms of the sale include customer acceptance provisions or an obligation of the
seller to install the product. In instances where these terms exist and the
Company is unable to demonstrate that the customer's acceptance criteria has
been met prior to customer use or when the installation is essential to
functionality or is not deemed inconsequential or perfunctory, SAB No. 101
requires that revenue recognition occur at completion of installation and/or
upon customer acceptance. In accordance with the requirements of SAB No. 101,
the Company adopted the pronouncement as of January 2, 2000, and recorded the
cumulative effect of the change in accounting principle on periods prior to 2000
in the restated results for the first quarter of 2000. The cumulative effect on
net income totaled $12.9 million, net of an income tax benefit of $8.5 million
and minority interest of $0.5 million. Revenues of $41.3 million in 2000 (as
restated for the adoption of SAB No. 101) related to shipments that occurred in
1999 but for which installation and/or acceptance did not occur until 2000.
These revenues were recorded in 1999 prior to the adoption of SAB No. 101 and
thus were a component in the determination of the cumulative effect of the
change in accounting principle for periods prior to 2000. The Company has not
provided pro forma data for 1999 as the amounts are not readily determinable
based on the nature of the revenue adjustments required by SAB No. 101.

17.   Reorganization and Discontinued Operations
--------------------------------------------------------------------------------

Reorganization
      During 2000 and 2001, the Company completed the principal aspects of a
major corporate reorganization. The reorganization split the Company into three
independent public entities and resulted in the divestiture of a number of
businesses. The Company spun off as a dividend to Company shareholders Kadant
Inc. and Viasys Healthcare Inc. in August and November 2001, respectively. The
Company's continuing operations solely include its instrument businesses.
      During 1999 and 2000, the Company acquired the minority interest in
certain of its privately held subsidiaries and all of its formerly publicly held
subsidiaries other than Spectra-Physics, Thermo Cardiosystems, Kadant, and
Thermo Fibergen. In connection with these acquisitions, the Company expended
$368.6 million and $43.2 million of cash in 2000 and 1999, respectively, and
issued 22.6 million shares of its common stock valued at $448.7 million in 2000.
In addition, the stock options of the subsidiaries were converted into stock
options that are exercisable into 13.9 million shares of Company common stock.
The stock options had a fair value of $115.3 million. As a result of the
completion of the cash tender offers and other repurchases, exchange offers, and
stock option conversions, the Company recorded an increase in goodwill of
approximately $380 million in 2000. In 2001, the Company increased its ownership
in Spectra-Physics to 93.6% through a cash tender offer. In connection with this
offer, the Company expended $63.6 million in 2001 and recorded an increase in
goodwill of $42.1 million (Note 19).
      As a result of the completion of the exchange offers for its formerly
majority-owned subsidiaries, Thermo Instrument Systems Inc., Thermedics Inc.,
Thermo Ecotek Corporation, ThermoLase Corporation, ThermoTrex Corporation, and
Thermo TerraTech Inc., $790.2 million principal amount of convertible
obligations of these subsidiaries became obligations convertible into Company
common stock.

<
                                       46

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


17.   Reorganization and Discontinued Operations (continued)
--------------------------------------------------------------------------------

      Details of the transactions summarized above are as follows:

Continuing Operations

   2001
      The Company completed a cash tender offer of $17.50 per share for
Spectra-Physics, which brought its ownership to 93.6% (Note 19).

   2000
      Thermo Instrument completed a merger with Thermo Vision Corporation
pursuant to which Thermo Instrument acquired, for $7.00 per share in cash, all
of the outstanding shares of common stock of Thermo Vision not already owned by
Thermo Instrument or the Company. The common stock of Thermo Vision ceased to be
publicly traded.
      Thermo Instrument completed cash tender offers of $28.00 per share for
Thermo BioAnalysis Corporation, $9.00 per share for Metrika Systems Corporation,
and $9.00 per share for ONIX Systems Inc. in order to bring its and the
Company's collective ownership of these businesses to at least 90%.
Subsequently, Thermo Instrument completed the acquisition of the outstanding
minority interest in each of these companies through short-form mergers at the
same prices as the tender offers and their common stock ceased to be publicly
traded. Because Thermo Instrument owned more than 90% of the outstanding shares
of Thermo Optek Corporation and ThermoQuest Corporation common stock, each of
these companies were repurchased through short-form mergers at $15.00 and $17.00
per share, respectively, and their common stock ceased to be publicly traded.
      Thermedics completed cash tender offers of $8.00 and $15.50 per share for
Thermedics Detection Inc. and Thermo Sentron Inc., respectively, in order to
bring its and the Company's collective ownership of these businesses to at least
90%. Subsequently, Thermedics completed the acquisition of the outstanding
minority interest in each of these companies through short-form mergers at the
same prices as the tender offers and their common stock ceased to be publicly
traded.
      The Company completed an exchange offer for Thermo Instrument in which
shares of Company common stock were offered to Thermo Instrument shareholders in
exchange for their shares in order to bring the Company's ownership in Thermo
Instrument to at least 90%. The exchange ratio for Thermo Instrument was 0.85
shares of Company common stock for each share of Thermo Instrument common stock.
Subsequently, Thermo Instrument was spun into the Company through a short-form
merger at the same exchange ratio that was offered in the exchange offer and its
common stock ceased to be publicly traded. As a result of the completion of the
merger with Thermo Instrument, the Company issued 12.6 million shares of its
common stock valued at $265.9 million.

   1999
      Thermedics completed a merger with Thermo Voltek Corp. pursuant to which
Thermedics acquired, for $7.00 per share in cash, all of the outstanding shares
of common stock of Thermo Voltek not already owned by Thermedics or the Company.
The common stock of Thermo Voltek ceased to be publicly traded.
      Thermo Instrument completed a merger with ThermoSpectra Corporation
pursuant to which Thermo Instrument acquired, for $16.00 per share in cash, all
of the outstanding shares of common stock of ThermoSpectra not already owned by
Thermo Instrument or the Company. The common stock of ThermoSpectra ceased to be
publicly traded.

Discontinued Operations

   2000
      The Company completed a merger with Thermedics pursuant to which the
Company acquired all of Thermedics' outstanding shares of common stock not
already owned by the Company in exchange for Company common stock at a ratio of
0.45 shares for each share of Thermedics common stock. The common stock of
Thermedics ceased to be publicly traded.

<
                                       47

>


Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


17.   Reorganization and Discontinued Operations (continued)
--------------------------------------------------------------------------------

      The Company completed a merger with Thermo TerraTech pursuant to which the
Company acquired all of Thermo TerraTech's outstanding shares of common stock
not already owned by the Company in exchange for Company common stock at a ratio
of 0.3945 shares for each share of Thermo TerraTech common stock. The common
stock of Thermo TerraTech ceased to be publicly traded.
      The Company completed a merger with ThermoLase pursuant to which the
Company acquired all of ThermoLase's outstanding shares of common stock not
already owned by ThermoTrex or the Company in exchange for Company common stock
at a ratio of 0.132 shares for each share of ThermoLase common stock. The common
stock of ThermoLase ceased to be publicly traded. In addition, under the
agreement, units of ThermoLase were modified so that each unit consisted of a
fractional share of Company common stock. The units were redeemed in April 2001
for cash of $7.5 million.
      The Company completed a merger with ThermoTrex pursuant to which the
Company acquired all of ThermoTrex's outstanding shares of common stock not
already owned by the Company in exchange for Company common stock at a ratio of
0.5503 shares for each share of ThermoTrex common stock. The common stock of
ThermoTrex ceased to be publicly traded.
      The Company completed a cash tender offer of $2.15 per share for Trex
Medical to bring its ownership of this business to at least 90%. Subsequently,
the Company completed the acquisition of the outstanding minority interest in
Trex Medical through a short-form merger at the same price as the tender offer
and the common stock of Trex Medical ceased to be publicly traded.
      The Company completed mergers with ThermoRetec Corporation and The Randers
Killam Group Inc. pursuant to which the Company acquired, for $7.00 and $4.50
per share in cash, respectively, all of the outstanding shares of common stock
of ThermoRetec and Randers Killam not already owned by Thermo TerraTech or the
Company. The common stock of each of ThermoRetec and Randers Killam ceased to be
publicly traded.
      Because the Company owned more than 90% of the outstanding shares of
Thermo Ecotek, the Company repurchased Thermo Ecotek through a short-form
merger. Thermo Ecotek shareholders received 0.431 shares of Company common stock
for each share of Thermo Ecotek common stock. The common stock of Thermo Ecotek
ceased to be publicly traded.
      As a result of the completion of the mergers with Thermedics, Thermo
TerraTech, ThermoLase, ThermoTrex, and Thermo Ecotek, the Company issued 10.0
million shares of its common stock valued at $182.8 million.

   1999
      The Company completed a merger with Thermo Power Corporation pursuant to
which the Company acquired, for $12.00 per share in cash, all of the outstanding
shares of common stock of Thermo Power not already owned by the Company. The
common stock of Thermo Power ceased to be publicly traded.

Discontinued Operations
      In January 2000, the Company also announced its intention to sell several
of its businesses. These businesses, together with the businesses spun off,
constituted the Company's former Biomedical and Emerging Technologies and
Resource Recovery segments as well as the Company's environmental businesses,
and Thermo Power. In addition, in June and July 2001, the Company sold its power
generation business. In accordance with the provisions of APB No. 30 concerning
reporting the effects of disposal of a segment of a business, the Company
classified the results of these businesses, as well as the results of the
businesses spun off as dividends (collectively, "the discontinued businesses"),
as discontinued operations in the accompanying statement of operations. In
addition, the net assets of the discontinued businesses were classified as net
assets of discontinued operations in the accompanying 2000 balance sheet. In
2001, net liabilities of discontinued operations principally represent remaining
obligations of the discontinued businesses including severance, lease,
litigation, and tax obligations, net of the carrying value of 14.6 million
shares of Thoratec common stock, and the net assets of three remaining operating
units held for sale. Current net assets of discontinued

<

48

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


17.   Reorganization and Discontinued Operations (continued)
--------------------------------------------------------------------------------

operations in 2000 primarily consisted of cash, inventories, and accounts
receivable, net of certain liabilities, primarily accrued expenses and accounts
payable. Long-term net assets of discontinued operations primarily consisted of
shares of common stock of Thoratec (see below), machinery and equipment, and
goodwill as well as subordinated convertible debentures of Thermo Cardiosystems
and Kadant (Note 10).
      Summary operating results for 1999 of the businesses discontinued in
January 2000 and for 1999 and 2000 for the power generation business, were as
follows:

(In thousands)                                                                            2000        1999
----------------------------------------------------------------------------------------------------------

Revenues                                                                            $  120,256  $2,009,130
Costs and Expenses                                                                      93,779   2,280,192
                                                                                    ----------  ----------

Income (Loss) from Discontinued Operations Before Income
 Taxes, Minority Interest, and Extraordinary Item                                       26,477    (271,062)
Income Tax (Provision) Benefit                                                         (10,427)     54,807
Minority Interest (Expense) Income                                                      (1,822)     52,282
                                                                                    ----------  ----------

Income (Loss) from Discontinued Operations Before
 Extraordinary Item                                                                     14,228    (163,973)
Extraordinary Item, Net of Income Taxes and Minority Interest                                -         648
                                                                                    ----------  ----------

Income (Loss) from Discontinued Operations                                          $   14,228  $ (163,325)
                                                                                    ==========  ==========

      During 2001, the Company's discontinued operations had revenues and
operating income of $658.3 million and $50.4 million, respectively. During 2000,
the Company's discontinued operations (excluding the power generation business)
had revenues and an operating loss of $1.49 billion and $40.2 million,
respectively. The Company received proceeds from the sale of discontinued
businesses of $347.8 million and $390.1 million in 2001 and 2000, respectively.
In 1999, the Company recorded a charge of $50 million, including a provision for
income taxes of $174 million, for the estimated loss on disposal of the
discontinued businesses. The charge was determined using management's best
estimate of the selling prices of the businesses and their estimated results
through the dates of sale. In 2000, the Company recorded an additional charge of
$100 million, net of an income tax benefit of $104 million, for changes in the
actual and estimated proceeds of businesses discontinued in 2000. Of the
businesses announced for sale, all but three with aggregate revenues of
approximately $100 million have been sold as of December 29, 2001.

Spinoffs
      On July 9, 2001, the Company's Board of Directors approved the spinoff of
the Company's 91%-owned Kadant subsidiary as a dividend to the Company's
shareholders. On August 8, 2001, the Company distributed all of its shares of
Kadant to Thermo Electron shareholders of record as of July 30, 2001.
Immediately after the distribution, the Company no longer owned shares of
Kadant. The Company received a ruling from the Internal Revenue Service (IRS)
that the dividend of Kadant shares qualifies in large part as a tax-free
distribution for U.S. federal income tax purposes. Approximately 8% of the
shares distributed to each shareholder are taxable because the Company purchased
them during the past five years. Cash distributed in lieu of fractional shares
is also taxable. The stock dividend resulted in a reduction of net assets of
discontinued operations and retained earnings of $197 million.

<
                                       49

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


17.   Reorganization and Discontinued Operations (continued)
--------------------------------------------------------------------------------

      In connection with the spinoff, the Company and Kadant entered into a plan
and agreement of distribution. The agreement provides for, among other things,
the Company to continue to guarantee Kadant's $153.0 million principal amount
subordinated convertible debentures due 2004. The agreement requires Kadant to
maintain certain financial ratios during the time that the Company guarantees
these obligations.
      On October 11, 2001, the Company's Board of Directors approved the spinoff
of the Company's wholly owned Viasys Healthcare Inc. subsidiary as a dividend to
the Company's shareholders. On November 15, 2001, the Company distributed all of
its shares of Viasys Healthcare to Thermo Electron shareholders of record as of
November 7, 2001. Immediately after the planned distribution, the Company no
longer owned shares of Viasys Healthcare. The Company received a ruling from the
IRS that the dividend of Viasys Healthcare shares qualifies as a tax-free
distribution for U.S. federal income tax purposes, except that the cash received
in lieu of fractional shares is taxable. The stock dividend resulted in a
reduction of net assets of discontinued operations and retained earnings of $298
million.
      The ruling from the IRS requires that the spinoffs raise additional equity
capital in public offerings within one year of their spinoffs.

Thermo Cardiosystems
      In February 2001, the Company sold Thermo Cardiosystems to Thoratec in
exchange for 19.3 million shares of Thoratec common stock. Certain restrictions
limit the Company's ability to sell these shares, although the restrictions
fully lapse in August 2002. Subsequent to receipt of the Thoratec common stock,
the market value of the shares declined significantly at the same time as a
downturn in major equity markets. The Company recorded an after-tax charge of
$66.0 million in the first quarter of 2001 for the decline in market value of
Thoratec common stock as a loss on disposal of discontinued operations. Further
changes in the market value of Thoratec common stock may materially affect the
ultimate proceeds from the disposal of discontinued operations. Excluding
potential changes in the market value of Thoratec common stock, the Company is
not currently aware of any known trends, events, or other uncertainties
involving discontinued operations that it expects will cause the ultimate loss
on disposal of discontinued operations to differ materially from the amounts
recorded to date. Any difference from the amounts recorded would be reported as
an adjustment to the ultimate loss on disposal of discontinued operations. In
2001, the Company completed the sale of 4.7 million shares of Thoratec for
proceeds of $75.5 million. In February 2002, the Company completed the sale of
6.9 million shares of Thoratec for proceeds of approximately $105 million.

Power Generation Business
      In June and July 2001, the Company sold the chief components of the power
generation business for proceeds of $249 million, net of cash divested. The
Company realized a gain on disposition of $15.6 million, net of tax.

<

50

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


18.   Unaudited Quarterly Information
--------------------------------------------------------------------------------

2001 (In thousands except per share amounts)                First (a)  Second (b)   Third (c)   Fourth (d)
----------------------------------------------------------------------------------------------------------

Revenues                                                     $573,089    $542,472    $512,941     $559,708
Gross Profit                                                  255,254     238,062     228,486      236,820
Income from Continuing Operations Before Extraordinary
 Item and Cumulative Effect of Change in Accounting
 Principle                                                     21,819       9,423      25,677       (7,327)
Income (Loss) Before Extraordinary Item and Cumulative
 Effect of Change in Accounting Principle                     (44,181)     24,983      25,677       (7,327)
Net Income (Loss) (e)                                         (45,175)     24,983      26,279       (6,868)
Earnings (Loss) per Share from Continuing Operations
 Before Extraordinary Item and Cumulative Effect of
 Change in Accounting Principle:
   Basic                                                          .12         .05         .14         (.04)
   Diluted                                                        .12         .05         .14         (.04)
Earnings (Loss) per Share (e):
   Basic                                                         (.25)        .14         .15         (.04)
   Diluted                                                       (.24)        .14         .14         (.04)


2000 (In thousands except per share amounts)                First (f)  Second (g)   Third (h)   Fourth (i)
----------------------------------------------------------------------------------------------------------

Revenues                                                     $576,604    $579,950    $546,949     $577,019
Gross Profit                                                  268,595     266,249     226,348      260,644
Income from Continuing Operations Before Extraordinary
 Item and Cumulative Effect of Change in Accounting
 Principle                                                     14,479      21,698       7,281       18,589
Income (Loss) Before Extraordinary Item and Cumulative
 Effect of Change in Accounting Principle                      15,940      24,255      12,279      (76,199)
Net Income (Loss) (j)                                           3,554      24,255      12,279      (76,199)
Earnings per Share from Continuing Operations Before
 Extraordinary Item and Cumulative Effect of Change in
 Accounting Principle:
   Basic                                                          .09         .14         .04          .10
   Diluted                                                        .09         .13         .04          .10
Earnings (Loss) per Share (j):
   Basic                                                          .02         .16         .07         (.42)
   Diluted                                                        .02         .15         .07         (.41)

      Amounts reflect aggregate restructuring and unusual items, net, and nonoperating items, net, as follows:

(a) Costs of $12.9 million, a net of tax charge of $66.0 million related to the Company's discontinued
    operations, and a $1.0 million charge for the cumulative effect of change in accounting principle for
    the adoption of SFAS No. 133.
(b) Costs of $37.0 million and a net of tax gain of $15.6 million related to the Company's discontinued
    operations.
(c) Costs of $9.6 million and gains of $8.6 million from the sale of shares of FLIR.
(d) Costs of $102.2 million and gains of $26.5 million from the sale of shares of FLIR.
(e) Extraordinary item, net of taxes, of $0.6 million and $0.5 million in the third and fourth quarters,
    respectively.
(f) Costs of $4.3 million and a $12.9 million charge for the cumulative effect of change in accounting
    principle for the adoption of SAB No. 101.
(g) Income of $1.5 million.
(h) Income of $31.9 million.  In July 2000, the Company sold its Spectra-Precision businesses.
(i) Costs of $25.7 million and a net of tax charge of $100 million related to the Company's discontinued
    operations.
(j) Extraordinary item, net of taxes, of $0.5 million in the first quarter.

<
                                       51

>

Thermo Electron Corporation                            2001 Financial Statements

                   Notes to Consolidated Financial Statements


19.   Subsequent Events
--------------------------------------------------------------------------------

Purchase of Minority Interest in Spectra-Physics
      Following the completion of a cash tender offer in December 2001 for all
of the shares of Spectra-Physics it did not previously own, the Company
completed a short-form merger with Spectra-Physics in February 2002. Following
the merger, Spectra-Physics was no longer publicly traded and became a wholly
owned subsidiary of the Company.

Redemption of Subordinated Convertible Debentures
      In February 2002, the Company announced that on March 21, 2002, it will
redeem all of its outstanding 4 1/4% and 4 5/8% subordinated convertible
debentures due 2003. As of December 29, 2001, the principal amount outstanding
for the 4 1/4% and 4 5/8% debentures was $398.5 million and $69.6 million,
respectively. The redemption price is 100% of the principal amount of the
debentures, plus accrued interest. Accordingly, the obligations have been
presented as current liabilities in the accompanying 2001 balance sheet.

<
                                       52

>


Thermo Electron Corporation                            2001 Financial Statements

                    Report of Independent Public Accountants


To the Shareholders and Board of Directors of Thermo Electron Corporation:

      We have audited the accompanying consolidated balance sheets of Thermo
Electron Corporation (a Delaware corporation) and subsidiaries as of December
29, 2001, and December 30, 2000, and the related consolidated statements of
operations, cash flows, and comprehensive loss and shareholders' investment for
each of the three years in the period ended December 29, 2001. These
consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
      We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
      In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Thermo
Electron Corporation and subsidiaries as of December 29, 2001, and December 30,
2000, and the results of their operations and their cash flows for each of the
three years in the period ended December 29, 2001, in conformity with accounting
principles generally accepted in the United States.
      As explained in Note 1 to the consolidated financial statements, effective
December 31, 2000, the Company changed its method of accounting for derivative
instruments and hedging activities through the adoption of Statement of
Financial Accounting Standards No. 133, "Accounting for Derivative Instruments
and Hedging Activities," as amended. As explained in Notes 1 and 16 to the
consolidated financial statements, effective January 2, 2000, the Company
changed its method of accounting for revenue recognition on certain product
shipments through the adoption of Staff Accounting Bulletin No. 101 "Revenue
Recognition in Financial Statements."



                                                             Arthur Andersen LLP



Boston, Massachusetts
February 7, 2002 (except
with respect to the
matters discussed in
Note 19, as to which the
date is February 25, 2002)

<
                                       53

>


Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


      Forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, are made throughout this Management's
Discussion and Analysis of Financial Condition and Results of Operations. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without limiting
the foregoing, the words "believes," "anticipates," "plans," "expects," "seeks,"
"estimates," and similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could cause the results
of the Company to differ materially from those indicated by such forward-looking
statements, including those detailed immediately after this Management's
Discussion and Analysis of Financial Condition and Results of Operations under
the heading "Forward-looking Statements."

Overview
--------------------------------------------------------------------------------

      The Company develops and manufactures a broad range of products that are
sold worldwide. The Company expands the product lines and services it offers by
developing and commercializing its own core technologies and by making strategic
acquisitions of complementary businesses. In January 2000, the Company announced
a major reorganization plan under which it planned to sell or spin off many
noncore businesses. As a result of these actions, the Company's continuing
operations solely include its instrument businesses. The results of the
businesses that have been spun off or have been or will be sold have been
presented as discontinued operations in the accompanying financial statements.
The Company's continuing operations fall into three principal business segments:
Life Sciences, Optical Technologies, and Measurement and Control.
      The Company's discussion and analysis of its financial condition and
results of operations is based upon its financial statements, which have been
prepared in accordance with generally accepted accounting principles. The
preparation of these financial statements requires the Company to make estimates
and judgments that affect the reported amounts of assets, liabilities, revenue
and expenses, and related disclosure of contingent liabilities. On an on-going
basis, the Company evaluates its estimates, including those related to bad
debts, inventories, intangible assets, warranty obligations, income taxes,
contingencies and litigation, restructuring, and discontinued operations. The
Company bases its estimates on historical experience, current market and
economic conditions, and other assumptions that management believes are
reasonable. The results of these estimates form the basis for judgments about
the carrying value of assets and liabilities where the values are not readily
apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.
      The Company believes the following represent its critical accounting
policies and estimates used in the preparation of its financial statements. a)
The Company maintains allowances for doubtful accounts for estimated losses
resulting from the inability of its customers to pay amounts due. If the
financial condition of the Company's customers were to deteriorate, reducing
their ability to make payments, additional allowances would be required. b) The
Company writes down its inventories for estimated obsolescence for differences
between the cost and estimated net realizable value based on recent usage and
expected demand. If ultimate usage varies significantly from expected usage,
additional writedowns may be required. c) The Company periodically reviews
intangible assets including goodwill for impairment based on estimated future
cash flows associated with the assets. Should future cash flows decline
significantly from estimated amounts, charges for impairment of intangible
assets may be necessary. d) At the time the Company recognizes revenue it
provides for the estimated cost of product warranties based primarily on
historical experience. Should product failure rates or the actual cost of
correcting product failures vary from estimates, revisions to the estimated
warranty liability would be necessary. e) The Company estimates the degree to
which tax assets and loss carryforwards will result in a benefit based on
expected profitability by tax jurisdiction and provides a valuation allowance
for tax assets and loss carryforwards that it believes will more likely than not
go unused. Should the Company's actual future taxable income by tax jurisdiction
vary from estimates, additional allowances may be necessary. f) The Company
estimates losses on contingencies and litigation and provides a reserve for
these losses. Should the ultimate losses on contingencies and litigation vary
from estimates, additional charges may be required. g) The Company recorded
restructuring charges for asset impairment in 2001 based on estimated future
cash flows

<
                                       54

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


Overview (continued)
--------------------------------------------------------------------------------

associated with the equipment and for the cost of vacating facilities based on
expected sub-rental income. Should actual cash flows associated with impaired
equipment and sub-rental income from vacated facilities vary from estimated
amounts, additional charges may be required. h) The Company estimates the
expected proceeds from the sale of its discontinued businesses and recorded
losses in 1999-2001 to reduce the carrying value of these businesses to
estimated realizable value. Should the actual proceeds vary from estimates,
actual results could differ from expected amounts.

Results of Operations
--------------------------------------------------------------------------------

2001 Compared With 2000

Continuing Operations
      Sales in 2001 were $2.188 billion, a decrease of $92.3 million from 2000.
Excluding the effect of acquisitions, divestitures, and currency translation,
revenues increased $113.5 million, or 5%. Currency translation had an
unfavorable effect on revenues as discussed below by segment, due to the
strengthening of the U.S. dollar relative to other currencies of countries in
which the Company operates.
      Operating income was $34.2 million in 2001, compared with $266.0 million
in 2000. Segment income decreased to $85.2 million in 2001 from $319.8 million
in 2000. (Segment income is defined as operating income excluding corporate
general and administrative expenses and corporate restructuring and other
unusual items, net.) Operating and segment income in 2001 were affected by
restructuring and other unusual costs. Operating and segment income in 2000 were
affected by gains from the sale of businesses, offset in part by restructuring
and other unusual costs as well as a $1.7 million operating loss in the third
quarter at a business that was sold. The unusual items in both periods are
discussed below and in more detail in Note 15. Excluding these unusual items,
which totaled $147.3 million of expense in 2001 and $67.3 million of income in
2000, segment income was $232.4 million in 2001 and $252.5 million in 2000.
Segment income excluding unusual items decreased due to a reduction in segment
income of $10.9 million from businesses divested. The Company also recorded $2.3
million of incremental amortization expense in 2001, which resulted primarily
from the purchase of the minority interests of formerly public subsidiaries in
2000, offset in part by lower amortization expense following a number of
divestitures. In addition, certain businesses discussed below had lower
profitability in 2001.
      The Company undertook restructuring actions in 2001 to reduce costs in
businesses affected by a severe slowdown in the telecommunications and
semiconductor industries as well as other market sectors hurt by a slowing
economy, including the U.S. steel and cement industries. The Company expects to
substantially complete the restructuring actions by the third quarter of 2002.
In addition to the actions to reduce costs, the Company recorded an impairment
charge for equipment used in telecommunication manufacturing at Spectra-Physics.
The Company also recorded provisions for inventories related to the
discontinuance of certain mature or unprofitable product lines and inventories
made redundant by combining businesses and for excess telecommunication
inventories at Spectra-Physics. The Company expects that the restructuring
actions will result in annual cost reductions of approximately $63 million with
approximately 40% beginning in the fourth quarter of 2001 and the balance by the
third quarter of 2002, including $12 million in the Life Sciences segment, $24
million in the Optical Technologies segment, $24 million in the Measurement and
Control segment, and $3 million at the Company's corporate office. The Company
expects to incur an additional $11 million of restructuring costs in 2002 for
charges that cannot be recorded until incurred. The Company will incur other
restructuring costs in 2002 as it integrates its formerly public subsidiary,
Spectra-Physics, with other businesses in its Optical Technologies sector. These
plans are being formed as of March 15, 2002, but are expected to include
severance and abandonment of certain redundant manufacturing processes and
related fixed assets and leased equipment with associated charges of at least $7
million, principally in the first quarter of 2002. The Company may incur other
restructuring costs in 2002 or thereafter as the Company continues its efforts
to consolidate the number of its operating locations. The particular actions,
costs, and timing of such undertakings have not been determined.

<
                                       55

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2001 Compared With 2000 (continued)
      During 2001, the Company moved its Thermo KeyTek unit from the Measurement
and Control segment to the Optical Technologies segment and moved its Thermo
Projects unit (the principal operating business of which was acquired in early
2001) from the Life Sciences segment to a separate segment (included as "Other"
in Note 3) due to organizational changes. Prior periods have been restated to
conform to this presentation where applicable.

Life Sciences
-------------
      Sales in the Life Sciences segment increased $54.2 million to $834.2
million in 2001. Sales increased $5.7 million due to acquisitions. The
unfavorable effects of currency translation resulted in a decrease in revenues
of $20.0 million in 2001. Excluding the effect of acquisitions and currency
translation, revenues increased $68.5 million, or 9%. Nearly half of the
increase was due to higher sales of mass spectrometry products in 2001 including
ion trap and triple quadrupole instruments used in proteomics and drug discovery
research. Of the remaining increase, approximately two thirds was from increased
sales of biosciences equipment including sample-preparation equipment and
microplate and liquid-handling products due to strong demand from the drug
discovery market and expanded distribution channels. In addition, the segment
had higher revenues from clinical diagnostic products, including rapid
diagnostic tests.
      Segment income margin decreased to 9.9% in 2001 from 11.9% in 2000. The
segment's margin in both periods was affected by restructuring and unusual
charges, discussed below. Excluding restructuring and unusual costs, net, of
$30.3 million in 2001 and $16.0 million in 2000, segment income margin was 13.5%
in 2001 and 14.0% in 2000. The decrease in segment income margin was primarily
due to an increase in goodwill amortization as a result of the purchase of the
minority interests of formerly public subsidiaries. Excluding the additional
amortization expense and the restructuring and unusual charges, segment income
margin was 13.9% in 2001. Lower profitability due to research and development
expenditures on proteomics initiatives was offset in part by the effect of
higher revenues, discussed above. In 2001, the segment recorded charges of $30.3
million, including cash costs of $15.1 million, primarily for severance and
abandoned facilities; $6.7 million of asset writedowns; $4.4 million of charges
to cost of revenues principally for discontinued product lines; and $0.7 million
of noncash severance costs (Note 15). The segment also recorded a charge of $3.4
million for the writeoff of in-process research and development at an acquired
business. Restructuring costs in 2000 represent $8.4 million of charges to cost
of revenues principally for discontinued product lines; $6.5 million of cash
costs, primarily for severance and abandoned facilities; and $1.4 million of
asset writedowns.

Optical Technologies
--------------------
      Sales in the Optical Technologies segment increased $30.0 million to
$526.4 million in 2001. Sales increased $2.3 million from acquisitions, net of a
small divestiture. The unfavorable effects of currency translation resulted in a
decrease in revenues of $8.5 million in 2001. Excluding the effect of
acquisitions, a divestiture, and currency translation, revenues increased $36.3
million, or 7%. The increase in revenues was due in part to $32.7 million of
increased demand for semiconductor-based lasers used in industrial, research and
development, and life sciences applications. The balance of the increase was due
to higher sales in the first half of 2001 of molecular beam epitaxy systems and
components to the semiconductor industry and, to a lesser extent, increased
sales of photonics products including gratings and other optical components used
in systems for lithography and telecommunication devices. These increases were
offset in part by a 11% decrease in sales of temperature-control products due to
a severe market downturn in the semiconductor industry. This downturn, together
with poor economic conditions in the telecommunications markets, resulted in a
decline in segment revenues in the third and fourth quarters of 2001 of 8% and
11%, respectively, (excluding currency effects), compared with the same quarters
of 2000. These market conditions are continuing in 2002 and unfavorable revenue
and profitability comparisons with corresponding periods in the prior year will
result for at least the near-term. The segment's backlog trended down throughout
2001 and was $171.6 million at December 29, 2001, a decrease of 33% from the end
of 2000, excluding a divestiture.

<
                                       56

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2001 Compared With 2000 (continued)
      Segment income margin decreased to negative 5.7% in 2001 from 7.3% in
2000. Excluding restructuring and unusual costs of $61.5 million in 2001 and
$6.5 million in 2000, segment income margin was 6.0% in 2001 and 8.6% in 2000.
The decrease in segment income margin excluding unusual costs was primarily due
to $2.8 million of operating losses at Spectra-Physics from its telecom product
introductions and associated start-up costs, compared with profitable operations
in 2000. The decrease in segment income margin was also due to a smaller
contribution toward fixed costs as a result of lower revenues from
temperature-control products together with $0.9 million of higher goodwill
amortization in 2001 following the purchase of the minority interests of
formerly public subsidiaries. In 2001, the segment recorded restructuring and
unusual charges of $61.5 million, including $25.2 million of cash costs for
severance, lease obligations for abandoned equipment and facilities, litigation
loss, and other cash costs; $24.6 million of asset writedowns, principally fixed
assets associated with telecommunication initiatives; and $11.8 million of
charges to cost of revenues for inventories (Note 15). Restructuring and unusual
costs in 2000 represent $2.9 million of charges to cost of revenues principally
for discontinued product lines, a $1.5 million writeoff of in-process research
and development at an acquired business, $1.2 million of cash costs, a $0.7
million writedown of goodwill on a business held for sale, and $0.2 million of
asset writedowns.

Measurement and Control
-----------------------
      Sales in the Measurement and Control segment decreased $189.7 million to
$831.3 million in 2001. Sales decreased $179.4 million due to divestitures, net
of an acquisition. The unfavorable effects of currency translation resulted in a
decrease in revenues of $17.9 million in 2001. Excluding the effect of
divestitures, an acquisition, and currency translation, revenues increased $7.6
million, or 1%. Revenues from the sale of environmental-monitoring equipment
increased $11.1 million due in part to increased sales of chemical and radiation
monitors as well as demand from the construction industry and upgrades of power
plants. In addition, revenues from the sale of spectroscopy instruments
increased due to new product introductions. These increases were offset in part
by $12.7 million of lower sales of process instruments. The lower sales of
process instruments primarily included weighing and inspection equipment due to
competitive pressures and equipment sold to the U.S. steel and cement industries
due to a downturn in those markets. In April 2001, the segment sold businesses
that contributed $4.4 million of the segment's internal revenue growth in 2001.
A downturn in some markets served by the segment resulted in a decline in
revenues in the third and fourth quarters of 2001 of 4% and 3%, respectively,
(excluding currency effects), compared with the same quarters of 2000. These
market conditions are continuing in 2002 and will unfavorably affect the
segment's revenue comparisons with corresponding periods in the prior year for
at least the near-term. The segment's backlog trended down in 2001 and was
$133.5 million at December 29, 2001, a decrease of 21% from the end of 2000,
excluding divestitures.
      In August 2001, the segment sold its Pharos Marine unit, which
manufactures and sells marine-navigation equipment and systems. In July 2001,
the segment sold its ThermoMicroscopes unit, a manufacturer of scanning probe
microscopes. In April 2001, the segment sold its CAC and Mid South businesses,
which provide the oil and gas industries with wellhead safety and control
products. The businesses were sold for net proceeds of approximately $46 million
and were cyclical and/or noncore units. The businesses had aggregate revenues
and segment income before restructuring and unusual costs of $31.3 million and
$3.4 million, respectively, in 2001 through the dates of sale. In 2000, the
segment's divestitures primarily included Spectra Precision, Nicolet Imaging
Systems, and Sierra Research and Technology, Inc. (Note 2).
      Segment income margin decreased to 4.0% in 2001 from 18.8% in 2000,
primarily due to restructuring and unusual charges, net, in 2001 and unusual
income, net, in 2000. Segment income margin, excluding restructuring and unusual
costs, net, of $55.4 million in 2001 and unusual income, net, of $90.1 million
in 2000, increased to 10.6% in 2001 from 10.0% in 2000. The increase in segment
income margin resulted primarily from higher revenues discussed above together
with cost reduction measures initiated in 2000 and 2001. These improvements were
offset in part by lower profitability at the business units discussed above that
had declining revenues. In 2001, the segment recorded

<
                                       57

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2001 Compared With 2000 (continued)
restructuring and unusual charges, net, of $55.4 million, including cash costs
of $30.0 million for severance, abandoned facilities, and other exit costs;
$11.0 million, net, for the loss on the sale of businesses and writedowns of
businesses subsequently sold; $9.9 million of charges to cost of revenues
principally for discontinued product lines; $5.5 million of asset writedowns;
and $0.1 million of other costs. These charges were offset in part by a gain of
$1.1 million on the sale of a building (Note 15). The businesses for which the
segment recorded a loss on or prior to sale were ThermoMicroscopes and Pharos
Marine. In 2000, restructuring and unusual income, net, totaled $90.2 million
and included gains on the sale of businesses, net, of $126.3 million, and the
related operating loss of $1.7 million of one of the divested businesses in the
third quarter of 2000 prior to its sale; $20.6 million of asset writedowns to
reduce the carrying value of businesses held for sale to estimated disposal
value and for fixed assets unique to certain discontinued products; charges to
cost of revenues of $8.0 million, primarily for discontinued product lines; $6.4
million of cash costs for severance and facility costs; and a gain of $0.6
million from the termination of a lease (Note 15).

Other Income (Expense), Net
---------------------------
      The Company reported other income, net, of $36.5 million in 2001 and other
expense, net, of $81.2 million in 2000 (Note 4). Other income (expense), net,
includes interest income, interest expense, equity in earnings (loss) of
unconsolidated subsidiaries, gain on investments, net, and other items, net.
Interest income increased to $68.5 million in 2001 from $40.2 million in 2000,
primarily due to proceeds from the sale of businesses, including discontinued
operations, offset in part by cash used in 2000 and 2001 for the purchase of the
minority interests of formerly public subsidiaries and in 2001 for repurchases
of the Company's debt and equity securities. Interest expense decreased to $71.8
million in 2001 from $83.1 million in 2000, as a result of the maturity and
repurchase of debentures.
      The Company recorded income from equity in earnings of unconsolidated
subsidiaries of $4.7 million in 2001 and incurred a net equity loss of $47.3
million in 2000, primarily related to its investment in FLIR Systems, Inc.,
which undertook significant restructuring actions in 2000. The Company reports
its pro rata share of FLIR's results on a one-quarter lag. In December 2001, the
Company's ownership of FLIR fell below 20%, following a sale of shares discussed
below. In the first quarter of 2002, the Company will record its pro rata share
of FLIR's fourth quarter 2001 earnings. Thereafter, the Company will account for
its investment in FLIR as an available-for-sale security and will no longer
record its share of FLIR's earnings. The Company had gains on investments, net,
of $35.6 million and $6.8 million in 2000. The gain in 2001 includes $35.1
million from the sale of 1,150,000 shares of FLIR. Of the total gain from the
sale of FLIR, $14.2 million represents a recovery of previous writedowns of
FLIR. The gain in 2001 was reduced by a charge of $2.8 million to writedown two
available-for-sale investments due to impairment that the Company deemed other
than temporary. In 2001, other income, net, includes $0.5 million of other
expense, principally currency losses. In 2000, other expense, net, also includes
$2.3 million of net currency gains, primarily resulting from hedging activities
at Spectra-Physics, which elected early adoption of Statement of Financial
Accounting Standards (SFAS) No. 133 "Accounting for Derivative Instruments and
Hedging Activities."

Provision for Income Taxes
--------------------------
      The Company's effective tax rate was 38% and 61% in 2001 and 2000,
respectively. Excluding the tax effect of restructuring and unusual costs or
income, the effective tax rate was 38% and 39% in 2001 and 2000, respectively.
The effective tax rate exceeded the statutory federal income tax rate in both
periods due to the impact of state income taxes and nondeductible expenses,
including amortization of goodwill.

<
                                       58

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2001 Compared With 2000 (continued)

Minority Interest Income (Expense)
----------------------------------
      The Company recorded minority interest income of $5.8 million in 2001 and
minority interest expense of $10.6 million in 2000, representing minority
shareholders' allocable share of subsidiary losses or earnings. Minority
interest expense decreased due to the purchase in 2000 of the minority interest
in all of the Company's formerly public subsidiaries in continuing operations
except Spectra-Physics (Note 17). In 2001, Spectra-Physics incurred a loss and
minority interest income represents the minority shareholders' share of the
loss. Following the purchase of the minority interest in Spectra-Physics in
February 2002 (Note 19), the Company has no material minority interests in its
subsidiaries.

Contingent Liabilities
----------------------
      At year-end 2001, the Company was contingently liable with respect to
certain lawsuits. An unfavorable outcome in one or more of the matters described
in Note 11 could materially affect the Company's financial position as well as
its results of operations and cash flows for a particular quarter or annual
period.

Income from Continuing Operations
---------------------------------
      Income from continuing operations before extraordinary item and cumulative
effect of change in accounting principle was $49.6 million in 2001, compared
with $62.0 million in 2000. Results were affected by restructuring and other
unusual items, discussed above. Excluding restructuring and other unusual items
in both periods as well as gains from the sale of shares of FLIR, income from
continuing operations before extraordinary item and cumulative effect of change
in accounting principle increased to $122.4 million in 2001 from $100.0 million
in 2000 due to the items discussed above.

Cumulative Effect of Change in Accounting Principle
---------------------------------------------------
      The Company adopted SFAS No. 133, as amended, in the first quarter of 2001
and recorded a charge representing the cumulative effect of the change in
accounting principle of $1.0 million, net of an income tax benefit of $0.7
million (Note 1). In addition, in accordance with the requirements of Securities
and Exchange Commission Staff Accounting Bulletin (SAB) No. 101 "Revenue
Recognition in Financial Statements," the Company adopted the pronouncement as
of January 2, 2000, and recorded a charge in the first quarter of 2000
representing the cumulative effect of the change in accounting principle of
$12.9 million, net of an income tax benefit of $8.5 million and minority
interest of $0.5 million (Note 16).

Discontinued Operations
      In February 2001, the Company sold Thermo Cardiosystems Inc. to Thoratec
Corporation in exchange for 19.3 million shares of Thoratec common stock.
Certain restrictions limit the Company's ability to sell these shares, although
the restrictions fully lapse in August 2002. Subsequent to the receipt of the
Thoratec common stock, the market value of the shares declined significantly.
The Company recorded a net of tax provision of $66.0 million in the first
quarter of 2001 for the decline in market value of Thoratec common stock as a
loss on disposal of discontinued operations. Further changes in the market value
of Thoratec common stock may materially affect the ultimate proceeds from the
disposal of discontinued operations. Excluding potential changes in the market
value of Thoratec common stock, the Company is not currently aware of any known
trends, events, or other uncertainties involving discontinued operations that it
expects will cause the ultimate loss on disposal of discontinued operations to
differ materially from the amounts recorded to date. Any difference from the
amounts recorded would be reported as an adjustment to the ultimate loss on
disposal of discontinued operations. In 2001, the Company sold 4.7 million
shares of Thoratec for proceeds of $75.5 million. In February 2002, the Company
sold an additional 6.9 million shares for proceeds of approximately $105
million.

<
                                       59

>


Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2001 Compared With 2000 (continued)
      The Company sold the chief components of its discontinued power generation
business in June and July 2001 for proceeds of $249 million, net of cash
divested, and realized a net of tax gain of $15.6 million on the disposition.
The power generation business had income of $14.2 million in 2000, net of taxes
and minority interest.
      The Company recorded a net of tax provision of $100 million in 2000 as a
revision to the estimate of loss on disposal of discontinued operations recorded
in 1999. The increase in the loss resulted from lower after-tax proceeds from
the sale of noncore businesses than had been anticipated at the time the
businesses were discontinued. The Company believes that deterioration in the
financial markets in the latter part of 2000, including tighter financing terms
and lower equity values, adversely affected the selling prices of the
discontinued businesses.

2000 Compared With 1999

Continuing Operations
      Sales in 2000 were $2.281 billion, a decrease of $14.1 million from 1999.
Excluding the effect of acquisitions, divestitures, and currency translation,
revenues increased $146.6 million, or 7%. Operating income was $266.0 million in
2000, compared with $182.1 million in 1999. Segment income increased to $319.8
million in 2000 from $219.2 million in 1999. The 2000 period included
significant gains on the sale of businesses, inventory provisions, and
restructuring and unusual costs as well as a $1.7 million operating loss in the
third quarter at a business that was sold. The 1999 period included significant
restructuring and unusual costs. These items are discussed below. Excluding
unusual income, net, of $67.3 million in 2000 and unusual costs of $41.0 million
in 1999, segment income decreased to $252.5 million in 2000 from $260.2 million
in 1999. Segment income excluding unusual items decreased in part due to a
reduction in segment income of $8.6 million from businesses divested. In
addition, $4.9 million of incremental amortization expense resulted primarily
from the purchase of the minority interests of formerly public subsidiaries,
offset in part by lower amortization expense following certain divestitures.
These decreases in segment income were offset in part by higher profitability at
certain units.
      The restructuring actions undertaken in 2000 were substantially completed
by the end of the second quarter of 2001. These actions resulted in annualized
savings of approximately $5 million in the Life Sciences segment, $2 million in
the Optical Technologies segment, $4 million in the Measurement and Control
segment, and $2 million in the corporate office, generally beginning in the
fourth quarter of 2000.

Life Sciences
-------------
      Sales in the Life Sciences segment increased $15.6 million to $780.0
million in 2000. The unfavorable effects of currency translation resulted in a
decrease in revenues of $29.6 million in 2000. Revenues increased $13.7 million
due to acquisitions, offset in part by a decrease of $2.0 million due to the
adoption of SAB No. 101. Excluding the effect of currency translation,
acquisitions, and the adoption of SAB No. 101, revenues increased $33.5 million,
or 4%. Over half of the increase resulted from increased demand for mass
spectrometers, due in part to strong sales in Japan and growth in the drug
discovery market. Approximately a third of the increase in revenues was from
increased sales of clinical diagnostic products due to higher demand for
clinical chemistry analyzers and reagents and rapid diagnostic tests. In
addition, a 10% increase in sales of controlled-environment laboratory equipment
was largely offset by lower revenues from laboratory information management
systems due to completion of year-2000 compliance projects in 1999.
      Segment income margin decreased to 11.9% in 2000 from 15.5% in 1999. The
segment's margin decreased primarily due to restructuring and related actions in
2000. Excluding restructuring and unusual costs, segment income margin decreased
to 14.0% in 2000 from 15.5% in 1999 due to lower sales of laboratory information
management systems, which have a higher profit margin than the segment's other
products. In addition, segment income margin was negatively affected by the
purchase of the minority interests of formerly public subsidiaries, which
resulted in an increase of $4.5 million in goodwill amortization expense, as
well as $1.8 million of research and development

<
                                       60

>


Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2000 Compared With 1999 (continued)
spending on proteomics initiatives. The restructuring and unusual costs totaled
$16.3 million and included $8.4 million of charges to cost of revenues,
primarily for discontinued product lines; $6.5 million of cash costs, primarily
for severance and facilities closures; and $1.4 million of asset writedowns in
connection with the closure of a small business and the consolidation and
abandonment of facilities. The segment recorded unusual income of $0.3 million
in 1999 for the reversal of previously recorded restructuring costs (Note 15).

Optical Technologies
--------------------
      Sales in the Optical Technologies segment increased $89.5 million to
$496.3 million in 2000. Sales increased $19.4 million due to acquisitions,
primarily the inclusion of a full year of revenues from the acquisition of a
majority interest in Spectra-Physics on February 22, 1999. The unfavorable
effects of currency translation resulted in a decrease in revenues of $13.3
million in 2000. The adoption of SAB No. 101 reduced revenues by $13.1 million.
Excluding the effect of acquisitions, currency translation, and the adoption of
SAB No. 101, revenues increased $96.5 million, or 25%. Sales of
semiconductor-based lasers increased $41.9 million due to higher demand from
computer and microelectronic manufacturers. Sales of temperature-control systems
increased $27.3 million in 2000 as a result of strong demand from the
semiconductor industry. Approximately 18% of the increase in revenues was from
higher sale of photonics products as a result of strong demand for gratings and
other optical components used in systems for lithography and telecommunication
devices. In addition, higher sales of molecular beam epitaxy systems resulted
from increased demand from semiconductor manufacturers.
      Segment income margin was 7.3% in 2000 and 6.2% in 1999. Excluding
restructuring and unusual costs, segment income margin was 8.6% in 2000 and 8.9%
in 1999. Segment income margin was unfavorably affected by the growth in
revenues at Spectra-Physics, which has lower operating margins due to heavy
investments in telecommunications products. In addition, the segment had $2.1
million of higher goodwill amortization expense, primarily resulting from the
purchase of the minority interests in formerly public subsidiaries. These
factors were offset in part by higher profitability resulting from increased
sales of photonics products and temperature-control systems. The restructuring
and unusual costs in 2000 totaled $6.5 million and included charges to cost of
revenues of $2.9 million, primarily for discontinued product lines; a $1.5
million charge for in-process research and development in connection with an
acquisition; $1.2 million of cash costs for severance and facility exit costs;
and $0.9 million of asset writedowns, primarily to reduce the carrying value of
a small business unit held for sale to estimated disposal value. The
restructuring and unusual costs in 1999 totaled $11.2 million and included $6.0
million of goodwill impairment in connection with the planned sale of the
Company's power electronics and test-equipment business; $3.2 million of charges
to cost of revenues for the sale of inventories revalued at the date of
acquisition; $1.0 million of facility closing costs and severance associated
with a restructuring plan undertaken in 1998 and completed in 1999; $0.9 million
of inventory provisions; and $0.1 million of other costs (Note 15). The Company
sold the operating units of the power electronics and test-equipment business in
2000 and 2001, except for its Thermo KeyTek unit, which it decided to retain.
The other components of the power electronics and test-equipment business were
part of the Measurement and Control segment.

Measurement and Control
-----------------------
      Sales in the Measurement and Control segment decreased $127.0 million to
$1.021 billion in 2000. Sales decreased $101.7 million due to divestitures, net
of acquisitions. The unfavorable effects of currency translation resulted in a
decrease in revenues of $37.1 million in 2000. Revenues increased $2.9 million
due to the adoption of SAB No. 101. Excluding the effect of divestitures,
acquisitions, currency translation, and the adoption of SAB No. 101, revenues
increased $8.9 million, or 1%. Revenues from the sale of process instruments
increased $8.1 million, primarily due to strong demand from the natural gas
industry, which benefited from higher gas prices. In addition, sales of
environmental-monitoring equipment increased $7.2 million. Revenues from the
sale of spectroscopy instruments increased $4.6 million due to higher demand.
These increases were offset in part by lower sales of

<
                                       61

>


Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2000 Compared With 1999 (continued)
weighing and inspection equipment resulting from reduced demand from the global
packaged food industry. This industry was in a period of consolidation and the
Company believes that a decrease in customers' capital spending resulted from
uncertainty in the marketplace.
      Segment income margin increased to 18.8% in 2000 from 6.7% in 1999,
primarily due to gains on the sale of businesses. Segment income margin,
excluding restructuring and unusual items, increased to 10.0% in 2000 from 9.3%
in 1999. Higher profitability from increased sales of process instruments and
environmental-monitoring equipment was offset in part by lower margins from
spectroscopy instruments due to price competition at certain of the segment's
elemental analysis businesses. Restructuring and unusual income, net, in 2000
totaled $90.2 million and included gains on the sale of businesses, net, of
$126.3 million, and the related operating loss of $1.7 million of one of the
divested businesses in the third quarter of 2000 prior to its sale; $20.6
million of asset writedowns to reduce the carrying value of businesses held for
sale to estimated disposal value and for fixed assets unique to certain
discontinued products; charges to cost of revenues of $8.0 million, primarily
for discontinued product lines; $6.4 million of cash costs for severance and
facility costs; and a gain of $0.6 million from the termination of a lease. The
1999 restructuring and unusual costs totaled $30.1 million, including $24.8
million of restructuring charges, primarily to reduce the carrying value of the
power electronics and test-equipment business to estimated disposal value; $3.5
million of charges for the sale of inventories revalued at the date of
acquisition; and $1.9 million of inventory provisions (Note 15).

Other Expense, Net
------------------
      The Company reported other expense, net, of $81.2 million and $57.3
million in 2000 and 1999, respectively (Note 4). Interest income increased to
$40.2 million in 2000 from $40.8 million in 1999 due to investment of cash
proceeds from the divestiture of noncore businesses, offset in part by lower
cash balances from the purchase of the minority interests in certain formerly
public subsidiaries. Interest expense decreased to $83.1 million in 2000 from
$91.9 million in 1999 as a result of the maturity and repurchase of Company and
subsidiary debentures in 1999 and 2000.
      The Company incurred a loss of $47.3 million in 2000 from its equity in
the results of unconsolidated subsidiaries, primarily $47.4 million at FLIR,
including a writedown of the carrying value of the investment in FLIR to market
value. In 1999, the Company's equity in the results of unconsolidated subsidiary
totaled a loss of $7.3 million, including $11.1 million of unusual charges
related to FLIR (Notes 2 and 15). During 2000, gain on investments, net, was
$6.8 million, compared with $3.7 million in 1999. The 1999 gain on investments,
net, includes $3.6 million of charges for impairment that was deemed other than
temporary. In 2000, other expense, net, also includes $2.3 million of net
currency gains, primarily resulting from hedging activities at Spectra-Physics,
which elected early adoption of SFAS No. 133. In 1999, the Company had $2.3
million of losses from Spectra-Physics' hedging activities (Note 15).

Provision for Income Taxes
--------------------------
      The Company's effective tax rate was 61% and 52% in 2000 and 1999,
respectively. The effective tax rate in 2000 includes the effect of the sale of
Spectra Precision, which had a lower tax basis than book basis, resulting in a
significant tax gain on the sale. Excluding unusual items, the effective tax
rate was 39% and 40% in 2000 and 1999, respectively. The effective tax rate in
each period exceeds the statutory federal income tax rate primarily due to state
income taxes and nondeductible expenses, including amortization of goodwill.

Minority Interest Expense
-------------------------
      The Company recorded minority interest expense of $10.6 million and $23.0
million in 2000 and 1999, respectively. Minority interest expense decreased due
to the purchase of the minority interests in a number of formerly public
subsidiaries.

<
                                       62

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


2000 Compared With 1999 (continued)

Income from Continuing Operations
---------------------------------
      Income from continuing operations before extraordinary item and cumulative
effect of change in accounting principle was $62.0 million in 2000, compared
with $37.3 million in 1999. Results were affected by restructuring costs and
unusual items, net, in both periods as well as the significant tax provision in
2000 on a gain on the sale of a business as discussed above. Excluding these
items, income from continuing operations before extraordinary item and
cumulative effect of change in accounting principle was $104.4 million in 2000
and $79.8 million in 1999.

Cumulative Effect of Change in Accounting Principle
---------------------------------------------------
      In accordance with the requirements of SAB No. 101, the Company adopted
the pronouncement as of January 2, 2000, and recorded a charge in the first
quarter of 2000 representing the cumulative effect of the change in accounting
principle of $12.9 million, net of an income tax benefit of $8.5 million and
minority interest of $0.5 million (Note 16).

Discontinued Operations
      The Company recorded a net of tax provision of $100 million in 2000 as a
revision to the estimate of $50 million recorded in 1999 for loss on disposal of
discontinued operations. The increase in the loss resulted from lower after-tax
proceeds from the sale of noncore businesses than had been anticipated at the
time the businesses were discontinued. The Company believes that deterioration
in the financial markets in the latter part of 2000, including tighter financing
terms and lower equity values, adversely affected the selling prices of the
discontinued businesses.
      In February 2001, the Company entered into a definitive agreement to sell
its power generation business and subsequently sold the chief components of this
business in June and July 2001. The power generation business had income of
$14.2 million in 2000, net of taxes and minority interest. The Company's
discontinued operations had an aggregate loss of $163.3 million in 1999, net of
taxes and minority interest, primarily as a result of asset impairment charges.

Liquidity and Capital Resources
--------------------------------------------------------------------------------

      Consolidated working capital was $823.2 million at December 29, 2001,
compared with $1.74 billion at December 30, 2000. Included in working capital
were cash, cash equivalents, and short-term available-for-sale investments of
$1.04 billion at December 29, 2001, compared with $1.03 billion at December 30,
2000. In addition, the Company had $9.4 million of long-term available-for-sale
investments at December 29, 2001, compared with $17.1 million at December 30,
2000. Half of the decrease in working capital resulted from the Company's
decision to redeem certain convertible debentures prior to their 2003 maturity
(Note 19). The balance of the decrease resulted primarily from repurchases of
the Company's debt and equity securities in 2001.
      Cash provided by operating activities was $188.4 million during 2001,
including $184.4 million from continuing operations. Accounts receivable used
$19.0 million of cash, of which $12.6 million occurred at the Company's Thermo
Finnigan business due to strong fourth quarter revenue growth in 2001 over the
fourth quarter of 2000. Accounts payable decreased by $19.1 million primarily
due to lower volume of purchasing activities resulting from slowdowns in several
businesses. Other current liabilities increased by $50.5 million, including an
increase of $39.7 million of restructuring reserves and an increase of $10.2
million of accrued interest, due to the timing of payments. In connection with
certain restructuring actions undertaken by the Company's continuing operations,
the Company had accrued $60.7 million for restructuring and unusual costs at
December 29, 2001. The Company expects to pay $39.1 million of this amount for
severance, employee retention, and other costs primarily through 2002. The
remaining balance of $21.6 million will be paid through the expiration of lease
obligations in 2012 (Note 15). In addition, at December 29, 2001, the Company
had accrued $7.1 million for acquisition expenses. This balance principally
represents abandoned-facility payments that will be paid over the remaining
terms of the leases through 2014 (Note 2).

<
                                       63

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


Liquidity and Capital Resources (continued)
--------------------------------------------------------------------------------

      During 2001, the primary investing activities of the Company's continuing
operations, excluding available-for-sale investment activities, included the
purchase of property, plant, and equipment, the purchase of shares of a
majority-owned subsidiary, the sale of businesses and other investments, and
acquisitions. The Company's continuing operations expended $73.2 million, net of
dispositions, for purchases of property, plant, and equipment, $69.5 million for
the purchase of shares of its majority-owned Spectra-Physics subsidiary, and
$14.1 million, net of cash acquired, for acquisitions. In addition, in 2001, the
Company's continuing operations sold businesses for aggregate proceeds, net of
cash divested, of $46.8 million and recorded proceeds of $43.3 million from the
sale of other investments, principally shares of FLIR. During 2001, investing
activities of the Company's discontinued operations provided $447.7 million of
cash, primarily representing proceeds, net of cash divested, of $347.8 million
from the sale of businesses and proceeds of $75.5 million from the sale of
Thoratec common stock.
      The Company's financing activities used $696.3 million of cash during
2001, including $503.0 million for continuing operations. During 2001, the
Company's continuing operations expended $43.1 million for the repayment of
long-term obligations and received net proceeds of $69.9 million from the
exercise of employee stock options. During 2001, the Company expended $511.4
million to repurchase its securities. In November 2001, the Company's Board of
Directors authorized the repurchase of an additional $100 million tranche of its
own securities through November 6, 2002. Such purchases may be made in the open
market, or in negotiated transactions. As of December 29, 2001, the Company had
$96 million remaining under Board of Directors authorizations to repurchase its
own securities. In March 2002, the Company's Board of Directors authorized the
repurchase of an additional $100 million tranche of its own securities through
March 6, 2003. During 2001, the financing activities of the Company's
discontinued operations used $193.3 million of cash, including cash at the
Company's Kadant subsidiary, which was spun off in August 2001 (Note 17), and
the repayment of debt.
      The table below summarizes the Company's contractual obligations and other
commercial commitments as of December 29, 2001, by period due or expiration of
commitment.

                                                Payments Due by Period or Expiration of Commitment
                                      ----------------------------------------------------------------------
                                       Less than
                                          1 year      1-3 Years     4-5 Years   After 5 Years          Total
                                      ----------------------------------------------------------------------

Contractual Obligations and Other
 Commercial Commitments:
   Long-term obligations              $  470,429     $  516,678    $      346      $  210,478     $1,197,931
   Operating leases                       36,265         60,873        35,906          59,044        192,088
                                      ----------     ----------    ----------      ----------     ----------

     Total contractual obligations       506,694        577,551        36,252         269,522      1,390,019
                                      ----------     ----------    ----------      ----------     ----------

Other Commitments:
   Standby letters of credit              40,099          4,174            98               -         44,371
   Guarantees                                  -        207,838             -               -        207,838
                                      ----------     ----------    ----------      ----------     ----------

     Total other commitments              40,099        212,012            98               -        252,209
                                      ----------     ----------    ----------      ----------     ----------

                                      $  546,793     $  789,563    $   36,350      $  269,522     $1,642,228
                                      ==========     ==========    ==========      ==========     ==========

      The Company does not use special purpose entities or other
off-balance-sheet financing techniques except for operating leases and other
commitments disclosed in the table above.

<
                                       64

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations


Liquidity and Capital Resources (continued)
--------------------------------------------------------------------------------

      The Company has no material commitments for purchases of property, plant,
and equipment and expects that for 2002, such expenditures will approximate $60
- 70 million.
      The Company believes that its existing resources are sufficient to meet
the working capital requirements of its existing businesses for the foreseeable
future, including at least the next 24 months.

Market Risk
--------------------------------------------------------------------------------

      The Company is exposed to market risk from changes in interest rates,
currency exchange rates, and equity prices, which could affect its future
results of operations and financial condition. The Company manages its exposure
to these risks through its regular operating and financing activities.
Additionally, the Company uses short-term forward contracts to manage certain
exposures to currencies. The Company enters into forward currency exchange
contracts to hedge firm purchase and sale commitments denominated in currencies
other than its subsidiaries' local currencies. The Company does not engage in
extensive currency hedging activities; however, the purpose of the Company's
currency hedging activities is to protect the Company's local currency cash
flows related to these commitments from fluctuations in currency exchange rates.
The Company's forward currency exchange contracts principally hedge transactions
denominated in U.S. dollars, Euros, British pounds sterling, Japanese yen,
French francs, Swiss francs, German marks, Swedish krona, and Netherlands
guilders. Income and losses arising from forward contracts are recognized as
offsets to income and losses resulting from the transactions being hedged. The
Company does not enter into speculative currency agreements.

Interest Rates
      Certain of the Company's short- and long-term available-for-sale
investments and long-term obligations are sensitive to changes in interest
rates. Interest rate changes would result in a change in the fair value of these
financial instruments due to the difference between the market interest rate and
the rate at the date of purchase or issuance of the financial instrument. A 10%
decrease in year-end 2001 and 2000 market interest rates would result in a
negative impact to the Company of $9 million and $16 million, respectively, on
the net fair value of its interest-sensitive financial instruments.

Currency Exchange Rates
      The Company generally views its investment in international subsidiaries
with a functional currency other than the Company's reporting currency as
long-term. The Company's investment in international subsidiaries is sensitive
to fluctuations in currency exchange rates. The functional currencies of the
Company's international subsidiaries are principally denominated in British
pounds sterling, Euros, Netherlands guilders, Swedish krona, French francs, and
German marks. The effect of a change in currency exchange rates on the Company's
net investment in international subsidiaries is reflected in the "Accumulated
other comprehensive items" component of shareholders' investment. A 10%
depreciation in year-end 2001 and 2000 functional currencies, relative to the
U.S. dollar, would result in a reduction of shareholders' investment of $72
million and $62 million, respectively.
      The fair value of forward currency exchange contracts is sensitive to
changes in currency exchange rates. The fair value of forward currency exchange
contracts is the estimated amount that the Company would pay or receive upon
termination of the contract, taking into account the change in currency exchange
rates. A 10% depreciation in year-end 2001 and 2000 currency exchange rates
related to the Company's contracts would result in an increase in the unrealized
loss on forward currency exchange contracts of $5.1 million and $7.0 million,
respectively. Since the Company uses forward currency exchange contracts as
hedges of firm purchase and sale commitments, the unrealized gain or loss on
forward currency exchange contracts resulting from changes in currency exchange
rates would be offset by a corresponding change in the fair value of the hedged
item.

<
                                       65

>

Thermo Electron Corporation                            2001 Financial Statements

                     Management's Discussion and Analysis of
                  Financial Condition and Results of Operations



Market Risk (continued)
--------------------------------------------------------------------------------

      Certain of the Company's cash and cash equivalents are denominated in
currencies other than the functional currency of the depositor and are sensitive
to changes in currency exchange rates. A 10% depreciation in the related
year-end 2001 and 2000 currency exchange rates would result in a negative impact
of $0.6 million and $0.3 million, respectively, on the Company's net income.

Equity Prices
      The Company's available-for-sale investment portfolio includes equity
securities that are sensitive to fluctuations in price. In addition, the
Company's convertible obligations are sensitive to fluctuations in the price of
Company common stock into which the obligations are convertible. Changes in
equity prices would result in changes in the fair value of the Company's
available-for-sale investments and convertible obligations due to the difference
between the current market price and the market price at the date of purchase or
issuance of the financial instrument. A 10% increase in the year-end 2001 and
2000 market equity prices would result in a negative impact to the Company of $7
million and $26 million, respectively, on the net fair value of its
price-sensitive equity financial instruments, principally its convertible
obligations.




<
                                       66

>

Thermo Electron Corporation                            2001 Financial Statements

                           Forward-looking Statements

      In connection with the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, Thermo Electron wishes to caution readers that
the following important factors, among others, in some cases have affected, and
in the future could affect, Thermo Electron's actual results and could cause its
actual results in 2002 and beyond to differ materially from those expressed in
any forward-looking statements made by, or on behalf of, Thermo Electron.

      Thermo Electron faces a number of challenges in integrating its instrument
businesses. Thermo Electron has historically operated its instrument businesses
largely as autonomous, unaffiliated operations. As part of its reorganization,
Thermo Electron has begun to manage these operations in a more coordinated
manner. The following factors may make it difficult to successfully integrate
and consolidate Thermo Electron's instrument operations:

      - Thermo Electron's success in integrating these businesses will depend on
its ability to coordinate geographically separate organizations and integrate
personnel with different business backgrounds and corporate cultures.

      - Thermo Electron's ability to combine these businesses will require
coordination of previously autonomous administrative, sales and marketing,
distribution, and accounting and finance functions, and expansion and
integration of information and management systems.

      - The integration process could become disruptive to Thermo Electron's
instrument businesses.

      Moreover, Thermo Electron may not be able to realize all of the cost
savings and other benefits that it expects to result from the integration
process, even if the process is completed.

      It may be difficult for Thermo Electron to expand because some of the
markets for its products are not growing. Some of the markets in which Thermo
Electron competes have been flat or declining over the past several years. To
address this issue, Thermo Electron is pursuing a number of strategies to
improve its internal growth, including:

      -  finding new markets for its products, including, most significantly, in
the areas of proteomics and photonics;

      -  developing new applications for its technologies;

      -  combining sales and marketing operations in appropriate markets to
         compete more effectively;

      -  actively funding research and development; and

      -  strengthening its presence in selected geographic markets.

      Thermo Electron may not be able to successfully implement these
strategies, and these strategies may not result in growth of Thermo Electron's
business.

      As a result of the spin-off of Kadant, Thermo Electron remains as the
guarantor of indebtedness issued by Kadant even though Thermo Electron no longer
controls Kadant's business or operations. Thermo Electron has guaranteed the
payment of principal and interest on $153 million principal amount of debentures
issued by Kadant. These debentures mature in July 2004. Thermo Electron remains
liable as a guarantor for this obligation following the spinoff, although it no
longer controls the business or operations of Kadant.

<
                                       67

>

Thermo Electron Corporation                            2001 Financial Statements

                           Forward-looking Statements


      Thermo Electron has significant international operations, which entail the
risk that exchange rate fluctuations may negatively affect demand for its
products and its profitability. International revenues account for a substantial
portion of Thermo Electron's revenues, and Thermo Electron intends to continue
expanding its presence in international markets. In 2001, Thermo Electron's
international revenues from continuing operations, including export revenues
from the United States, accounted for approximately 50% of its total revenues.
International revenues are subject to the risk that changes in exchange rates
may adversely affect product demand and the profitability in U.S. dollars of
products and services provided by Thermo Electron in international markets,
where payment for Thermo Electron's products and services is made in the local
currency. For example, in fiscal 2001, the unfavorable effects of currency
translation decreased revenues of Thermo Electron's continuing operations by
$46.5 million.

      Thermo Electron has acquired several companies and businesses; as a result
it has recorded significant goodwill on its balance sheet, which it must
continually evaluate for potential impairment. Thermo Electron has acquired
significant intangible assets, including approximately $1.3 billion of goodwill
that it has recorded on its balance sheet as of December 29, 2001. Thermo
Electron assesses the future useful life of the goodwill it has on its books
whenever events or changes in circumstances indicate that the current useful
life has diminished. These events or circumstances generally include operating
losses or a significant decline in earnings associated with the acquired
business or asset. Thermo Electron's ability to realize the value of the
goodwill that it has recorded as a result of its acquisition of the minority
interests in its formerly publicly-traded subsidiaries will depend on the future
cash flows of these businesses. These cash flows in turn depend in part on how
well Thermo Electron has integrated these businesses.

      Thermo Electron must develop new products, adapt to rapid and significant
technological change, and respond to introductions of new products in order to
remain competitive. Thermo Electron's growth strategy includes significant
investment in and expenditures for product development, including most
significantly in the areas of proteomics and photonics. Thermo Electron intends
to increase spending in the area of research and development. Thermo Electron
sells its products in several industries that are characterized by rapid and
significant technological changes, frequent new product and service
introductions, and enhancements and evolving industry standards. Without the
timely introduction of new products, services, and enhancements, Thermo
Electron's products and services will likely become technologically obsolete
over time, in which case its revenue and operating results would suffer.
      Thermo Electron's customers use many of its products to develop, test, and
manufacture their own products. As a result, Thermo Electron must anticipate
industry trends and develop products in advance of the commercialization of its
customers' products. If it fails to adequately predict its customers' needs and
future activities, Thermo Electron may invest heavily in research and
development of products and services that do not lead to significant revenue.
      Many of its products and products under development are technologically
innovative and require significant planning, design, development, and testing at
the technological, product, and manufacturing-process levels. These activities
require Thermo Electron to make significant investments.
      Products in Thermo Electron's markets undergo rapid and significant
technological change because of quickly changing industry standards and the
introduction of new products and technologies that make existing products and
technologies uncompetitive or obsolete. Thermo Electron's competitors may adapt
more quickly to new technologies and changes in customers' requirements than
Thermo Electron can. The products Thermo Electron is currently developing, or
those it will develop in the future, may not be technologically feasible or
accepted by the marketplace, and its products or technologies could become
uncompetitive or obsolete.

      Thermo Electron sells its products and services to a number of companies
that operate in cyclical industries, which could adversely affect its results of
operations when those industries experience a downturn. The growth and
profitability of Thermo Electron's Optical Technologies segment depends in part
on sales to the semiconductor and telecommunications industries, which are
subject to cyclical downturns. These industries are experiencing slowing trends.
A prolonged slowdown in these industries would adversely affect sales by the
Optical Technologies segment, which in turn could adversely affect Thermo
Electron's revenues and results of operations.

<
                                       68

>

Thermo Electron Corporation                            2001 Financial Statements

                           Forward-looking Statements


      Changes in governmental regulations may reduce demand for Thermo
Electron's products or increase its expenses. Thermo Electron competes in many
markets in which it and its customers must comply with federal, state, local,
and international regulations, such as environmental, health and safety, and
food and drug regulations. Thermo Electron develops, configures, and markets its
products to meet customer needs created by those regulations. Any significant
change in regulations could reduce demand for Thermo Electron's products. For
example, many of Thermo Electron's instruments are marketed to the
pharmaceutical industry for use in discovering and developing drugs. Changes in
the U.S. Food and Drug Administration's regulation of the drug discovery and
development process could have an adverse effect on the demand for these
products.

      Demand for some of Thermo Electron's products depends on capital spending
policies of its customers and on government funding policies. Thermo Electron's
customers include manufacturers of semiconductors and products incorporating
semiconductors, pharmaceutical and chemical companies, laboratories,
universities, healthcare providers, government agencies, and public and private
research institutions. Many factors, including public policy spending
priorities, available resources, and economic cycles, have a significant effect
on the capital spending policies of these entities. These policies in turn can
have a significant effect on the demand for our products. For example, sales of
weighing and inspection equipment have decreased as a result of lower demand
from the global packaged food industry, which is undergoing a period of
consolidation.



<
                                       69

>


Thermo Electron Corporation                                                      2001 Financial Statements

                                      Selected Financial Information

(In millions except per share amounts)              2001 (a)    2000 (b)   1999 (c)    1998 (d)       1997
----------------------------------------------------------------------------------------------------------

Statement of Operations Data
Revenues                                            $2,188.2    $2,280.5   $2,294.6    $1,880.9   $1,811.5
Gross Profit                                           958.6     1,021.8    1,048.8       872.8      859.2
Operating Income                                        34.2       266.0      182.1       191.3      235.5
Income from Continuing Operations Before
 Extraordinary Item and Cumulative Effect of
 Change in Accounting Principle                         49.6        62.0       37.3        93.8      142.4
Income (Loss) Before Extraordinary Item and
 Cumulative Effect of Change in Accounting
 Principle                                              (0.8)      (23.7)    (176.0)      181.5      239.3
Net Income (Loss)                                       (0.8)      (36.1)    (174.6)      181.9      239.3
Earnings per Share from Continuing Operations
 Before Extraordinary Item and Cumulative
 Effect of Change in Accounting Principle:
   Basic                                                 .27         .37        .24         .58        .93
   Diluted                                               .27         .36        .22         .55        .87
Earnings (Loss) per Share:
   Basic                                                   -        (.22)     (1.10)       1.12       1.57
   Diluted                                                 -        (.22)     (1.12)       1.08       1.45

Balance Sheet Data
Working Capital                                     $  823.2    $1,737.0   $1,291.6    $2,130.1   $1,983.8
Total Assets                                         3,825.1     4,863.0    5,071.8     5,217.9    4,731.6
Long-term Obligations                                  727.5     1,528.5    1,566.0     1,786.4    1,463.9
Minority Interest                                        6.9        24.7      348.4       378.9      442.1
Common Stock Subject to Redemption                         -           -        7.7        40.5       40.5
Shareholders' Investment                             1,908.1     2,534.0    2,013.5     2,256.1    2,004.0

(a) Reflects a $161.6 million pretax charge for restructuring and related costs, $35.1 million of gains
    from the sale of shares of FLIR Systems, Inc., a net of tax charge of $50.4 million related to the
    Company's discontinued operations, a $1.0 million charge reflecting the cumulative effect of change
    in accounting principle for the adoption of SFAS No. 133, and the reclassification of $468.1 million
    of subordinated convertible debentures from long-term obligations to current liabilities as a result
    of the Company's decision to redeem them in March 2002. Also reflects the spinoff of the Company's
    Kadant and Viasys Healthcare subsidiaries and the repurchase of $511.4 million of the Company's debt
    and equity securities.
(b) Reflects $3.4 million of pretax restructuring and related income, net, a net of tax charge of $100
    million related to the Company's discontinued operations, the issuance of Company common stock valued
    at $448.7 million to acquire the minority interest of certain subsidiaries, and a $12.9 million
    charge reflecting the cumulative effect of change in accounting principle for the adoption of
    SAB No. 101.
(c) Reflects a $65.2 million pretax charge for restructuring and related costs, a net of tax charge of
    $50 million related to the Company's discontinued operations, and the February 1999 acquisition of
    Spectra-Physics AB.
(d) Reflects a $32.5 million pretax charge for restructuring and related costs, the issuance of $150.0
    million principal amount of the Company's notes, and the Company's public offering of common stock for
    net proceeds of $290.1 million.

<

70

>

Thermo Electron Corporation                            2001 Financial Statements

Common Stock Market Information
      The Company's common stock is traded on the New York Stock Exchange under
the symbol TMO. The following table sets forth the high and low sale prices of
the Company's common stock for 2001 and 2000, as reported in the consolidated
transaction reporting system.

                                                                      2001                  2000
                                                               -----------------     -----------------
Quarter                                                          High        Low       High        Low
------------------------------------------------------------------------------------------------------

First                                                          $26.32     $17.12     $26.25     $14.25
Second                                                          28.57      20.97      21.77      17.94
Third                                                           22.02      17.38      26.94      20.06
Fourth                                                          23.86      15.98      31.10      24.25

      In August and November 2001, the Company spun off to shareholders its
Kadant Inc. and Viasys Healthcare Inc. subsidiaries.  Prices in the above table
for periods prior to these spinoffs have not been adjusted to reflect the
spinoffs.  As of January 25, 2002, the Company had 13,248 holders of record of
its common stock.  This does not include holdings in street or nominee names.

Shareholder Services
      Shareholders of Thermo Electron Corporation who desire information about
the Company are invited to contact the Investor Relations Department, Thermo
Electron Corporation, 81 Wyman Street, P.O. Box 9046, Waltham, Massachusetts
02454-9046, (781) 622-1111, or by e-mail at: investorrelations@thermo.com. We
maintain a mailing list to enable shareholders whose stock is held in street
name, and other interested individuals, to receive Company information as
quickly as possible. All material is also available from the Company's Internet
site at www.thermo.com, under "Investors."

Stock Transfer Agent
      American Stock Transfer & Trust Company is the stock transfer agent and
maintains shareholder activity records. The agent will respond to questions on
issuance of stock certificates, change of ownership, lost stock certificates,
and change of address. For these and similar matters, please direct inquiries
to: American Stock Transfer & Trust Company, 59 Maiden Lane, Plaza Level, New
York, New York 10038, (877) 777-0800. You may also send an e-mail to
info@amstock.com, or visit the transfer agent's Internet site at
www.amstock.com.

Dividend Policy
      The Company has never paid cash dividends and does not expect to pay cash
dividends in the foreseeable future because its policy has been to use earnings
to finance expansion and growth. Payment of dividends will rest within the
discretion of the Company's Board of Directors and will depend upon, among other
factors, the Company's earnings, capital requirements, and financial condition.

Form 10-K Report
      A copy of the Annual Report on Form 10-K for the fiscal year ended
December 29, 2001, as filed with the Securities and Exchange Commission, may be
obtained at no charge by contacting the Investor Relations Department, Thermo
Electron Corporation, 81 Wyman Street, P.O. Box 9046, Waltham, Massachusetts
02454-9046, (781) 622-1111, or by e-mail at: investorrelations@thermo.com. The
Form 10-K is also available from the Company's Internet site at www.thermo.com,
under "Investors."


Exhibit 10.55

November 27, 2001

By Facsimile: (203) 699-3216
SPX Corporation
90 Fieldstone Court
Cheshire, CT 06410-1212
Attn: Paul F. Hally, Group General Counsel

Kendro Laboratory Products, L.P.
C/o Paul F. Hally, Group General Counsel SPX Corporation

By Facsimile: (617) 566-0716
Mr. Marc N. Casper
144 Clark Road
Brookline, MA 02445

Re: Employment of Marc Casper as President of Thermo Electron's Life Sciences Sector

Gentlemen:

As you know, Thermo Electron Corporation ("Thermo") has been discussing with Marc Casper ("Mr. Casper") the possibility of hiring him as the President of its Life Sciences Sector. Thermo and Mr. Casper acknowledge SPX's view that Mr. Casper's existing obligations contained in his Employment Agreement with Kendro Laboratory Products, L.P. ("Kendro") dated May 15, 2000, and his Separation Agreement with SPX Corporation ("SPX"), dated July 23, 2001 (hereafter collectively referred to as the "Agreements"), would prohibit Mr. Casper's employment by Thermo. Thermo has been provided copies of, and is aware of the contents of, the Agreements. Thermo and Mr. Casper seek to: (1) modify certain obligations of Mr. Casper under the Agreements, subject to compliance by Mr. Casper and Thermo with the terms of this Letter Agreement; and (2) establish certain limitations relating to Mr. Casper's employment by Thermo in order to protect SPX and Kendro (hereafter collectively referred to as "SPX") from any prejudice as a result of the employment of Mr. Casper as President of Thermo's Life Sciences Sector.


In consideration of the mutual agreements specified herein, the sufficiency of which is hereby acknowledged, Thermo, Mr. Casper, and SPX agree as follows:

1. SPX acknowledges and agrees that the employment of Mr. Casper by Thermo will not be deemed to be in violation of the Agreements, so long as Mr. Casper complies with the terms and conditions set forth in the Agreements as modified by the terms of this Letter Agreement, and Thermo complies with the terms and conditions set forth in this Letter Agreement. In the event that Mr. Casper and/or Thermo fail to comply with the terms of this Letter Agreement, SPX will, at its election, be free to enforce the terms of this Letter Agreement and/or the Agreements as originally written.

2. The non-competition and non-solicitation obligations contained in the Agreements will be modified to extend the duration thereof until December 31, 2002, whether or not Mr. Casper accepts or continues employment by Thermo.

3. (a) For the duration of Mr. Casper's non-competition obligations under the Agreements (as modified in paragraph 2 above), Mr. Casper and Thermo agree that Mr. Casper will not be provided any material nonpublic information, participate in any discussions or meetings, or provide any advice or management, relating to any aspect of the operations of Thermo Forma Inc., Thermo IEC Inc. and/or any other aspect of Thermo's current or future business operations which are competitive with Kendro's current business (the "Competitive Businesses"), including without limitation any aspects of the Competitive Businesses that relate to research, design and development, production, and marketing of products and related services, any strategic management of the Competitive

<

2

>

Businesses including consideration of changes to products, product line expansions or enhancements, acquisitions or dispositions of businesses competitive with the Competitive Businesses, and the establishment or modification of any relationship between the Competitive Businesses and third parties, and any financial or administrative aspects of the Competitive Businesses, such as review of financial performance of the Competitive Businesses, or employee compensation, real estate or tax matters affecting the Competitive Businesses, PROVIDED HOWEVER, Mr. Casper's receipt, or communication to shareholders, analysts, other members of the financial community, press or media, of information regarding the consolidated financial performance of the Life Sciences Sector as a whole will not be deemed a breach of this paragraph 3 of this Letter Agreement as long as Mr. Casper's communications clearly include the disclaimers described in paragraph 3(b)(2) below.

(b) During the period of the non-compete, SPX agrees that Mr. Casper can hold the title of President of the Life Sciences Sector of Thermo, provided that Thermo and Mr. Casper agree and acknowledge that: (1) Mr. Casper will not serve as Thermo's spokesperson for the Competitive Businesses of the Life Sciences Sector, and another representative of Thermo will serve as Thermo's spokesperson for the Competitive Businesses; (2) all public communications and announcements by Mr. Casper pertaining to his employment by Thermo or to his commentary on the consolidated financial performance of the Life Sciences Sector as a whole will clearly indicate that Mr. Casper is restricted by the terms of a non-compete agreement with his former employer from managing or discussing the Competitive Businesses; and (3) the Competitive Businesses will report to the Division President, who reports to the President of Thermo and who does not report to Mr. Casper.

<

3

>

(c) During the period of the non-compete, Mr. Casper and Thermo agree and acknowledge that it is their obligation to take affirmative steps to ensure that the public does not perceive that Mr. Casper is managing the Competitive Businesses, and that such affirmative actions are material to SPX's agreement to Mr. Casper's employment by Thermo as President of the Life Sciences Sector and to Thermo's and Mr. Casper's compliance with this Agreement. During the period of the non-compete, Thermo and Mr. Casper agree to take affirmative steps to dispel any public perception that Mr. Casper is managing the Competitive Businesses. For example, at any presentation to Wall Street analysts, Mr. Casper will refrain from providing any information regarding the Competitive Businesses, will affirmatively indicate that the Competitive Businesses do not report to him and will defer any questions about the Competitive Businesses to another Thermo representative. During the period of the non-compete, Thermo and Mr. Casper will take similar affirmative steps in other public settings, such as trade shows, sales conventions and/or customer presentations.

(d) Nothing is this paragraph 3 is intended to preclude Mr. Casper from receiving any information or engaging in any activity with respect to any aspect of the Life Sciences Sector of Thermo which is not part of the Competitive Businesses.

4. Except as modified by this letter, Mr. Casper will continue to be bound by the terms of the Agreements in accordance with their terms, including without limitation, and without modification, Mr. Casper's confidentiality and trade secret obligations contained in the Agreements. Thermo acknowledges and agrees to use reasonable best efforts to cause Mr. Casper to comply with the confidentiality, nonsolicitation and trade secret obligations contained in the Agreements during Mr. Casper's employment with Thermo.

<

4

>

5. In order to permit SPX to confirm that Mr. Casper and Thermo continue to comply with the terms of this Letter Agreement, Mr. Casper and Thermo will cooperate with SPX by providing access to any five officers or employees of Thermo designated by name, title or function by SPX, and to records of Thermo relating to the Competitive Businesses which are reasonably required to determine Mr. Casper's and Thermo's compliance with this Letter Agreement, to a third party auditor identified by SPX, upon request through December 31, 2004, provided however, if after completing such an audit, SPX has reasonable cause to believe that Mr. Casper and Thermo have not complied with the terms of this Letter Agreement, SPX's auditors will be provided access to additional Thermo officers, employees and records which are reasonably required to determine Mr. Casper's and Thermo's compliance with this Letter Agreement. SPX may not request an audit more often than once per any 6 month period through December 31, 2004, unless SPX has reasonable cause to believe that Mr. Casper and Thermo have not complied with the terms of this Letter Agreement, in which case SPX may undertake one additional audit in any 6 month period. If SPX elects to have an auditor confirm compliance by Mr. Casper and Thermo with their obligations under this letter, SPX will use an office of Arthur Anderson (or of the then current auditing firm for SPX ) other than the office that usually audits SPX. Thermo will ensure that such accounting firm will have reasonable access to the persons and records referred to above for purposes of confirming any factual information reasonably required in order to confirm that Mr. Casper and Thermo have complied with the terms of this letter. The third party auditor must be instructed by SPX and agree in writing, a copy of which must be provided to Thermo at the time of the audit, not to disclose to SPX any confidential or proprietary information of Thermo, including any confidential or proprietary information relating to the Competitive Businesses.

<

5

>

6. At the time Mr. Casper's employment with Thermo commences, and as appropriate or reasonably requested by SPX from time to time thereafter, Thermo will advise all senior management of Thermo and all managers in Thermo's Competitive Businesses of the limitations imposed by paragraph 3 of this Letter Agreement on Mr. Casper and Thermo, as well as the penalties imposed for violations thereof by paragraph 7 of this Letter Agreement, in writing, as set forth in Exhibit A.

7. In order to ensure that SPX has adequate remedies available for any violation of this Letter Agreement, without limiting any of the other remedies available to SPX at law or in equity, in the event of a violation of this Letter Agreement by Mr. Casper or Thermo, SPX will be entitled to injunctive relief, including any temporary restraining order or emergency, preliminary or final injunction, and damages. In the event of litigation regarding a violation of this Letter Agreement, the prevailing party will be entitled to reimbursement of costs and reasonable attorneys' fees incurred from the losing party. If SPX is successful in any way in obtaining injunctive relief or damages, SPX will be a prevailing party for purposes of recovering costs and fees. The foregoing entitlement of the prevailing party to collect costs and reasonable attorneys' fees only applies to litigation between the parties regarding the enforcement or breach of this Letter Agreement, and not to litigation of any other claim or counterclaim that a party may assert in such litigation between the parties.

8. SPX agrees that, notwithstanding anything to the contrary in the Agreements, Mr. Casper will be permitted to acquire and hold securities of Thermo, including shares of stock and stock options, so long as Mr. Casper owns not more than 2% of the outstanding stock of any class of Thermo, provided however, Mr. Casper may not acquire or hold securities, including stock and stock options, of any enterprise Thermo establishes, acquires, or divests, in which sales in a

<

6

>

Competitive Business are 15% or more of the sales of the enterprise, for the duration of Mr. Casper's non-competition obligations under the Agreements (as modified in paragraph 2 above).

9. This Letter Agreement will be governed by the laws of the State of Connecticut, and all disputes arising under this Letter Agreement must be filed in a court of competent jurisdiction in the State of Connecticut. No dispute arising under this Letter Agreement will be subject to mandatory arbitration.

10. Mr. Casper and Thermo will be jointly and severally liable for any breach of this Letter Agreement arising from Mr. Casper's employment by Thermo.

11. Nothing in this Letter Agreement will be construed to limit the rights of discovery of SPX in any litigation with Mr. Casper or Thermo.

12. This Letter Agreement is binding upon Thermo and SPX, and their successors, and on Mr. Casper, and his heirs, executors and administrators. The obligations of Mr. Casper under this Letter Agreement are not assignable. The obligations of Thermo under this Letter Agreement are not assignable, except to an assignee of substantially all of the stock or assets of the entire Life Sciences Sector, including the Competitive Businesses, of Thermo.

13. This Letter Agreement may not be amended or modified in any manner except in a writing signed by the parties.

<

7

> If the foregoing is acceptable to you please sign four counterparts of this letter where indicated below and return one original to each of Thermo, SPX, Kendro and Mr. Casper. This letter will become effective once it has been signed and delivered by each of Thermo, SPX, Kendro and Mr. Casper to each of the other parties.

AGREED:

THERMO ELECTRON CORPORATION

By:  /s/ Seth H. Hoogasian
     ---------------------------------------------
     Name: Seth H. Hoogasian
     ---------------------------------------------
     Title: Vice President and General Counsel
     ---------------------------------------------
     Date: November 27, 2001
     ---------------------------------------------

SPX CORPORATION

By:  /s/ Lewis M. Kling
     ---------------------------------------------
     Name: Lewis M. Kling
     ---------------------------------------------
     Title: Vice President
     ---------------------------------------------
     Date: November 27, 2001
     ---------------------------------------------

KENDRO LABORATORY PRODUCTS, L.P.

By:  /s/ Dennis Pope
     ---------------------------------------------
     Name: Dennis Pope
     ---------------------------------------------
     Title: President
     ---------------------------------------------
     Date: December 11, 2001
     ---------------------------------------------


     /s/ Marc N. Casper
     ---------------------------------------------
     Marc N. Casper

     Date: 11/29/01
     ---------------------------------------------

<

8

>

                                                                       Exhibit A

                                                                Legal Department
                                                                      Memorandum

To:     Distribution

From:   Seth H. Hoogasian

Date:   11/27/01

Re:     Marc N. Casper


Please be advised that Thermo Electron and Marc N. Casper, the new President of our Life Sciences Sector, have certain obligations to Marc's former employer, Kendro Laboratory Products, L.P. ("Kendro") and its parent company, SPX Corporation, based on Marc's non-competition undertakings.

Specifically, until December 31, 2002, Marc may not receive any material non-public information, participate in any discussions or meetings, or provide any advice or management relating to any aspect of the operations of Thermo Forma Inc., Thermo IEC Inc., and/or any other aspect of Thermo Electron's current or future business operations which are competitive with Kendro's current business (the "Competitive Businesses").

Activities in which Marc may not participate include, without limitation, all aspects of Competitive Businesses that relate to research, design and development, production, and marketing of products and related services, and strategic management of Competitive Businesses, including consideration of changes to products, product line expansions or enhancements, acquisitions or dispositions of Competitive Businesses, and the establishment or modification of any relationship between Competitive Businesses and third parties, as well as any financial or administrative aspects of Competitive Businesses, such as review of financial performance of Competitive Businesses, employee compensation, real estate or tax matters affecting Competitive Businesses. He may receive, or communicate to shareholders, analysts, other members of the financial community, press or media, information regarding the consolidated financial performance of the Life Sciences Sector as a whole, as long as his communications clearly include disclaimers that he is restricted by the terms of a non-compete agreement with his former employer from managing or discussing the Competitive Businesses.

Until December 31, 2002, Marc may not serve as Thermo's spokesperson for the Competitive Businesses, and another representative of Thermo will serve as spokesperson for the Competitive Businesses. Thermo Forma Inc. and Thermo IEC Inc. will continue to report to Lewis Rosenblum, who will report to Marijn Dekkers until December 31, 2002. Thermo Electron and Marc have an obligation to take affirmative steps to ensure that the public does not perceive that Marc is managing the Competitive Businesses.

<

9

>

In the event that Marc or Thermo Electron violate the terms of the restrictions described above, Kendro and SPX Corporation will be entitled to injunctive relief (including any temporary restraining order or emergency, preliminary or final injunction), damages, and reimbursement of costs and reasonable attorneys' fees from Marc and Thermo Electron.

Please let me know if you have any questions regarding what is prohibited by this restriction.


Exhibit 10.12

THERMO ELECTRON CORPORATION

EMPLOYEES EQUITY INCENTIVE PLAN

As amended and restated effective as of February 7, 2002

1. Purpose

The purpose of this Employees Equity Incentive Plan (the "Plan") is to secure for Thermo Electron Corporation (the "Company") and its Stockholders the benefits arising from capital stock ownership by employees of, and consultants to, the Company and its subsidiaries or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries. The Plan is intended to accomplish these goals by enabling the Company to offer such persons equity-based interests, equity-based incentives or performance-based stock incentives in the Company, or any combination thereof ("Awards").

2. Administration

The Plan will be administered by the Board of Directors of the Company (the "Board"). The Board shall have full power to interpret and administer the Plan, to prescribe, amend and rescind rules and regulations relating to the Plan and Awards, and full authority to select the persons to whom Awards will be granted ("Participants"), determine the type and amount of Awards to be granted to Participants (including any combination of Awards), determine the terms and conditions of Awards granted under the Plan (including terms and conditions relating to events of merger, consolidation, dissolution and liquidation, change of control, vesting, forfeiture, restrictions, dividends and interest, if any, on deferred amounts), waive compliance by a participant with any obligation to be performed by him or her under an Award, waive any term or condition of an Award, cancel an existing Award in whole or in part with the consent of a Participant, grant replacement Awards, accelerate the vesting or lapse of any restrictions of any Award, correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award and adopt the form of instruments evidencing Awards under the Plan and change such forms from time to time. Any interpretation by the Board of the terms and provisions of the Plan or any Award thereunder and the administration thereof, and all action taken by the Board, shall be final, binding and conclusive on all parties and any person claiming under or through any party. No Director shall be liable for any action or determination made in good faith. The Board may, to the full extent permitted by law, delegate any or all of its responsibilities under the Plan to a committee (the "Committee") appointed by the Board and consisting of members of the Board. All references in the Plan to the "Board" shall mean the Board or a Committee of the Board to the extent that the Board's powers or authority under the Plan have been delegated to such Committee.


3. Effective Date

The Plan shall be effective as of the date first approved by the Board of Directors. Grants of Awards under the Plan made prior to such approval shall be effective when made (unless otherwise specified by the Board at the time of grant.

4. Shares Subject to the Plan

Subject to adjustment as provided in Section 10.6, the total number of shares of common stock of the Company, par value $1.00 per share ("Common Stock"), reserved and available for distribution under the Plan shall be 3,000,000 shares. Such shares may consist, in whole or in part, of authorized and unissued shares or treasury shares.

If any Award of shares of Common Stock requiring exercise by the Participant for delivery of such shares expires or terminates without having been exercised in full, is forfeited or is otherwise terminated without a payment being made to the Participant in the form of Common Stock, or if any shares of Common Stock subject to restrictions are repurchased by the Company pursuant to the terms of any Award or are otherwise reacquired by the Company to satisfy obligations arising by virtue of any Award, such shares shall be available for distribution in connection with future Awards under the Plan.

5. Eligibility

Employees of, and consultants to, the Company and its subsidiaries, or other persons who are expected to make significant contributions to the future growth and success of the Company and its subsidiaries shall be eligible to receive Awards under the Plan. Directors and executive officers of the Company shall not be eligible to receive Awards under the Plan. The Board, or other appropriate committee or person to the extent permitted pursuant to the last sentence of Section 2, shall from time to time select from among such eligible persons those who will receive Awards under the Plan.

6. Types of Awards

The Board may offer Awards under the Plan in any form of equity-based interest, equity-based incentive or performance-based stock incentive in Common Stock of the Company or any combination thereof. The type, terms and conditions and restrictions of an Award shall be determined by the Board at the time such Award is made to a Participant.

An Award shall be made at the time specified by the Board and shall be subject to such conditions or restrictions as may be imposed by the Board and shall conform to the general rules applicable under the Plan as well as any special rules then applicable under federal tax laws or regulations or the federal securities laws relating to the type of Award granted.

2

Without limiting the foregoing, Awards may take the following forms and shall be subject to the following rules and conditions:

6.1 Options

An option is an Award that entitles the holder on exercise thereof to purchase Common Stock at a specified exercise price. Options granted under the Plan shall be options that are not intended to meet the requirements of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code") applicable to incentive stock options ("non-statutory options").

6.1.1 Option Price. The price at which Common Stock may be purchased upon exercise of an option shall be determined by the Board, provided however, the exercise price shall not be less than 85% of the fair market value per share of the Common Stock as of the date of the grant.

6.1.2 Option Grants. The granting of an option shall take place at the time specified by the Board. Options shall be evidenced by option agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including but not limited to vesting and forfeiture provisions, acceleration, change of control, protection in the event of merger, consolidations, dissolutions and liquidations) as the Board shall deem advisable. Option agreements shall expressly state that the option grant is intended to qualify as a non-statutory option.

6.1.3 Option Period. An option will become exercisable at such time or times (which may be immediately or in such installments as the Board shall determine) and on such terms and conditions as the Board shall specify. The option agreements shall specify the terms and conditions applicable in the event of an option holder's termination of employment during the option's term.

Any exercise of an option must be in accordance with the instructions described in "The Guide for Employees of Thermo Electron Corporation Stock Option Plans," as may be amended from time to time (the "Guide").

6.1.4 Payment of Exercise Price. Stock purchased on exercise of an option shall be paid for in accordance with the instructions described in the Guide.

6.1.5 Buyout Provision. The Board may at any time offer to buy out for a payment in cash, shares of Common Stock, deferred stock or restricted stock, an option previously granted, based on such terms and conditions as the Board shall establish and communicate to the option holder at the time that such offer is made.

6.2 Restricted and Unrestricted Stock

An Award of restricted stock entitles the recipient thereof to acquire shares of Common Stock upon payment of the purchase price subject to restrictions specified in the instrument evidencing the Award.

<

3

>

6.2.1 Restricted Stock Awards. Awards of restricted stock shall be evidenced by restricted stock agreements. Such agreements shall conform to the requirements of the Plan, and may contain such other provisions (including restriction and forfeiture provisions, change of control, protection in the event of mergers, consolidations, dissolutions and liquidations) as the Board shall deem advisable.

6.2.2 Restrictions. Until the restrictions specified in a restricted stock agreement shall lapse, restricted stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of, and upon certain conditions specified in the restricted stock agreement, must be resold to the Company for the price, if any, specified in such agreement. The restrictions shall lapse at such time or times, and on such conditions, as the Board may specify. The Board may at any time accelerate the time at which the restrictions on all or any part of the shares shall lapse.

6.2.3 Rights as a Stockholder. A Participant who acquires shares of restricted stock will have all of the rights of a stockholder of the Company with respect to such shares except as otherwise limited pursuant to the Participant's restricted stock agreement. Unless the Board otherwise determines, certificates evidencing shares of restricted stock will remain in the possession of the Company until such shares are free of all restrictions under the Plan.

6.2.4 Purchase Price. The purchase price of shares of restricted stock shall be determined by the Board, in its sole discretion, but such price may not be less than the par value of such shares.

6.2.5 Other Awards Settled With Restricted Stock. The Board may provide that any or all the Common Stock delivered pursuant to an Award will be restricted stock.

6.2.6 Unrestricted Stock. The Board may, in its sole discretion, sell to any Participant shares of Common Stock free of restrictions under the Plan for a price determined by the Board, but which may not be less than the par value per share of the Common Stock.

6.3 Deferred Stock

6.3.1 Deferred Stock Award. A deferred stock Award entitles the recipient to receive shares of deferred stock, which is Common Stock to be delivered in the future. Delivery of the Common Stock will take place at such time or times, and on such conditions, as the Board may specify. The Board may at any time accelerate the time at which delivery of all or any part of the Common Stock will take place.

6.3.2 Other Awards Settled with Deferred Stock. The Board may, at the time any Award described in this Section 6 is granted, provide that, at the time Common Stock would otherwise be delivered pursuant to the Award, the Participant will instead receive an instrument evidencing the right to future delivery of deferred stock.

6.4 Performance Awards

<

4

>

6.4.1 Performance Awards. A performance Award entitles the recipient to receive, without payment, an amount, in cash or Common Stock or a combination thereof (such form to be determined by the Board), following the attainment of performance goals. Performance goals may be related to personal performance, corporate performance, departmental performance or any other category of performance deemed by the Board to be important to the success of the Company. The Board will determine the performance goals, the period or periods during which performance is to be measured and all other terms and conditions applicable to the Award.

6.4.2 Other Awards Subject to Performance Conditions. The Board may, at the time any Award described in this Section 6 is granted, impose the condition (in addition to any conditions specified or authorized in this Section 6 of the Plan) that performance goals be met prior to the Participant's realization of any payment or benefit under the Award.

7. Purchase Price and Payment

Except as otherwise provided in the Plan, the purchase price of Common Stock to be acquired pursuant to an Award shall be the price determined by the Board, provided that such price shall not be less than the par value of the Common Stock. Except as otherwise provided in the Plan, the Board may determine the method of payment of the exercise price or purchase price of an Award granted under the Plan and the form of payment. The Board may determine that all or any part of the purchase price of Common Stock pursuant to an Award has been satisfied by past services rendered by the Participant. The Board may agree at any time, upon request of the Participant, to defer the date on which any payment under an Award will be made.

8. Intentionally Omitted

9. Change in Control

9.1 Impact of Event

In the event of a "Change in Control" as defined in Section 9.2, the following provisions shall apply, unless the agreement evidencing the Award otherwise provides (by specific explicit reference to Section 9.2 below). If a Change in Control occurs while any Awards are outstanding, then, effective upon the Change in Control, (i) each outstanding stock option or other stock-based Award awarded under the Plan that was not previously exercisable and vested shall become immediately exercisable in full and will no longer be subject to a right of repurchase by the Company, (ii) each outstanding restricted stock award or other stock-based Award subject to restrictions and to the extent not fully vested, shall be deemed to be fully vested, free of restrictions and no longer subject to a right of repurchase by the Company, and (iii) deferral limitations and conditions that relate solely to the passage of time, continued employment or affiliation will be waived and removed as to deferred stock Awards and performance Awards; performance of other conditions (other than conditions relating solely to the passage of time, continued employment or affiliation) will continue to apply unless otherwise provided in the agreement evidencing the Award or in any other agreement between the Participant and the Company or unless otherwise agreed by the Board.

<

5

>

9.2 Definition of "Change in Control"

"Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of beneficial ownership of any capital stock of Thermo Electron Corporation ("Thermo Electron") if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of Thermo Electron (the "Outstanding TMO Common Stock") or (ii) the combined voting power of the then-outstanding securities of Thermo Electron entitled to vote generally in the election of directors (the "Outstanding TMO Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by Thermo Electron, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by Thermo Electron or any corporation controlled by Thermo Electron, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this definition; or

(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board of Directors of Thermo Electron (the "Thermo Board") (or, if applicable, the Board of Directors of a successor corporation to Thermo Electron), where the term "Continuing Director" means at any date a member of the Thermo Board (i) who was a member of the Thermo Board as of July 1, 1999 or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Thermo Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Thermo Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving Thermo Electron or a sale or other disposition of all or substantially all of the assets of Thermo Electron in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns Thermo Electron or substantially all of Thermo Electron's assets either directly or through one or

<

6

>

more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding TMO Common Stock and Outstanding TMO Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by Thermo Electron or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of Thermo Electron of a complete liquidation or dissolution of Thermo Electron.

10. General Provisions

10.1 Documentation of Awards

Awards will be evidenced by written instruments, which may differ among Participants, prescribed by the Board from time to time. Such instruments may be in the form of agreements to be executed by both the Participant and the Company or certificates, letters or similar instruments which need not be executed by the participant but acceptance of which will evidence agreement to the terms thereof. Such instruments shall conform to the requirements of the Plan and may contain such other provisions (including provisions relating to events of merger, consolidation, dissolution and liquidations, change of control and restrictions affecting either the agreement or the Common Stock issued thereunder), as the Board deems advisable.

10.2 Rights as a Stockholder

Except as specifically provided by the Plan or the instrument evidencing the Award, the receipt of an Award will not give a Participant rights as a stockholder of the Company with respect to any shares covered by an Award until the date of issue of a stock certificate to the participant for such shares.

10.3 Conditions on Delivery of Stock

The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove any restriction from shares previously delivered under the Plan (a) until all conditions of the Award have been satisfied or removed, (b) until, in the opinion of the Company's counsel, all applicable federal and state laws and regulations have been complied with, (c) if the outstanding Common Stock is at the time listed on any stock exchange, until the shares have been listed or authorized to be listed on such exchange upon official notice of issuance, and (d) until all other legal matters in connection with the issuance and delivery of such shares have been approved by the Company's counsel. If the sale of Common Stock has not been registered under the Securities Act of 1933, as amended, the Company may require, as a condition to exercise of the Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of such act and may require that the certificates evidencing such Common Stock bear an appropriate legend restricting transfer.

<

7

>

If an Award is exercised by the participant's legal representative, the Company will be under no obligation to deliver Common Stock pursuant to such exercise until the Company is satisfied as to the authority of such representative.

10.4 Tax Withholding

The Company will withhold from any cash payment made pursuant to an Award an amount sufficient to satisfy all federal, state and local withholding tax requirements (the "withholding requirements").

In the case of an Award pursuant to which Common Stock may be delivered, the Board will have the right to require that the participant or other appropriate person remit to the Company an amount sufficient to satisfy the withholding requirements, or make other arrangements satisfactory to the Board with regard to such requirements, prior to the delivery of any Common Stock. If and to the extent that such withholding is required, the Board may permit the participant or such other person to elect at such time and in such manner as the Board provides to have the Company hold back from the shares to be delivered, or to deliver to the Company, Common Stock having a value calculated to satisfy the withholding requirement.

10.5 Transferability of Awards

Except as may be authorized by the Board, in its sole discretion, no Award (other than an Award in the form of an outright transfer of cash or Common Stock not subject to any restrictions) may be transferred other than by will or the laws of descent and distribution, and during a Participant's lifetime an Award requiring exercise may be exercised only by him or her (or in the event of incapacity, the person or persons properly appointed to act on his or her behalf). The Board may, in its discretion, determine the extent to which Awards granted to a Participant shall be transferable, and such provisions permitting or acknowledging transfer shall be set forth in the written agreement evidencing the Award executed and delivered by or on behalf of the Company and the Participant.

10.6 Adjustments in the Event of Certain Transactions

(a) In the event of a stock dividend, stock split or combination of shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the Board will make (i) appropriate adjustments to the maximum number of shares that may be delivered under the Plan under Section 4 above, and (ii) appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding or subsequently granted, any exercise prices relating to Awards and any other provisions of Awards affected by such change.

(b) In the event of any recapitalization, merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the Board, the Board in its discretion may make appropriate adjustments to outstanding Awards, including, without limitation: (i) accelerate the exercisability of the Option,

<

8

>

or (ii) adjust the terms of the Option (whether or not in a manner that complies with the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended (the "Code")), or (iii) if there is a survivor or acquiror entity, provide for the assumption of the Option by such survivor or acquiror or an affiliate thereof or for the grant of one or more replacement options by such survivor or acquiror or an affiliate thereof, in each case on such terms (which may, but need not, comply with the requirements of Section 424(a) of the Code) as the Board may determine, or (iv) terminate the Option (provided, that if the Board terminates the Option, it shall, in connection therewith, either (A) accelerate the exercisability of the Option prior to such termination, or (B) provide for a payment to the holder of the Option of cash or other property or a combination of cash or other property in an amount reasonably determined by the Board to approximate the value of the Option assuming an exercise immediately prior to the transaction, or (C) if there is a survivor or acquiror entity, provide for the grant of one or more replacement options pursuant to clause
(iii) above), or (v) provide for none of, or any combination of, the foregoing.

(c) No fraction of a share or fractional shares shall be purchasable or deliverable pursuant to this Section 10.6.

10.7 Employment Rights

Neither the adoption of the Plan nor the grant of Awards will confer upon any person any right to continued employment with the Company or any subsidiary or interfere in any way with the right of the Company or subsidiary to terminate any employment relationship at any time or to increase or decrease the compensation of such person. Except as specifically provided by the Board in any particular case, the loss of existing or potential profit in Awards granted under the Plan will not constitute an element of damages in the event of termination of an employment relationship even if the termination is in violation of an obligation of the Company to the employee.

Whether an authorized leave of absence, or absence in military or government service, shall constitute termination of employment shall be determined by the Board at the time. For purposes of this Plan, transfer of employment between the Company and its subsidiaries shall not be deemed termination of employment.

10.8 Other Employee Benefits

The value of an Award granted to a Participant who is an employee, and the amount of any compensation deemed to be received by an employee as a result of any exercise or purchase of Common Stock pursuant to an Award or sale of shares received under the Plan, will not constitute "earnings" or "compensation" with respect to which any other employee benefits of such employee are determined, including without limitation benefits under any pension, stock ownership, stock purchase, life insurance, medical, health, disability or salary continuation plan.

<

9

>

10.9 Legal Holidays

If any day on or before which action under the Plan must be taken falls on a Saturday, Sunday or legal holiday, such action may be taken on the next succeeding day not a Saturday, Sunday or legal holiday.

10.10 Foreign Nationals

Without amending the Plan, Awards may be granted to persons who are foreign nationals or employed outside the United States or both, on such terms and conditions different from those specified in the Plan, as may, in the judgment of the Board, be necessary or desirable to further the purpose of the Plan.

11. Termination and Amendment

The Plan shall remain in full force and effect until terminated by the Board. Subject to the last sentence of this Section 11, the Board may at any time or times amend the Plan or any outstanding Award for any purpose that may at the time be permitted by law, or may at any time terminate the Plan as to any further grants of Awards. No amendment of the Plan or any agreement evidencing Awards under the Plan may adversely affect the rights of any participant under any Award previously granted without such participant's consent.


Exhibit 10.34

Thermo Electron
81 Wyman Street
Post Office Box 9046 (781) 622-1000 Waltham, MA 02454-9046 Fax: (781) 622-1207

Brian Holt
President and CEO
Thermo Ecotek Corporation

May 18, 2000

Dear Brian:

As we have discussed, Thermo Electron Corporation (the Company) has announced a reorganization of the company in which certain of the company's assets will be sold. We recognize that your past contributions have been integral to the success of the Company and that your continued involvement will be necessary in order to facilitate these sales and to assure a smooth transition for potential buyers.

In order to provide an incentive for you to remain with the company through the completion of these sales, we will pay you a Transaction Bonus.

Transaction Bonus

You will be paid the amounts indicated below for the sale or disposition of the following businesses. If the actual sale price of any business exceeds its target price, .5% of the difference between the actual sale price and the target price will be added to your transaction bonus for that business. If the actual sale price on any business is below its target price, you will be paid a portion of the Transaction Bonus. The portion will equal the sale price divided by the target price times the listed Transaction Bonus rounded up to the nearest hundred. (EXAMPLE: If FES sold for $40,000,000 your bonus would be $44,500 ($40,000,000 divided by $45,000,000 times $50,000 equals $44,444. Rounded up to the next hundred equals $44,500)

These Transaction Bonuses will be paid to you in a lump sum payment on or before ninety (90) days following the closing date of each sale unless you and I mutually agree to an alternate payment date.

                                                          Transaction Bonus
Businesses to be sold               Target Price           At Target Price
---------------------               ------------          -----------------

FES                                 $ 45,000,000              $ 50,000
NuTemp Inc.                         $ 16,000,000              $ 18,000
Tecogen                             $  6,000,000              $  7,000
Optronics                           $  6,000,000              $  7,000
Peek                                $ 85,000,000              $ 93,000
Retec Consulting                    $ 45,000,000              $ 49,000
Nutech                              $ 17,000,000              $ 19,000
TPST Soil                           $ 15,000,000              $ 16,000
Fluids                              $ 13,000,000              $ 14,000
Killam                              $ 45,000,000              $ 49,000
Lancaster Labs                      $ 60,000,000              $ 66,000
Eurotech                            $  5,000,000              $  6,000
Normandeau                          $  5,000,000              $  6,000
Green Sunrise                       $  5,000,000              $  6,000
Metal Treaters                      $ 12,000,000              $ 13,000
Trilogy                             $ 30,000,000              $ 31,000
                                    ------------              --------

Total                               $410,000,000              $450,000

Terms of Agreement

1. The Company agrees to continue to employ you on the same terms and with the same benefits you currently enjoy as an employee-at-will. In return, you agree to remain in such employ and to continue to devote your full time and best efforts to the Company as an employee-at-will until the closing date of the sale of these businesses.


2. You understand that the Company retains the right to terminate your services without cause (as defined below) and you retain the right to terminate your services from the Company at any time. If your employment is terminated by the company without cause prior to the closing of these business sales, you will be paid your full and unreduced Transaction Bonus payments at the time of the sales. If you terminate your employment prior to the final closing date, or the Company terminates your employment for "cause" (as defined below), you will forfeit any and all payments that you would be entitled to for unsold businesses covered under this agreement.

3. For the purposes of this agreement, "cause" shall be determined by the Company in the exercise of good faith and reasonable judgment and will include any breach of this agreement by you or any act by you of gross personal misconduct, insubordination, misappropriation of funds, fraud, dishonesty, gross neglect of or failure to perform the duties reasonably required of you pursuant to this agreement or any conduct which is in willful violation of any applicable law or regulation pertaining to the business.

4. For purposes of this agreement we agree that the businesses will be considered to be sold when any person or entity, other than a person or entity affiliated with the Company, purchases at least fifty percent (50%) of the assets or shares of the individual businesses, whether through a purchase of the business or a purchase of the company of which the business is a part.

5. You understand that all payments made under this agreement are subject to appropriate federal, state, city or other tax withholding requirements.

6. You acknowledge that this Transaction Bonus Agreement supersedes any prior agreements or understandings oral or written between you and the Company pertaining to any Transaction Bonus incentive payments being offered to employees of businesses being sold in connection with the reorganization and that this agreement constitutes the entire agreement between us with regard to Transaction Bonuses.

On behalf of Thermo Electron, I thank you for your continued assistance and support. If you have any questions regarding any of the terms of this Agreement, please do not hesitate to contact me.

Once you have read and understood the terms of this Agreement, please indicate your agreement by signing below on the line above your typewritten name, make a copy for your records and return the original document to me.

Very truly yours,

                                            /s/ Anne Pol
                                            -----------------------
                                            Sr. Vice President
                                            Thermo Electron


Accepted and agreed:

/s/ Brian D. Holt                          01/06/2000
-----------------------------              ------------
Brian Holt                           Date: June 1, 2000

<
                                       2


>


Exhibit 23

Consent of Independent Public Accountants

As independent public accountants, we hereby consent to the incorporation by reference of our reports dated February 7, 2002 (except with respect to the matters discussed in Note 19, as to which the date is February 25, 2002), included in or incorporated by reference into Thermo Electron Corporation's Annual Report on Form 10-K for the year ended December 29, 2001, into the Company's previously filed Registration Statement No. 33-00182 on Form S-8, Registration Statement No. 33-8993 on Form S-8, Registration Statement No. 33-8973 on Form S-8, Registration Statement No. 33-16460 on Form S-8, Registration Statement No. 33-16466 on Form S-8, Registration Statement No. 33-25052 on Form S-8, Registration Statement No. 33-37865 on Form S-8, Registration Statement No. 33-37867 on Form S-8, Registration Statement No. 33-36223 on Form S-8, Registration Statement No. 33-52826 on Form S-8, Registration Statement No. 33-52804 on Form S-8, Registration Statement No. 33-52806 on Form S-8, Registration Statement No. 33-52800 on Form S-8, Registration Statement No. 33-37868 on Form S-8, Registration Statement No. 33-51187 on Form S-8, Registration Statement No. 33-51189 on Form S-8, Registration Statement No. 33-54347 on Form S-8, Registration Statement No. 33-54453 on Form S-8, Registration Statement No. 33-65237 on Form S-8, Registration Statement No. 33-61561 on Form S-8, Registration Statement No. 33-58487 on Form S-8, Registration Statement No. 333-01277 on Form S-3, Registration Statement No. 333-01893 on Form S-3, Registration Statement No. 333-19535 on Form S-8, Registration Statement No. 333-19633-01 on Form S-4, Registration Statement No. 333-34909-01 on Form S-3, Registration Statement No. 333-14265 on Form S-8, Registration Statement No. 333-62957 on Form S-3, Registration Statement No. 333-90761 on Form S-8, Registration Statement No. 333-90823 on Form S-8, Registration Statement No. 333-94627 on Form S-8, Registration Statement No. 333-32035-01 on Form S-3, Registration Statement No. 333-48432 on Form S-8, Registration Statement No. 333-46408 on Form S-8, Registration Statement No. 333-43702 on Form S-8, Registration Statement No. 333-43698 on Form S-8, Registration Statement No. 333-40578 on Form S-8, Registration Statement No. 333-40576 on Form S-8, Registration Statement No. 333-33070 on Form S-8, Registration Statement No. 333-33062 on Form S-8, Registration Statement No. 333-33068 on Form S-8, Registration Statement No. 333-33064 on Form S-8, Registration Statement No. 333-33058 on Form S-8, Registration Statement No. 333-33066 on Form S-8, Registration Statement No. 333-33060 on Form S-8, Registration Statement No. 333-33074 on Form S-8, Registration Statement No. 333-33072 on Form S-8, Registration Statement No. 333-60024 on Form S-3, Registration Statement No. 333-62004 on Form S-8, Registration Statement No. 333-76670 on Form S-8, and Registration Statement No. 333-83470 on Form S-8.

Arthur Andersen LLP

Boston, Massachusetts
March 14, 2002


                                                                                               Exhibit 21
                                   THERMO ELECTRON CORPORATION

                                  Subsidiaries of the Registrant

As of February 28, 2002, Thermo Electron Corporation owned the following companies:


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
---------------------------------------------------------------------------------------------------------

Thermo Coleman Corporation                                                   Delaware             100
    Thermo Information Solutions Inc.                                        Delaware             100
Peter Brotherhood Holdings Ltd.                                               England             100
    Aircogen Ltd.                                                             England              80
    Peter Brotherhood Limited                                                 England             100
        Peter Brotherhood Pension Fund Trustees Ltd.                          England             100
        Thermo Electron Realty Limited                                        England             100
    Thermo Holdings Limited                                                   England             100
Thermo Electron, S.A. de C.V.                                                 Mexico              100
Fi SA                                                                         France              100
Gulf Precision, Inc.                                                          Arizona             100
    Seeley Enterprises, Inc.                                                New Mexico            100
Thermo Hypersil-Keystone Inc.                                              Pennsylvania           100
Loftus Furnace Company                                                     Pennsylvania           100
Met-Therm, Inc.                                                                Ohio               100
NAPCO, Inc.                                                                 Connecticut           100
Nicolet Biomedical of California Inc.                                       California            100
North East Surgical Tool Corp.                                             Massachusetts          100
North Carbondale Minerals, Inc.                                             California            100
Thermo WI, Inc.                                                              Wisconsin            100
Perfection Heat Treating Company                                             Michigan             100
San Marcos Resource Recovery, Inc.                                          California            100
Staten Island Cogeneration Corporation                                       New York             100
TE Great Lakes Inc.                                                          Michigan             100
TEC Cogeneration Inc.                                                         Florida             100
South Florida Cogeneration Associates                                         Florida              50*
TEC Energy Corporation                                                      California            100
    North County Resource Recovery  Associates                              California            100*
    (50% of which is owned directly by
     San Marcos Resource Recovery, Inc.)
Thermo Electron Export Inc.                                                  Barbados             100
Thermo Foundation, Inc.                                                    Massachusetts          100
Thermo Leasing Corporation                                                   Delaware             100
    Thermo Capital Company LLC                                               Delaware              50
Walpak Company                                                               Illinois             100
Thermo Detection Inc.                                                        Delaware             100
    Thermo Orion Inc.                                                      Massachusetts          100
        Orion Research Limited                                                England             100
        Thermo Orion Puerto Rico Inc.                                        Delaware             100
        Russell pH Limited                                                   Scotland             100
    Thermo Keytek LLC                                                        Delaware             100
    ThermedeTec Corporation                                                  Delaware             100

                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

        Thermedics Detection de Argentina S.A.                               Argentina             99
        (additionally 1% of the shares are owned
        directly by Thermo Detection Inc.)
        Thermedics Detection de Mexico, S.A. de C.V.                          Mexico               99
        (additionally 1% of the shares are owned
        directly by Thermo Detection Inc.)
        Thermedics Detection Limited                                          England             100
        Thermedics Detection Scandinavia AS                                   Norway              100
Allen Coding Systems Limited                                                  England             100
    Thermo Allen Coding Corporation                                          Delaware             100
Goring Kerr Limited                                                           England             100
    Best Checkweighers Limited                                                England             100
    Intertest (UK) Limited                                                    England             100
Goring Kerr Detection Limited                                                 England             100
    Goring Kerr (NZ) Limited                                                New Zealand           100
    Goring Kerr Canada Inc.                                                   Canada              100
Ramsey France S.A.R.L.                                                        France              100
Ramsey Ingenieros S.A.                                                         Spain              100
Ramsey Italia S.R.L.                                                           Italy              100
    Tecno Europa Elettromeccanica S.R.L.                                       Italy              100
Thermo Ramsey Inc.                                                         Massachusetts          100
Xuzhou Ramsey Technology Development Co., Limited                              China               50*
Thermo Sentron Australia Pty. Ltd.                                           Australia            100
Thermo Sentron Canada Inc.                                                    Canada              100
Thermo Sentron Limited                                                        England             100
    Hitech Electrocontrols Limited                                            England             100
        Hitech Licenses Ltd.                                                  England             100
        Hitech Metal Detectors Ltd.                                           England             100
    Westerland Engineering Ltd.                                               England             100
Thermo Sentron (South Africa) Pty. Ltd.                                    South Africa           100
Thermo Voltek Europe B.V.                                                   Netherlands           100
    Comtest Italia S.R.L.                                                      Italy              100
    Comtest Limited                                                           England             100
UVC Realty Corp.                                                             New York             100
Thermo Administrative Services Corporation                                   Delaware             100
Independent Power Services Corporation                                        Nevada              100
KFP Operating Company, Inc.                                                  Delaware             100
KFx Fuel Partners, L.P.                                                      Delaware             100
MBPL Agriwaste Corporation                                                  California            100
Thermo Electron of Maine, Inc.                                                 Maine              100
    Gorbell/Thermo Electron Power Company                                      Maine               80*
Star/RESC LLC                                                                  Texas               75
Ulna Incorporated                                                           California            100
Thermo Electron Foundation, Inc.                                           Massachusetts          100
Thermo Electron Metallurgical Services, Inc.                                   Texas              100
Analytical Instrument Development, Inc.                                    Pennsylvania           100
Eberline Instrument Company Limited                                           England             100
Thermo Eberline Corporation                                                 New Mexico            100


<
                                       2

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

Epsilon Industrial Inc.                                                        Texas              100
Thermo Life Sciences Limited                                                  England             100
    Kenbury Limited                                                           England             100
    Denley Ltd.                                                               England             100
Thermo Gas Tech, Inc.                                                       California            100
    Gas Tech Partnership                                                    California             50*
    Thermo Gastech Ltd.                                                       Canada              100
Life Sciences International Limited                                           England             100
    Comdata Services Limited                                                  England             100
        Lipshaw Limited                                                       England             100
        Luckham Limited                                                       England             100
        Phicom Limited                                                        England             100
        Southions Investments Limited                                         England             100
        Sungei Puntar Rubber Estate Limited                                   England             100
        Westions Limited                                                      England             100
        Whale Scientific Limited                                              England             100
        Forma Scientific Ltd.                                                 England             100
    Ravensward Ltd.                                                           England             100
    E-C Apparatus Ltd.                                                        England             100
    Shandon (Germany) Ltd.                                                    England             100
    Savant Instruments Ltd.                                                   England             100
    Helmet Securities Limited                                                 England             100
        Life Sciences International Kft                                       Hungary             100
        Life Sciences International, Inc.                                  Pennsylvania           100
           LSI (US) Inc.                                                     Delaware             100
        LSI North America Service Inc.                                       Delaware             100
        Life Sciences International Holdings BV                             Netherlands           100
           Life Sciences International (Poland) SP z O.O                      Poland              100
    Britlowes Limited                                                         England             100
    Commendstar Limited                                                       England             100
    Consumer & Video Holdings Limited                                         England             100
        Video Communications Limited                                          England             100
    Greensecure Projects Limited                                              England             100
        Hybaid Limited                                                        England             100
           Equibio Limited                                                    England             100
               Cell One S.A.R.L.                                              France              100
    Labsystems Europe SA                                                       Spain              100
    Labsystems Ges mbH                                                        Austria             100
    Omnigene Limited                                                          England            58.50
    Shenbridge Limited                                                        England             100
    Southern Instruments Holdings Limited                                     England             100
        Finishlong Ltd.                                                       England             100
Gamma-Metrics Minerals Pty Ltd.                                              Australia            100
Thermo Gamma-Metrics Inc.                                                   California            100
    Thermo Electron India Private Limited                                      India              100
Thermo MF Physics Corporation                                                Delaware             100
Thermo Radiometrie Corporation                                               Delaware             100
    Spectra-Physics VisionTech, Inc.                                         Delaware             100


<
                                       3

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

Radiometrie U.S.A., Inc.                                                    California            100
Radiometrie Limited                                                           England             100
National Nuclear Corporation                                                California            100
    Thermo Nucleonics LLC                                                    Delaware              51
    (additionally, 49% of the shares are owned directly
    by TBA Nucleonics Holding Corporation)
ONIX Systems Inc.                                                            Delaware             100
    Thermo Process Instruments GP, LLC                                       Delaware             100
    Thermo Process Instruments LP                                            Delaware             99.9
    (an additional 0.1% of Thermo Process Instruments LP
    is owned by Thermo Process Instruments GP, LLC)
    ONIX Holdings Limited                                                     England             100
        CAC UK Limited                                                        England             100
        ONIX Measurement Limited                                              England             100
        ONIX Process Analysis Limited                                         England             100
           Thermo ONIX B.V.                                                 Netherlands           100
VG Systems Japan K.K.                                                          Japan              100
Thermo Nicolet Corporation                                                   Wisconsin            100
    Thermo Electron German Holdings Inc.                                     Delaware             35.4
    (7.2% of shares are owned directly by Dynex
    Technologies Inc., 6.6% of shares are owned directly
    by Radiometrie Corporation, 19.3% of shares are owned
    directly by Thermo Electron Corporation, 29.3% of
    shares are owned directly by Finnigan MAT (Nevada)
    Inc., 2.2% of shares are owned directly by ThermedTec Corp.)
    Thermo Vacuum Generators Inc.                                            Delaware             100
    FI Instruments Inc.                                                      Delaware             100
    Thermo Haake Inc.                                                        Delaware             100
    Scintag, Inc.                                                           California            100
    Thermo Spectronic Inc.                                                   Delaware             100
        SLM International Inc.                                               Illinois             100
    Thermo Elemental Inc.                                                  Massachusetts          100
        Thermo ARL U.S. LLC                                                  Delaware             100
        A.R.L. Applied Research Laboratories S.A.                           Switzerland           100
           Fisons Instruments (Proprietary) Limited                        South Africa           100
           Thermo Optek Wissenschaftliche Gerate GesmbH                       Austria             100
        Baird Do Brazil Representacoes Ltda.                                  Brazil              100
        Beijing Baird Analytical Instrument Technology Co. Limited             China              100
    Thermo Cahn Corporation                                                  Wisconsin            100
        Mattson Instruments Limited                                           England             100
        Thermo Optek Limited                                                  England             100
           Thermo VG Systems Limited                                          England             100
           Norlab Instruments Ltd.                                            England             100
           Thermo Elemental Limited                                           England             100
           Unicam Limited                                                     England             100
               Unicam Export Limited                                          England             100
        Unicam Italia SpA                                                      Italy              100
        Unicam S.A.                                                           Belgium             100


<
                                       4

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

    Thermo Instruments Nordic AB                                              Sweden              100
    Nicolet Japan K.K.                                                         Japan              100
    Thermo Spectra-Tech Inc.                                                 Wisconsin            100
    Optek Securities Corporation                                           Massachusetts          100
    Planweld Holding Limited                                                  England             100
        Thermo Electron Limited                                               England             100
    Thermo Nicolet Limited                                                    England             100
        Hilger Analytical Limited                                             England             100
    Thermo Instrument Systems Japan Holdings, Inc.                           Delaware             100
        Nippon Jarrell-Ash Company, Ltd.                                       Japan              100
    Thermo Instruments (Canada) Inc.                                          Canada              100
        Unicam Analytical Inc.                                                Canada              100
Thermo Optek Materials Analysis (S.E.A.) Pte Limited                         Singapore            100
Gould Instrument Systems, Inc.                                                 Ohio               100
    Gould & Nicolet S.A.                                                      France               95
        (additionally, 5% of the shares are owned directly by
        Thermo Electron Corporation)
Thermo Kevex X-Ray Inc.                                                      Delaware             100
Thermo NESLAB Inc.                                                         New Hampshire          100
Nicolet Instrument Technologies Inc.                                         Wisconsin            100
Thermo Noran Inc.                                                            Wisconsin            100
ThermoSpectra Limited                                                         England             100
    Nicolet Technologies Ltd.                                                 England             100
Spectrace Instruments Inc.                                                  California            100
Thermo Electron Sweden Forvaltning AB                                         Sweden              100
    Spectra-Physics AB                                                        Sweden               99
        Spectra-Physics Holdings USA, Inc.                                   Delaware             100
           Pharos Holdings, Inc.                                             Delaware             100
               Thermo BLH Inc.                                               Delaware             100
                  Pharos de Costa Rica S.A.                                 Costa Rica            100
               Automatic Power, Inc.                                         Delaware             100
           Pharos Tech, Inc.                                                 Delaware             100
           Spectra-Physics, Inc.                                             Delaware             100
               Laser Analytical Systems GmbH                                  Germany             100
                  Laser Analytical Systems, Inc.                            California            100
               Opto Power Corporation                                        Delaware             100
               Spectra-Physics Laser Data Systems, Inc.                      Delaware             100
               Spectra-Physics France S.A.                                    France              100
               Spectra-Physics GmbH                                           Germany             100
               Spectra-Physics K.K.                                            Japan              100
               Spectra-Physics Lasers B.V.                                  Netherlands           100
               Spectra-Physics Lasers Ltd.                                    England             100
           Spectra-Physics Foreign Sales Corp.                               Barbados             100
           Spectra-Physics Canada Ltd.                                        Canada              100
        Spectra-Physics Holdings Plc                                          England             100
           Automatic Power Ltd.                                               England             100
           Prizerest Ltd.                                                     England             100
        Spectra-Physics Holdings S.A.                                         France              100


<
                                       5

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

        Saroph B.V.                                                         Netherlands           100
        Thermo Radiometrie Oy                                                 Finland             100
        Thermo Radiometrie KK                                                  Japan              100
        Spectra Precision (Asia) Pte. Ltd.                                   Singapore            100
        Saroph Sweden AB                                                      Sweden              100
           Thermo Nobel AB                                                    Sweden              100
               Nobel Electronique S.A.R.L.                                    France              100
               Thermo Nobel Oy                                                Finland             100
               Nobel Elektronikk A/S                                          Norway              100
               AB Givareteknik                                                Sweden              100
               Thermo Nobel  Ltd.                                             England             100
Thermo Finnigan LLC                                                          Delaware             100
    Finnigan Instruments, Inc.                                               New York             100
    Finnigan International Sales, Inc.                                      California            100
    Finnigan MAT China, Inc.                                                California            100
    Finnigan MAT (Delaware), Inc.                                            Delaware             100
    Finnigan MAT Instruments, Inc.                                            Nevada              100
    Finnigan MAT International Sales, Inc.                                  California            100
    Finnigan MAT (Nevada), Inc.                                               Nevada              100
        Finnigan MAT S.R.L.                                                    Italy              100
           Thermo Separation Products S.R.L.                                   Italy              100
        Thermo Masslab Limited                                                England             100
           H.D. Technologies Limited                                          England             100
        Thermo Instruments Australia Pty. Limited                            Australia            100
        Thermo Finnigan Ltd.                                                  England             100
           Hypersil Limited                                                   England             100
           ThermoQuest AB                                                     Sweden              100
    Finnigan Properties, Inc.                                                Delaware             100
        Thermo Electron Business Trust                                     Massachusetts          100
           TMOI Inc.                                                         Delaware             100
Thermo Forma Inc.                                                            Delaware             100
    Thermo IEC Inc.                                                          Delaware             100
        International Equipment Company Limited                               England             100
    Thermo Savant Inc.                                                       New York             100
Life Sciences International (Hong Kong) Limited                              Hong Kong            100
TMQ SEG (Hong Kong) Limited                                                  Hong Kong            100
ThermoQuest Italia S.p.A.                                                      Italy              100
ThermoQuest Spain S.A.                                                         Spain              100
ThermoQuest Wissenschaftliche Gerate GmbH                                     Austria             100
Thermo Separation Products AG                                               Switzerland           100
ThermoQuest K.K.                                                               Japan              100
Thru-Put Systems, Inc.                                                        Florida             100
Fisons Instruments NV                                                         Belgium             100
Fisons Instruments K.K.                                                        Japan              100
Thermo Haake Ltd.                                                             England             100
Thermo Haake (U.K.) Limited                                                   England             100
Thermo Instrumentos Cientificos S.A.                                           Spain              100
Thermo BioAnalysis Corporation                                               Delaware             100


<
                                       6

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

    Thermo Holding European Operations Corp.                                 Delaware              85
    (an additional 15% is owned by Thermo Electron German Holdings Inc.)
        Thermo Luxembourg Holding S.a.r.l.                                  Luxembourg            100
           Grond & Watersaneringstechniek Nederland B.V.                    Netherlands           100
               Thermo Instruments B.V.                                      Netherlands           100
                  ThIS Automation B.V.                                      Netherlands           100
                  Thermo Instruments NV                                       Belgium             100
                  Thermo Analytical B.V.                                    Netherlands           100
                  This Lab Systems B.V.                                     Netherlands           100
                  Thermo Scientific B.V.                                    Netherlands           100
                  This Gas Analysis Systems B.V.                            Netherlands           100
                      Thermo Euroglas B.V.                                  Netherlands           100
                          Thermo Electron Deutschland Verwaltvngs GmbH        Germany             100
                          Thermo Luxembourg S.a.r.l.                        Luxembourg            100
                             Thermo Electron Deutschland GmbH & Co. KG        Germany             100
                                 Thermo BioSciences GmbH                      Germany             100
                                    Thermo Finnigan GmbH                      Germany              90
                                    (additionally, 10% of the shares
                                    are owned directly by Thermo
                                    Electron Corporation)
                                        Thermo Life Sciences GmbH             Germany             100
                                        Thermo Hypersil GmbH                  Germany             100
                                        Thermo Finnigan GmbH                  Germany             100
                                    Thermo Nicolet  GmbH                      Germany             100
                                    Thermo Haake GmbH                         Germany              90
                                    (additionally, 10% of the shares
                                    are owned directly by Thermo
                                    Nicolet Corporation)
                                    ESM Andersen Instruments GmbH             Germany             100
                                 ITC Grundstucksverwaltungs GmbH              Germany             100
                                    ITC Grundstucksverwaltungs GmbH & Co.     Germany              90
                                    (additionally 10% of the shares
                                    are owned by ITC Holdings Inc.)
                                 Thermo BLH GmbH                              Germany             100
                                 Thermo Shandon GmbH                          Germany             100
                                 Thermo Radiometrie GmbH                      Germany              90
                                 (additionally 10% of the shares are
                                 owned directly by Thermo Electron
                                 Corporation)
                                    ESM Eberline Instruments GmbH             Germany             100
                                 Thermo LabSystems Vertriebs GmbH             Germany             100
                                 Thermo Ramsey GmbH                           Germany             100
                                 Thermo Nobel GmbH                            Germany             100
                                 Thermo Detection GmbH                        Germany             100


<
                                       7

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

                                 ThermoSpectra GmbH                           Germany             100
                                    Gould Nicolet Messtechnik GmbH            Germany             100
                                        Thermo NORAN GmbH                     Germany             100
                  ThermoSpectra  B.V.                                       Netherlands           100
                      Thermo Finance Company B.V.                           Netherlands           100
                      Thermo Neslab BV                                      Netherlands           100
                      Thermo Finnigan B.V.                                  Netherlands           100
                          Thermo Separation Products B.V. B.A.                Belgium             100
                      Fisons Instruments BV                                 Netherlands           100
                      Thermo LabSystems B.V.                                Netherlands           100
                      Life Sciences International (Benelux) B.V.            Netherlands           100
                      Thermo Ramsey B.V.                                    Netherlands           100
                      Thermo Moisture Systems B.V.                          Netherlands           100
                      Thermo MeasureTech B.V.                               Netherlands           100
                          Thermo Measuretech Canada Inc.                      Canada              100
                      Thermo Optek Holding B.V.                             Netherlands           100
                      Thermo Optek B.V.                                     Netherlands           100
                          Thermo Optek N.V.                                   Belgium              99
                          (additionally, 1% of the shares are owned
                          by Thermo Optek Holding B.V.)
                      Nicolet Technologies B.V.                             Netherlands           100
                      NORAN Instruments B.V.                                Netherlands           100
           Thermo TLH (U.K.) Limited                                          England             100
           Thermo TLH LP                                                     Delaware            99.99*
           (additionally 0.01% is owned by Thermo TLH (U.K.) Limited
    Thermo BioStar Inc.                                                      Delaware             100
    Data Medical Associates, Inc.                                              Texas              100
        DMA Latinoamericana S.A. de C.V.                                      Mexico               50
    Labsystems (SEA) Pte. Ltd.                                               Singapore            100
    Fastighets AB Skrubba                                                     Sweden              100
    Dynex Technologies spol. s.r.o.                                       Czech Republic          100
    Thermo DYNEX Inc.                                                        Virginia             100
    Labsystems, Inc.                                                         Delaware             100
    Thermo BioAnalysis Japan K.K.                                              Japan              100
    Thermo Labsystems OY                                                      Finland             100
        Thermo Labsystems (Shanghai) Co. Ltd.                                  China               90
        Thermo Labsystems India Pvt. Ltd.                                      India              100
        Thermo Clinical Labsystems Oy                                         Finland             100
        Labsystems (Hong Kong) Limited                                       Hong Kong             99
        JSC Thermo Labsystems                                                 Russia               95
    Labsystems Sweden AB                                                      Sweden              100
    Thermo Shandon Ltd.                                                       England             100
        Anglia Scientific Instruments Limited                                 England             100
        Shandon Southern Instruments Limited                                  England             100
    Thermo Shandon Inc.                                                    Pennsylvania           100
        E-C Apparatus Corporation                                             Florida             100
        Whale Scientific Corporation                                         Colorado             100
        ALKO Diagnostic Corporation                                        Massachusetts          100


<
                                       8

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

    TBA Nucleonics Holding Corporation                                       Delaware             100
    Thermo BioAnalysis (Guernsey) Ltd.                                    Channel Islands         100
    Thermo BioAnalysis Limited                                                England             100
        Thermo Fast U.K. Limited                                              England             100
    Thermo Projects Limited                                                   England             100
        Dynex Technologies Limited                                            England             100
        Thermo LabSystems Limited                                             England             100
    Thermo Electron Holding France SA.                                        France              100
        Thermo Finnigan France                                                France              100
           Finnigan Automass S.A.                                             France              100
           Thermo Hypersil S.A.                                               France              100
        Konelab SA                                                            France              100
        Shandon France S.A.                                                   France              100
        Thermo Radiometrie                                                    France              100
        Thermo Instruments SAS                                                France              100
           Rutter Instrumentation S.A.R.L.                                    France              100
        Thermo Optek S.A.R.L.                                                 France              100
        Thermo LabSystems S.A.R.L.                                            France              100
        Thermo Rheo S.A.                                                      France              100
        Labsystems S.A.R.L.                                                   France              100
    Thermo LabSystems (Australia) Pty Limited                                Australia            100
    Thermo LabSystems Inc.                                                 Massachusetts          100
    BioAnalysis Labsystems, S.A.                                              Spain               100
    Thermo Trace Ltd.                                                        Australia            100
        Trace BioSciences Pty. Ltd.                                          Australia            100
        Thermo Trace BioSciences NZ Limited                                 New Zealand            99
        Trace America, Inc.                                                   Florida             100
        Herbos Dijaganosticka                                                 Croatia              50
        Shanghai Long March Chiron Trace Medical Science Co. Ltd.              China               22
Thermo Environmental Instruments Inc.                                       California            100
    Thermo Andersen Inc.                                                     Delaware             100
        Andersen Instruments Limited                                          England             100
Thermo Instruments do Brasil Ltda.                                            Brazil              100
(1% of which shares are owned directly
by Thermo Jarrell Ash Corporation)
Van Hengel Holding B.V.                                                     Netherlands           100
    Thermo Optek S.A.                                                          Spain              100
Thermo Automation Systems Inc.                                               Delaware             100
    Thermo CIDTEC Inc.                                                       New York             100
    Thermo Centro Vision Inc.                                                Delaware             100
    Hilger Crystals Limited                                                   England             100
    Thermo Laser Science Inc.                                                Delaware             100
    Thermo Oriel Corporation                                                 Delaware             100
Thermo Power Corporation                                                   Massachusetts          100
    ACI Holdings Inc.                                                        New York             100
    T-Lyte Corporation                                                       Delaware              98
Holcroft (Canada) Limited                                                     Canada              100


<
                                       9

>


                                                                             STATE OR
                                                                          JURISDICTION OF      PERCENT OF
                                 NAME                                      INCORPORATION       OWNERSHIP
------------------------------------------------------------------------------------------------------------

TTT Metals of Minnesota Inc.                                                 Minnesota            100
    TTT Metals of California Inc.                                           California            100
TTT Metals of Wisconsin Inc.                                                 Wisconsin            100
TMA/Hanford, Inc.                                                           Washington            100
Clark-Trombley Consulting Engineers, Inc.                                    Michigan             100
Thermo REI Inc.                                                              Michigan             100
Randers Engineering of Massachusetts, Inc.                                   Michigan             100
RGPC Inc.                                                                    Michigan             100
Thermo RDC Inc.                                                              Michigan             100
Thermo VTC Inc.                                                              Michigan             100
Fellows, Read & Associates, Inc.                                            New Jersey            100
    George A. Schock & Associates, Inc.                                     New Jersey            100
    Jennison Engineering, Inc.                                                Vermont             100
Lancaster Laboratories LLC                                                   Delaware             100
    Skinner & Sherman, Inc.                                                Massachusetts          100
Thermo EuroTech (Delaware) Inc.                                              Delaware             100
Thermo EuroTech Ireland Ltd.                                                  Ireland             100
ThermoRetec Corporation                                                      Delaware             100
    ThermoRetec Construction Corporation                                     Virginia             100
    GeoWest Golden Inc.                                                      Colorado             100
        GeoWest TriTechnics of Ohio, LLC                                     Colorado             100
    RETEC Thermal, Inc.                                                      Delaware             100
        TRI Oak Ridge LLC                                                    Delaware              50
        (additionally, 50% of the shares are owned
        directly by Coleman Services Incorporated)
        TRUtech L.L.C.                                                       Delaware            47.5*
Thermo Securities Corporation                                                Delaware             100
    Thermo Amex Finance, L.P.                                                Delaware              99*
        Thermo Amex Convertible Growth Fund I., L.P.                         Delaware              99*
Thermo Technology Ventures Inc.                                                Idaho              100
    Plasma Quench Investment Limited Partnership                             Delaware              60*
ThermoLase LLC                                                               Delaware             100
    ThermoLase Japan L.L.C.                                                   Wyoming              50*
Trex Medical Corporation                                                     Delaware             100
    Trex Medical Systems Corporation                                         Delaware             100
        Trophy Dental Inc.                                                   Virginia             100
    Trex Medical France S.A.                                                  France              100
        Trophy Radiologie S.A.                                                France              100
           Trophy Benelux S.A.                                                Belgium             100
           Trophy Radiologie Italia S.R.L.                                     Italy              100
           Trophy Radiologie Japan KK                                          Japan              100
           Trophy Radiologie GmbH                                             Germany             100
           P.T. Trophy Rajawali Indonesia                                    Indonesia             51*
           Trophy Radiologia Espana SA                                         Spain              100
           Trophy Radiologie U.K. Ltd.                                        England             100
Thermo Corporation                                                           Delaware             100

 * Joint Venture/Partnership


Exhibit 10.36

THERMO ELECTRON CORPORATION

EXECUTIVE SEVERANCE AGREEMENT

THIS AGREEMENT by and between THERMO ELECTRON CORPORATION, a Delaware corporation (the "Company"), and Seth H. Hoogasian (the "Executive") is made as of January 27, 2000 (the "Effective Date").

WHEREAS, the Company recognizes that the uncertainty regarding the future employment prospects for key personnel may result in the departure or distraction of key personnel to the detriment of the Company and its stockholders;

WHEREAS, the Board of Directors of the Company (the "Board") has determined that appropriate steps should be taken to reinforce and encourage the continued employment and dedication of the Company's key personnel without distraction from such uncertainty and related events and circumstances; and

NOW, THEREFORE, as an inducement for and in consideration of the Executive remaining in its employ, the Company agrees that the Executive shall receive the severance benefits set forth in this Agreement in the event the Executive's employment with the Company is terminated under the circumstances described below.

1. Key Definitions.

As used herein, the following terms shall have the following respective meanings:

1.1 "Change in Control" means an event or occurrence set forth in any one or more of subsections (a) through (d) below (including an event or occurrence that constitutes a Change in Control under one of such subsections but is specifically exempted from another such subsection):

(a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 promulgated under the Exchange Act) 40% or more of either (i) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control: (i) any acquisition by the Company, (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (iii) any acquisition by any corporation pursuant to a transaction which complies with clauses (i) and (ii) of subsection (c) of this Section 1.1; or


(b) such time as the Continuing Directors (as defined below) do not constitute a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term "Continuing Director" means at any date a member of the Board (i) who was a member of the Board on the date of the execution of this Agreement or (ii) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (ii) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or

(c) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company in one or a series of transactions (a "Business Combination"), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (i) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company's assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the "Acquiring Corporation") in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively; and (ii) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 40% or more of the then outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors; or

(d) approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

1.2 "Cause" means the Executive's willful engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company. For purposes of this Section 1.2, no act or failure to act by the Executive shall be considered "willful" unless it is done, or omitted to be


done, in bad faith and without reasonable belief that the Executive's action or omission was in the best interests of the Company.

2. Term of Agreement. This Agreement, and all rights and obligations of the parties hereunder, shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) or
(b) the fulfillment by the Company of all of its obligations under Sections 4 and 5.2 if the Executive's employment with the Company terminates prior to the expiration of the Term. "Term" shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2002.

3. Not an Employment Contract. The Executive acknowledges that this Agreement does not constitute a contract of employment or impose on the Company any obligation to retain the Executive as an employee and that this Agreement does not prevent the Executive from terminating employment at any time.

4. Benefits to Executive.

4.1 Compensation.

(a) Termination Without Cause. If the Executive's employment with the Company is terminated by the Company (other than for Cause) then the Executive shall be entitled to the following benefits:

(i) the Company shall pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts:

(1) the sum of (A) two times the Executive's annual base salary as in effect immediately prior to the date of termination, and (B) the amount of any cash compensation previously deferred by the Executive (together with any accrued interest or earnings thereon) and any accrued vacation pay, in each case to the extent not previously paid; and

(ii) for two years after the date of termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue to provide benefits to the Executive and the Executive's family at least equal to those which would have been provided to them if the Executive's employment had not been terminated, in accordance with the applicable benefit plans in effect on the date of termination or, if more favorable to the Executive and the Executive's family, in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies; provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive a particular type of benefits (e.g., health insurance benefits) from such employer on terms at least as favorable to the Executive and the


Executive's family as those being provided by the Company, then the Company shall no longer be required to provide those particular benefits to the Executive and the Executive's family;

(iii) to the extent not previously paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive following the Executive's termination of employment under any plan, program, policy, practice, contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"); and

(iv) for purposes of determining eligibility (but not the time of commencement of benefits) of the Executive for retiree benefits to which the Executive is entitled, the Executive shall be considered to have remained employed by the Company until two years after the date of termination.

(b) Termination for Cause. If the Company terminates the Executive's employment with the Company for Cause, then the Company shall (i) pay the Executive, in a lump sum in cash within 30 days after the date of termination, the sum of (A) the Executive's base salary through the date of termination and (B) the amount of any cash compensation previously deferred by the Executive, in each case to the extent not previously paid and (ii) timely pay or provide to the Executive the Other Benefits.

4.2 Mitigation. The Executive shall not be required to mitigate the amount of any payment or benefits provided for in this Section 4 by seeking other employment or otherwise. Further, except as provided in Section 4.1(a)(ii), the amount of any payment or benefits provided for in this Section 4 shall not be reduced by any compensation earned by the Executive as a result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company or otherwise.

5. Disputes.

5.1 Settlement of Disputes; Arbitration. All claims by the Executive for benefits under this Agreement shall be directed to and determined by the Board of Directors of the Company and shall be in writing. Any denial by the Board of Directors of a claim for benefits under this Agreement shall be delivered to the Executive in writing and shall set forth the specific reasons for the denial and the specific provisions of this Agreement relied upon. The Board of Directors shall afford a reasonable opportunity to the Executive for a review of the decision denying a claim. Any further dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator's award in any court having jurisdiction.

5.2 Expenses. The Company agrees to pay as incurred, to the full extent permitted by law, all legal, accounting and other fees and expenses which


the Executive may reasonably incur as a result of any claim or contest (regardless of the outcome thereof) by the Company, the Executive or others regarding the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive regarding the amount of any payment or benefits pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Internal Revenue Code.

6. Successors.

6.1 Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as defined above and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise.

6.2 Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive should die while any amount would still be payable to the Executive or the Executive's family hereunder if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal representatives or administrators of the Executive's estate.

7. Notice. All notices, instructions and other communications given hereunder or in connection herewith shall be in writing. Any such notice, instruction or communication shall be sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii) prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company, at 81 Wyman Street, Waltham, Massachusetts and to the Executive at the Executive's principal residence as currently reflected on the Company's records (or to such other address as either the Company or the Executive may have furnished to the other in writing in accordance herewith). Any such notice, instruction or communication shall be deemed to have been delivered five business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service. Either party may give any notice, instruction or other communication hereunder using any other means, but no such notice, instruction or other communication shall be deemed to have been duly delivered unless and until it actually is received by the party for whom it is intended.


8. Miscellaneous.

8.1 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

8.2 Injunctive Relief. The Company and the Executive agree that any breach of this Agreement by the Company is likely to cause the Executive substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Executive shall have the right to specific performance and injunctive relief.

8.3 Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the internal laws of the Commonwealth of Massachusetts, without regard to conflicts of law principles.

8.4 Waivers. No waiver by the Executive at any time of any breach of, or compliance with, any provision of this Agreement to be performed by the Company shall be deemed a waiver of that or any other provision at any subsequent time.

8.5 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but both of which together shall constitute one and the same instrument.

8.6 Tax Withholding. Any payments provided for hereunder shall be paid net of any applicable tax withholding required under federal, state or local law.

8.7 Entire Agreement. This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein, and any prior agreement of the parties hereto in respect of the subject matter contained herein is hereby terminated and cancelled, except as provided in the next sentence. Notwithstanding the foregoing sentence, if the Executive is party to an agreement with the Company providing for the payment of benefits in the event employment is terminated after a Change in Control (a "Change in Control Agreement"), such Change in Control Agreement shall not be terminated or cancelled by this Agreement and such Change in Control Agreement shall survive and remain in effect in accordance with its own terms. In the event the Executive actually receives benefits under the Change in Control Agreement, the Executive shall not also be entitled to receive benefits under this Agreement.

8.8 Amendments. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first set forth above.

THERMO ELECTRON CORPORATION

By:     /s/ Anne Pol
        --------------------------------
        Anne Pol
       Senior Vice President, Human Resources

EXECUTIVE:

/s/ Seth H. Hoogasian
-----------------------------------
Seth H. Hoogasian